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Abstract
Adjunctive colposcopy technologies for assessing suspected
cervical abnormalities: systematic reviews and
economic evaluation
Mathilde Peron,1 Alexis Llewellyn,2 Thirimon Moe-Byrne,2
Simon Walker,3 Matthew Walton,2 Melissa Harden,2 Stephen Palmer3
and Mark Simmonds2*
1Department of Economics and Related Studies, University of York, York, UK
2Centre for Reviews and Dissemination, University of York, York, UK
3Centre for Health Economics, University of York, York, UK
*Corresponding author mark.simmonds@york.ac.uk
Background: Dynamic Spectral Imaging System (DySIS)map (DySIS Medical Ltd, Edinburgh, UK) and
ZedScan (Zilico Limited, Manchester, UK) can be used adjunctively with conventional colposcopy, which
may improve the detection of cervical intraepithelial neoplasia (CIN) and cancer.
Objectives: To systematically review the evidence on the diagnostic accuracy, clinical effectiveness and
implementation of DySISmap and ZedScan as adjuncts to standard colposcopy, and to develop a
cost-effectiveness model.
Methods: Four parallel systematic reviews were performed on diagnostic accuracy, clinical effectiveness
issues, implementation and economic analyses. In January 2017 we searched databases (including
MEDLINE and EMBASE) for studies in which DySISmap or ZedScan was used adjunctively with standard
colposcopy to detect CIN or cancer in women referred to colposcopy. Risk of bias was assessed with the
Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2 tool. Summary estimates of diagnostic
accuracy were calculated using bivariate and other regression models when appropriate. Other outcomes
were synthesised narratively. A patient-level state-transition model was developed to evaluate the
cost-effectiveness of DySISmap and ZedScan under either human papillomavirus (HPV) triage or the
HPV primary screening algorithm. The model included two types of clinics [‘see and treat’ and ‘watchful
waiting’ (i.e. treat later after confirmatory biopsy)], as well as the reason for referral (low-grade or
high-grade cytological smear). Sensitivity and scenario analyses were undertaken.
Results: Eleven studies were included in the diagnostic review (nine of DySISmap and two of ZedScan),
three were included in the clinical effectiveness review (two of DySISmap and one of ZedScan) and five
were included in the implementation review (four of DySISmap and one of ZedScan). Adjunctive DySISmap
use was found to have a higher sensitivity for detecting CIN grade 2+ (CIN 2+) lesions [81.25%, 95%
confidence interval (CI) 72.2% to 87.9%] than standard colposcopy alone (57.91%, 95% CI 47.2% to
67.9%), but with a lower specificity (70.40%, 95% CI 59.4% to 79.5%) than colposcopy (87.41%,
95% CI 81.7% to 91.5%). (Confidential information has been removed.) The base-case cost-effectiveness
results showed that adjunctive DySISmap routinely dominated standard colposcopy (it was less costly and
more effective). The only exception was for high-grade referrals in a watchful-waiting clinic setting. The
incremental cost-effectiveness ratio for ZedScan varied between £272 and £4922 per quality-adjusted
life-year. ZedScan also dominated colposcopy alone for high-grade referrals in see-and-treat clinics.
These findings appeared to be robust to a wide range of sensitivity and scenario analyses.
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v
Limitations: All but one study was rated as being at a high risk of bias. There was no evidence directly
comparing ZedScan with standard colposcopy. No studies directly compared DySIS and ZedScan.
Conclusions: The use of adjunctive DySIS increases the sensitivity for detecting CIN 2+, so it increases the
number of high-grade CIN cases that are detected. However, it also reduces specificity, so that more
women with no or low-grade CIN will be incorrectly judged as possibly having high-grade CIN. The
evidence for ZedScan was limited, but it appears to increase sensitivity and decrease specificity compared
with colposcopy alone. The cost-effectiveness of both adjunctive technologies compared with standard
colposcopy, under both the HPV triage and primary screening algorithms, appears to be favourable when
compared with the conventional thresholds used to determine value in the NHS.
Future work: More diagnostic accuracy studies of ZedScan are needed, as are studies assessing the
diagnostic accuracy for women referred to colposcopy as part of the HPV primary screening programme.
Study registration: This study is registered as PROSPERO CRD42017054515.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Acetowhitening A whitening effect following the application of acetic acid to epithelial tissue, used to
identify zones of squamous cell change for biopsy.
Adjunctive dynamic spectral imaging system A dynamic spectral imaging system map used as an
adjunct to a dynamic spectral imaging system map colposcope.
Adjunctive ZedScan A ZedScan used as an adjunct to a standard colposcope.
Cervical intraepithelial neoplasia Abnormal changes in the squamous epithelial cells of the cervix. This
precancerous disorder is graded in accordance with its pathological progress, from cervical intraepithelial
neoplasia 1 to cervical intraepithelial neoplasia 3.
Colposcope An instrument producing an illuminated, magnified view of cervical and vaginal tissues
designed to facilitate visual inspection and biopsy of the cervix.
Cost-effectiveness analysis An economic analysis that converts effects into health terms and describes
the costs for additional health gain.
Decision modelling A theoretical construct that allows the comparison of the relationship between costs
and outcomes of alternative health-care interventions.
Dynamic Spectral Imaging System A digital video colposcope using dynamic spectral imaging to assist
in detecting cancerous and precancerous cervical tissue.
Dynamic Spectral Imaging System map A colour-coded image of the cervix indicating the intensity of
epithelial acetowhitening.
Dyskaryosis Abnormal cytological changes of squamous epithelial cells. A synonym for dysplasia.
Classified into degrees of severity: low grade (including borderline or mild cellular changes) and high grade
(moderate and severe changes).
Electrical impedance spectroscopy A form of spectroscopy assessing different patterns of electrical
conductivity to assess tissue composition.
False negative Incorrect negative test result – an affected individual with a negative test result.
False positive Incorrect positive test result – an unaffected individual with a positive test result.
Histology/histopathology The microscopic study of tissue samples to enable the diagnosis of cancerous
and precancerous cells.
Human papillomavirus A type of virus that can infect the skin and the mucous membranes. Some types
of human papillomavirus can cause dyskaryosis in the cells of the cervix and are strongly associated with
cancer.
Incremental cost-effectiveness ratio The difference in the mean costs of two interventions in the
population of interest divided by the difference in the mean outcomes in the population of interest.
Index test The test for which performance is being evaluated.
DOI: 10.3310/hta22540 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 54
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Peron et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xix
Liquid-based cytology A method of preparation for microscopic examination of smear test samples.
This method superseded Pap smear tests in the NHS cervical cancer screening programme.
Markov model An analytical method particularly suited to modelling repeated events or the progression
of a chronic disease over time.
Meta-analysis Statistical techniques used to combine the results of two or more studies and obtain a
combined estimate of effect.
Negative predictive value The probability that people with a negative test result truly do not have
the disease.
NHS Cervical Screening Programme The programme set up in the UK aimed at detecting and treating
cervical abnormalities and high-risk human papillomavirus infection to prevent future cases of cervical
cancer.
Opportunity costs The cost of forgone outcomes that could have been achieved through
alternative investments.
Positive predictive value The probability that people with a positive test result truly have the disease.
Receiver operating characteristic curve A graph that illustrates the trade-offs between sensitivity and
specificity that result from varying the diagnostic threshold.
Reference standard The best currently available diagnostic test against which the index test is compared.
See and treat The removal of an abnormal area during a colposcopy examination.
Sensitivity The proportion of people with the target disorder who have a positive test result.
Specificity The proportion of people without the target disorder who have a negative test result.
Transformation zone An area of the cervix in which nearly all precancerous and cancerous
changes occur.
True negative A correct negative test result – an unaffected individual with a negative test result.
True positive A correct positive test result – an affected individual with a positive test result.
ZedScan A device that utilises electrical impedance spectroscopy to make judgements on the status of
cervical tissue.
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List of abbreviations
ARTISTIC A Randomised Trial in Screening to
Improve Cytology
BIC Bayesian information criterion
BMD borderline or mild dyskaryosis
BSCCP British Society for Colposcopy and
Cervical Pathology
CDSR Cochrane Database of Systematic
Reviews
CE Conformité Européenne
CENTRAL Cochrane Central Register of
Controlled Trials
CI confidence interval
CIN cervical intraepithelial neoplasia
CIN 2+ cervical intraepithelial neoplasia
grade 2+
CINAHL Cumulative Index to Nursing and
Allied Health Literature
CRD Centre for Reviews and
Dissemination
DARE Database of Abstracts of Reviews
of Effects
DOR diagnostic odds ratio
DSI dynamic spectral imaging
DySIS Dynamic Spectral Imaging System
EIS electrical impedance spectroscopy
FIGO International Federation of
Gynecology and Obstetrics
HPV human papillomavirus
hrHPV high-risk human papillomavirus
HRQoL health-related quality of life
HTA Health Technology Assessment
ICER incremental cost-effectiveness ratio
LLETZ large-loop excision of the
transformation zone
MeSH medical subject heading
NHSCSP NHS Cervical Screening Programme
NHS EED NHS Economic Evaluation Database
NICE National Institute for Health and
Care Excellence
NPV negative predictive value
ONS Office for National Statistics
PPV positive predictive value
PSA probabilistic sensitivity analysis
QALY quality-adjusted life-year
QUADAS Quality Assessment of Diagnostic
Accuracy Studies
ROC receiver operating characteristic
RR relative risk
SE standard error
TOMBOLA Trial Of Management of Borderline
and Other Low-grade Abnormal
smears
Note
This monograph is based on the Technology Assessment Report produced for NICE. The full
report contained a considerable number of data that were deemed confidential. The full
report was used by the Appraisal Committee at NICE in their deliberations. The full report
with each piece of confidential data removed and replaced by the statement ‘confidential
information (or data) removed’ is available on the NICE website: www.nice.org.uk.
The present monograph presents as full a version of the report as is possible while retaining
readability, but some sections, sentences, tables and figures have been removed. Readers
should bear in mind that the discussion, conclusions and implications for practice and research
are based on all the data considered in the original full NICE report.
DOI: 10.3310/hta22540 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 54
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Peron et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxi
Plain English summary
Cervical cancer is the 12th most common cancer among women in the UK. In order to prevent thiscancer, women in England and Wales used to receive a cervical smear test, typically every 3–5 years,
although this will be replaced with a human papillomavirus (HPV) test in the future. If a smear test
suggests that there may be abnormal cells or if HPV infection is detected, a woman will be offered a
colposcopy examination. In this test a physician visually examines the cervix using a special device called a
colposcope to identify areas that may be affected by changes called cervical intraepithelial neoplasia (CIN).
If this is suspected, further tests may be performed or the affected area may be removed.
Dynamic Spectral Imaging System (DySIS)map (DySIS Medical Ltd, Edinburgh, UK) and ZedScan (Zilico
Limited, Manchester, UK) are two new methods designed to improve colposcopy. DySISmap provides a
colour-coded map to make it easier to identify areas affected by CIN; ZedScan uses a small current applied
to the cervix to detect CIN. This report assesses whether or not DySISmap and ZedScan are improvements
on standard colposcopy, in terms of the ability to detect CIN and cancer and in reducing costs. This assessment
was achieved by a thorough review of all studies examining the potential benefits of the DySISmap and ZedScan
technologies, and a new model to assess the economic value of using the technologies.
The review found that both DySISmap and ZedScan successfully detect more women with CIN or cancer,
but more women who do not have CIN or cancer will undergo unnecessary further testing or treatment.
However, the data reported for ZedScan are limited and further studies are needed to confirm the added
value provided by this method. Although both methods are more expensive to use than standard
colposcopy, the additional instances of CIN and cancer detected means that both DySISmap and ZedScan
are likely to represent good value for money for the NHS.
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Scientific summary
Background
Colposcopy is used to detect cervical intraepithelial neoplasia (CIN) and cervical cancer in women with
abnormal results from a cervical smear test or with high-risk human papillomavirus (hrHPV) infection.
Dynamic Spectral Imaging System (DySIS)map (DySIS Medical Ltd, Edinburgh, UK) and ZedScan (Zilico
Limited, Manchester, UK) are two technologies that can be used as adjuncts to conventional colposcopy,
which may improve the detection of CIN and cancer.
Women are referred to colposcopy from the cervical screening programme. This programme currently has
two different algorithms for referral. In the human papillomavirus (HPV) triage algorithm, a cytology test
(e.g. a Pap smear) is performed and, if positive, this is followed by a HPV test. In the HPV primary screening
algorithm, the HPV test is performed first, and only if the test result is positive is a cytology test performed.
Objectives
To assess the clinical effectiveness and cost-effectiveness of adjunctive colposcopy technologies (DySISmap
and ZedScan) for assessing suspected cervical abnormalities in people referred for colposcopy as part of the
NHS Cervical Screening Programme (NHSCSP) under either the HPV triage screening algorithm (including
test of cure) or the HPV primary screening algorithm (including test of cure).
Methods
Assessment of clinical effectiveness
Three systematic reviews were conducted. A range of bibliographic sources (including MEDLINE and
EMBASE) were searched from inception to April 2017 for published and unpublished literature.
For the diagnostic accuracy outcomes, we included prospective cohort studies of DySISmap or ZedScan
reporting data to calculate diagnostic accuracy estimates. For the clinical effectiveness outcomes, we
included any study in which DySISmap or ZedScan was used that reported relevant clinical outcomes,
such as adverse events. For the implementation outcomes, we considered all publications reporting issues
related to the implementation of DySISmap or ZedScan.
For all reviews, the eligible population was patients who were referred to colposcopy through a cervical
screening programme because of a suspected abnormality.
The index tests were DySISmap or ZedScan as an adjunct to colposcopy used for the diagnosis of CIN or
cervical cancer. The reference standard was histopathology based on excisional or treatment biopsies.
Two researchers screened the titles and abstracts and all full-text papers subsequently obtained for
assessment. Data extraction and quality assessment were performed by at least one researcher and
checked by a second researcher. The risk of bias of diagnostic accuracy studies was assessed using a
modified version of the Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2 checklist.
For the diagnostic accuracy outcomes, bivariate models were fitted to calculate the summary estimates of
sensitivity and specificity with 95% confidence intervals (CIs). Additional diagnostic accuracy results and
results from the clinical effectiveness and implementation reviews were reported narratively.
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Assessment of cost-effectiveness
Bibliographic databases were searched to identify cost-effectiveness evidence. Only full economic
evaluations were considered. Study characteristics and design issues were extracted and critically appraised.
The main findings of existing economic evaluations were summarised and important structural assumptions
and areas of uncertainty were highlighted.
The review informed the de novo decision-analytic model. This ‘York model’ used a patient-level
state-transition modelling approach to estimate the cost-effectiveness of DySISmap and ZedScan for people
who are referred for colposcopy through the NHSCSP under either HPV triage or the HPV primary screening
algorithm.
The model was populated using results from the systematic clinical effectiveness and cost-effectiveness
reviews, routine sources of cost data, expert clinical opinion and data provided by the manufacturers and
other investigators. A time horizon of 60 years (lifetime) was used and the costs and outcomes were
discounted at a rate of 3.5%. A 2015–16 price year was used.
Analyses were run separately for each routine screening model (HPV triage protocol and HPV primary
screening protocol), different types of clinic (see and treat, watchful waiting) and for different reasons for
referral (all referrals, referrals for low-grade dyskaryosis and referrals for high-grade dyskaryosis). The
incremental cost-effectiveness of DySISmap and ZedScan, compared with conventional colposcopy alone,
was determined based on an assessment of long-term NHS and Personal Social Services costs and quality-
adjusted life-years (QALYs). Sensitivity and scenario analyses were undertaken to explore the robustness of
the results to changes in the parameter inputs, structural assumptions of the model and the time horizon.
Results
Diagnostic accuracy
Eleven studies were included in the diagnostic review: nine of DySIS and two of ZedScan. Only one study
was rated as being at a low risk of bias overall; the remaining 10 studies were rated as being at a high risk
of bias.
The sensitivity of adjunctive DySIS use was found to be higher (81.25%, 95% CI 72.2% to 87.9%) than
that of standard colposcopy alone (57.91%, 95% CI 47.2% to 67.9%), but with lower specificity
(70.40%, 95% CI 59.4% to 79.5%) than colposcopy (87.41%, 95% CI 81.7% to 91.5%).
Only two included studies investigated ZedScan, led by the same researchers in Sheffield. One was a study
of the ZedScan and did not report the full diagnostic accuracy results for colposcopy alone. The other was
a study of a precommercial ZedScan prototype. These issues significantly limited our ability to assess the
diagnostic accuracy of ZedScan. (Confidential information has been removed.)
The specificity of all methods was strongly dependent on what reference standard was used in women
with no colposcope-detected high-grade CIN. This means that the actual diagnostic accuracy of colposcopy
and adjunctive colposcopy is uncertain.
Clinical effectiveness
Three studies (two of DySIS and one of ZedScan) were included and reported very limited data on
adverse events.
Implementation
Five studies (four of DySIS and one of ZedScan) were included. There is some evidence that DySISmap as
an adjunct to colposcopy is generally well received by patients referred for colposcopy and that adjunctive
DySIS was perceived by clinicians to improve the accuracy of colposcopy and confidence in their diagnostic
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decisions and biopsy site selection (two studies). There is evidence that the additional time required to use
ZedScan is minimal in experienced colposcopists.
Cost-effectiveness
Two studies were included in the review of cost-effectiveness. One was an independent assessment of the
cost-effectiveness of DySIS developed for the previous National Institute for Health and Care Excellence
(NICE) DG4 assessment [NICE. Adjunctive Colposcopy Technologies for Examination of the Uterine Cervix –
DySIS and the Niris Imaging System. Diagnostics guidance (DG4). NICE. 2012. URL: www.nice.org.uk/
guidance/dg4 (accessed 10th January 2016).]. The other study was a company-funded assessment of a
prototype version of ZedScan. Neither study fully informed the current decision problem, which includes the
current HPV triage protocol (including test of cure) and also the proposed HPV primary screening protocol.
The main results of the base-case analysis from the York model under the HPV triage protocol are:
l Dynamic Spectral Imaging System routinely dominated colposcopy alone, regardless of the type of
clinics or the reason for referral. The only exception was for high-grade referrals in a watchful-waiting
clinic setting, in which DySIS was more costly and more effective, with an associated incremental
cost-effectiveness ratio (ICER) of £675 per QALY.
l ZedScan also dominated colposcopy alone in see-and-treat clinics. However, in watchful-waiting clinics,
ZedScan was always more effective than colposcopy alone, but was also more costly. The ICER for ZedScan
in watchful-waiting clinics ranged from £272 (low-grade referrals) to £4070 per QALY (high-grade referrals).
l The indirect comparison between ZedScan and DySIS showed that ZedScan routinely appeared to be more
effective but also more costly than DySIS. The ICER for ZedScan ranged from £109 per QALY for high-grade
referrals in see-and-treat clinics to £9918 per QALY for high-grade referrals in watchful-waiting clinics.
The main results of the base-case analysis from the York model under the HPV primary screening protocol are:
l Dynamic Spectral Imaging System dominated colposcopy alone, except for high-grade referrals in
watchful-waiting clinics in which the ICER was estimated to be £1095 per QALY.
l ZedScan dominated only colposcopy alone for high-grade referrals in a see-and-treat clinic. In all other
cases, ZedScan was more effective but also more costly than colposcopy alone. The ICER ranged from
£417 per QALY for low-grade referrals in see-and-treat clinics to £4922 per QALY for high-grade referrals
in watchful-waiting clinics.
l ZedScan was always more effective but also more costly than DySIS. The ICER ranged from £426 per
QALY for high-grade referrals in see-and-treat clinics to £8190 per QALY for high-grade referrals in
watchful-waiting clinics.
The results appeared to be robust to a variety of sensitivity and scenario analyses.
There remains uncertainty regarding the cost-effectiveness of ZedScan given the challenges of comparing it
with colposcopy. In the absence of a direct comparison between the alternative technologies, an indirect
comparison was performed. However, these results should be considered to be exploratory in nature, given
the lack of a robust direct comparison and the challenges identified more generally that arise from the
limitations in the evidence base for ZedScan.
The cost-effectiveness results presented for the HPV primary screening protocols also require careful
consideration. Our analysis is based on the current protocol and the assumption that the final HPV primary
screening protocol may alter prior to HPV primary screening being rolled out nationally. Furthermore, key
input data were derived from unpublished and preliminary results collected in the HPV pilot sites. Data
collection is still ongoing and selection issues may limit the generalisability of the data used. Hence, the
results under the HPV primary screening protocol should be considered to be exploratory and further
analyses should ideally be undertaken when data collection has been completed and the implications of
any selection effect are clearer.
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Discussion
Extensive literature searches were conducted with an attempt to maximise the retrieval of potentially
relevant studies. These included electronic searches of a variety of bibliographic databases, as well as the
screening of clinical trial registers and conference proceedings to identify unpublished studies. The search
strategy did not restrict by study design. The device manufacturers and study authors were contacted to
provide additional data, and the review includes additional data from published studies and data from
as-yet-unpublished studies. The review process followed recommended methods to minimise the potential
for error and/or bias. The quality of the included studies was assessed and accounted for when interpreting
the review results. Appropriate synthesis methods were employed by taking into account the heterogeneity
of the study characteristics.
Only one study of the current version of ZedScan was available, limiting the ability to compare it with
colposcopy. No studies directly compared DySIS and ZedScan. Very few data on participant subgroups
were available. All but one study was rated as being at a risk of bias. In particular, there were few data on
diagnostic accuracy in women with high-risk HPV.
There was very limited evidence relating to the clinical effectiveness of adjunctive DySIS or ZedScan, with
little reporting of any potential adverse effects.
Conclusions
The use of adjunctive DySIS (DySISmap with DySIS video colposcope) increases sensitivity when compared
with colposcopy alone, so it increases the number of high-grade CIN cases that are detected. However, it
also reduces specificity when compared with colposcopy, so more women with no or low-grade CIN will
be incorrectly judged as possibly having high-grade CIN. It might therefore increase unnecessary anxiety in
women with an incorrect test result. It could lead to an increase in the number of unnecessary diagnostic
biopsies (although evidence on whether or not this is actually the case is limited) and complications in
subsequent pregnancies in women who did not require a biopsy.
The limited evidence precludes any definitive conclusions regarding the diagnostic accuracy of ZedScan,
although it appears, like DySIS, to increase sensitivity and decrease specificity compared with colposcopy
alone, when using the currently implemented ZedScan assessment algorithm. There is currently too little
evidence to assess whether or not ZedScan is superior to DySIS.
The cost-effectiveness of both adjunctive technologies compared with standard colposcopy, under both
the HPV triage and primary screening algorithms, appears to be favourable when compared against
conventional thresholds used to determine value in the NHS. However, the limitations and uncertainties in
the evidence base identified for ZedScan need to be carefully considered. The cost-effectiveness of both
adjunctive technologies under the HPV primary screening protocol should also be reassessed when
additional data become available from the pilot sites.
Given the limited number of studies of ZedScan, further and well-conducted diagnostic accuracy studies
of ZedScan are needed, particularly to compare its diagnostic accuracy with that of standard colposcopy
and in groups independent of the manufacturers. Diagnostic accuracy studies comparing DySIS and
ZedScan directly may also be useful.
As most current studies have been in women referred to receive colposcopy on the basis of cytology
screening, diagnostic accuracy studies in women referred from HPV primary screening (or specifically in
women with hrHPV) are needed to assess whether or not the new screening programme will alter
diagnostic accuracy.
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Chapter 1 Background
Description of the health problem
In 2014, 3224 people were diagnosed with cervical cancer in the UK, making it the 12th most common
cancer in women, and 890 people died as a result of the disease.1 More than 80% of people diagnosed with
cervical cancer in England and Wales will survive for ≥ 1 year and almost 65% will survive for ≥ 10 years
after their diagnosis.1 The mortality rate is low because of the NHS Cervical Screening Programme (NHSCSP),
and because cervical cancer is preventable if detected in its early stages.2 However, mortality rates are higher
for those living in the most deprived areas.
Detectable changes in the cervix develop many years before progressing to cancer. The cells lining the
surface of the cervix may go through a series of changes called cervical intraepithelial neoplasia (CIN). The
neoplasia is often harmless and may resolve without intervention; however, sometimes these changes can
become cancerous.3
Cervical intraepithelial neoplasia is classified as CIN 1, 2 or 3, depending on the depth of abnormal cells
within the surface layer of the cervix observed on a diagnostic or excisional (treatment) biopsy:
l CIN 1 – one-third of the thickness of the surface layer of the cervix is affected.
l CIN 2 – two-thirds of the thickness of the surface layer of the cervix is affected.
l CIN 3 – the full thickness of the surface layer of the cervix is affected.
Cervical intraepithelial neoplasia 1 is associated with benign viral replication, and in most cases will regress
spontaneously.4 CIN 3 is considered to be precancerous with the potential to progress to invasive cancer.5
CIN 2 is also generally considered to be, and managed as, precancerous, although the average regression
rate of CIN 2 to normal/negative high-risk human papillomavirus (hrHPV) in adult people is significant,
with estimates of 21% over 12 months in a pooled analysis of three studies,6 and approximately 40%
regression over 2 years in a large US trial.7
Cervical cancer typically develops from precancerous changes over a period of 10–20 years. The most
common types of cervical cancer cases are squamous cell carcinomas (approximately 90%) and
adenocarcinomas.8
One of the strongest risk factors for cervical cancer is hrHPV infections. There are around 13 types of
hrHPV.9,10 Of those, human papillomavirus (HPV) 16 and HPV 18 are associated with changes in the
cervical cells leading to abnormalities (precancerous changes or CIN), which can progress into cervical
cancer (around 70% of patients in the UK). However, most HPV infections will not progress to CIN, as the
virus is usually cleared without any treatment.11 Certain risk factors are associated with the progression of
HPV infection to CIN, in particular the HPV genotype, smoking, other sexually transmitted infections, early
age at first intercourse and a large number of different sexual partners.12
There is evidence to suggest that cellular changes caused by HPV 16 may be more apparent on colposcopy
examination than cellular changes caused by other hrHPV genotypes.13 Therefore, the accuracy of colposcopy
and the adjunctive technologies may differ in these subgroups.
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Current service provision and care pathways
In England, women aged 25–49 years are offered screening every 3 years, and women aged 50–64 years
are offered screening every 5 years under the NHSCSP.14,15 Women are referred for colposcopy if cytological
testing is abnormal or they have symptoms that are suggestive of cervical cancer.
Human papillomavirus immunisation
Since September 2008, all girls aged 12–13 years have been offered a HPV vaccination against the
HPV 16 and 18 genotypes (a catch-up programme was initially implemented for girls aged between
14 and 18 years).14 This cohort is now entering the NHSCSP but may not be fully protected against HPV 16
and 18. The relative sizes of subgroups with HPV 16 and 18 may change in the future, as people who
are vaccinated enter the NHSCSP.
The full impact of HPV vaccination on the screening programme is therefore not fully understood at
present, and the prevalence of disease is likely to change over time, as partially vaccinated and fully
vaccinated cohorts enter screening and colposcopy services.
As HPV immunisation is new, very few immunised people will have entered the cervical screening
programme or will have developed CIN or cervical cancer.
Cervical screening
Cervical screening is conducted by taking a sample of cells brushed from the cervix (liquid-based cytology).14
These cells are tested for possible changes that may or may not develop into cancer. Cytological assessment
is performed to detect nuclear abnormalities, referred to as dyskaryosis, which is graded on the basis of its
severity.15 Grading systems for cervical cytology differ by country, and the current system used in the NHS is
shown in Smith and Patrick16 and Solomon and Nayar.17
In 2015–16, a total of 4.21 million people aged 25–64 years were invited for screening, of whom 3.1 million
(around 73%) attended, leading to the examination of 3.25 million samples.18 Among those with an adequate
test, a negative result was recorded in 94.5% and an abnormal result (from borderline change through to
potential cervical cancer) in was recorded 5.5%; in 1.1% of those tested, a high-grade abnormality was detected.
High-risk human papillomavirus triage
The current HPV triage management protocols for cervical cytology and management options for patients
are outlined in Table 1. Under the hrHPV triage protocol, people whose cervical samples show borderline
change or low-grade dyskaryosis (abnormal cell changes) are given a reflex hrHPV test. If the test is HPV
positive, the person will be invited to attend a colposcopy clinic. If the test is HPV negative, they will
be returned to routine screening. People with high-grade dyskaryosis or worse are referred straight to
colposcopy without a hrHPV test.15 National implementation of hrHPV triage for people with borderline or
low-grade cytology results and hrHPV test of cure was completed in 2013. From 1 April 2014, hrHPV
triage has been implemented across England.19
Human papillomavirus primary screening
Following the piloting of HPV primary screening, which commenced in six sites in England in 2013–14,20
the Department of Health and Social Care announced a change to the cervical screening process in July
2016.21 In several sites in England where HPV primary screening was piloted, it has now been adopted as
the standard of care.
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In HPV primary screening, a cervical cytology sample is first tested for the presence of hrHPV, prior to
cytology triage. The algorithm for the HPV primary screening pilots is shown in Figure 1. In general,
primary screening with hrHPV testing detects over 90% of all cases of CIN 2, CIN 3 and invasive cancer.
It is reported as being 25% more sensitive than liquid-based cytology in detecting borderline changes or
worse, although it is approximately 6% less specific.23
When genotyping tests are used, people testing HPV 16 or 18 positive and cytology normal at baseline
and at their first 12-month follow-up test can be referred to colposcopy without further repeat tests.
The patient group of interest for this assessment is people referred for colposcopy through the NHSCSP
under the HPV triage screening algorithm (with test of cure) or the HPV primary screening algorithm, as
currently recommended for use in pilot sites (with test of cure). People referred because of symptoms
indicative of cervical cancer (e.g. postcoital bleeding or appearance suggestive of cancer) are not of
relevance to this assessment.
Colposcopy management and treatment
Standard binocular colposcopy, with directed biopsy/treatment when necessary, is the current usual
management for people referred with abnormal cytology results. The colposcopist applies solutions such as
acetic acid or Lugol’s iodine to the surface of the cervix. These help to highlight any areas of abnormality
on the cervical epithelium. Video colposcopy may also be used, particularly for the Dynamic Spectral
Imaging System [(DySIS) DySIS Medical Ltd, Edinburgh, UK] when the DySISmap is overlaid onto a video
colposcopic image and no separate binocular colposcopy will be performed.
Colposcopy involves a significant amount of subjective assessment, and the final histological diagnosis
depends on training, experience and the number of patients seen, as well as the ability of the colposcopist
to identify the most appropriate sites for biopsies.24–26 Details of the referral cytology results, HPV status,
other clinical information, the type of management available and the number of biopsies taken may also
be relevant when interpreting the results of colposcopy.
TABLE 1 Human papillomavirus triage management protocol
Result Management recommendation
Inadequate: insufficient cells were available for analysis Repeat in 3 months, refer to colposcopy after three
consecutive inadequate samples
Negative: adequate sample with no abnormal cells Return to routine recall (3 or 5 years depending on age)
Borderline change in squamous cells Test residual sample for hrHPV:
hrHPV detected – refer for colposcopy
hrHPV not detected – return for routine recall
Borderline change in endocervical cells
LG dyskaryosis
HG dyskaryosis (moderate) Refer for colposcopy
HG dyskaryosis (severe)
HG dyskaryosis/suspected invasive squamous carcinoma
Suspected glandular neoplasia of endocervical type
Suspected glandular neoplasia (non-cervical) Refer to gynaecology
HG, high grade; LG, low grade.
Source: NHSCSP publication.19 Contains information from NHS Digital, licenced under the current version of the Open
Government Licence. See www.nationalarchives.gov.uk/doc/open-government-licence/version/3/.
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The 2015 NHSCSP publication19 recommends that, when a successful colposcopy has been performed,
the positive predictive value (PPV) to detect high-grade lesions [CIN grade 2+ (CIN 2+)] should be at least
65%. It also recommends that treatment at first visit to colposcopy should not be offered to patients
referred with borderline or low-grade dyskaryosis. It also recommends that, unless an excision is planned,
a diagnostic biopsy should be performed when cytology results indicate high-grade dyskaryosis (moderate)
or worse, and always when a recognisably atypical transformation zone is observed. In some circumstances,
such as the presence of low-grade colposcopic change and high-grade dyskaryosis (severe), an excisional
form of biopsy (rather than punch biopsy) is recommended.
Negative
Routine recall
Cytology normal
Negative
Routine recall
Negative
Routine recall
Cytology normal
Rescreen in
12 months
Rescreen in
12 months
Positive
Cytology triage
hrHPV test
hrHPV test
hrHPV test
Cytology abnormal
Positive
Cytology triage
Positive
Colposcopy
Colposcopy
Colposcopy
Cytology abnormal
FIGURE 1 The HPV primary screening algorithm (pilot sites). Adapted from: Public Health England.22 Contains
public sector information licensed under the Open Government Licence v3.0. See www.nationalarchives.gov.uk/
doc/open-government-licence/version/3/. © Crown copyright, 2015.
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The results of biopsies are used to guide treatment decisions. Typically, areas of CIN 2 or worse would
usually be treated, although CIN 2 may be managed more conservatively if only part of the transformation
zone is affected, and in younger women who have not completed their family. Treatment options during
the colposcopy examination include excising the area of abnormal cells. If an abnormality is detected
during the colposcopy examination, the colposcopist may treat an abnormality during the first clinic
appointment (‘see and treat’) by excising the area of abnormal cells in which high-grade changes are
suspected or, in rarer cases, by destroying them in situ (ablation).15
The aim of excision is to remove all abnormal tissue. Excision is usually performed with a thin, electrically
heated looped wire in a procedure called a large-loop excision of the transformation zone (LLETZ) under
local anaesthesia. The excised tissue is sent to histopathology to confirm the extent of the abnormality
and to inform further management. For some patients, notably when glandular abnormalities are present
(Cervical Glandular Intraepithelial Neoplasia), a deeper excision (cone biopsy) is required, which is likely to
be performed under general anaesthesia. The depth of the excision depends on the nature of the cervical
transformation zone.15
A number of ablative techniques exist, including laser ablation, cryocautery and cold coagulation.
The NHSCSP publication21 recommends that ablative treatments are performed only when the entire
transformation zone is visible, there is no evidence of glandular abnormality or invasive disease and
there is no major discrepancy between cytology and histology.
If cervical cancer is identified, treatment options include cone biopsy (at a very early stage), trachelectomy,
hysterectomy, radiotherapy and chemotherapy. Conservative treatment may also be offered. Further details
are reported elsewhere.27
NHS colposcopy and treatment
In 2015–16, 188,179 patients were referred for colposcopy: 65.6% as a result of screening, 23.1% were
clinically indicated and 11.3% for other reasons (e.g. CIN treatment follow-up).18 In the same period, 61%
of all people referred to receive colposcopy in England underwent a procedure or treatment at their first
appointment. Diagnostic biopsy was the most common procedure (47%), followed by an excision (12%).
Only a small percentage underwent ablation (0.6%).
Treatment patterns vary significantly at the local and regional levels. In 2015–16, the percentage of all
women receiving some treatment or procedure in England at their first appointment ranged from 53.5%
in the North West of England to 70.5% in the North East of England.18 Among those with high-grade
abnormalities, the percentage who received a diagnostic biopsy ranged from 21.7% in the West Midlands
to 71.1% in London; for low-grade abnormalities, the rates ranged from 51.6% in the East to 80.9% in
the North East. The percentage of patients with high-grade abnormalities who underwent excision ranged
from 11.6% in London to 65.4% in the North West. However, it is likely that most people presenting with
high-grade abnormalities and reported as having either no treatment or a diagnostic biopsy at their first
attendance went on to receive therapeutic treatment at a subsequent appointment.
Follow-up and test of cure
Post-colposcopy follow-up depends on whether treatment has been performed or surveillance has been
recommended. Surveillance can be done within the colposcopy service or within the community.
The NHSCSP publication21 recommends that people referred with low-grade dyskaryosis or lower who
are hrHPV positive and have a satisfactory and normal colposcopic examination can be returned to
community-based recall.15 People with a low-grade lesion based on colposcopy may be followed up at
12 months in the colposcopy clinic or the community. If the lesion has not resolved within 2 years of
referral to colposcopy, a biopsy should be performed. For people referred with high-grade dyskaryosis who
do not have treatment, surveillance with colposcopy and cytology at 6 months is recommended, even if no
abnormality is seen with colposcopy. For patients who are not treated following a colposcopic diagnosis of
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a low-grade lesion, multiple directed biopsies should be performed. Treatment is recommended for people
with high-grade cytology at follow-up.
When CIN 1 or lower is confirmed, colposcopy and cytology at 6 months is recommended. Follow-up for
people referred under the HPV primary screening pilot algorithm is described in more detail elsewhere.28
Under the hrHPV ‘test-of-cure protocol’, patients who have previously received treatment for CIN (all
grades) are invited for screening 6 months after treatment for a repeat cervical sample in the community.
Under HPV triage, a woman whose sample is reported as negative, borderline change or low-grade
dyskaryosis is given a hrHPV test. If the HPV test result is negative, the woman is recalled for a screening
test in 3 years (irrespective of age) and can be returned to routine recall if the subsequent cytology test
result is negative. hrHPV-positive patients are referred back to colposcopy. People whose cytology is
reported as high-grade dyskaryosis or worse are referred straight to colposcopy without a hrHPV test.15
Under HPV primary screening, the test of cure differs and is described in the NHS Cancer Screening
Programme pilot.28
During 2015–16 in England, a total of 433,624 appointments were reported at colposcopy clinics,
of which 163,859 (37.8%) were follow-ups.
Current service cost
Currently, the NHS spends around £21M per year on treating cervical cancer, mostly in women diagnosed
at stage 2 (the cancer has grown beyond the cervix and uterus, but has not spread to the walls of the
pelvis or the lower part of the vagina) or above.29
Description of the technologies under assessment
Following a previous diagnostic assessment report (DG4),30 National Institute for Health and Care
Excellence (NICE) diagnostics guidance (DG4)31 recommended using DySIS as an adjunct to colposcopy.
ZedScan (Zilico Limited, Manchester, UK), previously known as APX100, was not included in the final
guidance, as it had not received its Conformité Européenne (CE) mark prior to publication. Both DySIS
and ZedScan are now being used in several hospitals in England and Wales.
Dynamic Spectral Imaging System with Dynamic Spectral Imaging System map
(Dynamic Spectral Imaging System Medical)
Dynamic Spectral Imaging System is a high-resolution digital video colposcope. It also uses spectral imaging
technology and an inbuilt algorithm to produce an adjunctive map of the cervical epithelium, which is
known as the DySISmap (or pseudo-colour imaging). The DySISmap is intended to be used as an adjunct
to colposcopy to assist clinicians in the diagnosis, biopsy and treatment of CIN.
The DySISmap maps the whitening effect following the application of acetic acid (acetowhitening) to the
epithelium of the cervix in order to aid diagnosis, as well as selecting areas for biopsy and treatment. It
does this by producing a quantitative measurement of the rate, extent and duration of acetowhitening,
which is highly correlated with the altered structure and functionality of abnormal epithelial cells of the
cervix. The DySISmap is produced during the period of the acetowhitening reaction. An inbuilt algorithm
assigns each area of the cervix a colour on the DySISmap that corresponds to the likelihood of an
abnormality being present. The DySISmap is displayed on the screen, overlaid on a live image of the cervix.
The colour spectrum ranges from cyan, which represents weak acetowhitening, to white, which represents
intense acetowhitening; the greater the intensity of the measured acetowhitening reaction, the greater
the likelihood of an abnormality. Imaging typically takes 3 minutes, and the average duration of use per
examination is < 15 minutes.
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The manufacturer claims that new users can be trained to use DySIS in 2–4 hours (personal communication).
Imaging takes 3 minutes and can be stopped manually; however, the company recommends at least
125 seconds of imaging to allow the system to calculate and display the DySIS map.32 The list price for the
latest version of DySIS (DySIS Touch colposcope) is £24,000 (personal communication). This is around twice
the cost of a standard colposcope. The 5-year maintenance plan is an additional £6500, and the viewer
licence is £650 in the first year and £500 per year in subsequent years. The DySIS includes a colposcope and
no additional equipment is needed. The cost of specula is £3.50 per examination.33
The DySIS is CE marked and is developed by DySIS Medical. The currently available version of DySIS is
DySIS version 3, but the company intends that it will be superseded by the DySIS Touch and DySIS Ultra
colposcopes in early 2017. Each updated version of the system has had modifications to both the
hardware and the software, but the DySISmap algorithm has remained unchanged.
ZedScan (Zilico)
ZedScan is an electrical impedance spectroscopy (EIS) device. It is designed to be used as an adjunct to
colposcopy to aid in the diagnosis, biopsy and treatment of high-grade CIN. It applies a small alternating
current at different frequencies to the cells lining the cervix and measures the resulting voltage. By using
EIS, one can measure the resistivity of cervical epithelial cells to distinguish between normal and abnormal
tissue. Electrical impedance is measured at 14 different frequencies, producing a spectrum that varies
depending on the structure and properties of the tissue. The degree of impedance is related to tissue
structure, which is classed as normal, precancerous or cancerous. A handset displays a diagram of the
measurement zone by coloured circles that indicate the location and results from each measurement point:34
l clear/white – no reading
l green – high-grade CIN is unlikely to be present
l amber – high-grade CIN is likely to be present
l red – the highest likelihood that high-grade CIN is present.
The results from each reading site are compared with reference spectra, derived from models of different
cervical tissues, to calculate the probability of high-grade neoplasia. The device is also designed to indicate
the location of high-grade CIN for biopsy. Further details on the ZedScan algorithm are reported in
Appendix 1.
The manufacturer estimates that each cervical scan using the ZedScan takes 2–3 minutes. The device can
also be used in a single-point mode to help to select sites for diagnostic biopsy after the initial 10–12
readings have been taken. The manufacturer states that it takes approximately 2 hours to train the new
users. ZedScan is CE marked and is developed by Zilico Ltd. ZedScan was previously known as APX100,
which was the name used in the previous assessment (DG4).31 The ZedScan costs £3000, including
computer software. The cost per case with the ZedScan is approximately £30 plus clinician time. There are
no routine maintenance costs.
The previous assessment (DG4)30 found evidence to suggest that DySIS with DySISmap had higher
sensitivity but lower specificity than colposcopy alone for detecting CIN 2+ disease, and it found limited
evidence for other adjunctive technologies [LuViva Advanced Cervical Scan (developed by Guided
Therapeutics, Norcross, GA, USA) and Niris Imaging System (developed by Imalux Corporation, Cleveland,
OH, USA)].
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Chapter 2 Definition of the decision problem
Women in England between the ages of 25 and 64 years are invited for regular cervical screening every3–5 years in order to detect abnormal cells in the cervix. Screening is conducted using liquid-based
cytology; women may also be tested for hrHPV.
Depending on the results of the cervical screening, people may be referred for a colposcopy examination.
Colposcopy is largely a subjective examination, and diagnosis will partly depend on the opinion and
expertise of the colposcopist. The DySIS digital video colposcope with DySISmap and the ZedScan device
have been developed to be used alongside colposcopy. The aim of these adjunctive technologies is to help
the colposcopist to find abnormal cells more accurately. The DySIS system provides a coloured map of
the cervix on a computer screen, on which different colours represent different risks of abnormal cells.
ZedScan uses an electrical current to distinguish between normal and abnormal cells, and shows coloured
circles on a diagram ranging from green (low risk of abnormal cells) to red (high risk of abnormal cells).
The DySIS was previously reviewed in the DG4 assessment.31 However, additional information on this
technology, the development of ZedScan since that review and recent changes in the NHSCSP mean
that the relative value of using these new tests is uncertain.
This report, undertaken for the NICE Diagnostics Assessment Programme, examines the clinical
effectiveness and cost-effectiveness of DySISmap and ZedScan used adjunctively alongside regular
colposcopy for women referred for colposcopy as part of the cervical cancer screening programme.
Decision problem in terms of participants, interventions, comparisons,
outcomes, study design and other key issues
The primary population of interest is women referred for colposcopy as part of the NHSCSP under either:
l the HPV triage screening algorithm (including test of cure)
l the HPV primary screening algorithm (including test of cure).
All women who have been referred to colposcopy on the basis of a positive cytology test or because of the
presence of hrHPV infection will be considered, bearing in mind that, outside the UK, the algorithms for
deciding who should be referred for colposcopy may differ from those listed above.
The tests of interest are the DySISmap system, which generates a coloured map representing the level of
acetowhitening of the cervix, and ZedScan, which uses EIS to detect abnormal cervical tissue. Both
technologies should be used alongside standard colposcopy; DySIS video colposcopy is used with
DySISmap and binocular colposcopy is used with ZedScan. The combination of tests is referred to as
adjunctive colposcopy.
The key comparator of interest is standard colposcopy alone, whether using a binocular or video colposcope.
When assessing diagnostic accuracy, the accepted reference standard is histopathological diagnosis of CIN
or cancer based on cells extracted from the cervix by punch biopsy or excision.
The key outcomes of interest were the diagnostic accuracy of adjunctive colposcopy (i.e. sensitivity,
specificity and related measures), its broader clinical effects, ease of implementation and cost-effectiveness.
Any prospective study reporting data on any of these outcomes was considered for inclusion in this review.
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Overall aims and objectives of the assessment
The aim of the project was to determine the clinical effectiveness and cost-effectiveness of adjunctive
colposcopy technologies (DySISmap and ZedScan) for assessing suspected cervical abnormalities in people
who are referred for colposcopy through the NHSCSP under either HPV triage (including test of cure)
or the HPV primary screening algorithm (including test of cure). To achieve this, the following objectives
were proposed:
1. To perform a systematic review and meta-analysis of the diagnostic accuracy of adjunctive colposcopy
technologies (DySISmap and ZedScan) in conjunction with standard colposcopy for the examination of
the uterine cervix of the people who are referred for colposcopy.
2. To perform a systematic review of the clinical impact and implementation of adjunctive colposcopy.
This would include an assessment of the associated mortality and morbidity, patient-centred outcomes,
adverse events, acceptability to clinicians and patients, and compliance.
3. To perform a systematic review of published cost-effectiveness studies of adjunctive colposcopy
technologies (DySISmap and ZedScan) for assessing suspected cervical abnormalities in people
who are referred for colposcopy.
4. To develop a decision model to estimate the cost-effectiveness of adjunctive colposcopy technologies
(DySISmap and ZedScan) for people who are referred for colposcopy through the NHSCSP under either
HPV triage (including test of cure) or the HPV primary screening algorithm (including test of cure).
This report is in two parts: clinical effectiveness (covering objectives 1 and 2) is discussed in Chapter 3 and
cost-effectiveness (covering objectives 3 and 4) is discussed in Chapters 4 and 5.
DEFINITION OF THE DECISION PROBLEM
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Chapter 3 Assessment of clinical effectiveness
This report contains reference to confidential information provided as part of the NICE appraisal process.This information has been removed from the report and the results, discussions and conclusions of the
report do not include the confidential information. These sections are clearly marked in the report.
The review of clinical effectiveness of adjunctive colposcopy was broken down into the following three
systematic reviews:
1. a review of the diagnostic accuracy (i.e. sensitivity/specificity and related statistics) of adjunctive
colposcopy technologies (DySISmap and ZedScan) in conjunction with standard colposcopy for
the examination of the uterine cervix of the people who are referred for colposcopy
2. a review of the broader clinical effects of adjunctive colposcopy technologies, including an assessment
of the associated mortality and morbidity, patient-centred outcomes and adverse events
3. a review of the implementation of adjunctive colposcopy technologies, including their acceptability to
patients and clinicians.
Throughout this report, diagnostic accuracy is taken to refer strictly to how well adjunctive colposcopy can
diagnose CIN by distinguishing between women with CIN and women without CIN, measured using
sensitivity, specificity and related statistics. Clinical effectiveness refers to the broader clinical impact that
adjunctive colposcopy may have beyond altering diagnostic accuracy, such as its impact on biopsy rates,
cancer rates and adverse events relating to the testing procedures. Implementation refers to practical issues
relating to using the tests, such as ease of interpretation, compliance and acceptability to practitioners
and patients.
The methodology of these reviews is now described.
Methodology of the clinical effectiveness review
The systematic reviews were conducted following the general principles recommended in the Centre for
Reviews and Dissemination (CRD) guidance35 and the PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) statement.36
Searches
The literature searches aimed to systematically identify research related to the clinical effectiveness of
DySISmap and ZedScan.
The search strategy was developed in MEDLINE (via Ovid) and was based on the search strategy used for
the previous Health Technology Assessment (HTA) review of adjunctive colposcopy by Wade et al.30 The
original strategy was checked and updated to reflect the changed scope of the current review. Updates
were also necessary to account for changes to the database search interface or provider, and when new
subject headings had been introduced or changed since the previous searches.
The strategy consisted of a set of terms for ‘cervix’, which were combined using the Boolean operator ‘AND’,
with a set of terms for the two adjunctive colposcopy technologies. A date limit was applied to the search
strategy to restrict retrieval to those studies published since 2000. No further limits relating to language or
study design were applied. The MEDLINE strategy was adapted for use in all other resources searched.
The searches were carried out during January 2017, with a further updated search undertaken on 10 April
2017. The following databases were searched: MEDLINE (including Epub Ahead of Print, In-Process &
Other Non-Indexed Citations, Ovid MEDLINE Daily and Ovid MEDLINE), Cochrane Central Register of
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Controlled Trials (CENTRAL), Cochrane Database of Systematic Reviews (CDSR), Cumulative Index to
Nursing and Allied Health Literature (CINAHL) Plus, Database of Abstracts of Reviews of Effects (DARE),
EMBASE, Health Management Information Consortium, HTA Database, NHS Economic Evaluation
Database (NHS EED), PubMed and Science Citation Index. In addition, ongoing studies and unpublished
and grey literature were identified using the following resources: ClinicalTrials.gov, Conference
Proceedings Citation Index – Science, European Union Clinical Trials Register, PROSPERO, World Health
Organization (WHO)’s International Clinical Trials Registry Platform portal, technology manufacturer websites
and NHS Digital data. Data were requested and obtained from the NHSCSP HPV screening pilot (sentinel
sites). Data submitted to NICE by manufacturers as part of this assessment were also used. Abstracts from
recent relevant conferences, including that of the British Society for Colposcopy and Cervical Pathology
(BSCCP) and the International Federation for Cervical Pathology and Colposcopy, were also consulted.
Relevant guidelines were identified through searches of the following resources: NICE, NHS Evidence,
National Guideline Clearinghouse, Scottish Intercollegiate Guidelines Network (SIGN), Public Health
England, BSCCP, the Royal College of Obstetricians and Gynaecologists and the Turning Research Into
Practice (TRIP) database. Search results were imported into EndNote X8 [Clarivate Analytics (formerly
Thomson Reuters), Philadelphia, PA, USA] and deduplicated against the results from the previous 2013
HTA review of adjunctive colposcopy.30 Full details of the search strategies can be found in Appendix 2.
Additional searches
Owing to the lack of evidence found in the review of clinical effectiveness, additional pragmatic PubMed
searches were conducted to identify recent systematic reviews reporting on the adverse effects of CIN
treatments on fertility, pregnancy and neonatal outcomes.
Selection criteria
Two researchers independently screened the titles and abstracts of all reports identified by the
bibliographic searches and full-text papers were subsequently obtained for assessment and screened by at
least two researchers. Disagreements were resolved by consensus.
Types of studies
Diagnostic accuracy
Prospective cohort studies in which the index test (DySISmap or ZedScan performed as an adjunct to
colposcopy) and reference standard test (histopathology) were performed independently in the same group
of participants, and which reported sufficient data to calculate diagnostic accuracy (sensitivity and specificity).
Effectiveness and implementation
Any experimental or observational study in which adjunctive DySIS and/or adjunctive ZedScan testing was
used was included. As no studies included a parallel control group that underwent standard colposcopy
alone, non-comparative studies that only recruited people who received adjunctive colposcopy were included.
The following types of report were excluded: editorials and opinions, case reports and reports focusing
only on technical aspects of the technologies (such as technical descriptions of the testing process or
specifications of machinery). When multiple reports for a particular study were identified, all studies were
included, with the most recent or the most complete report included as the main study selected for
inclusion. The authors of studies were contacted in cases in which it was unclear which was the most
appropriate paper for inclusion.
ASSESSMENT OF CLINICAL EFFECTIVENESS
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Participants
Eligible studies included participants who were referred to colposcopy through a cervical screening
programme as a result of a suspected abnormality identified via liquid-based cytology, Pap smear test or
positive hrHPV test. People referred for colposcopy as a follow-up after a previous CIN diagnosis (including
test of cure) were also eligible for inclusion.
Intervention
DySISmap (DySIS Medical) or ZedScan (Zilico Ltd) as an adjunct to binocular or video colposcopy used for
the diagnosis of CIN or cervical cancer was the intervention of interest. Studies on all versions of these
tools (including prototypes) were considered for inclusion.
Comparators
Standard colposcopy was the comparator of interest; however, data from standard colposcopy alone
did not need to be reported in order for a paper to be eligible. Both binocular and video colposcopy
were included.
Reference standard
The reference standard was histopathology based on excisional or treatment biopsies, used to classify
samples into three CIN grades or cervical cancer. Studies that did not perform biopsies to confirm the
absence of disease when colposcopic examination did not reveal any abnormalities were included.
Outcomes
The following outcomes were eligible for study inclusion:
l diagnostic accuracy – including sensitivity and specificity, or sufficient data to calculate these
l test failure rates (and reasons for test failure)
l number of biopsies (and type) performed
l diagnostic results of biopsies
l number of treatments and treatment type
l number of see-and-treat procedures
l duration of colposcopy examination
l number of people discharged from colposcopy.
Eligibility depended on the study reporting results from both the index test and the reference standard.
Only studies that reported results in terms of graded CIN, differentiating between mild dysplasia or
lower-grade dysplasia (≤ CIN 1, i.e. negative diagnostic result) and moderate dysplasia or worse (CIN 2
or higher-grade dysplasia, i.e. positive diagnostic result) were included.
The following clinical outcomes were also eligible for study inclusion:
l morbidity and mortality associated with treatment and biopsies conducted as part of the colposcopy
examination (including subsequent obstetric outcomes, such as miscarriage and infertility)
l morbidity and mortality associated with cervical cancer (in studies of DySIS and ZedScan)
l health-related quality of life (HRQoL)
l pain and anxiety associated with colposcopic examination, biopsies, treatment and waiting for results
l any other adverse event that may have an impact on resource use or quality of life (e.g. infection,
infertility, miscarriage).
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Outcomes related to the implementation of the interventions of interest and related practical issues were
eligible for study inclusion:
l acceptability of the adjunctive technologies (to clinicians and patients)
l patient satisfaction
l successful database and record management
l training requirements
l capacity to perform colposcopies
l uptake and compliance.
Data extraction
A standardised data extraction form was designed, piloted and finalised to extract data relating to study
design, patient characteristics, index, comparator and reference standard tests. Outcome data were
extracted by one reviewer and the extracted data were independently checked for accuracy by at least
one other reviewer. Duplicate data extraction was not performed. Disagreements were resolved through
discussion until consensus was achieved, or with the involvement of an additional reviewer if necessary.
For studies reporting diagnostic accuracy data, the numbers of true-positive, true-negative, false-positive and
false-negative results for each index test evaluated in each study were extracted to construct 2 × 2 tables.
Otherwise, we calculated the number of true-positive, true-negative, false-positive and false-negative results
from the summary estimates of sensitivity and specificity of the index test, if available. It should be noted that
these values assume that the reference standard test (biopsy or excision) is assumed to be 100% accurate
when extracting these data. This is not necessarily the case. In particular, cases of CIN 2 may be missed in
women who do not receive any biopsy after a negative colposcopy result, and punch biopsies may not be as
accurate as deeper excisions.37
When available, the number of patients in the diagnostic categories (normal, CIN 1, CIN 2, CIN 3 or cancer)
was also extracted. When only a subgroup of patients included in a study was eligible, we extracted,
analysed and presented data for this subgroup only. Manufacturers and corresponding authors were
contacted for all included studies to obtain additional data on diagnostic accuracy.
Diagnostic accuracy data were extracted using Microsoft Excel® software (Microsoft Corporation, Redmond,
WA, USA). Data on study characteristics and results informing the reviews of clinical effectiveness and
implementation were extracted using EPPI-Reviewer (Evidence for Policy and Practice Information and
Co-ordinating Centre, Social Science Research Unit, Institute of Education, University of London, London, UK).
Additional data from manufacturers and study authors
For all studies, additional data on diagnostic accuracy were requested. Requests were made to the device
manufacturers (DySIS Medical or Zilico) for studies in which they had direct involvement, or to the first
author of the primary publication for those manufacturers that were not involved in the study.
Diagnostic accuracy data for both colposcopy and adjunctive colposcopy (with either DySISmap or
ZedScan) were requested as a 5 × 5 table, with the results categorised as < CIN 1, CIN 1, CIN 2, CIN 3 and
cancer. Also requested were 2 × 2 tables of diagnostic accuracy in the following participant subgroups:
l participants with hrHPV infection (HPV 16 or 18)
l participants with low-risk HPV or no HPV infection
l participants referred to colposcopy with high-grade dyskaryosis or worse
l participants referred to colposcopy with low-grade dyskaryosis or lower
l participants with a previous history of CIN or cervical cancer (including test of cure).
ASSESSMENT OF CLINICAL EFFECTIVENESS
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Critical appraisal
Risk-of-bias assessments of all included studies included in the diagnostic accuracy review were performed
using a modified version of the Quality Assessment tool of Diagnostic Accuracy Studies (QUADAS)-2
checklist. The modified version of the QUADAS-2 tool used in Wade et al.,30 and further described
elsewhere,38 to assess the risk of bias in comparative diagnostic accuracy studies (i.e. a comparison of the
index test with both standard care and the gold standard) was used. Further questions were added to
inform judgements about study quality in the following domains: index/comparator test, flow and timing,
and other concerns. The quality of survey studies included in the implementation review was assessed
using guidance from Burns et al.39 and the Center for Evidence-Based Management.40 Further details are
presented in Appendix 3. Owing to the limited evidence, the quality of studies included in the clinical
effectiveness review was not formally assessed.
The risk-of-bias assessments were performed by one reviewer and independently checked by a second
reviewer. Disagreements were resolved through consensus and, if necessary, a third reviewer was consulted.
Methods of data synthesis
Statistical analyses
Estimates of sensitivity and specificity were calculated using diagnostic accuracy data from the constructed
2 × 2 tables or the 5 × 5 tables supplied by manufacturers, and presented both as forest plots and in the
receiver operating characteristic (ROC) space to examine the within- and between-study variability of
diagnostic test accuracy. PPVs and negative predictive values (NPVs) were also calculated, as were
diagnostic odds ratios (DORs).
When equivalent clinical thresholds were used to diagnose CIN/cancer in three or more studies, the
hierarchical bivariate model described by Reitsma et al.41 was fitted, providing summary estimates of
sensitivity and specificity, and associated 95% confidence intervals (CIs). The hierarchical summary ROC
model42 was also fitted to provide summary ROC curves. As the bivariate model does not account for the
fact that different diagnostic tests may be performed in the same study, a further logistic regression
analysis43 was performed to meta-analyse sensitivity and specificity, accounting for the fact that standard
colposcopy and adjunctive colposcopy were performed on the same participants.
Unless otherwise specified, all analyses used the threshold of CIN 2 or higher as the cut-off point for
defining a positive diagnostic test. Data on other thresholds were generally too limited for analyses to be
performed, and CIN 2 or higher is the standard threshold used in colposcopy in the NHS.
All statistical analyses assume that standard colposcopy and adjunctive colposcopy (DySISmap or ZedScan)
are performed independently. This is not the case in practice, as the tests are performed together. It is
therefore possible that knowledge of one test could bias interpretation of the other. For example, because
it is known that a ‘second look’ will happen after standard colposcopy, the results may not be the same as
if standard colposcopy had been performed without access to adjunctive tests. As this applies equally to all
studies, it was not possible to investigate this possible bias further.
If at least two studies reported on the same clinical or implementation outcome, the results were pooled if
reporting was consistent enough for feasible analysis; otherwise, the results were synthesised narratively.
Meta-analyses were performed using standard random-effects DerSimonian and Laird methods.
Analyses were conducted in the R software package (The R Foundation for Statistical Computing,
Vienna, Austria).
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Investigation of heterogeneity and subgroup analyses
A visual inspection of forest plots and ROC space was performed to check for between-study heterogeneity
of the diagnostic accuracy results. Sources of heterogeneity were investigated by performing meta-analyses of
diagnostic accuracy within defined study subgroups and, when there were sufficient studies, by incorporating
covariates in the logistic regression models of diagnostic accuracy. Heterogeneity was assessed using the
I2-statistic and through visual inspection of forest plots. Subgroup analyses and metaregression were used
when feasible. The following potential sources of heterogeneity were accounted for in the interpretation of
the results:
l presence of the hrHPV genotype, stratified by HPV 16, other hrHPV infection and no hrHPV infection
l cytology results, stratified by low-grade dyskaryosis or lower and high-grade dyskaryosis (moderate)
or worse
l people with a previous diagnosis or history of CIN or cervical cancer.
Sensitivity analyses
Study quality based on the QUADAS-2 domain results was planned as a basis for conducting sensitivity
analyses for diagnostic accuracy studies. This involved the exclusion of studies that were thought to be
rated as having a high risk of bias in each particular domain, using this to explore the robustness of results.
Results from the Cochrane risk-of-bias tool44 and study date (reflecting improvements in technology) were
also used as a basis for the analyses.
The impact of excluding studies that performed biopsies only in patients with suspected high-grade lesions
(rather than in all patients) was explored. Studies that were suspected of recruiting a substantial proportion
of their population from another study cohort were excluded from the analysis to examine the effect of
overlap on outcomes. Only the study with the most reliable or complete reporting was included in the
main analyses.
Narrative and qualitative syntheses
Qualitative synthesis was performed for outcomes pertaining to implementation. Summary information
relating to implementation outcomes, the conclusions of these studies, the consequences of colposcopy,
recommendations for practice and suggested needs for further research were tabulated and summarised.
Narrative summaries were also performed for outcomes for which meta-analyses or other statistical
analyses were not deemed feasible. This included tabulation or plotting of results as reported, which
were then narratively described and compared.
Summary of clinical effectiveness evidence
This chapter is structured as follows. The next section provides information on the quantity of research
available, including characteristics and the risk of bias of the included studies. This is then followed by the
results sections with the diagnostic accuracy, clinical effectiveness and implementation of DySISmap and
ZedScan as adjunctive technologies presented separately.
Number of studies included
The literature searches of bibliographic databases identified 3617 references. After the initial screening of
titles and abstracts, 179 of these were considered to be potentially relevant and were ordered for full-
paper screening. In total, 11 studies were included in the diagnostic review, three studies were included in
the clinical effectiveness review and five studies were included in the review of implementation (from a
total of 73 reports). Figure 2 shows a flow diagram outlining the screening process with reasons for the
exclusion of full-text papers.
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
16
Most studies were reported in several papers and abstracts, with considerable overlaps in data and
reporting. For each study and each review, we selected the paper with the most up-to-date and complete
data, which was then treated as the main paper. Consequently, some papers were included in more
than one review, and some papers (mostly conference abstracts with limited or outdated data) were not
included in any analysis. Table 2 presents an overview of these studies, their included studies and how
papers were included in each review.
Excluded studies
A list of full-text papers that were excluded, along with the reasons for their exclusion, is available on
request. These papers were excluded because they failed to meet one or more of the inclusion criteria in
terms of the type of study, participants, test, reference standard or outcomes reported. This includes four
studies of EIS for the diagnosis of CIN,114–117 which were identified by the bibliographic database searches
and were also submitted by Zilico. These studies were excluded because their focus was on demonstrating
the potential of spectroscopy for detecting CIN and calculating the impedance levels that could be used to
diagnose CIN 2+, rather than formal diagnostic accuracy assessment.
Studies included in the review
(from n = 73 papers)
• Diagnostics review, n = 11
• Clinical effectiveness review,
   n = 3
• Implementation review, n = 5
Full-text articles excluded
(n = 106)
• Ineligible intervention, n = 8
• Ineligible population, n = 6
• Ineligible outcome, n = 11
• Ineligible study design, n = 66
• Irretrievable conference abstracts, n = 15
Records identified from
searches and citations
(n = 3715)
Excluded on title/abstract
(n = 3612)
Full papers screened
(n = 179)
Additional records received
from manufacturers
(n = 76)
FIGURE 2 Flow diagram: study selection process.
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TABLE 2 Overview of included studies
Study (country)
Number of
full-text
papers
Number of
conference
abstracts
References included in the review
Diagnostic accuracy
(full/main paper)
Clinical
effectiveness
(full/main paper)
Implementation
(full/main paper) Linked conference abstracts
Budithi et al.45 (Wales) 1 4 Budithi et al.45 None Budithi et al.46 Budithi et al.;47 Budithi et al.;48 and
Budithi et al.49
Coronado and Fasero50 (Spain) 2 2 Coronado and Fasero50 None Coronado and
Fasero51
Coronado et al.;52 and Coronado et al.53
Founta et al.54 (England) 1 5 Founta et al.54 None None Founta et al.;55 Founta et al.;56 Founta
et al.;57 Founta et al.;58 and Founta et al.59
Louwers et al.60
(the Netherlands)
5 9 Louwers et al.;60 Louwers et al.;61
Zaal et al.;62 and personal
communication (A Zaal,
University Medical Centre
Utrecht, 2017)
Louwers et al.60 Louwers et al.63 Louwers et al.;64 Louwers;65 Louwers
et al.;66 Louwers et al.;67 Louwers
et al.;60 Louwers et al.;68 Zaal et al.;69
Louwers et al.;70 and Louwers et al.71
Lowe et al.72 (England) 0 3 None None Lowe (2016)72 Lowe et al.;72 and Brady et al.73
Natsis et al.74 (England) 0 5 None None None Natsis et al.;74 Founta et al.;75 Founta
et al.;76 Founta et al.;77 and Natsis et al.78
Roensbo et al.79 (Denmark) 1 0 Roensbo et al.79 None None None
Salter and Livingston80 (USA) 0 8 None None None Salter and Livingston;80 Salter et al.;81
Livingston and Salter;82 Papagiannakis
et al.;83 Livingston and Papagiannakis;84
Weinberg et al.;85 Cholkeri-Singh et al.;86
and DySIS Medical87
Soutter et al.88 (England) 1 5 Soutter et al.88 Soutter et al.88 None Soutter et al.;89 Balas et al.;90 Soutter
et al.;91 Soutter et al.;92 and Soutter et al.93
Tidy et al.94 (England) 4 5 Tidy et al.;94 Macdonald et al.;95
Palmer et al.;96 and Zilico et al.97
None Palmer et al.96 Tidy et al.;98 Macdonald et al.;99 Tidy
et al.;100 Tidy et al.;101 and Tidy et al.102
Tidy et al.103 (England and
Ireland)
2 7 Tidy et al.;103 and (confidential
information has been removed)104
Tidy et al.103 None Tidy et al.;105 Tidy et al.;106 Tidy
et al.;106 Tidy and Brown;107 Tidy
et al.;108 Tidy et al.;109 and Tidy et al.110
Tsetsa et al.111 (Greece) 0 3 None None None Tsetsa et al.;111 Tsetsa et al.;112 and
Tsetsa et al.113
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Results: assessment of diagnostic accuracy
Characteristics of the included studies
Table 3 presents the summary information of the characteristics of the included diagnostic accuracy
studies. There were 11 studies included in the diagnostic review, including nine studies of
DySIS45,50,54,60,74,79,80,88,111 and two studies of ZedScan.94,103 A total of six studies were unpublished, including
three full-text studies45,54,94 and three studies reported only as conference abstracts.74,80,111 Two studies were
ongoing but reported sufficient preliminary diagnostic accuracy data to be included in this review.74,80 The
manufacturers were involved in the design, conduct and/or interpretation of all ZedScan studies and all
DySIS studies apart from two.50,79
Risk of bias of the included studies
All included studies were conducted in hospital-based colposcopy clinics and used a prospective cohort
design. All patients underwent colposcopy with an adjunctive colposcopy technology, except for participants
included in two DySIS two-arm studies that included a separate parallel control group examined with
colposcopy alone.74,80 Six studies were conducted in more than one centre.45,60,74,80,88,103
Five studies were conducted in England.54,74,88,94,103 Of those studies, one also recruited patients in Greece88
and one involved a clinic in Ireland.94 Other studies were conducted in Wales,45 the Netherlands,60 Spain,50
Denmark,79 the USA80 and Greece.111
The sample size of studies (defined as the total number of participants analysed) ranged from 54 to 1237.
The mean/median age of participants ranged from 29 to 37 years for studies in which this was reported. The
prevalence of hrHPV was reported in only five studies and ranged from 37.5% to 100%,50,54,60,74,94 and three
studies included patients with hrHPV exclusively.54,74,94
The majority of patients included in the studies were referred to colposcopy because of an abnormal
cytology/smear test, although one study included only test-of-cure patients referred with a negative
cytology who tested positive for hrHPV either 6 months after LLETZ or in the context of the NHS catch-up
programme.54 All patients included in the study by Tidy et al.94 were referred to colposcopy through the
NHS HPV Primary Screening Pilot.20 A substudy of Tidy et al.94 included 613 patients with a known hrHPV
genotype already included in Tidy et al., as well as an additional 226 (26.9%) patients, of whom most
(187 patients; 82.7%) had a persistent HPV test and cytology-negative result.95 No other study included
patients referred from HPV primary screening.
When reported, the percentage of low- and high-grade referrals varied widely across the studies. One
study of test-of-cure patients reported a high prevalence of high-grade referral (84.7%),54 and another
study included only patients with low-grade cytology and hrHPV.74 In other studies, between 17.1% and
52.8% of participants were referred to colposcopy with high-grade dyskaryosis or worse and 9.5–82.9%
of participants were referred with low-grade dyskaryosis or less severe disease. The prevalence of
histology-confirmed CIN 2+ varied widely, from (confidential information has been removed)54 to 45.2%.
Further details of histology-confirmed CIN and cancer prevalence are reported in Appendix 4.
One study excluded women with a type 3 transformation zone.94 Five studies excluded pregnant
women45,60,88,94,103 and two studies also excluded women with active menstruation.94,103 Further details of
the patient selection criteria and exclusions are reported in Appendix 5.
All but one of the nine DySIS studies evaluated DySISmap as an adjunct to colposcopy; the single exception
reported only the diagnostic accuracy of DySISmap alone against colposcopy.79 Four studies evaluated the
accuracy of DySISmap both alone and as an adjunct to colposcopy.50,80,88,95 Both ZedScan studies used
ZedScan as an adjunct to colposcopy. All of the DySIS studies used a DySIS video colposcope and both
ZedScan studies used a binocular colposcope.
DOI: 10.3310/hta22540 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 54
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Peron et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
19
TABLE 3 Study and population characteristics
Study Country
Sample size
(number of
participants
analysed)
Number of
centres
involved
Recruitment
dates
Adjunctive
technology Age (years)
hrHPV
prevalence Reason for referral
LG
dyskaryosis
or less
HG
dyskaryosis
Budithi et al.
45
(unpublished)
Confidential
information has
been removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information
has been
removed
Confidential information
has been removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Coronado and Fasero
50
Spain 443 1 March 2012
to February
2014
DySIS (DySIS v3) Mean 36,
SD 10.9
37.5%
a
Abnormal Pap smear 82.9% 17.1%
Founta et al.
54
Confidential
information has
been removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information
has been
removed
Confidential information
has been removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Louwers et al.
60
The Netherlands 239 3 July 2008 to
September
2009
DySIS (DySIS v2.1) Mean 36.7,
median 35.3,
range 18.7–62.6
66.1%
b
Abnormal cytology: 91.6%;
follow-up of untreated CIN
1–2: 8.4%
66.1% 33.9%
Natsis et al.
74
(conference abstract,
ongoing study)
England
(Gateshead and
Taunton)
287 (and 948
in the parallel
standard
colposcopy
control group)
2 NR DySIS (DySIS v3) NR 100% LG cytology and hrHPV 100% 0
Roensbo et al.
79
Denmark 239 1 December
2013 to
January 2014
DySIS (version NR) Mean 34.3,
SD 11.5
NR Abnormal cytology NR NR
Salter and Livingston
80
(conference abstract,
ongoing study,
IMPROVE-COLPO)
USA 210 (and 1788
retrospective
standard
colposcopy
control group)
c
2 NR DySIS (DySIS v3) Median 31,
range 21–62
NR Abnormal cytology/Pap test
(99%), test of cure (1%)
74%
d
25%
e
Soutter et al.
88
England (London),
Greece
308 3 May 2004 to
July 2005
DySIS (FPC-03
prototype)
Median 37,
IQR 29–46
NR Abnormal Pap test: 96.1%;
symptoms: 3.9%
NR NR
Tidy et al.
103
(Phase I) England (Sheffield) 214 (Phase I) 2 April 2009 to
May 2011
ZedScan (third-
generation
prototype)
Median 31.3,
range 20–60
NR Abnormal cytology 47.2% 52.8%
Tidy et al.
103
(Phase II) England (Sheffield),
Ireland
196 (Phase II) 3 April 2009 to
May 2011
ZedScan (third-
generation
prototype)
Median 29.5,
range 20–64
NR Abnormal cytology 56.3% 43.7%
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Study Country
Sample size
(number of
participants
analysed)
Number of
centres
involved
Recruitment
dates
Adjunctive
technology Age (years)
hrHPV
prevalence Reason for referral
LG
dyskaryosis
or less
HG
dyskaryosis
Tidy et al.
94
Confidential
information has
been removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information
has been
removed
Confidential information
has been removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Macdonald et al.
95
(linked to Tidy et al.
94
)
f
England (Sheffield) 839 1 January 2014
to December
2015
ZedScan
(commercial
version)
Mean 32.9,
range 20.3–66.1
100% Known hrHPV genotype
(100%), abnormal cytology
(73.1%), persistent hrHPV/
negative cytology (22.3%),
follow-up (4.2%), clinical
indication (0.6%)
49.0% 24.1%
Tsetsa et al.
111
(conference abstract,
unpublished completed
study)
Greece 57 (54) 1 NR DySIS (version
unknown)
NR NR Abnormal cytology NR NR
HG, high grade; IMPROVE-COLPO, IMproved PRactice Outcomes and Value Excellence in Colposcopy; IQR, interquartile range; LG, low grade; NR, not reported; SD, standard deviation.
a Low-risk HPV: 31.8%; not determined: 30.7%.
b Low-risk HPV: 30.5%; not determined: 3.3%.
c Details and results of retrospective arm reported only in a linked separate study of low-grade squamous intraepithelial lesions and atypical squamous cells of undetermined
significance/hrHPV.87.
d Low-grade squamous intraepithelial lesion, atypical squamous cells of undetermined significance/HPV, persistent HPV and HPV 16/18.
e High-grade squamous intraepithelial lesion, atypical glandular cells and atypical squamous cells – cannot exclude high-grade squamous intraepithelial lesion.
f (Confidential information has been removed.)
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Six studies evaluated a commercial version of DySISmap, of which five used DySIS v345,50,54,74,80 and one
used DySIS v2.1.60 One study evaluated a precommercial prototype version of DySISmap (FPC-03),88 and
two studies did not report which version was used.79,111 Most studies of DySIS reported using the upper
end of the acetowhitening scale of the colour-coded DySIS map to identify predicted high-grade lesions
(red/yellow/white).50,54,60,80,88 One study also included areas with weaker acetowhitening (coloured as dark
blue and green, in addition to the standard red, yellow and white) as potential high-grade lesions,79 and
three studies did not report which part of the colour-coded scale was used to predict CIN 2+.45,74,111
Following a request for information from NICE, the manufacturer stated that the DySISmap algorithm had
not changed after the FPC-03 version, and that DySIS v3 had undergone improvements in the following
areas compared with earlier versions: increased image resolution, ergonomic set-up to allow for flexible
positioning, improved working distance to allow for easier biopsy and treatment, improved software
usability and availability of single-use specula.
One ZedScan study was a two-phase study evaluating a precommercial version of the tool (third-
generation prototype);103 in Phase I, 12 colposcopically guided ZedScan measurements were taken from
the cervix and analysed from a group of 214 people on a per-point basis to determine the cut-off points
for the detection of CIN 2+. The cut-off points were then used in the second phase to evaluate the
diagnostic accuracy of adjunctive ZedScan with colposcopy alone and to conduct further analyses to test
and determine further cut-off points.
The more recent ZedScan study, by Tidy et al.,94 evaluated a commercial version of ZedScan. Clarification
from the manufacturer indicated that (confidential information has been removed).
All 11 included studies were assessed for risk of bias and applicability using a modified version of the
QUADAS-2 tool. Table 4 presents a summary of the results for the assessed risk of bias across all studies in
the five main risk-of-bias domains: patient selection, index test, comparator test, reference standard and
flow and timing. Appendix 3 presents the complete results of the quality assessment with the justifications
for decisions.
Dynamic Spectral Imaging System studies
Only one study was rated as being at a low risk of bias overall,60 and the remaining eight studies were
rated as being at a high risk of bias. Significant levels of concern regarding applicability were raised for five
of the nine DySIS studies.50,60,79,88,111 The main source of bias in DySIS studies was related to verification
bias. Only three studies conducted biopsies in all patients analysed.60,79,88 (Confidential information has
been removed.) The remaining two DySIS studies were conference abstracts and did not report sufficient
data to assess the risk of verification bias.80,111
The DySIS technology used in the earlier study by Soutter et al.88 was a precommercial model (FPC-03). The
study reported technical issues relating to the software, speculum and a batch of faulty disposable nozzles,
leading to the exclusion of a large proportion of eligible participants (31%) from the analyses. Therefore,
the applicability of the results of this study may be limited.
ZedScan studies
Both studies of ZedScan were rated as having a high risk of bias overall,94,103 and significant levels of
concern regarding applicability were raised for both studies.
Neither study conducted biopsies in participants with a normal cervical transformation zone to confirm
the absence of CIN, and so both were rated as having a high risk of verification bias. Both studies were
rated as having a high risk of study selection bias, notably because of the exclusion of patients with
transformation zone type 3, in whom colposcopy may be harder to perform.94
(Confidential information has been removed.) However, one study94 did collect data on whether or not
biopsy would have been taken with colposcopy alone regardless of the ZedScan result, and the diagnostic
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accuracy results for standard colposcopy were reported in a linked substudy.95 Therefore, the ZedScan
results were rated as having a high risk of reporting bias.
(Confidential information has been removed) and most patients included in the study by Tidy et al.103 were
examined in a single centre (Sheffield), and the extent to which the results of this study are applicable to
other settings is uncertain.
Risk of bias associated with the reference standard
In all included studies, nearly all histology was performed based on samples collected from punch biopsies
rather than from deeper treatment biopsies. Although it is obviously unethical to perform treatment
biopsies when this is not clinically indicated, samples from punch biopsies may be less accurate.37
Therefore, all studies were rated as having a high risk of bias associated with the reference standard.
Additional data provided by the manufacturers
(Confidential information has been removed.)
In all analyses, these additional data were used in preference over published results. If additional data were
not provided, the data extracted from publications were used.
We intended to further analyse the 5 × 5 diagnostic data provided. (Confidential information has been
removed.) It was decided that a more detailed analysis of this additional analysis was not appropriate, as it
may be biased by the availability and structure of the data provided.
Statistical synthesis of diagnostic accuracy
The initial meta-analyses of diagnostic accuracy were based on data presented in the publications listed in
Table 2. Two studies were excluded from these analyses because they were conducted in very specific
subpopulations: (confidential information has been removed). One other study74 was excluded because it
was conducted only in women with both a hrHPV infection and low-grade cytology results. The statistical
analyses therefore included eight studies, six of DySIS and two of ZedScan.
In performing the analyses, we made the following assumptions: we assumed that the DySIS video
colposcope (used in DySIS studies) was equivalent, in diagnostic accuracy, to a binocular colposcope (used
in ZedScan studies). DySIS was used in one study,80 but it was not clear whether this was DySISmap alone
(without colposcopy) or DySISmap adjunctive to colposcopy. We have assumed the latter, as it is assumed
that the colposcopists must have seen the video colposcopic image as part of the assessment. One study79
reported whether the colposcopists agreed or disagreed with the DySISmap result, rather than the result
of adjunctive colposcopy. We have assumed that when either the colposcopists or the DySISmap result
found CIN 2 (or greater) to be present, the test was taken to be positive for CIN 2. This differs from the
interpretation in the original paper.
The threshold used for colposcopy in all publications was CIN 2 or greater, and that has been used in
these analyses. Only one study50 reported diagnostic accuracy at CIN 1 or greater.
Only two ZedScan studies were available for analysis – one was of the current ZedScan device94 and the
other was of a ZedScan prototype.103 We have therefore not performed meta-analyses of these studies;
instead, we report the diagnostic accuracy results on ROC plots without meta-analytic summary results.
Dynamic Spectral Imaging System forest plots of diagnostic accuracy
In this section we present diagnostic accuracy results from the studies of DySIS in the form of forest plots.
Figure 3 shows estimates of sensitivity and Figure 4 shows estimates of specificity. Colposcopy alone has
moderate sensitivity (58.4%, 95% CI 50.3% to 66.5%) but high specificity (confidential information has
been removed); colposcopy therefore misses many women who do have CIN of grade 2 or greater,
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but produces relatively few false-positive test results. DySISmap alone has similar performance (confidential
information has been removed). For adjunctive DySIS use, the sensitivity rises to (confidential information
has been removed), so using DySISmap in addition to colposcopy correctly identifies more CIN 2 cases,
but with a higher false-positive rate, which may mean performing biopsies in a larger proportion of
women who do not have CIN 2 (or greater).
Figure 17 in Appendix 6 presents the DORs for each study. The diagnostic ratio is a combination of
sensitivity and specificity (formally, log-odds of sensitivity minus log-odds of specificity), which increases
as the overall diagnostic accuracy of a test increases. The results show almost no difference between
colposcopy and adjunctive DySIS (confidential information has been removed), suggesting that DySISmap
does not improve the diagnostic accuracy of colposcopy when defined in terms of DORs.
Figures 18 and 19 (Appendix 6) show the studies’ PPVs and the NPVs, respectively. These are harder to
interpret, as PPVs and NPVs vary with prevalence, which is different across the studies. The PPV for adjunctive
colposcopy is lower than that for colposcopy alone (confidential information has been removed), so fewer
than half of all women who receive a DySIS-guided biopsy will have high-grade CIN. The summary PPV, and
the estimated PPV in most studies, is lower than the 65% level recommended by UK guidance.15 The NPV is
slightly higher with adjunctive DySIS (confidential information has been removed), so fewer high-grade CIN
cases will be missed.
Heterogeneity was substantial in almost all meta-analyses. The I2 values are summarised in Table 5.
All but one analysis had an I2 value above 60%.
Bivariate and regression models of diagnostic accuracy
The analyses presented so far have not accounted for the correlation between sensitivity and specificity.
A formal bivariate meta-analysis of diagnostic accuracy should be used to account for this correlation.41
The analyses have also not accounted for the fact that colposcopy and DySIS are performed in the same
study on the same participants. Full individual-level data would be needed to properly account for the
within-person correlation between test results. These were not available, but extensions to the bivariate
model can account for the fact that the tests were compared within the same study.43
Figure 5 shows the sensitivity and specificity for all included studies. It can be seen that, for all studies,
adjunctive DySIS has higher sensitivity but lower specificity than using colposcopy alone. Using DySISmap
alone generally falls somewhere between the two.
FIGURE 4 Forest plot of the diagnostic specificity of DySIS. (Confidential information has been removed.)
TABLE 5 Heterogeneity I2 values in the diagnostic meta-analyses
Variable
Technology
Colposcopy only DySISmap only DySISmap and colposcopy
Sensitivity 62.7 94.4 0
Specificity 90.2 91.5 94.5
DOR 78.6 92.7 74.4
PPV 64.9 79.4 88.4
NPV 94.8 97.7 89.8
FIGURE 3 Forest plot of the diagnostic sensitivity of DySIS. (Confidential information has been removed.)
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Table 6 shows the results of the bivariate meta-analyses; Appendix 6, Figure 20, shows the results in the
ROC space, including the 95% confidence regions (the ellipses) and the summary ROC curves. The results
are consistent with those seen in the forest plots of diagnostic accuracy (see Figures 3 and 4), and show
that using adjunctive DySIS increases sensitivity when compared with colposcopy alone, but at the cost of
reduced specificity. As only three studies reported the use of DySISmap alone, no bivariate model was
fitted for that test.
The bivariate model analyses colposcopy and adjunctive DySIS separately, and does not account for the
fact that these are measured in the same studies. To correct for this, we fitted logistic regression models,
including study-level parameters, to account for a possible correlation between test results within studies
(see Statistical synthesis of diagnostic accuracy for details).
The summary results for this regression model are shown in Table 7. The results are similar to the standard
bivariate model in Table 6. This model also permits a direct comparison of colposcopy and adjunctive
DySIS. This found evidence of a difference in specificity between the tests [difference in log-odds of
specificity 1.33, standard error (SE) 0.33; p < 0.0001] but no evidence of a difference in diagnostic
accuracy (difference in log-DORs 0.04, SE 0.20; p = 0.84). This suggests that using DySIS changes the test
threshold for the diagnosis of CIN 2 such that more women go on to receive biopsy, but that it is not
improving diagnostic accuracy (in terms of DOR) when compared with colposcopy alone.
To confirm this, we also fitted a regression model that constrains adjunctive DySIS and colposcopy to have
the same diagnostic accuracy (but which permits differences in specificity). The Bayesian information
criterion (BIC) is used when comparing regression models; generally, a lower BIC suggests a better-fitting
and more parsimonious model. This new model had a BIC of 198.3, which is lower than the previous
model, which had a BIC of 201.5. This confirms that assuming that DySIS and colposcopy have the same
diagnostic accuracy is reasonable.
ZedScan
Two studies of ZedScan are included in this analysis. The most recent study94 reported data for adjunctive
ZedScan only, using the current ZedScan device, with no data on the performance of colposcopy alone;
the other one103 was a study of a ZedScan prototype, which assessed the diagnostic accuracy at six
TABLE 6 Results of the bivariate diagnostic meta-analyses
Technology Sensitivity, % (95% CI) Specificity, % (95% CI)
Colposcopy alone 57.74 (49.7 to 63.4) 87.34 (79.7 to 92.4)
DySISmap and colposcopy 80.97 (76.0 to 85.1) 70.90 (60.8 to 79.3)
TABLE 7 Results from the logistic regression model of diagnostic accuracy
Technology Sensitivity, % (95% CI) Specificity, % (95% CI)
Colposcopy alone 57.91 (47.2 to 67.9) 87.41 (81.7 to 91.5)
DySISmap and colposcopy 81.25 (72.2 to 87.9) 70.40 (59.4 to 79.5)
FIGURE 5 Sensitivity and specificity for all DySIS studies in the ROC space. (Confidential information has been
removed.)
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different cut-off points of the ZedScan algorithm. This was compared with two colposcopy cut-off points:
(1) ‘colposcopic impression’, whereby the colposcopy was considered to have a positive finding if it judged
that high-grade CIN was present, and (2) ‘disease present’, whereby colposcopy was considered to have
given a positive result if at least one measurement point was suggested for biopsy. The six ZedScan cut-off
points were selected such that one had the same sensitivity as colposcopy (colposcopic impression or
disease present), one had the same specificity as colposcopy and the third was a trade-off between
sensitivity and specificity. Because only two studies were available, and there were the differences between
the precommercial device and ZedScan, no meta-analysis was performed. Instead, the sensitivity and
specificity data from the studies are shown in the ROC space in Figure 6. The black lines show summary
ROC curves for adjunctive ZedScan and for colposcopy. The sensitivity and specificity results from the two
studies are also presented in Table 8.
These results suggest that adjunctive ZedScan may have better diagnostic accuracy than colposcopy alone.
In the prototype study, ZedScan had greater sensitivity for the same specificity as colposcopy or greater
specificity for the same sensitivity. Greater diagnostic accuracy for ZedScan is also suggested by the fact
that the summary ROC curve for ZedScan had greater sensitivity than that for colposcopy. However, the
small size of the study, and the wide CIs, mean that it is uncertain if difference is clinically meaningful.
Fitting a logistic regression model to the data from the prototype study found that the improvement in
diagnostic accuracy was not quite statistically significant (difference in log-diagnostic accuracy 0.488,
SE 0.28; p = 0.078).
(Confidential information has been removed.)
TABLE 8 Diagnostic accuracy data from the ZedScan studies
Study
Technology
Colposcopy
cut-off point
Colposcopy alone
ZedScan
cut-off point
ZedScan and colposcopy
Sensitivity, %
(95% CI)
Specificity, %
(95% CI)
Sensitivity, %
(95% CI)
Specificity, %
(95% CI)
Tidy et al.94 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Tidy et al.103 Colposcopic
impression
73.6
(64.3 to 82.8)
83.5
(76.5 to 90.5)
1.321 73.6
(64.3 to 82.8)
90.8
(85.4 to 96.2)
1.083 78.2
(69.5 to 86.8)
83.5
(76.5 to 90.5)
1.568 62.1
(51.9 to 72.3)
95.4
(91.5 to 99.3)
Disease present 88.5
(81.8 to 95.2)
38.5
(29.4 to 47.7)
0.768 88.5
(81.8 to 95.2)
65.2
(56.2 to 74.1)
0.390 96.6
(92.7 to 100)
38.5
(29.4 to 47.7)
0.568 92.0
(86.2 to 97.7)
51.4
(42.0 to 60.8)
FIGURE 6 Receiver operating characteristic presentation of results from the ZedScan studies. (Confidential
information has been removed.)
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Test positive rates
Figure 21 in Appendix 6 shows the test positive rate (the proportion of women in whom colposcopy or
adjunctive colposcopy suggests the presence of high-grade CIN) for each test in each study of DySIS. In
every study, adjunctive use of DySIS increased the positive rate compared with colposcopy alone, often
substantially. In the Louwers et al.60 study, for example, the use of DySIS increased the positive rate from
33.1% to 55.5%. Hence, the use of DySIS will substantially increase the number of women who receive
biopsies after colposcopy. The results for ZedScan are shown in Figure 22 in Appendix 6. These suggest
that the positive rate for ZedScan is similar to that for colposcopy alone, regardless of the cut-off point
used. The disease-present cut-off point, unsurprisingly, produces higher positive rates than the colposcopic
impression cut-off point.
Subgroup analyses
Some of the studies provided diagnostic accuracy data for key identified subgroups, namely:
l high-grade and low-grade cytology referral
l high-risk HPV (including HPV 16) and low-risk HPV
l the ‘test-of-cure’ population.
We include here data on these subgroups provided by the manufacturers or study authors, data from
primary publications and data from secondary reports of primary studies when those papers included
subgroup data not reported in the original study publication. Appendix 6, Table 44, provides an overview
of the subgroups reported in each study.
Figure 7 shows sensitivity and specificity forest plots by subgroup for colposcopy alone, Figure 8 shows
the same analyses for adjunctive DySIS and Figure 9 shows the same analyses for adjunctive ZedScan.
Summary meta-analyses are not presented because of the small number of studies in each subgroup.
Colposcopy appears to be less sensitive than average at detecting high-grade CIN in women with low-grade
referrals. This may partly be a consequence of interpretation bias (the colposcopic results are analysed with
more caution if a woman is known to have a high-grade cytology referral) or it may be because lesions
are harder to detect in women with a low-grade cytology referral. The same applies to women who have
low-grade referrals combined with hrHPV. This difference is not observed when using DySIS or ZedScan; in
both cases, the sensitivity and the specificity are similar for both low- and high-grade referrals. This suggests
that adjunctive colposcopy may improve the detection of high-grade CIN in women with a low-grade referral
(i.e. mild dyskaryosis).
There is no convincing evidence that diagnostic accuracy differs between women who are infected with
hrHPV and those who are not infected with hrHPV; however, data are limited. For women infected with
hrHPV, both the sensitivity and the specificity are higher than average (see Figures 3 and 4) when using
adjunctive DySIS, suggesting that high-grade CIN is easier to detect in women infected with hrHPV.
The sensitivity appears to be higher among women with hrHPV when using adjunctive DySIS than with
colposcopy alone. This suggests that adjunctive DySIS may improve the detection of high-grade CIN in
women infected with hrHPV.
FIGURE 7 Diagnostic accuracy of colposcopy by subgroup. (Confidential information has been removed.)
FIGURE 8 Diagnostic accuracy of adjunctive DySIS by subgroup. (Confidential information has been removed.)
FIGURE 9 Diagnostic accuracy of adjunctive ZedScan by subgroup. (Confidential information has been removed.)
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The results for ZedScan are more limited, with no apparent evidence of differences between subgroups.
We note that all of these conclusions are based on small subgroups, generally of only one to three studies,
and so the results should be considered as speculative only.
Meta-analyses were generally not possible within subgroups, as only one or two studies reported data
for each subgroup. For high- and low-grade referrals for DySIS, a logistic regression model (as shown
in Table 7) was fitted in each subgroup to meta-analyse diagnostic accuracy within these subgroups, as
there were two DySIS studies for each subgroup. The results of this analysis are shown in Table 9. These
results suggest that, for colposcopy alone, the sensitivity to detect CIN 2 among low-grade referrals is
much lower than that for high-grade referrals, for a similar specificity. This difference was not quite
statistically significant (p = 0.072), owing to the limited data available. There was no evidence of any
difference between types of referral when using adjunctive DySIS, suggesting that adjunctive DySIS may be
preferable to colposcopy for women with a low-grade referral. Similar regression models did not find any
evidence of differences between HPV subgroups.
Sensitivity analyses
The study by Roensbo et al.79 differed from the other included studies, as it did not assess DySIS as an adjunct
to colposcopy directly, but only whether a colposcopist agreed or disagreed with the DySISmap result. As
noted in Characteristics of the included studies, the study also used the DySISmap more conservatively than
other DySIS studies, by interpreting areas with weaker acetowhitening on the coloured map (including dark
blue and green) as being ‘suspicious for high-grade disease’.
We performed a sensitivity analysis of the logistic regression model in Table 7 for sensitivity and specificity,
excluding this study. The results are shown in Table 10. There is little change when excluding Roensbo
et al.,79 with all estimates being similar to when the study was included.
A particular concern identified during the quality assessment was that different studies had different
practices, when neither colposcopy nor adjunctive DySIS or ZedScan identified any abnormal areas
requiring biopsy. In four studies45,50,74,80 no biopsy was performed in those women, in two studies60,88
a single biopsy was typically performed at a randomly location and in one79 study multiple biopsies were
performed. In the case of one study, 80 insufficient information was provided. Table 11 shows the results of
the meta-analyses categorised by the type of biopsy performed in the DySIS studies. These results suggest
that specificity and sensitivity tend to decline as more biopsies are performed on colposcopy-negative
women. This was observed for colposcopy alone and adjunctive DySIS. Despite these differences, the
TABLE 9 Diagnostic accuracy in accordance with referral grade
Technology Referral grade Sensitivity, % (95% CI) Specificity, % (95% CI)
Colposcopy alone LG 38.27 (18.9 to 62.4) 75.57 (53.4 to 89.3)
HG 64.06 (42.2 to 81.3) 71.49 (50.5 to 86.0)
DySISmap and colposcopy LG 80.53 (57.9 to 92.5) 53.36 (28.6 to 76.3)
HG 83.16 (58.4 to 94.6) 57.00 (30.7 to 79.8)
HG, high grade; LG, low grade.
TABLE 10 Sensitivity bivariate analysis excluding Roensbo et al.79
Technology Sensitivity, % (95% CI) Specificity, % (95% CI)
Colposcopy alone 56.4 (47.5 to 64.9) 90.2 (86.3 to 93.1)
DySIS and colposcopy 82.9 (75.0 to 88.7) 72.9 (63.3 to 80.7)
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comparison between colposcopy and adjunctive DySIS is unchanged; using DySISmap as an adjunct to
colposcopy increases sensitivity but decreases specificity in all cases.
Comparison of Dynamic Spectral Imaging System and ZedScan
All analyses so far have considered DySIS versus colposcopy and ZedScan versus colposcopy. Here, we
briefly compare all three technologies.
As no studies in the review included both DySIS and ZedScan, a direct comparison is not possible. Instead,
we consider an indirect comparison of the technologies. This is less reliable than a direct comparison, as
there are differences in the study populations and conduct that may alter diagnostic accuracy over and
above the differences in the diagnostic technology used.
Table 12 presents what we consider to be the best estimates of diagnostic accuracy. For DySIS, these are
sourced from the logistic regression model comparing adjunctive DySIS with colposcopy (see Table 7).
(Confidential information has been removed.) When comparing ZedScan with colposcopy, the situation is
more complex, as the most recent study did not report colposcopy diagnostic data. If we are willing to
assume that binocular and video colposcopes have the same diagnostic performance, then the best
evidence is that found from the DySIS studies. Only the ZedScan prototype study103 has reported diagnostic
accuracy data for binocular colposcopy, so an alternative estimate is the ‘colposcopic impression’ cut-off
point from that study, as that cut-off point is closest to that used to diagnose high-grade CIN.
These results show that both adjunctive DySIS and adjunctive ZedScan substantially increase sensitivity,
but also have substantially reduced specificity when compared with colposcopy. It would appear that
adjunctive ZedScan more strongly favours high sensitivity, with a corresponding loss of specificity, when
compared with adjunctive DySIS, but this is an indirect comparison.
TABLE 11 Results of the diagnostic meta-analyses in accordance with the number of additional biopsies performed
Additional biopsies
Technology
Colposcopy alone Adjunctive colposcopy
Sensitivity, %
(95% CI)
Specificity, %
(95% CI)
Sensitivity, %
(95% CI)
Specificity, %
(95% CI)
No additional biopsy
(four studies)45,50,74,80
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
One additional biopsy
(two studies)60,88
50.27 (43.0 to 57.5) 86.22 (79.1 to 93.3) 78.7 (72.6 to 85.6) 70.02 (57.9 to 82.2)
Multiple additional biopsies
(one study)79
67.65 (56.5 to 78.8) 67.25 (60.2 to 74.3) 75.00 (64.7 to 85.3) 57.31 (49.9 to 64.7)
TABLE 12 Best-evidence estimates of diagnostic accuracy
Technology Sensitivity, % (95% CI) Specificity, % (95% CI) Source
DySIS and colposcopy 81.25 (72.2 to 87.9) 70.40 (59.4 to 79.5) Regression model (see Table 7)
ZedScan and
colposcopy
Confidential
information has been
removed
Confidential
information has been
removed
Tidy et al.94
Colposcopy (DySIS
video colposcope)
57.91 (47.2 to 67.9) 87.41 (81.7 to 91.5) Regression model (see Table 7)
Colposcopy (binocular
colposcope)
57.91 (47.2 to 67.9) or
73.56 (64.3 to 82.8)
87.41 (81.7 to 91.5) or
83.49 (76.5 to 90.5)
Regression model (see Table 7) or Tidy et al.
(2013) ZedScan prototype (colposcopic
impression cut-off point)
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We also performed a further logistic regression model to indirectly compare all three diagnostic tests.
This model included all diagnostic data from all DySIS and ZedScan studies, and accounted for the fact
that tests were conducted in the same studies and for the differing cut-off points used in the ZedScan
prototype study. Compared with colposcopy alone, DORs were not higher with adjunctive DySIS
(difference in log-DOR 0.06; p = 0.74), but were increased by adjunctive ZedScan (difference in log-DOR
0.84; p = 0.003). Hence, ZedScan had a greater DOR than DySIS (difference in log-DOR 0.59; p = 0.003),
suggesting that ZedScan could have better diagnostic accuracy than DySIS, but the exact benefit would
depend on the choice of cut-off point and the corresponding sensitivity and specificity values.
Narrative synthesis of further diagnostic accuracy results
Six studies reported diagnostic accuracy data that could not be included in the statistical synthesis: five DySIS
studies54,62,74,83,111 and one ZedScan study.95 Three of these studies were linked to studies also included in
the meta-analyses62,83,95 and three studies could be reported only in the narrative synthesis.54,74,111 Tables 45
and 46 in Appendix 7 report the results of the studies of DySIS and ZedScan, respectively.
Dynamic Spectral Imaging System
Overall, the results of the five DySIS studies included in this section confirm the results of the meta-analysis.
Adjunctive DySIS improves sensitivity for detecting CIN 2+ compared with colposcopy alone, although this
is associated with a reduction in specificity. (Confidential information has been removed.)
Louwers et al.61 was a secondary analysis of Louwers et al.,60 which aimed to reanalyse the performance
of dynamic spectral imaging (DSI) and conventional colposcopy to determine the difference between
low-grade cytology [borderline or mild dyskaryosis (BMD)] referrals and high-grade cytology referrals.
The study also aimed to reanalyse the performance of DSI and conventional colposcopy by retrospectively
assigning them to two referral strategies based on their initial cytology and hrHPV test results: (1) hrHPV
testing as the primary screening test and cytology as triage (including patients with a positive hrHPV test
and BMD or high-grade cytology), or (2) reflex hrHPV testing in patients with BMD cytology (including
patients with BMD cytology and a hrHPV positive test or high-grade cytology, irrespective of the hrHPV
test result). Compared with standard colposcopy, the sensitivity of adjunctive DySIS was higher and the
specificity was lower in both referral strategies. Diagnostic accuracy estimates were similar between HPV
primary and cytology primary referral strategies for adjunctive DySIS (sensitivity 81% vs. 80%, respectively;
specificity 64% vs. 61%, respectively) and for colposcopy alone (sensitivity 53% vs. 54%, respectively;
specificity 82% vs. 78%, respectively).
Natsis et al.74 estimated the accuracy of adjunctive DySIS in a population of 287 hrHPV-positive patients
with low-grade cytology. Initial colposcopy impression and potential biopsy sites were recorded before and
after the appearance of the DySISmap. Colposcopy alone had low sensitivity (27%) but high specificity
(91%) for detecting CIN 2+. Incorporation of DySISmap improved sensitivity (82%) but reduced
specificity (36%).
Salter and Livingston80 reported some preliminary data from two colposcopy clinics as part of a large
cohort of US community-based colposcopy clinics using adjunctive DySIS. Consistent with other studies,
the addition of DySISmap increased sensitivity compared with colposcopy alone (83.9% with adjunctive
DySIS compared with 61.3% for colposcopy alone), but was associated with a reduction in specificity
(75.4% vs. 91.1%, respectively).
Tsetsa et al.111 carried out a single-centre prospective diagnostic cohort study that assessed the performance
of adjunctive DySIS in three different concentrations of acetic acid solution (3%, 4% and 5%). The study was
reported only in conference abstracts and enrolled 57 patients with abnormal cytology, of whom 54 were
analysed. Each patient was examined with DySIS colposcope and DySISmap in three successive examinations.
Biopsies were collected from sites corresponding to the most atypical indications of the coloured map
and sent for histology. The diagnostic performance of adjunctive DySIS was higher in examinations that
used 3% acetic acid (sensitivity 86%, specificity 81%) than in those using 4% acetic acid (sensitivity 79%,
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specificity 77%) and 5% acetic acid (sensitivity 82%, specificity 77%); however, the study was small and it is
not clear if these differences were statistically significant. The authors noted that morphological characteristics,
such as mosaic pattern and atypical vessels, were better highlighted when 5% acetic acid was used.
Cervical cancer (> cervical intraepithelial neoplasia grade 3)
Six studies reported on the prevalence of cervical cancer [> CIN grade 3 (> CIN 3)]. (Confidential
information has been removed.)
All of these were studies evaluating DySIS. Of those, three identified at least one histology-confirmed
patient (a total of 15 patients) with the disease and reported sufficient data to evaluate the number of
additional cases identified with DySISmap as an adjunct to colposcopy. (Confidential information has been
removed.) Only one of these studies indicated that the addition of the DySISmap to colposcopy helped to
identify additional cancer cases (two additional cases).84 In Appendix 7, Table 47 summarises the ability of
colposcopy and adjunctive DySIS to identify the cancer cases. There is insufficient evidence to suggest that
adjunctive DySIS improves the detection of cancer cases.
ZedScan
(Confidential information has been removed.)
Macdonald et al.95 evaluated the diagnostic accuracy of ZedScan in patients infected with known hrHPV
and compared its performance between those with HPV 16 and those with other hrHPV genotypes.
The study included 839 participants, of which 607 (72%) had abnormal cytology and were included in
Tidy et al.94 An additional 226 patients were included, of which most (82%) had a persistent HPV test and
cytology-negative result. The sensitivity of adjunctive ZedScan was high (100%) regardless of the hrHPV
genotype. The sensitivity of colposcopy alone was also high, and slightly higher in patients with the HPV
16 genotype (86.9%) than in those with other high-risk genotypes (79.7%), although this difference may
not be significant as a result of overlapping CIs. Specificity estimates were not reported in this study.
Human papillomavirus primary screening
(Confidential information has been removed.)
Test failures
Appendix 7, Table 48, presents the rates of, and the reasons for, test failures. Reported rates of test
failure varied widely across the studies. One study88 of a prototype version of DySIS reported a high rate of
failure (31.4%), which was primarily attributable to unsatisfactory DySISmap image and issues with faulty
disposable nozzles through which the acetic acid was delivered. Studies of a more recent version of DySIS
reported lower failures rates, ranging from 2.9% to 16.7%, with a lack of/poor-quality imaging being the
most common reason. The failure rates in the ZedScan and ZedScan prototype studies were (confidential
information has been removed) and 13.4%, respectively. (Confidential information has been removed.)
Diagnostic and treatment biopsies
All included diagnostic accuracy studies reported some data on the diagnostic and treatment biopsies
performed. However, owing to limited data, the impact of adjunctive technology on the rates of diagnostic
biopsies and treatment (including unnecessary treatments) is uncertain.
Appendix 7, Table 49 presents the number of diagnostic biopsies and treatment biopsies performed in the
diagnostic accuracy studies.
Three studies performed biopsies in all patients, as reported previously.60,79,88 In other studies, the
proportion of adjunctive colposcopy patients biopsied ranged from (confidential information has been
removed).80,94 The mean number of biopsies varied widely,60,83,88,103 (confidential information has been
removed) to up to five in Roensbo et al.79 when reported. Only four studies reported on the number of
treatments performed during or after the examination, which were nearly always conducted as loop
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excisions.60,79,94,103 See-and-treat cases ranged from 0 in Roensbo et al.79 to (confidential information has
been removed).
Only three studies provided data on the number of additional biopsies performed that were associated
with the use of adjunctive colposcopy. However, these results are limited, as a result of the lack of
randomised evidence comparing adjunctive colposcopy with standard colposcopy in parallel groups.
(Confidential information has been removed.) Papagiannakis et al.83 found that the addition of DySIS led to
an increase of approximately one additional biopsy per five patients (from 1.03 biopsies per patient with
standard colposcopy to 1.25 biopsies with adjunctive colposcopy), although this result is derived from a
non-randomised comparison with a retrospective arm. Natsis et al.74 reported that the proportion of
patients undergoing biopsies was lower among patients undergoing colposcopy with adjunctive DySIS
(80.8%) than in a parallel group of patients undergoing colposcopy alone (85.9%). (Confidential
information has been removed.)
Results: assessment of clinical effectiveness
The review of clinical effectiveness aimed to evaluate the following outcomes in studies of DySIS
and ZedScan:
l morbidity and mortality associated with treatment and biopsies conducted as part of the colposcopy
examination (including obstetric outcomes such as miscarriage and infertility)
l morbidity and mortality associated with cervical cancer, and HRQoL
l pain and anxiety associated with the colposcopy examination, biopsies, treatment and waiting
for results
l any other adverse event that may have an impact on resource use or quality of life.
Only three studies reported data on the clinical effectiveness outcomes. All three studies were also
included in the review of diagnostic accuracy.60,88,103 The characteristics of the studies are reported in
Table 3.
Results of the studies on clinical effectiveness
Three studies reported data on adverse events.60,88,103 One study of ZedScan103 reported one serious
adverse event and two adverse events following colposcopy: one patient ‘felt unwell’ and two instances
of bleeding after biopsies. It is not clear which of these three events was serious and whether or not any
of these adverse events could be attributed to the use of adjunctive colposcopy. Both studies of DySIS
reported that no patients experienced adverse events following colposcopy.60,88 No further data on adverse
events were reported.
No data were reported on morbidity and mortality associated with treatment and biopsies conducted as
part of the colposcopy examination or associated with cervical cancer in studies of DySIS and ZedScan.
No data on outcomes related to HRQoL were found. Data on pain and anxiety associated with colposcopy
examination with DySIS were collected only in patient surveys using non-validated scales, and these results
are reported in Systematic reviews of adverse outcomes of cervical intraepithelial neoplasia treatment.
Systematic reviews of adverse outcomes of cervical intraepithelial neoplasia treatment
Owing to the limited evidence identified by the review of clinical effectiveness, a pragmatic search for recent
good-quality systematic reviews on the impact of CIN treatment on adverse fertility, pregnancy and obstetric
outcomes was conducted. Two relevant systematic reviews with meta-analysis were identified.118,119 This
section provides a critical summary of these reviews.
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Kyrgiou et al. (2015)118
Kyrgiou et al.118 assessed the effect of excisional or ablative CIN treatment on fertility and early pregnancy
(< 24 weeks’ gestation)-related outcomes. The review included studies that compared fertility and early
pregnancy (< 24 weeks’ gestation)-related outcomes in women with a history of CIN treatment with the
same outcomes in women who had not received treatment. Any types of excisional and ablative
treatments were included.
The review included 15 studies (2,223,592 participants, of whom 25,008 received treatment for CIN). All
included studies were non-randomised and heterogeneity was high. The quality of the evidence for early
pregnancy-related outcomes was low [Grading of Recommendations Assessment, Development and
Evaluation (GRADE) classification]. The results of the meta-analysis showed that CIN treatment did not
have an adverse effect on fertility outcomes. The overall pregnancy rate was higher for treated women
than for those who were untreated [43% and 38%, respectively; relative risk (RR) 1.29, 95% CI 1.02 to
1.64; four studies]. There was no statistically significant difference in pregnancy rates in treated and
untreated women with an intention to conceive and women taking more than 12 months to conceive.
There was no increase in the total miscarriage rate or the first-trimester miscarriage rate between the treated
and untreated groups; however, CIN treatment was associated with an increased risk of miscarriage in the
second trimester (1.6% vs. 0.4%, RR 2.60, 95% CI 1.45 to 4.67; eight studies). Ectopic pregnancies (1.6%
vs. 0.8%, RR 1.89, 95% CI 1.50 to 2.39; six studies) and terminations (12.2% vs. 7.4%, RR 1.71, 95% CI
1.31 to 2.22; seven studies) were also more frequent in treated women. The authors concluded that CIN
treatment is unlikely to have an adverse effect on fertility and there was a slight increase in the risk of
miscarriage in the second trimester associated with treatment; there was no stratification of risk by treatment
type or magnitude. The authors also further emphasised the low quality of the evidence, but suggested that
women should be advised that fertility is not compromised by treatment for CIN. The conclusions of this
generally well-conducted review are likely to be reliable.
Kyrgiou et al. (2016)119
Kyrgiou et al.119 focused on studies reporting obstetric (> 24 weeks’ gestation) and neonatal outcomes
following local treatment for CIN or early-stage cervical cancer. The review included studies reporting on
obstetric outcomes (> 24 weeks’ gestation) in women who had previously received local treatment for CIN
or early-stage invasive cervical cancer compared with women with no history of treatment. All types of
excisional and ablative treatments were included.
Outcomes pertaining to the risk of overall preterm birth were reported by 60 studies, with 25 reporting
on ‘severe’ preterm birth (< 32–34 weeks’ gestation) and nine reporting on ‘extreme’ prematurity
(< 28–30 weeks’ gestation). Other outcomes included the length of labour [precipitous or prolonged,
use of analgesia (epidural, pethidine, other)], oxytocin use, cervical stenosis and haemorrhage. Neonatal
outcomes were low birthweight, admission to neonatal intensive care, stillbirth, Apgar scores and
perinatal mortality.
The review included 71 studies (6,338,982 participants, with 65,082 participants treated for CIN or
early-stage invasive cancer). Nearly all of the studies were retrospective cohort studies and none was a
randomised trial. Most studies were considered to be high-quality observational studies (Newcastle–Ottawa
Scale scores 8–10 in all but two studies). For all treatment types, the risk of overall prematurity (< 37
weeks’ gestation) was increased in the treated group versus the untreated group (RR 1.78, 95% CI 1.60 to
1.98; 60 studies), as was severe prematurity (< 32–24 weeks’ gestation, RR 2.40, 95% CI 1.92 to 2.99; 25
studies) and extreme prematurity (< 28–30 weeks’ gestation, RR 2.54, 95% CI 1.77 to 3.63; nine studies).
Compared with untreated women, all patients who were treated with LLETZ were at a higher risk of giving
birth prematurely (RR 1.56, 95% CI 1.36 to 1.79; 26 studies), severely prematurely (RR 2.13, 95% CI
1.66 to 2.75; 11 studies) and extremely prematurely (RR 2.57, 95% CI 1.97 to 3.35; three studies). The
meta-analysis showed that treatment for CIN increased the risk of preterm birth regardless of treatment
method, with a higher magnitude of treatment effect associated with treatment techniques removing or
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ablating more tissue; deeper excisions were consistently associated with increased risk of preterm
birth (≤ 10–12 mm: RR 1.54, 95% CI 1.09 to 2.18 mm; ≥ 10–12 mm: RR 1.93 mm, 95% CI 1.62 to
2.31 mm; ≥ 15–17 mm: RR 2.77 mm, 95% CI 1.95 to 3.93 mm; ≥ 20 mm: RR 4.91 mm, 95% CI 2.06 to
11.68 mm). There was also an association between the number of procedures undergone and the risk of
preterm birth; pregnant women who had underone more than one treatment were significantly more
likely to deliver prematurely (RR 3.78, 95% CI 2.65 to 5.39).
The risk of other adverse outcomes, such as spontaneous preterm birth, premature rupture of the
membranes, chorioamnionitis, low birthweight, admission to neonatal intensive care and perinatal
mortality, was also significantly increased after treatment. The authors concluded that any local treatment
for preinvasive or early-stage invasive disease will increase the risk of preterm birth in a subsequent
pregnancy and that the frequency and severity of adverse outcomes increases with greater cone depth and
is higher for excision than for ablation. However, the authors noted that the risks associated with small
excisions are likely to be smaller than those related to untreated CIN during pregnancy, which is itself
linked to preterm birth (RR 1.24, 95% CI 1.14 to 1.35). The authors rightly noted the need to interpret the
review results with caution, owing to the lack of prospective and randomised evidence, a high risk of
confounding in the included studies and significant heterogeneity. Given this, the conclusions of this
generally well-conducted review are likely to be reliable. However, as most of the studies included in these
reviews were not recent UK cohort studies, the applicability of the conclusions of these reviews to the NHS
context may be limited.120–122
Results: assessment of implementation
The review of implementation aimed to evaluate the following outcomes in studies of DySIS and ZedScan:
the acceptability of the adjunctive technologies (clinicians and patients), patient satisfaction, successful
database and record management, training requirements, the capacity to perform colposcopies, and
uptake and compliance.
As part of the wider database search for diagnostic accuracy studies and studies of clinical effectiveness,
five studies were identified that reported data on any of these implementation outcomes. These included
four DySIS studies46,51,63,72 and one ZedScan study.96 All of these studies were linked to the diagnostic
accuracy studies included in the review of diagnostic accuracy (see Table 2).
Characteristics of the included studies
Table 13 presents a summary of the characteristics of the five studies46,51,63,72,96 included in the review of
implementation. Three studies were conducted in the UK,46,72,96 one study was conducted in Spain51 and
one study was conducted in the Netherlands.63 Three studies reported data on patient satisfaction with
adjunctive DySIS,46,63,72 one study reported on the acceptability of DySIS to clinicians51 and one study
reported views from both patients and colposcopists on DySIS.46 One study reported data on the
colposcopist training requirements associated with ZedScan.
Quality assessment of the implementation studies
The quality of the studies that used a survey questionnaire was limited overall. The validity and the
reliability of the questionnaires were not established in any of the studies. Two studies included a sample
that was considered likely to be representative of the population of interest.46,63 Only two studies51,63
accounted for relevant confounding factors (e.g. age, education, number of pregnancies or colposcopist
experience). The methods used to estimate the training requirements in the ZedScan study were limited,
making the validity of this study uncertain. Further results of the quality assessment of the survey
questionnaires are reported in Appendix 8.
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TABLE 13 Characteristics of implementation studies
Study
Linked
diagnostic
accuracy study
Characteristics
Location Study dates
Population and
sample size Study design
Adjunctive colposcopy
technology Outcomes
Budithi et al.46 Budithi et al.45 Confidential
information has been
removed
Confidential
information has been
removed
Confidential
information has been
removed
Confidential
information has been
removed
Confidential
information has been
removed
Confidential
information has been
removed
Coronado and
Fasero51
Coronado and
Fasero50
San Carlos Hospital,
Madrid
NR 63 colposcopists Survey questionnaires,
retrospective case
reviews
DySIS Acceptability of the
adjunctive technologies
to colposcopists
Louwers et al.63 Louwers et al.60 Three Dutch hospitals July 2008 to
September 2009
239 participants Survey questionnaires DySIS Patient satisfaction
Lowe et al.72 None Four NHS colposcopy
clinics, UK
June 2015 to May
2016
763 patients Survey questionnaires DySIS Acceptability of the
adjunctive technologies
to patients
Palmer et al.96 Tidy et al.94 Sheffield Teaching
Hospitals
January 2014 to
December 2015
Five colposcopists Observational, single
arm
ZedScan Training requirements
NR, not reported.
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Results of the implementation studies
Acceptability to patients and patient satisfaction
Lowe et al.72
Lowe et al.72 conducted a survey in 763 patients referred to colposcopy clinics in four NHS hospitals to
assess their experience with a DySIS colposcope with DySISmap. Two questionnaires were designed: one
for patients undergoing their first colposcopy examination and one for patients with prior experience of
colposcopy. The study was reported only as a conference abstract and the number of respondents for each
questionnaire was not reported. Responses were given on a scale of 1–10, with higher scores indicating
greater satisfaction/acceptability.
Both sets of participants, those receiving their first colposcopy and those with prior colposcopy experience,
found that their examination did not take longer than their previous smear test or colposcopy. The level of
anxiety for all patients dropped during and after the examination with DySIS colposcopy compared with
the result of a prior examination, from a median score of 7 out of 10 before colposcopy to a median score
of 4 during and 1 after the examination in patients undergoing their first colposcopy examination. The
results were similar for patients with prior colposcopy experience (median scores of 6 before, 3 during and
1 after the examination).
All patients reported that they understood the DySIS colour-coded map and found the map reassuring.
Finally, all patients with previous colposcopy experience declared that they preferred having their future
colposcopies with DySIS and would recommend DySIS to family and friends requiring colposcopy.
The authors concluded that DySIS with DySISmap is very well received by patients and is not intimidating,
and it does not require longer examination times. It also helped to improve patients’ experience and
their understanding of their condition, which in turn improves their overall experience and may reduce
non-attendance rates.
Louwers et al.63
Louwers et al.63 was a substudy of the trial by Louwers et al.60 and included 239 women who underwent
colposcopy with DySIS and DySISmap. All participants were asked to complete a patient satisfaction
questionnaire.
The results showed that 93.9% of the participants agreed or strongly agreed to have colposcopy with DSI if
it assisted in locating cervical neoplasia, 29.5% agreed or strongly agreed that DySIS was less comfortable
than a Pap smear, 16.5% reported that DySIS made them feel nervous during the examination colposcopy
and only 6.5% of participants thought that DySIS colposcopy took too long.
When asked which test characteristics were considered to be most important, 88.3% of participants ranked
test accuracy as the most important factor. Rapid testing was considered to be the second most important
factor and comfort was considered to be the third most important factor. Quick turnaround on results was
considered to be the second least important factor and cost was considered to be the least important.
Among a subset of 19 participants who had experienced colposcopy examination prior to the study, results
were similar to those of participants who had never had colposcopy before. However, all participants
disagreed or strongly disagreed with the statement ‘Colposcopy with DSI takes too much time’.
The authors concluded that women are willing to accept discomfort (in the form of an additional or longer
test) if the test has clear clinical benefits.
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Budithi et al.46
(Confidential information has been removed.)
Acceptability of the adjunctive technologies to clinicians
Coronado and Fasero51
Coronado and Fasero51 surveyed 63 medical practitioners with different levels of colposcopy experience to
gather their views on using DySISmap images compared with conventional colposcopy alone. The study
also included a retrospective review of colposcopy and DySISmap images to estimate the accuracy of
conventional colposcopy and DySIS when diagnosing cervical pathology based on different levels of
practitioners’ experience.
Images from 50 participants with normal and abnormal cervices collected during colposcopy examinations
and the corresponding DySIS maps were projected consecutively to the colposcopists. For each case,
participants were asked to select one of the following four probable results for that case: normal,
low-grade lesion, high-grade lesion or cancer.
The study population comprised 27 practitioners with a low level of colposcopic experience (i.e. first-
to third-year residents), 18 practitioners with a medium level of experience (fourth-year residents and
gynaecologists with a low level of experience) and 18 practitioners with a high level of experience
(experienced gynaecologists and accredited colposcopists). None of the participants had any previous
experience with DySIS.
Correct diagnosis was more frequent with DySIS than with conventional colposcopy in the low-level
experience group and the medium-level experience group, but not in the high-level experience group
(Table 14).
Table 15 presents the results of the survey. All experience groups agreed that DySIS was generally better
than colposcopy at guiding biopsy site selection and tended to agree that DySIS allows practitioners to
perform a colposcopy without experience.
Compared with the high-level experience group, the low-level and medium-level experience groups were
more likely to agree that DySIS interpretation is easier than interpretation with conventional colposcopy,
DySIS is better at directing diagnosis, DySIS provides more information than conventional colposcopy and
DySIS is generally better than conventional colposcopy.
The authors concluded that adjunctive DySIS improves diagnostic accuracy compared with colposcopy
alone, especially among less experienced colposcopists. The authors also stated that the inclusion of the
DySIS map into colposcopy is an easy and intuitive way to improve a conventional colposcope, particularly
for clinicians with limited colposcopic experience.
TABLE 14 Results of the diagnostic decisions in Coronado and Fasero51
Group Number of practitioners
Mean number of correct diagnoses by
method, n (95% CI)
DySIS Colposcopy
Low level of colposcopic experience 27 24.4 (22.7 to 26.2) 20.4 (18.8 to 21.9)
Medium level of colposcopic experience 18 26.0 (25.0 to 27.0) 21.9 (20.4 to 23.4)
High level of colposcopic experience 18 26.5 (24.4 to 28.7) 24.8 (22.8 to 26.9)
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(Confidential information has been removed.)
Training requirements
One study, which was conducted in a single centre in Sheffield that involved in-house colposcopists and
was linked to Tidy et al.,103 reported the time needed to train the colposcopists in using ZedScan for the
first time.96 The study reported that 5–10 minutes of additional time were needed for the initial training
period and the colposcopists were able to complete the initial 10–20 ZedScan measurements within
2–3 minutes after examining 10–20 patients. No further details were reported.
The authors concluded that ZedScan as an adjunct to colposcopy has added minimal time to each
appointment and exerted a negligible impact on the clinical output.
Other outcomes
No evidence was found for the following outcomes: successful database and record management,
the capacity to perform colposcopies, and uptake and compliance.
Clinical effectiveness summary and conclusions
Diagnostic accuracy
Nine studies that evaluated adjunctive DySIS (DySISmap and DySIS colposcope) were identified. Adjunctive
DySIS use was found to have a higher sensitivity (81.25%, 95% CI 72.2% to 87.9%) than standard
colposcopy alone (57.91%, 95% CI 47.2% to 67.9%), but a lower specificity (70.40%, 95% CI 59.4%
to 79.5%) than colposcopy alone (87.41%, 95% CI 81.7% to 91.5%). This difference appears to be
primarily because adjunctive DySIS leads to more positive test results (i.e. more women are judged to have
possible high-grade CIN); in all studies, the number of women with positive test results was higher with
adjunctive DySIS than that with colposcopy alone. However, the summary PPV for colposcopy alone was
only 55.8%, and so did not reach the recommended level of 65% for UK colposcopy. This may suggest
that how colposcopy was used in the included studies may differ from UK practice. There was no evidence
that DySIS improved diagnostic accuracy (in terms of DORs). There was insufficient evidence to assess
whether or not adjunctive DySIS improves cancer detection.
TABLE 15 Results of the colposcopists’ survey in Coronado and Fasero51
Question
Level of colposcopic experience, mean (95% CI)
Low (n= 27) Medium (n= 18) High (n= 18) p-value
Is the DySIS interpretation easier than
conventional colposcopy?
4.0 (3.6 to 4.4) 4.2 (3.7 to 4.7) 2.8 (2.2 to 3.5) 0.001
Did DySIS orient better my diagnosis? 4.0 (3.6 to 4.4) 3.9 (3.4 to 4.4) 3.2 (2.6 to 3.8) 0.028
Did DySIS orient better my biopsy site? 4.3 (4.0 to 4.5) 4.1 (3.7 to 4.5) 3.7 (3.2 to 4.3) 0.127
Do you believe that DySIS offers more
information than conventional colposcopy?
3.1 (2.6 to 3.6) 3.5 (3.0 to 4.0) 2.6 (2.1 to 3.1) 0.074
Do you believe that DySIS allows performing a
colposcopy without experience?
3.4 (2.9 to 3.9) 3.4 (2.7 to 4.2) 3.7 (3.2 to 3.8) 0.731
Do you believe that DySIS is better than
conventional colposcopy?
2.8 (2.3 to 3.3) 2.9 (2.2 to 3.5) 1.9 (1.5 to 2.4) 0.030
Answers were graded as follows: 1 (complete disagreement), 2 (disagreement), 3 (agreement), 4 (good agreement) or
5 (fully agree).
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Only two included studies investigated ZedScan. Both were led by the same researchers in Sheffield.
(Confidential information has been removed.) The other was a study of a precommercial ZedScan
prototype. These issues limited our ability to assess the diagnostic accuracy of ZedScan as an adjunct to
colposcopy. The results from the prototype study suggested that adjunctive ZedScan could improve
diagnostic accuracy when compared with colposcopy alone (i.e. it could increase sensitivity at the same
specificity as colposcopy or vice versa). (Confidential information has been removed.)
Data on participant subgroups, including women infected with hrHPV or high-grade referrals, were limited.
The results suggested that colposcopy alone has poor sensitivity to detect high-grade CIN in women
with low-grade referrals (e.g. mild dyskaryosis). Adjunctive DySIS and ZedScan appeared to improve the
diagnosis in low-grade referral cases. There was some limited evidence that the diagnostic accuracy of
adjunctive DySIS may be greater in women infected with hrHPV.
The sensitivity analyses identified that the specificity of all methods was strongly dependent on what
reference standard was used in women who were given a normal colposcopic evaluation result. Specificity
was much higher when no biopsies were performed in those women, suggesting a possible verification
bias caused by underdiagnosis of high-grade CIN. This verification bias could, in theory, also affect the
estimates of sensitivity, although the evidence for this was less conclusive for standard colposcopy. This
means that the actual specificity and sensitivity of colposcopy and adjunctive colposcopy are uncertain, as
it depends on the use of the reference standard. Verification bias may not affect the relative differences in
diagnostic accuracy between index and comparator tests in such studies, assuming that it will affect the
accuracy of both tests equally.
Test failure rates ranged from 2.9% to 16.7% in studies evaluating a commercial version of DySIS.
(Confidential information has been removed.)
There were limited data on diagnostic biopsies and treatments conducted during or following examination
with adjunctive colposcopy. Owing to the lack of randomised evidence comparing adjunctive technology
with colposcopy alone, evidence of the impact of adjunctive technology on the rates of diagnostic biopsies
and treatment (including unnecessary treatments) is very limited.
Clinical effectiveness
Only three studies that reported data on our prespecified clinical effectiveness outcomes were included.
One study of ZedScan reported three adverse events, of which one was serious, and two studies of DySIS
with DySISmap reported that no adverse events occurred following colposcopy examination. No data were
reported on mortality, morbidity and HRQoL in studies of DySIS and ZedScan.
Implementation
There is reasonable evidence that DySISmap as an adjunct to colposcopy is generally well received by
patients referred for colposcopy and that patients are generally satisfied with the duration of examination
(two studies). There is evidence to suggest that DySISmap was generally reassuring and that pre-examination
levels of anxiety decreased significantly during and after the examination (one study), and that only a
minority of patients (16.5%) felt nervous during the examination (one study).
There is evidence from two surveys that adjunctive DySIS was consistently perceived by clinicians to
improve the accuracy of colposcopy and confidence in their diagnostic decisions and biopsy site selection.
There is evidence that adjunctive DySIS was intuitive for clinicians with limited colposcopy experience and
that it improved their evaluations (one study). There is evidence that the additional time required to use
ZedScan is minimal for experienced colposcopists. All included studies had significant limitations; therefore,
these findings need to be interpreted with caution.
No evidence was found for several of the prespecified outcomes (successful database and record
management, the capacity to perform colposcopies and uptake and compliance). No evidence was found
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regarding the training requirements for DySIS. The limited evidence for ZedScan precludes conclusions for
any of the implementation review prespecified outcomes.
Conclusions
The review of diagnostic accuracy found that adjunctive DySIS increased sensitivity, but decreased
specificity, when compared with colposcopy alone. This appears to be because the number of women
classed as having possible high-grade CIN is increased, rather than being attributable to any improvement
in diagnostic accuracy per se. ZedScan also appears to be associated with a higher level of sensitivity and a
lower level of specificity than colposcopy alone when compared with the evidence from other included
studies. However, the evidence for the accuracy of ZedScan as an adjunct to colposcopy is limited, as it is
based on a single study that was rated as being at a high risk of bias, and it also results from a lack of
direct comparative evidence with standard colposcopy. This precludes any definitive conclusions regarding
the diagnostic accuracy of ZedScan as an adjunct to colposcopy. There was insufficient evidence to directly
compare DySIS with ZedScan.
There was too little evidence to assess whether or not the technologies have any adverse effects. DySIS
appears to be well received by both patients and colposcopists.
Increased sensitivity should lead to more women with high-grade CIN being correctly diagnosed, but
decreased specificity is also likely to lead to more unnecessary diagnostic biopsies and treatments in
women without high-grade CIN. The clinical value of adjunctive colposcopy, whether with DySIS or
ZedScan, therefore depends on whether or not the value of diagnosing more women with CIN outweighs
the disadvantages of more unnecessary biopsies and treatment.
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Chapter 4 Assessment of existing
cost-effectiveness evidence
Relevant cost-effectiveness evidence of adjunctive colposcopy technologies (DySIS with DySISmap andZedScan, hereafter referred to as ‘DySIS’ and ‘ZedScan’) was systematically identified, appraised for
quality and summarised. The objectives of the review were to identify key structural assumptions, highlight
areas of uncertainty and assess the generalisability of the results of existing models to the current decision
problem. The findings from the review also informed the development of a new decision-analytic model
reported in Chapter 5.
Methods
Searches
The literature search previously reported in Chapter 3, Methodology of the clinical effectiveness review was
also used to identify studies relating to the cost-effectiveness of adjunctive colposcopy techniques.
Study selection
A broad range of studies were considered in the review, including economic evaluations conducted
alongside trials, modelling studies and analyses of administrative databases. Only full economic evaluations
that compared two or more options and considered both costs and consequences (i.e. cost minimisation,
cost-effectiveness and cost–utility and cost–benefit analyses) were included in the review.
Relevant studies were then selected in two stages. Titles and abstracts identified by the search strategy
were examined and screened for possible inclusion. Full texts of the potentially relevant studies were
obtained. Two researchers (MP and PM) examined these independently for inclusion or exclusion and
disagreements were resolved by discussion.
A quality appraisal was carried out using the checklist of Drummond and Jefferson,123 which is available in
Appendix 9. This checklist evaluates the extent to which each review result provides details on different
aspects, such as study design, data collected, the use of these data in the economic evaluation and
analysis, and interpretation of the results. The checklist was completed by one researcher and checked by
another. Any disagreements were resolved by discussion.
Results of the review of existing cost-effectiveness evidence
The initial search of economic databases identified a total of 182 references. After the initial screening of
titles and abstracts, only two studies30,124 were considered to be potentially relevant and were ordered for
full-paper screening. Both studies met the selection criteria and were included in the review.
Of the two studies included, one was an independent assessment of the cost-effectiveness of DySIS
developed for the previous NICE DG4 assessment31 (i.e. Wade et al.).30 The other study was a company-
funded assessment of a prototype version of ZedScan (i.e. Whyte et al.).124 A summary and a critique of
these studies are reported in the following sections.
DOI: 10.3310/hta22540 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 54
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Peron et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
43
Review of Wade et al.30
Decision problem/objective
A decision-analytic model was developed to assess the cost-effectiveness of adjunctive colposcopy
technologies for assessing suspected cervical abnormalities in women referred for colposcopy as part of
the NHSCSP under the HPV triage screening protocol.
Three technologies were initially considered: DySIS, LuViva Advanced Cervical Scan and Niris Imaging
System. Owing to the lack of reliable data, LuViva Advanced Cervical Scan and Niris Imaging System were
subsequently excluded from the base-case analysis.
The model evaluated costs from the perspective of the NHS and Personal Social Services, expressed in
Great British Pounds (GBP) at a 2011 price base. The outcomes in the model were expressed in terms of
quality-adjusted life-years (QALYs). The model employed a lifetime (50-year) horizon, and costs and
outcomes were discounted at a rate of 3.5% per annum.
Strategies/comparators
The base-case economic evaluation compared the costs and health outcomes of DySIS, alone and as
a colposopic adjunct, with standard colposcopy. The base-case results were presented by reason for
referral (borderline and HPV-positive, mild and HPV-positive, moderate, severe, possible invasion, possible
neoplasia, three times inadequate) and, for the whole population, were based on a weighted average of
the results of each reason for referral. A separate indicative analysis was undertaken to test the sensitivity
needed for Niris and LuViva to be considered to be cost-effective, given their reported costs and an
assumed specificity.
Model structure
The model incorporated two elements: first, a decision tree to represent the initial diagnostic and treatment
pathways for patients referred to colposcopy from the NHSCSP (under the HPV triage screening protocol),
and, second, a Markov model that simulated the natural history of patients and captured future cytological
screening and referrals to capture the long-term costs and outcomes of the initial diagnostic and
treatment pathways.
The decision tree was specifically developed for the appraisal informing NICE DG4,31 whereas the Markov
model was based on a revised model previously used by Hadwin et al.,125 and was referred to as the
‘Sheffield model’. The decision tree had three main components: (1) diagnostic outcome, (2) treatment
decision and (3) treatment outcome.
The diagnostic outcome depends on the diagnostic accuracy in relation to a patient’s true underlying
health state. Specifically, diagnostic accuracy is modelled as the probability of being diagnosed with health
state h, conditional on the true underlying health state h.
Treatment decisions depend on diagnostic outcome and the reason for referral. A patient may either not
receive treatment or be referred for a diagnostic biopsy, a treatment biopsy (LLETZ) or a cancer treatment.
Treatment outcome has an impact on both the true underlying health state and subsequent screening.
The impact on a patient’s health state depends on the probability of being cured. If patients have not
been treated, they enter the natural history Markov model with their initial true underlying health state.
In the case of patients with precancerous lesions who have been treated with excision biopsy, there is a
probability that this will be cured. If treatment has been successful, patients enter the natural history model
Markov in the ‘clear’ state; if not, they enter the natural history model with their initial health state.
As previously stated, a state-transition (Markov) cohort model is used to capture the long-term costs and
outcomes of the initial diagnostic and treatment pathways by simulating the natural history of the patient
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and incorporating future cytological screening and referrals. Although the use of a cohort model was
appropriate for the specific decision problem, the model itself subsequently required hundreds of separate
states to be included in order to capture the complexity of screening pathways and the heterogeneity in
treatment decisions and outcomes. This complexity arose because the screening pathways and treatment
decisions depended on a patient’s characteristics (e.g. age, health state) and previous history (e.g.
screening results, treatment outcomes, follow-up), and these also had an impact on the transitions
between health states in the natural history model. With a cohort approach, the only way to account for
individual heterogeneity and to build sufficient ‘memory’ to capture the complexities is to increase the
number of states. Although the complexity could have been potentially more efficiently reflected by using
a patient-level simulation, the final model structure appeared to rely heavily on the use of an existing
natural history cohort model from Sheffield, which may have constrained the authors in terms of their
chosen modelling approach.
The treatment pathways incorporated in the model were based on NHSCSP guidelines,15 which describe good
practice in treatment decisions and the follow-up of precancerous lesions and invasive cancer. However, the
authors identified an important discrepancy between guidelines and clinical practice and chose to use
evidence from the latter based on data from Gateshead to capture heterogeneity in treatment pathways. For
instance, national guidelines state that a patient with low-grade referral with normal colposcopy should be
discharged without any treatment and returned to routine screening. Observational data from the Gateshead
clinic suggested that 73.5% of these patients would receive a diagnostic biopsy and only 10.7% would be
sent back to routine screening.
Adjunctive technologies to colposcopy were assumed to be used for the initial referral and for subsequent
colposcopy appointments (treatment, follow-up). The model also assumed that there is no loss to follow-up
and, hence, all women were assumed to attend subsequent appointments for colposcopy and cytology.
Main sources of data
The model incorporated three main sources of data input: (1) diagnostic accuracy, (2) natural history of
cervical cancer and (3) characteristics of the population referred for colposcopy.
Diagnostic accuracy
The diagnostic accuracy of colposcopy and DySIS was based on the specificity and sensitivity reported by
Louwers et al.60 Louwers et al.60 reported diagnostic accuracy based on a CIN 2+ cut-off point leading to
a dichotomous classification of the performance of the diagnostic technologies. However, the economic
model required the probability of the diagnoses of the different stages of disease, whether these were
correct or incorrect, conditional on a patient’s true underlying health state (e.g. clear, HPV-positive, CIN 1
present). For example, a true ‘clear’ patient correctly classified as being below the CIN 2+ cut-off point
(and hence defined as a true-negative patient based on the dichotomous cut-off point) could either have
been correctly diagnosed as ‘clear’ or they could have been incorrectly diagnosed as having ‘CIN 1’. Hence,
additional assumptions were employed in Wade et al.30 to convert the diagnostic accuracy data into the
probabilities required for the model.
The probabilities required for the model were calculated using two main steps. First, the probability of being
diagnosed as true positive, true negative, false positive or false negative was derived from Louwers et al.60
These probabilities depend on the devices’ diagnostic accuracy. Second, the probability of being diagnosed
with a specific stage of the disease, conditional on a patient’s true underlying state and on being true
positive, true negative, false positive or false negative was derived from a study by Gallwas et al.,126 who
reported the diagnostic accuracy of a different diagnostic device (the Niris Imaging System).
This approach relies on two strong assumptions, with the first being that the results reported by Gallwas
et al.126 are reliable and can be generalised for other types of devices. The study by Gallwas et al.126
includes a 2 × 2 table with the outcome of colposcopy by patients’ health state, confirmed by histology.
However, biopsies were performed only when precancerous lesions were suspected. The population
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targeted by the study therefore excludes false negatives. This was considered by Wade et al.30 as a
significant bias and motivated the decision to exclude the Niris Imaging System from the main analysis. The
second main assumption is that the diagnostic accuracy of the Niris Imaging System, conditional on being
true positive, true negative, false positive or false negative, is similar for colposcopy alone, DySIS alone and
DySIS plus colposcopy.
Furthermore, the model aimed to capture subsequent referrals for colposcopy when patients are followed
up or called for routine screening under the HPV triage scheme. Data on the performance of the cytology
and HPV tests were derived from personal communication (S Eggington, University of Sheffield, 2017).
The sensitivity and specificity of the HPV test given the patient’s age and her cytology result were derived
from the TOMBOLA (Trial Of Management of Borderline and Other Low-grade Abnormal smears) study
(Cotton et al.).127
Natural history of cervical cancer
The natural history model was based on the Sheffield model and simulated the progression of patients
between nine mutually exclusive health states: clear, HPV, CIN 1, CIN 2/3, invasive cancer stages from 1
to 4 and death. Patients entered the natural history model in the health state based on screening and
treatment outcomes. Patients were allowed to progress or regress between these states every 6 months.
Age-related transition probabilities of progression and regression in the Sheffield model were derived from
Myers et al.128
The natural history model relies on three main structural assumptions: (1) the linear progression of patients
between states, (2) a single combined state for CIN 2 and CIN 3 and (3) patients diagnosed with cancer
who survive 5 years after treatment are cured and move to the ‘clear’ state. These assumptions are
summarised below:
1. First, patients are allowed to progress stage by stage only. They are initially infected with HPV, then
they develop CIN 1, CIN 2/3 and, finally, invasive cancer from stages 1 to 4. Cancer cannot regress
without treatment. However, precancerous lesions can regress without intervention to an earlier stage
or directly to the clear state.
2. Second, because the study by Myers et al.128 did not provide separate transition probabilities for the
CIN 2 and CIN 3 states, CIN 2 and CIN 3 were combined in the natural history model into a single
combined health state. No additional mortality risk was assumed for precancerous lesions and HPV,
CIN 1 and CIN 2/3, and these states were also assumed to be asymptomatic. Patients cured of CIN
were assumed to have the same risk of future CIN as the general population.
3. Finally, the modelling of cervical cancer relies on a series of assumptions. The model uses different
mortality rates for undiagnosed and treated cancer. Patients progressed between cancer stages only
if they were not treated. Undetected cancer was assumed to be asymptomatic, with a probability of
developing symptoms during each 6-month cycle that increased by stage. It was assumed that a patient
who develops symptomatic cancer would be systematically diagnosed and treated within the next
6 months. When a patient was diagnosed with asymptomatic cancer during a routine screening,
it was assumed that they would be diagnosed with stage 1 cancer. After being diagnosed with cancer,
patients faced a 5-year elevated mortality risk. Patients who survived for 5 years were assumed to
transition to the ‘clear’ state, and at this point were assigned a QALY decrement and cost associated
with their previous cancer treatment. Patients who died from cancer immediately entered the death
state, but were assigned a QALY decrement and cost associated with their previous cancer treatment.
Characteristics of the population referred for colposcopy
Estimating the characteristics of patients referred for colposcopy is critical to the cost-effectiveness
assessment of adjunctive colposcopy technologies. Women entered the model with a ‘true underlying
health state’ (e.g. clear, HPV, CIN 1) and a reason for referral (borderline changes, mild dyskaryosis, etc.).
The reason for referral has an impact on treatment pathways and outcomes and the initial true underlying
health state has an impact on colposcopy results and disease progression. To be representative of the
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population referred for colposcopy, the estimated joint distribution has to capture the impact of both the
disease prevalence and the screening programme.
The joint distribution of the reason for referral and the true underlying health state in Wade et al.30 was
based on three sources of data: a study by Kelly et al.,129 data collected from sentinel sites for HPV triage
implementation and data collected from Gateshead hospital. The distribution of patients by reason for
referral, under the HPV triage protocol, was based on data from the NHSCSP, together with a study by
Kelly et al.129 Kelly et al.129 reported the proportion of women with borderline or mild cytology results
who tested positive for HPV. Data from sentinel sites for HPV triage implementation (10% of the English
cervical screening programme) were used to estimate the impact of HPV triage on the distribution of
women referred to colposcopy. The weighted population used in the base-case analysis was 38.52% of
women infected with borderline HPV and HPV, 35.39% of women with mild dyskaryosis and infected with
HPV, 11.51% of women with moderate dyskaryosis, 13.06% of women with severe dyskaryosis, 0.51% of
women with possible invasion and 1.01% of women with possible glandular neoplasia.
The proportion of women with a true underlying health state h, given the reason for referral r, was based
on a retrospective study conducted at the Northern Gynaecological Oncology Centre, Queen Elizabeth
Hospital, Gateshead (hereafter referred to as the Gateshead data). The Gateshead data included 4533
patients who attended a colposcopy examination in 2008–9. Patients’ true health states were revealed by
biopsy when available. The Gateshead data have two potential limitations. First, the data were collected
from a single centre, whose patients may not be representative of the general population in terms of the
prevalence of the disease. Second, the biopsies were not systematically performed. When a biopsy was not
performed, the study reported the colposcopy diagnostic only. As colposcopy is not 100% sensitive and
specific, the colposcopy outcome may not reflect the true prevalence of the disease. Hence, CIN 1 and
‘clear’ health states, which do not need to be confirmed by histopathology, may be over-represented. In
an alternative scenario, the sample was restricted to diagnosis confirmed by histopathology. However,
this approach tends to select more severe cases and therefore is likely to underestimate the prevalence of
normal, HPV and CIN 1.
Resource use and costs
The resource use and cost estimates included the acquisition costs of the alternative technologies (including
maintenance and use of disposables) and further treatments. The number of patients managed under a
single colposcopy device was provided by clinical advisors and was used to calculate the average cost per
procedure for each technology. To capture the additional costs of a colposcopy visit (e.g. diagnostic and
treatment biopsy), treatment costs from the TOMBOLA study130 were used. Cancer costs by stage were
derived from a UK-based study by Wolstenholme et al.131
The cost per patient of colposcopy and adjunctive technologies has two main components: (1) a cost per
patient, common to all devices, which includes costs related to the examination itself, such as facilities
and staff, and (2) an additional cost that depends on the device and includes the cost of acquisition,
maintenance and disposables. The UK-based TOMBOLA study was used to estimate the cost of colposcopy
alone (including the price of the device and maintenance) as well as the per-patient costs of biopsy and
excision treatment (LLETZ).130 The examination with DySIS was assumed to be equivalent to colposcopy
alone in terms of staff resources (i.e. the same length of consultation and negligible staff training). The
additional cost includes the acquisition cost, annual maintenance costs and disposables, all provided by
the manufacturer. It was assumed that clinics have the choice between investing in a binocular colposcope
or the DySIS device (colposcope plus digital map). Therefore, the purchase price of a binocular colposcope
was included in the cost of colposcopy alone, but not for DySIS. Another important assumption is the
number of patients examined per year per colposcope. This is critical when estimating the cost per
patient, especially if technologies differ in terms of the initial investment and throughput. An estimate
of 1229 patients per year was assumed based on clinical advice. This was assumed to be exogeneous to
the performance of the device.
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The management costs of cervical cancer by stage at the initial diagnosis were derived from Wolstenholme
et al.131 The study was based on an audit of resources and costs over 5 years on 261 women in the Trent
region of central England in 1990. Although these costs appear to be based on the best evidence available
at the time, there exists uncertainty regarding how representative these estimates are, given the historic
nature of the study and the need to inflate costs over a significant time period.
Quality of life/utilities
Within the model, colposcopy and DySIS were assumed to have an impact on health outcomes in two
ways: (1) through the disutility associated with the examination itself and with subsequent treatment and
tests, and (2) through the disutility associated with the development of invasive cancer.
The direct disutility associated with colposcopy alone and DySIS was not assumed to be different. However,
because diagnostic accuracy has an impact on the number of subsequent treatments and follow-up, QALY
decrements associated with colposcopy examination, cytology test and biopsy were important for the
assessment of cost-effectiveness.
The disutility associated with cytology examination was assumed to be 0.02 (Insinga et al.132) over 1 month
(i.e. –0.0016 per cytology exam). The disutility of colposcopy and biopsies was derived from a time trade-off
analysis by Birch et al.133 The study reported HRQoL for three different scenarios: ‘three repeat Pap Smears’
(0.958), ‘immediate colposcopy with no pathology’ (0.927) and ‘cone biopsy after immediate colposcopy’
(0.922). The difference of 0.031 between Pap smears and immediate colposcopy was used as a QALY
decrement applied for each colposcopy examination. The difference of 0.005 between colposcopy with no
pathology and cone biopsy was used as a QALY decrement for diagnostic and treatment biopsies. As noted
by the authors, this rather small decrement, which was similar for diagnostic and treatment biopsies, is a
strong assumption and may underestimate the impact of biopsies on health. As noted in Chapter 3,
Systematic reviews of adverse outcomes of cervical intraepithelial neoplasia treatment, recent evidence exists
that indicates that treatment biopsies may increase the risk of adverse obstetric outcomes, and specifically
preterm delivery. However, the evidence at the time at which the model was conducted was reported to be
scarce and inconclusive. Given this uncertainty, the QALY decrement of a treatment biopsy on health
outcomes was further explored in a separate scenario analysis. The HPV, CIN 1 and CIN 2/3 states were
assumed to be asymptomatic and hence were assigned the same utility as the clear state, reported as 0.91.
Health utilities associated with the four stages of invasive cancer were derived from Chuck et al.134 It was
assumed that invasive cancer would be detected only at an asymptomatic stage through routine screening.
Patients who subsequently developed symptoms were assumed to be immediately referred for colposcopy
and were appropriately diagnosed and treated. The model thus made an important distinction in the
health utilities between undiagnosed and diagnosed cancer. Specifically, the model incorporated much
lower HRQoL scores for untreated (and therefore undiagnosed) cancer than for treated cancer. These
estimates were reported to be based on estimates reported by Chuck et al.134
In our review, we identified some important uncertainties surrounding the source and subsequent
application of the estimates within the model by Wade et al.30 The estimates reported by Chuck et al.134
are actually referenced to a separate study by Goldie et al.5 Goldie et al.5 distinguished ‘quality weights’ for
detected invasive cancer, by stage and quality weights after treatment for invasive cancer. The use of the
estimates from Goldie et al.5 and their application in the model by Wade et al.30 raises several potential
issues. First, it is unclear whether or not ‘detected invasive cancer’ as described by Goldie et al.5 can be
interpreted as cancer ‘without treatment’. This appears to be inconsistent with the fact that undiagnosed
cancer is assumed to be asymptomatic. Our interpretation of the estimates reported by Goldie et al.5 is
that the lower weights of detected cancer might more appropriately indicate that disutility is higher at the
time of diagnosis and initial treatment than ‘after treatment’.5 The ‘detected invasive cancer’ stage might
therefore be considered to capture the disutility associated with the initial period after diagnosis. This
would appear to be more consistent with the initial treatment burden that patients treated for cervical
cancer may face after being diagnosed, but who may subsequently recover relatively quickly, particularly
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when cancer is detected at an early stage. Second, the method to estimate these ‘quality weights’
reported by Goldie et al.5 cannot be identified and hence the extent to which these appropriately represent
health utilities is unclear.5 Finally, there appears to be a reporting error in the Chuck et al.134 study, and this
was subsequently reproduced in the model by Wade et al.:30 the score associated with stage 2 cancer
‘without treatment’ is reported as 0.67 (higher than stage 1) in Chuck et al.134 and 0.56 in Goldie et al.5
Main results (including of the base-case and key sensitivity analyses)
The results of the economic evaluation compared DySIS plus colposcopy with colposcopy alone, for each
reason for referral and for the whole population. In most instances, colposcopy alone was found to be
dominated by DySIS plus colposcopy. That is, colposcopy alone had higher costs and lower health
outcomes than DySIS plus colposcopy (Table 16).
We identified the potentially counterintuitive result that an increase in a diagnostic device’s specificity
resulted in worse outcomes. In particular, it appeared to be better to falsely identify patients with CIN 1
as having CIN 2/3 than to find that they truly have CIN 1. According to the authors, this result suggested
that the treatment of CIN 1 is more cost-effective than watchful waiting, because of the low cost and
low QALY decrements associated with treatment biopsy. Further analyses subsequently determined the
threshold of each input at which an increase in specificity would improve outcomes. The QALY decrement
of treatment biopsy needed to be increased from 0.005 to 0.13 or its cost needed to be increased from
£97 to £2758.
Assessment of uncertainty
Several scenario analyses were considered, with the following variations in the base-case assumptions:
the patient’s age, duration of the HRQoL decrements as a result of cancer, cancer treatment costs,
perfect health for the clear and HPV states, the QALY decrement associated with treatment biopsies and
cytological screening, the alternative costs of a colposcope, alternative treatment probabilities, and the
assumption that patients who received negative test results through the use of colposcopy or adjunct
technologies would be diagnosed as ‘clear’. Overall, for all of the sensitivity analyses undertaken,
colposcopy alone was dominated by DySIS plus colposcopy.
A secondary analysis considered a higher cost and QALY decrement associated with treatment biopsy
(–0.13 from 0.005 in the base case). At this value, a higher level of specificity is expected to generate improved
outcomes. The secondary analysis was also combined with the sensitivity analyses previously described.
The results suggested that colposcopy alone was still dominated by DySIS plus colposcopy (Table 17).
TABLE 16 Base-case results for the whole population, Wade et al.30
Technology Costs (£) QALYs ICER
Colposcopy alone 1313.59 20.41339
DySIS and colposcopy 1254.00 20.42805 Dominant
ICER, incremental cost-effectiveness ratio.
TABLE 17 Secondary analysis results with a treatment biopsy QALY decrement of 0.13 for the whole population,
Wade et al.30
Technology Costs (£) QALYs ICER
Colposcopy alone 1313.59 20.33799
DySIS and colposcopy 1254.00 20.34705 Dominant
ICER, incremental cost-effectiveness ratio.
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A probabilistic sensitivity analysis (PSA) was not conducted and all of the results were based on
deterministic estimates.
Review of Whyte et al.124
Decision problem/objective
The aim of Whyte et al.124 was to assess the cost-effectiveness of a prototype version of ZedScan as an
adjunct to colposcopy relative to standard colposcopy alone from a NHS perspective. The population
included in the analysis was women referred to colposcopy from the NHSCSP (under the HPV triage
screening protocol).
The analysis focused on assessing the impact of ZedScan on initial colposcopy appointments and
colposcopy follow-up appointments. Outcomes were predicted for three different types of colposcopy
clinic [‘see-and-treat’, ‘treat-later’ (watchful waiting) and ‘triage’ clinics], which allowed for the optimal
screening pathway to be established, as well as the cost-effectiveness of ZedScan in each type of clinic.
The different types of clinic were formally defined as follows:
1. See-and-treat clinic – women may receive treatment at their initial colposcopy appointment if the
diagnosis suggests that this is appropriate.
2. Treat-later clinic – no treatment at the initial colposcopy appointment. Biopsy confirmation before
treatment at a later colposcopy appointment.
3. Triage clinic – high-grade referral patients are seen in a see-and-treat clinic, so women may receive
diagnosis and treatment at the same colposcopy appointment. Low-grade referral patients are seen in a
treat-later clinic.
The analysis used a diagnostic threshold for ZedScan, which set the sensitivity at a similar level to that of
standard colposcopy, resulting in the main difference between the two devices being their specificity rates.
The analysis assessed the cost-effectiveness of ZedScan by assessing several outcomes, which included the
number of colposcopy appointments, the number of biopsies conducted, the costs related to colposcopy
and adverse events, and overtreatment rates. In addition, the analysis also considered the treatment rates
of CIN and associated adverse event rates, as well as whether or not an increased sensitivity level with
ZedScan might increase clinicians’ confidence to offer more ‘see-and-treat’ appointments as a result
of reductions in the numbers of unnecessary treatments and the associated cost-effectiveness of
such changes.
The time horizon of the evaluation was 3 years and was justified on the basis that most patients would be
returned to routine screening within this time period. Costs and outcomes were discounted at a rate of
3.5% and a price year was not stated.
Strategies/comparators
Using ZedScan as an adjunct to colposcopy was compared with colposcopy alone. No attempt was made
to compare ZedScan with alternative diagnostic tools that can be used as an adjunct to colposcopy.
Model structure
The economic evaluation modelled the natural history of women at risk of developing cervical cancer
and the colposcopy diagnostic pathway. A patient-level model was constructed, allowing the model to
track the underlying health state of patients and their location within the colposcopy pathway. After an
initial colposcopy in the first cycle, patients were located in one of the following discrete locations within
the colposcopy pathway: ‘low-grade CIN 1 follow-up’, ‘high-grade follow-up pathway’, ‘Test of cure’,
‘routine screening’, ‘refer to colposcopy following fail at test of cure’, and ‘cancer’. Following the
diagnostic pathway, the model tracked patients’ natural history, with women able to progress or regress
through the CIN stages. The discrete health states included in the analysis were ‘clear’, ‘HPV’, ‘CIN 1’,
‘CIN 2’, ‘CIN 3’ and ‘cancer’, with cancer divided into International Federation of Gynecology and
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Obstetrics (FIGO) stages of severity from I to IV. A cycle length of 6 months was selected, as this is the
shortest length of time between repeat colposcopies.
The model estimated the number of colposcopy appointments and biopsies conducted at each of the clinic
types, as well as the number of women who received treatment for CIN for each type of colposcopy. This
allowed for the estimation of costs associated with each scenario, as well as the average utility decrements
associated with colposcopy, biopsy and treatment. The model simulated 1,000,000 women for each
diagnostic tool and each clinic type.
The distribution of the colposcopy population on the basis of the women’s health states and cytology
grades was estimated using data on the outcome of colposcopy given the referral cytology. After patients
received their initial cytology examination, there were assumed to be seven possible outcomes. If the result
was negative, then patients were returned to routine screening, a mild or borderline outcome results in a
HPV test being conducted, with a positive HPV test result leading to a low-grade referral to colposcopy,
and a negative result leading to patients being returned to routine screening. If the cytology result was
‘moderate’, ‘severe’ or ‘invasive cancer’, then patients were sent to colposcopy as a high-grade referral.
If the outcome of cytology was inadequate, then patients were sent for a repeat cytology test in 3 months’
time, with three consecutive inadequate results leading to a low-grade colposcopy referral. Patients’
referral type was tracked, as it was assumed that ZedScan would be used with a different threshold for
low-grade and high-grade referrals, resulting in different sensitivities and specificities.
Whether or not patients received treatment and the timing of treatment was dependent on their referral
grade, their colposcopy result and the clinic type. The three types of clinics that were considered in
the analysis were ‘see-and-treat’, ‘treat-later’ and ‘triage’ clinics. At the ‘see-and-treat’ clinics, women
could receive treatment at their initial colposcopy appointment if the diagnosis was clear that this was
appropriate. ‘Treat-later’ clinics do not provide treatment at the initial colposcopy appointment; instead,
patients receive a biopsy confirmation and are treated at a future appointment. ‘Triage clinics’ split patients
by their referral grade, with patients with high-grade referrals being managed in a ‘see-and-treat’ clinic
and those with low-grade referrals being managed in a ‘treat-later’ clinic. Women treated for CIN are
assumed to be treated with LLETZ, although in practice a range of treatment options are available.
After colposcopy, patients follow one of six pathways. First, women with a low-grade referral who are
identified as clear are sent back to routine screening in 3 years’ time. Second, patients who are identified
with cancer are sent to oncology regardless of their referral grade. The third pathway results in women
with a low-grade referral identified as having CIN 1 receiving a further colposcopy in 12 months’ time.
If they are found to have CIN 1 at the follow-up colposcopy then they are sent for a further colposcopy
1 year later, but after a third CIN 1 result, they are treated. At the second or third colposcopy those who
are identified as clear return to routine screening, women found to have CIN 2+ are sent for treatment
and those identified with cancer are referred to oncology. The fourth pathway involves women with a
high-grade referral who are identified as clear or having CIN 1 being referred to colposcopy in 6 months’
time, with a subsequent result of CIN 1+ resulting in treatment and a result of cancer leading to an
oncology referral. Those who are identified as clear in the repeat colposcopy are sent back for a colposcopy
in a further 6 months, with five consecutive clear colposcopy results resulting in patients being sent back to
routine screening. The fifth pathway results in patients who are treated for CIN going on to receive a test
of cure, which consists of a cytology test at 6 months and a subsequent HPV test if the cytology result is
negative. The final pathway involves referring patients who receive a test of cure and have a positive
cytology or a positive HPV test then patients to colposcopy.
Following completion of the screening phase, patients enter a natural history model. This model assumes
that patients start with a high risk of HPV infection, which can either clear or progress to CIN, with
patients starting with mild changes (CIN 1) and either progressing to more severe stages (CIN 2 and CIN 3)
or regressing back to clear. If patients progress to cancer, then it is assumed that they can regress back to
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a non-cancer state with or without treatment. Progression and regression rates of CIN 2/3 to and from
cancer were assumed to be similar to the rates from CIN 1 to CIN 2/3 and clear.
Owing to the analysis focusing on a time horizon of only 3 years, the natural history model is unable to
capture the long-term effects of failing to identify and treat CIN caused by ZedScan having a lower
sensitivity than colposcopy for low-grade referrals. In the short term, failing to treat those with CIN will
reduce costs; however, there will be longer-term treatment cost, HRQoL and mortality impacts that are
not captured within the time horizon.
Main sources of data
The methods used to identify appropriate parameter estimates were not transparently reported. The study
makes reference to a review that was conducted in order to identify studies with information useful for
understanding the natural history of HPV. However, the details of the search were not reported. No review
was explicitly reported for other parameters.
Natural history/baseline data
The review conducted to identify publications reporting data on the natural history of HPV and CIN found
eight studies135–142 of relevance. Data taken from a French prospective study conducted by Sastre-Garau135
were used to estimate the 6-month progression and regression rates between states in the natural history
model. The study tracked 86 women with confirmed CIN 1 and observed how many patients progressed and
regressed over a median follow-up time of 24 months. The transition probabilities utilised in the model were
highly uncertain because of the small sample size of the study. In addition, strong assumptions were made
that the progression and regression rates from CIN 2/3 to CIN 1 and cancer were the same as those from
CIN 1 to clear/infected with HPV and CIN 2/3, with little justification provided for this assumption.
The proportions of the initial true underlying states of patients in the analysis and their reason for referral
were estimated using data from a study published by Blanks and Kelly.143 This study examined cytology
data from 102 laboratories and presented findings for patients who had received a follow-up colposcopy.
The assumption was therefore made that the result that patients received at colposcopy accurately determined
their true underlying health status, which is a strong assumption, as the sensitivity of colposcopy is below
100%. In order to address this limitation, a sensitivity analysis was conducted in which the prevalence of
CIN 2+ was increased by 10%.
Treatment effects
The performance of ZedScan and standard colposcopy in terms of their sensitivity and specificity rates
was measured using two methods: colposcopic impression and disease present. Colposcopic impression
measured performance by assessing whether or not a patient was correctly identified as either having
CIN 2+ or having a normal result/having CIN 1 by clinical impression only. However, disease present
measured performance by looking at whether or not a patient was correctly identified or scheduled to
receive a biopsy, when a biopsy was assumed to have 100% sensitivity and specificity. The colposcopic
impression method therefore results in a higher specificity value for the devices, whereas the disease
present method results in the devices having a higher sensitivity.
The data on the sensitivity and specificity of standard colposcopy and ZedScan were taken from the EpiCIN
trial (Tidy, 2013).90 The study recruited 474 women who were referred to colposcopy with an abnormal
cytology result and included two phases. The first phase involved using ZedScan to take EIS readings from
different points on the cervix before and after the application of acetic acid and assessing its performance
against colposcopic impression and disease present. This allowed for a probability index and a threshold
value for the detection of CIN to be calculated, which indicated the sites for biopsy in the second phase.
The second phase involved clinicians selecting biopsy sites before using ZedScan to identify additional sites
based on whether the probability of high-grade CIN was greater than the selected threshold value. The
sensitivity and specificity values for ZedScan and colposcopy used in the model were taken from Phase II
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of the trial. Different sensitivity and specificity values were estimated for high-grade and low-grade
referrals, respectively.
A limitation of the analysis is that the sensitivity and specificity were assumed to be equal for clear/CIN 1
and for CIN 2/3, which is a simplification of reality. These sensitivity and specificity values are likely to
differ, as, for example, patients with CIN 1 will be likely to have a greater chance of being incorrectly
identified as having CIN 2+ than those who are clear. This is an issue, as the identification of CIN 1
patients is important because they will experience a different follow-up treatment pathway from those
who are diagnosed as being clear.
Estimates of the frequency of biopsy at colposcopy were calculated from data found in Phases I and II of
the EpiCIN trial and using several assumptions. The data used were estimated rather than being observed,
which made the data susceptible to error, and the estimates did not come from a ‘see-and-treat’ clinic,
so the generalisability of these may be limited.
Resource use and costs
The costs of colposcopy, biopsy and treatment were estimated using data from Sheffield Teaching
Hospitals, and, therefore, it is unclear whether or not they are generalisable to the wider UK population.
These costs were calculated using the price of components and staff time, with a fixed cost included
for colposcopy.
The cost per use of the ZedScan device was assumed to be £31, which was stated to include the
disposable tip, cost of device, training and maintenance. However, no calculations were reported to
demonstrate how this cost had been derived. The ZedScan device was assumed to be used for all
diagnostic colposcopies, but not for treatment colposcopies following biopsy confirmation of disease.
The costs of HPV testing and cytology were taken from the HPV sentinel sites. Adverse event costs were
included for women experiencing severe bleeding or discharge (the TOMBOLA Group).144
Quality of life/utilities
Quality-of-life decrements were included for bleeding, pain and discharge, with data on adverse event
frequency and the duration of each event taken from the TOMBOLA trial, a large, multicentre, UK-based
study.144 Utility decrements were also included to capture patients’ preferences for the follow-up they
receive after an abnormal cytology result, which were estimated for colposcopy, colposcopy with biopsy
and colposcopy with LLETZ using the time trade-off method.133 The potential cost and quality-of-life impact
of the increased risk of preterm birth as a result of treatment or biopsy was not included in the model.
This was justified based on conflicting results from the identified studies.
Main results (including base-case and key sensitivity analyses)
The base-case results reported a lower frequency of biopsy, as well as lower total costs and a lower cost
per woman with CIN 2/3 treated for those diagnosed using ZedScan than for those treated with standard
colposcopy for each clinic type. ZedScan was also reported to lower the rates of overtreatment, with 12%
of the level of overtreatment occurring in ‘see-and-treat’ clinics, and 17% of the level of overtreatment
occurring in ‘triage-by-cytology-result’ clinics compared with the level of overtreatment in women who
received standard colposcopy.
The lower costs reported for ZedScan were also reported to be attributable to a reduction in the number of
follow-up appointments for CIN 1. The authors concluded that using the disease present method resulted
in fewer biopsies being taken following ZedScan and more women being followed up with a cytology test
rather than a repeat colposcopy appointment. Importantly, the lower sensitivity of ZedScan for low-grade
referrals also resulted in a lower number of women with CIN 2+ being diagnosed using ZedScan, as well
as a minor reduction in the number of cancers identified at colposcopy across all clinic types. Hence, some
of the reduction in total costs for ZedScan was as a result of undertreatment for CIN 2+.
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The base-case results also found that ‘treat-later’ clinics had the lowest cost per woman treated for CIN 2/3,
for both ZedScan and standard colposcopy. Based on their findings, the authors concluded that the results
did not appear to support a move from a ‘treat-later’ clinic to a ‘see-and-treat’ clinic using ZedScan. This was
because the cost per woman treated for CIN 2/3 was lower for a ‘treat-later’ clinic using standard colposcopy
than for a ‘see-and-treat’ clinic using ZedScan.
The authors noted the limitations arising from restricting the scope of the model to initial colposcopy and
follow-up for up to 3 years. Specifically, the long-term costs and consequences of failing to identify and treat
CIN 2+ or the impact of identifying and treating CIN or cancer at an earlier stage were not captured. The
authors noted that care should thus be taken regarding the interpretation of the results, as a reduction in the
treatment of CIN 2+ or cancer will appear to be beneficial in the short time horizon of the model (reducing
treatment costs), but would actually lead to higher costs and lower outcomes over a longer time horizon.
From a policy perspective, these limitations mean that it is not possible to determine whether or not the
short-term benefits of ZedScan arising from a reduction in unnecessary treatments offset any potential
reduction in benefits over a longer time horizon and, hence, whether over a more appropriate horizon in
which this could be reflected ZedScan would be cost-effective or not.
Assessment of uncertainty
A range of sensitivity analyses were conducted in order to assess the uncertainty around particular
parameters. For underlying disease prevalence, the proportion of CIN 2+ patients was increased by 10%,
and for costs, the values used in a previous diagnostics assessment report (Wade et al.30) were used as an
alternative (with the authors noting an important disparity in the cost of biopsy). In addition, the threshold
at which a biopsy was taken was lowered for ZedScan and colposcopy. Different values for the frequency
of biopsy for patients who were diagnosed using ZedScan were also used: a low estimate that assumed
that only one biopsy was required based on clinical guidance and a high estimate that assumed that
clinicians could take additional biopsies. An analysis was also conducted in which ZedScan was assumed
to have the same specificity as colposcopy, and therefore the only difference between the devices was
their sensitivity.
A PSA was also conducted to assess the joint uncertainty of the parameter inputs. Distributions were
assigned to the test characteristic parameters, the initial distribution of health states, utility decrements and
transition probabilities. However, it appears that an arbitrary estimate of uncertainty (± 5% the base-case
value) was used to inform the distributions for both the natural history transition probabilities and the
utility decrements. No details were reported in terms of the number of simulations undertaken within
the PSA.
The results of the sensitivity analyses demonstrated that the findings appeared to be robust to a range of
alternative assumptions. However, the findings were reported to be particularly sensitive to assumptions
surrounding the costs of colposcopy. When the estimates reported in Wade et al.30 were applied to the
model, standard colposcopy appeared to be cheaper than ZedScan, in terms of both total costs and the
cost per woman with CIN 2/3 treated. The authors highlighted that the costs reported in Wade et al.30
for both cervical biopsy and LLETZ appeared to be markedly lower than those based on the estimates
derived from the Sheffield Teaching Hospitals.
The sensitivity analysis also found that setting the threshold in a way that resulted in the specificity of
ZedScan being equal to that of colposcopy also increased the sensitivity and reduced the specificity of
ZedScan. This resulted in an increase in the cost of using ZedScan and the number of patients treated,
which reduced the benefits of the device in terms of cost per woman with CIN 2/3 treated. However,
ZedScan was still reported to be cheaper than using colposcopy alone.
Using the higher estimate of the number of biopsies taken when patients were diagnosed using ZedScan
had a small impact on the cost per woman with CIN 2/3 treated, but not enough to make ZedScan the
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more expensive option. Adjusting the disease prevalence data and the length of colposcopy appointments
had a minimal impact on the results. The PSA results were reported to be comparable to the deterministic
outcomes, demonstrating linearity in the parameter values.
Discussion of existing cost-effectiveness evidence and relevance to the
current decision problem
Our review identified two published studies30,124 that reported the cost-effectiveness of DySIS and an earlier
prototype version of ZedScan and that are partially relevant to the current decision problem. Although both
studies evaluated the use of adjunctive colposcopy techniques for women referred for colposcopy only as
part of the NHSCSP based on the current HPV triage screening protocol, only Whyte et al.124 included a test
of cure. As a result, neither study fully informs the current decision problem, which includes the current HPV
triage protocol (including test of cure) and also the proposed HPV primary screening protocol.
Despite both studies considering a similar decision problem and referral population, there were important
differences between the scope of the models and the analytic approaches employed. Only Wade et al.30
attempted to capture the longer-term impacts of adjunctive colposcopy technologies in terms of the
lifetime costs and QALYs. In contrast, the evaluation of ZedScan was restricted to a much shorter time
horizon (3 years). The shorter time horizon precluded an overall assessment of the cost-effectiveness of
ZedScan, as relevant longer-terms costs and outcomes were not quantified. However, one potential
strength of the ZedScan study124 was that it provided a more granular assessment of the impact on a
variety of different outcomes (including the rates of unnecessary treatment), as opposed to focusing on
the final outcomes expressed in terms of life-years gained and QALY outcomes, as was the case in Wade
et al.30 From a policy perspective, the focus on final outcomes expressed in terms of life-years gained and
QALYs is clearly not a limitation. However, the additional granularity in the reporting by Whyte et al.124
provided greater transparency in relation to how costs and benefits manifest themselves with an adjunctive
technology, which may be particularly informative in understanding how the trade-off between sensitivity
and specificity has an impact on the intermediate outcomes, which then drive the estimates of life-years
gained and QALY differences.
Structurally and conceptually, the models reflected similar pathways over the 3-year period, which was
common to both models. The main difference was that Whyte et al.124 included additional pathways for
test of cure as part of the HPV triage screening protocol. Test of cure was not included by Wade et al.,30
as this was not formally part of the HPV triage screening protocol at the time at which the study
was conducted.
Although both models shared similar pathways over the initial 3-year period, there were important differences
both in terms of the analytic approaches employed and in terms of how heterogeneity in the subsequent
management of patients was characterised. In terms of the analytic approaches, Wade et al.30 employed a
cohort approach, utilising several hundred mutually exclusive states. The patient-level approach employed by
Whyte et al.124 resulted in a more efficient overall structure, albeit potentially at the computational expense of
requiring 1,000,000 individual patients to be simulated to derive expected values for costs and outcomes.
In terms of characterising the subsequent management of patients, the study by Wade et al.30 assigned
probabilities to different management strategies based on clinical practice reported in the Gateshead study.
The study by Whyte et al.124 characterised the different management strategies as a source of observable
heterogeneity (as opposed to a source of uncertainty) and hence reported estimates to reflect three different
types of clinical practice defined in accordance with clinic type (i.e. see-and-treat, treat-later/watchful-waiting
and triage clinics). The approach by Whyte et al.124 may confer potential advantages compared with treating
treatment practice as an uncertain variable (and hence assigning a probability to subsequent management
strategies), as it provides a basis both for determining how the cost-effectiveness of the adjunctive
technologies might vary in accordance with different clinical practices, as well as potentially informing the
efficiency of these practices.
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The studies also differed in terms of several key inputs. The most notable differences were in the source
of transition probabilities for the natural history model, which was derived from different studies, and
particularly the costs of biopsy and LLETZ. The impact of the different natural history transition probabilities
is not possible to determine, although the rationale for using a data set of only 84 patients was not clearly
reported by Whyte et al.124 In contrast, the impact of different costs for biopsies and LLETZ was identified
as an important factor by Whyte et al.124
Both studies also share two important and common limitations. First, both studies acknowledged a key
assumption that followed from the use of diagnostic accuracy data based on a CIN 2+ cut-off point and
the dichotomous classification of the performance of the diagnostic technologies; that is, the probability
of a positive colposcopy result (CIN 2+) is assumed to be identical within the clear, HPV and CIN 1 states
and within the CIN 2/3 and invasive cancer states. Second, both studies acknowledged that there may be
additional risks of treatment (e.g. fertility and adverse obstetric outcomes), but neither study considered
that these risks could be formally quantified, given the sparseness of, and conflicting results from, existing
studies. To address the issues and uncertainties identified in the review, and particularly to inform the
cost-effectiveness of both adjunctive technologies under both HPV triage and HPV primary screening
protocols, a new independent model was developed.
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Chapter 5 Independent economic assessment:
York model
Overview
Chapter 4 identified a number of issues and uncertainties arising from previously published studies.
A number of important limitations were also identified in relation to the current decision problem,
specifically (1) the lack of any previously published studies reporting on the cost-effectiveness of the
commercial version of ZedScan (ZedScan), (2) the lack of any attempt to formally compare different
adjunctive technologies and (3) the absence of any studies evaluating the cost-effectiveness of either DySIS
or ZedScan within a HPV primary screening protocol. For this reason, it has been necessary to develop a de
novo decision model (hereafter referred to as the ‘York model’).
The York model was developed to estimate the cost-effectiveness of adjunctive colposcopy technologies
(DySIS with DySISmap and ZedScan) for people who are referred for colposcopy through the NHSCSP,
under either HPV triage (including test of cure) or the HPV primary screening protocol (including test of
cure). The York model is implemented using a patient-level, state-transition modelling approach.
The model provides a link between diagnostic test accuracy and final health outcomes expressed in terms of
QALYs. This is necessary in order to provide decision-makers with an indication of the health gain achieved
by adjunctive colposcopy technologies, relative to their additional cost, in units that permit comparison
with other uses of health service resources. This requires consideration of how each technology has an
impact on the identification of cancerous and precancerous cervical tissue and linking this identification
to treatment or monitoring options and their effect on disease progression. The model also includes the
impact of the technologies on unnecessary biopsies and excisions, which may increase the risk of adverse
obstetric outcomes.
The incremental cost-effectiveness of adjunctive colposcopy technologies (DySIS with DySISmap and
ZedScan, hereafter referred to as ‘DySIS’ and ‘ZedScan’) compared with that of conventional colposcopy
alone is determined based on an assessment of long-term NHS and Personal Social Services costs and
QALYs. The time horizon of the model is a lifetime (60 years), costs and outcomes are discounted at 3.5%
per annum, and a 2015–16 price year is used.
Contribution of the York model
Although the York model shares some of the assumptions and parameters from existing studies, it also
provides a number of significant developments to existing cost-effectiveness analyses.
In the previous model used to inform DA4 (Wade et al.30), the model structure required the probability of
the diagnoses of the different stages of the disease, whether these were correct or incorrect, conditional on
a patient’s true health state. Consequently, Wade et al.30 used more granular data from Gallwas et al.,126
which were based on another technology (Niris Imaging System), with the assumptions that the results
from this study were reliable and generalisable to colposcopy alone and DySIS (S Eggington, personal
communication). As previously highlighted in Chapter 4, the study by Gallwas et al.126 was subject to a
significant level of bias, and the use of data from another technology to inform the diagnosis accuracy of
colposcopy and DySIS could be seen as an important limitation.
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In the York model, the treatment pathways depend on the reason for referral (cytology result) and the
dichotomous colposcopy result (CIN 2+) only. This allows for the use of diagnostic accuracy estimates with
a CIN 2+ cut-off point. For patients referred for having low-grade dyskaryosis with a negative colposcopy
result, the treatment pathway is identical whether the patients are diagnosed by the colposcopist as being
clear, being infected with HPV or having CIN 1. For patients referred as having high-grade dyskaryosis
and/or with a positive colposcopy result, a biopsy will be systematically performed, revealing the patient’s
true underlying health state.
The York model still relies on two key assumptions: (1) the biopsy and the histopathology test are 100%
accurate and (2) the probability of a positive colposcopy result (CIN 2+) is identical for patients who are clear,
patients who are infected with HPV and patients with CIN 1, CIN 2/3 and invasive cancer. However, based
on additional data provided by the DySIS manufacturer on the diagnostic accuracy of colposcopy alone and
DySIS, we are able to explore the impact of the second assumption on the cost-effectiveness results.
An important limitation of the two cost-effectiveness studies identified (Wade et al.30 and Whyte et al.124)
is that neither of the studies formally modelled the long-term adverse consequences of treatment excision.
Based on more recent evidence of the impact of treatment on obstetric outcomes (Kyrgiou et al.119), the
York model includes the excess risk of preterm delivery for women who received LLETZ. We were therefore
able to measure the consequences of an increase in treatments that arise from the higher sensitivity and
lower specificity of adjunctive technologies than those of conventional colposcopy alone.
Finally, an important contribution of the York model is to inform the cost-effectiveness of adjunctive
technologies under the HPV primary screening protocol. The implementation of HPV primary screening has
two main consequences for the economic evaluation of adjunctive technologies: (1) the routine screening
pathway is different and (2) the characteristics of the population referred for colposcopy are likely to
be different. The impact of both of these issues is an important consideration regarding the possible
differences in the cost-effectiveness of adjunctive colposcopy technologies under the current and potential
future screening programmes.
Model structure
Choice of modelling approach
State-transition models can be used to conceptualise a decision problem in terms of the health states or
conditions that individuals can be in (‘states’), how individuals move among these states (‘transitions’)
and how likely such moves are [‘transition probabilities’ (Siebert et al.145)]. State values (sometimes called
‘rewards’) are used to reflect the costs and HRQoL implications of residing in, or transitioning between,
each health state. Estimates of expected costs and QALYs are derived by assigning state values to the time
spent by patients in each health state.
A state-transition model is appropriate for modelling events, such as routine screening tests, that occur
at fixed points of time and for conditions that have health states that may change repeatedly over time.
Disease progression can be characterised in a state-transition model as a set of transitions among the
states for time periods, typically of fixed duration (e.g. months, years).
State-transition models can use either a patient-level or a cohort-level (Markov) modelling approach to
estimate the expected costs and outcomes across a particular population (Davis et al.146). In a patient-level
simulation, the costs and outcomes for individual patients are modelled and the expected (mean) values
are derived from an average taken across the entire sample of patients. In a cohort approach, the expected
cost and outcomes are estimated for an entire cohort and hence the costs and outcomes for individual
patients are not explicitly modelled. The choice between using a patient-level simulation and a cohort
approach requires careful consideration and appropriate justification (Davis et al.146).
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The challenge for a cohort approach arises from the complexity that comes from interactions between
the natural history model (Figure 10) and the screening and treatment pathways (Figure 11). The natural
history of cervical cancer can be schematically represented as an eight-state state-transition model (see
Natural history model for further details). Such a model could be implemented using either a patient-level
simulation or cohort approach. The main consideration in determining the choice of modelling approach is
whether or not the ‘Markovian’ assumption (i.e. that transition probabilities do not depend on past history
or time in state), which underpins the cohort approach, is appropriate. Inevitably, transitions between
the natural history states will depend both on patient characteristics and also on patient history through
previous screening outcomes (e.g. being referred to CIN 1 follow-up) or treatment outcomes (e.g. being
cured of CIN 2/3). Appropriately accounting for patient heterogeneity and history using a cohort approach
would require a series of subcohorts, which exponentially increases the required number of model states
and would require hundreds of mutually exclusive states to be characterised. In this context, a cohort
model becomes increasingly difficult to implement and manage. In contrast, patient-level state-transition
models are not limited by the Markovian assumption, ensuring that transitions can appropriately reflect
both individual patient characteristics and their history (using ‘tracker variables’). As a result, the
complexities with the current decision problem can be more efficiently characterised using a patient-level
simulation by significantly reducing the number of mutually exclusive states that are required.
Patient-level Monte Carlo simulation
The model simulates individuals’ experiences with a Monte Carlo simulation and can be formally defined
as a state-transition, patient-level Monte Carlo simulation. A patient-level model estimates the mean costs
and benefits for a group of patients by considering the costs and benefits of each individual within the
group. Each individual has specific characteristics that both affect and depend on the occurrence of events
and associated transitions. In the present model, these characteristics are age, health state (clear, HPV, CIN 1,
CIN 2/3, cancer), reason for referral to colposcopy (high-grade or low-grade dyskaryosis), next scheduled
screening (routine call, 6-month cytology, 6-month colposcopy, test of cure, CIN 1 follow-up), time elapsed
since last screening and type of clinic visited by the patient (see and treat or watchful waiting).
A cycle length of 6 months was selected, as this is the shortest time between repeat colposcopies. The
cytology retesting (when inadequate) is the only event in the model that occurs after 3 months and can
easily be taken into account in the 6-month probability of having a twice-inadequate cytology result.
A 6-month cycle also avoids the computational burden of having to double the total number of cycles
per individual simulation.
Death Cancer
(distant)
Cancer
(regional)
Cancer
(local)
CIN 2/3CIN 1HPVClear
FIGURE 10 Natural history of cervical cancer.
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The decision-analytic model simulates for each patient the occurrence of uncertain events, such as disease
progression, diagnostic results or treatment outcomes with a random walk (i.e. a series of uniform,
pseudo-random numbers). A large number of simulations ensure that the proportion of patients in each
state equals the individual probability. It is important to notice that a large number of simulations will
appropriately characterise first-order uncertainty (i.e. the variability in the simulated experiences between
patients), but not second-order uncertainty, which is linked to uncertainty around parameter values.
Implementation and schematics
The model is implemented with the TreeAge Pro 2016 software (TreeAge Software, Inc., Williamstown,
MA, USA) and was run to simulate 500,000 women who were referred for an initial colposcopy
appointment. The model has a decision tree structure, which represents events occurring sequentially as a
pathway that is followed by individual patients. ‘Logic nodes’ (circles with an ‘L’ in the schematics) are
used when the occurrence of the event is certain and depends on a patient’s characteristics only. ‘Chance
nodes’ (an empty circle in the schematics) are used when the occurrence of the event is uncertain and
depends on a probability. ‘Clones’ refer to subparts of the model that are common to different pathways
(such as the natural history subpart) and therefore do not appear on the schematics for the sake of clarity.
A triangle marks the end of a cycle; if the patient is still alive at the end of the cycle, they enter the model
again; if they die, from cancer or other causes, they exit the model. The model structure is identical for
the three strategies (colposcopy alone, DySIS and ZedScan), and only the input parameters vary (diagnostic
accuracy and costs).
Main features of the model
The model can be separated into three main elements: (1) a natural history model, (2) screening and
treatment pathways and (3) adverse obstetric outcomes. Although the time within each 6-month cycle is
not explicitly modelled, screening events are assumed to occur before the natural history transitions,
Death
Patients
cured
Patients
not cured
Treatment No treatment
Treatment pathway
Colposcopy
Patients not referred
for colposcopy
Patients referred for colposcopy:
true underlying health state
reason for referral
Enter as
‘clear’
Keep same
health state
Keep same
health state
CIN1 follow-up
12 months
Follow-up cytology
6 months
Follow-up
colposcopy
6 months
Clinical
indications
(cancer
symptoms)
Test of cure
6 months
Routine screening
3–5 years
Screening pathway (cytology and/or HPV tests)
Natural history model
FIGURE 11 Links between screening, treatment pathways and the natural history model.
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because treatment outcomes may affect a patient’s health state. The natural history model is derived from
a widely used epidemiological model of cervical cancer and is discussed in more detail in Natural history
model. Screening and treatment pathways are modelled based on NHSCSP guidelines15 and expert
clinical opinion.15
A patient enters the natural history model at each 6-month cycle. However, they do not necessarily
experience a screening episode every 6 months. Indeed, the occurrence of screening events depends on
the patient’s characteristics (age, cancer symptoms) and history (previous exams and treatment). A patient
who received treatment faces a risk of adverse obstetric outcomes every year.
Natural history model
The natural history model (see Appendix 10, Figure 23) captures the progression of cervical cancer from
the ‘clear’ state to stage 3 (distant) of invasive cancer. A patient enters the model with an initial health
state and faces a 6-month transition probability to stay in the same state, progress or regress. The
probability will determine the patient’s subsequent health state at the beginning of the next cycle.
The natural history model incorporates eight health states: clear, HPV infection without precancerous
lesion, CIN 1, CIN 2/3, invasive cancer (local, regional and distant) and death. The structure of the natural
history model is derived from Kulasingam et al.,147 an update of Myers et al.,128 which was used for the
previous cost-effectiveness model by Wade et al.30 Consequently, it relies on similar structural assumptions:
HPV infection is a precondition to developing precancerous lesions, CIN 2 and CIN 3 are modelled as a
single combined health state and patients are assumed to be cured from cancer if they survive for 5 years
after treatment. The only update to the previous model is that HPV patients are allowed to develop CIN 2/3
within 6 months based on new evidence reported by Kulasingam et al.147 on the possibility that women can
progress in a short amount of time from being infected with HPV to developing CIN 2/3.
The modelling of cancer progression relies on several assumptions; most of these are similar to those in
the previous model by Wade et al.:30 cancer cannot be cured without treatment and a patient progresses
across stages until they receive treatment (i.e. while cancer remains undetected). Although Wade et al.30
modelled cancer progression with four stages, our model considers only three stages (local, regional and
distant). Indeed, the progression and mortality rates have been updated, based on a study by Campos
et al.,148 which relied on a three-stage model. Consistently with Wade et al.,30 a patient with undetected
cancer faces a 6-month probability to develop symptoms; the model assumes that a patient with
symptoms is immediately referred for colposcopy, identified and treated.30 When asymptomatic cancer is
detected by the NHSCSP, it is assumed that the patient is in stage 1 of the model (local). A patient who
survives for 5 years after treatment is assumed to be cured and is back to the ‘clear’ health state.
Screening and treatment pathways
At the beginning of each cycle, the patient follows one of four main screening and treatment pathways
(which all end with the natural history model):
1. No screening – the patient directly enters the natural history model.
2. Colposcopy pathway – the patient is directly referred for colposcopy (first cycle and cancer symptoms).
3. Routine screening – the patient is recalled to routine screening every 3 or 5 years after their last test,
depending on their age.
4. Follow-up pathways – after treatment, diagnosis or an inadequate result, the patient may be referred to
follow-up, such as a test of cure (6 months after treatment), cytology and/or colposcopy (6 months after
the initial test) or CIN 1 follow-up (12 months after diagnosis).
During the first cycle, all patients have a colposcopy examination with different outcomes depending on
their health state, the reason for referral and the diagnostic accuracy of the colposcopy technologies.
After the first cycle, subsequent examinations (follow-up or routine screening) depend on the patient’s
characteristics and history.
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Colposcopy pathway
All patients are directed to the colposcopy pathway during the initial cycle. Patients can also be referred
for colposcopy subsequently after routine screening or follow-up tests, or directly, if they develop cancer
symptoms. A patient who has a colposcopy is characterised by their health state, the reason for their referral
(low-grade or high-grade dyskaryosis) and the type of clinic they visit (see-and-treat or watchful-waiting
clinic). These characteristics affect the diagnostic and treatment outcomes (see Appendix 10, Figure 24).
The diagnostic outcome is modelled as the probability of being diagnosed after colposcopy as having CIN 2
or worse (‘colposcopy positive’). This probability depends on a patient’s health state and the diagnostic
accuracy of colposcopy and adjunctive colposcopy technologies.
According to the NHSCSP guidelines15 and clinical experts, there are two possible types of management
following a positive colposcopy result.15 A patient with suspected CIN 2 or worse can be treated immediately
after colposcopy during the same appointment. An excision sample is then sent for histopathology to
confirm the initial diagnosis. The alternative is to perform a diagnostic biopsy, wait for histopathology to
confirm CIN 2 or worse and treat the patient during a second colposcopy appointment. To take into account
the heterogeneity in clinical practice and to analyse the cost-effectiveness of colposcopy devices in different
settings, the model considers two types of clinics: ‘see-and-treat’ clinics and ‘watchful-waiting’ clinics.
Modelling practice heterogeneity requires two further assumptions. First, the choice between see-and-treat
clinics and watchful-waiting clinics is assumed to be independent of diagnostic accuracy. Instead, it is
modelled as a patient characteristic; patients visit either a see-and-treat clinic or a watchful-waiting clinic.
Second, based on the NHSCSP guidelines15 and usual practice reported by clinical experts, immediate
treatment after colposcopy is performed only when both cytology and colposcopy indicate CIN 2 or worse
(i.e. for patients with a referral based on high-grade dyskaryosis and a positive colposcopy result).15 For all
other patients (referral based on low-grade dyskaryosis with a positive colposcopy result and referral based
on high-grade dyskaryosis with a negative colposcopy result), a diagnostic biopsy is performed and the
patient is called again for colposcopy and a treatment biopsy if necessary. Patients with a referral based on
low-grade dyskaryosis with a negative colposcopy result do not receive any diagnostic biopsy or treatment.
The diagnostic outcome, the reason for referral and a patient’s health state (revealed by diagnostic biopsy)
determine future screening tests. Patients with a referral based on low-grade dyskaryosis and a normal
colposcopy result or histopathology results are discharged from the colposcopy clinic and sent back to
routine screening. Patients with a referral based on high-grade dyskaryosis but normal histopathology
results are not discharged and are sent to a 6-month colposcopy follow-up. Based on the NHSCSP
guidance, confirmed CIN 1 lesions are not treated, but patients are sent to receive a CIN 1 follow-up
12 months later.15 Confirmed CIN 2/3 lesions are systematically treated and patients are sent to receive a
test of cure 6 months later. A patient who has been treated for CIN lesions faces a probability to be cured.
If the treatment is successful, they enter the natural history model in the ‘clear’ health state. If a patient
has not received treatment or if the treatment has failed, they enter the natural history model with their
initial health state. Patients who are diagnosed with cancer are assumed to be immediately treated and
enter the natural history model with the ‘cancer/treated’ health state.
A key assumption is that diagnostic biopsy is assumed to be 100% specific and sensitive; it always reveals
a patient’s true underlying health state. Consequently, watchful-waiting clinics never perform unnecessary
treatments and patients referred for colposcopy with cancer symptoms, considered as having a referral for
high-grade dyskaryosis, are always diagnosed and treated appropriately. The model does not consider
conservative management for CIN 2 lesions.
Routine screening
The NHSCSP invites women aged 25–64 years to have a cervical screening test. Women aged < 50 years
are invited 3 years after their last test, and women aged > 50 years are invited 5 years after their last test.
Women who have been treated for precancerous lesions are invited 3 years after their last test, regardless
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of age. The model therefore keeps track of a patient’s age as well as the number of cycles elapsed since
their last screening.
Cervical cytology test results are graded depending on the degree of abnormality. To be consistent
with the data used for the diagnostic accuracy of cytology, the model refers to the previous NHS system
terminology (British Society for Clinical Cytology 1986) and considers six possible cytology results:
(1) negative, (2) inadequate, (3) borderline change, (4) mild dyskaryosis, (5) moderate dyskaryosis and
(6) severe dyskaryosis. The current NHS system terminology (ABC3) is used in a second step to characterise
patients referred for colposcopy: borderline change and mild dyskaryosis are defined as being low grade,
whereas moderate or severe dyskaryosis is defined as being high grade.
The current management protocol is described in the NHSCSP colposcopy and programme management
and referred to as ‘HPV triage’ (Figure 12).15 An alternative protocol, known as ‘HPV primary’, has been
implemented in pilot sites across England and is to be rolled out in the future within the NHSCSP (Figure 13).
The cost-effectiveness analysis considers these two protocols using separate models.
Human papillomavirus triage Under HPV triage, the patient is first tested with cytology. The diagnostic
outcome is modelled as a probability of having a cytology result, r, given the underlying health state h.
This probability depends on the cytology test performance. If the cytology is negative, the patient is sent
back to routine screening and will be invited again 3 or 5 years later. When the cytology shows moderate
or severe dyskaryosis, the patient is referred for colposcopy as a high-grade referral. When the cytology
shows borderline changes or mild dyskaryosis, the sample collected during the cervical screening is used
for hrHPV testing. The probability of being HPV-positive depends on the cytology result, the patient’s
health state and the patient’s age. When HPV is detected, the patient is referred for colposcopy as a
low-grade referral. Otherwise, she is sent back to routine screening. When the cytology is inadequate, the
patient is tested again 3 months later. Because the cycle length is 6 months in the model, the probability
of having a first inadequate result is included in the probability of having a negative, borderline, mild,
moderate or severe cytology result. In the case of two consecutive inadequate results, the patient is invited
3 months later for another cytology test (i.e. 6 months after her initial cytology test). The protocol is similar
to routine screening (under HPV triage), except that a patient with a third inadequate cytology result is
referred for colposcopy. Although a patient with three inadequate cytology results is not defined as having
low-grade dyskaryosis based on the ABC3 reporting terminology, clinical experts confirm that management
after colposcopy is similar to that in low-grade dyskaryosis patients, hence the low-grade referral used in
the model.
Human papillomavirus primary screening Under HPV primary screening, the patient is first tested for
hrHPV. If the HPV test is negative, the patient is sent back to routine screening. If the HPV test is positive,
a cytology test is used as a triage to refer patients for colposcopy. A patient with a borderline/mild or
moderate/severe cytology result is immediately referred for colposcopy, as a low-grade referral or a high-
grade referral, respectively. Similarly to the HPV triage, patients are tested again 3 months after a first
inadequate cytology result. Consequently, in the model, the probability of having a first inadequate result
is included in the probability of having a negative, borderline, mild, moderate or severe cytology result.
If the cytology is inadequate or negative twice, the patient is rescreened 12 months later (‘HPV primary
rescreen at 12 months’ in the model).The 12-month follow-up protocol is similar to the initial routine
test, except that a patient with inadequate cytology is referred for colposcopy. Patients with a second
consecutive HPV-positive/cytology-negative result are rescreened 12 months later (i.e. 24 months after the
initial test (‘HPV primary rescreen at 24 months’ in the model). In this case, a HPV-positive test result is
sufficient for a patient to be referred for colposcopy. A patient with a HPV-negative test result is sent back
to routine screening. Because HPV primary screening has not been implemented yet, there are uncertainties
regarding the post-colposcopy management of patients with two consecutive negative cytology results.
Indeed, under the HPV triage protocol, these patients were not referred to colposcopy clinics. According
to clinical experts, it is likely that these patients would be managed in the same way as those with
low-grade referrals.
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FIGURE 12 Human papillomavirus triage: routine screening and follow-up.
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FIGURE 13 Human papillomavirus primary: routine screening and follow-up.
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Follow-up: test of cure
Based on the NHSCSP guidelines,15 patients who receive treatment for CIN lesions are tested 6 months
later (see Appendix 10, Figure 25). As the model assumes that screening occurs at the beginning of a
6-month cycle, patients who have been treated during a specific cycle will be sent to the test-of-cure
pathway at the next cycle. First, the patient is tested with a cytology test. In the case of inadequate,
moderate or severe results, the patient is directly referred for colposcopy (with either a low-grade referral
or a high-grade referral). When the cytology results are negative, borderline or mild, the patient is tested
for HPV and referred for colposcopy as a low-grade referral if the HPV test is positive. The patient then
enters the colposcopy pathway as described previously. When the HPV test is negative, the patient is sent
back to routine screening and enters the natural history model.
Follow-up: colposcopy at 6 months
The NHSCSP guidelines15 do not explicitly define the ‘colposcopy at 6 months’ pathway. However, clinical
experts suggest that a patient with a referral for high-grade dyskaryosis and negative histopathology is
usually not discharged from the colposcopy clinic. The patient will be tested again with cytology and
colposcopy 6 months later (see Appendix 10, Figure 26). Given that high-grade dyskaryosis has been
previously identified, a HPV test is unlikely.
Follow-up: cervical intraepithelial neoplasia 1 follow-up
The NHSCSP guidelines15 recommend conservative management for confirmed CIN 1 lesions. Instead
of receiving treatment biopsy, the patient is tested 12 months after the first diagnosis. If CIN 1 is still
present, she is tested again 12 months later. According to clinical experts, there is heterogeneity in the
management of CIN 1 follow-up. It is most likely that the patient is sent back to the community and
follows a similar pathway to routine screening (see Appendix 10, Figure 27). The model assumes that in
the case of a positive colposcopy result and/or a high-grade referral, a diagnostic biopsy is systematically
performed (no ‘see and treat’). Based on the NHSCSP guidelines,15 confirmed CIN 1 is treated only if
lesions are persistent after 24 months. When the CIN 2/3 lesions or cancer are detected at any stage,
the patient receives appropriate treatment.
Adverse obstetric outcomes
The adverse obstetric outcomes model (see Appendix 10, Figure 28) captures the impact of treatment for
CIN on the adverse obstetric outcomes. The findings from two recent systematic reviews were previously
summarised and discussed in Chapter 3, Systematic reviews of adverse outcomes of cervical intraepithelial
neoplasia treatment. The two reviews reported results across a range of adverse fertility, pregnancy and
obstetric outcomes. In the absence of robust evidence indicating an adverse treatment effect on fertility
and early pregnancy (< 24 weeks’ gestation) outcomes, the adverse obstetric outcome model was limited
to capturing the impact of an increased risk of preterm birth reported by Kyrgiou et al.119
Following treatment for CIN, the adverse obstetric outcomes model captures the excess risk of treatment
on preterm birth (< 37 weeks’ gestation) rates and applies a payoff to capture the associated costs and
QALY decrements. As the model attempts to characterise the excess treatment risk only, only women who
receive treatment for CIN enter the adverse obstetric outcome model. Within the model, a tracker variable
is assigned to an individual patient following treatment with CIN. For each 12-month period following
treatment (and up to the age of 45 years), the model captures the excess risk of preterm birth (< 37 weeks’
gestation) based on age-specific conception rates (adjusted for legal abortion), the risk of preterm birth for
untreated women and the higher RR reported with treatment. The cost and QALY decrements capture the
additional initial management costs associated with preterm birth and the increased probability of neonatal
mortality, as well as the QALY decrements associated with higher risks of disability among survivors.
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Model input parameters
Diagnostic accuracy
Colposcopy and adjunctive technologies
The sensitivity and specificity of colposcopy alone and the adjunctive use of DySIS and ZedScan are based
on the best-evidence estimates of diagnostic accuracy reported in Chapter 3, Comparison of Dynamic
Spectral Imaging System and Zedscan. An assumption is made that the binocular and video colposcopes
have the same diagnostic performance and hence the diagnostic accuracy of colposcopy is based on the
evidence reported in the DySIS studies. From the estimates of diagnostic accuracy, we derive the probability
of a positive colposcopy result (i.e. CIN 2 or greater), given a patient’s true underlying health state. A key
assumption is that the probability of a positive colposcopy result is similar for patients who are clear or
have CIN 1 and for patients with CIN 2/3 or invasive cancer. A consequence of the CIN 2 threshold is that
detecting CIN 1 during the colposcopy examination is not considered to be a positive colposcopy result.
However, if the patient is referred for having high-grade dyskaryosis, a diagnostic biopsy will systematically
reveal CIN 1 and the patient will be managed appropriately.
Based on the limitations identified in the clinical effectiveness review section, and particularly the lack
of data on the diagnostic accuracy of colposcopy alone compared with the current version of ZedScan,
separate pairwise analyses are presented comparing adjunctive DySIS with colposcopy alone, ZedScan with
colposcopy alone and ZedScan with DySIS. Table 18 details the sensitivities and specificities used in the
base-case analyses.
Cytology and human papillomavirus tests
The performance of cytology and HPV tests is also required for the model when patients are recalled for
routine screening or follow-up (cytology at 6 months, test of cure, CIN 1 follow-up).
The performance of cytology test is modelled as the probability of having a certain cytology result (negative,
borderline changes, mild dyskaryosis, moderate dyskaryosis, severe dyskaryosis), given a patient’s true
underlying health state (Table 19). The diagnostic accuracy of cytology was derived from a published
UK-based study on the cost-effectiveness of the NHSCSP [Hadwin et al.125 – the probabilities were displayed
in an unpublished document (S Eggington, personal communication)]. The probability of an inadequate
cytology result was estimated to be 2.7%, based on Cervical Screening Programme, England – 2015–2016.18
The probability of having an inadequate cytology result is assumed to be independent of a patient’s
underlying health state and previous cytology results. These data were used for both HPV triage and the HPV
primary screening protocol.
The performance of the HPV test is modelled as the probability of having a positive HPV test result
given the patient’s true underlying health state, cytology result and age. The diagnostic accuracy of
the HPV test under the HPV triage protocol (i.e. after a borderline or mild cytology result) was based on
Cotton et al.127 using data from the TOMBOLA trial.130 The TOMBOLA trial aimed to compare different
methods of management for women with low-grade cervical abnormalities under the NHSCSP in the UK.
The study included 4439 women between 1999 and 2002, aged 20–59 years, with a cytology test
showing borderline nuclear abnormalities or mild dyskaryosis. A cross-sectional analysis of trial data
TABLE 18 Sensitivities and specificities used in the base-case analyses: CIN 2+ cut-off point
Technology Sensitivity, % (95% CI) Specificity, % (95% CI) Source
Colposcopy alone 57.91 (47.2 to 67.9) 87.41 (81.7 to 91.5) Regression model
DySIS 81.25 (72.2 to 87.9) 70.40 (59.4 to 79.5) Regression model
ZedScan 97.85 (96.5 to 99.2) 58.63 (55.1 to 62.1) Tidy et al.94
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provided the sensitivity and specificity of a single HPV test in detecting CIN 2 or worse by cytology result
and age (Table 20). Under the HPV primary screening protocol, the probabilities of a positive HPV test
result by health state were derived from the ARTISTIC (A Randomised Trial in Screening to Improve
Cytology) study, which based these estimates on extensive data in the literature on hrHPV testing
[Kitchener et al.149 (Table 21)].
TABLE 20 Human papillomavirus triage protocol: sensitivity and specificity (detecting CIN 2+) of the HPV test by
previous cytology result and age group
Age group (years)
Sensitivity, % Specificity, %
Source
Borderline
cytology
Mild
cytology
Borderline
cytology
Mild
cytology
20–24 79.7 80.8 46.3 32.5 Cotton et al.127
25–29 74.3 76.0 63.0 43.2 Cotton et al.127
30–39 66.7 70.5 73.4 52.2 Cotton et al.127
40–59 31.3 64.7 86.5 63.6 Cotton et al.127
TABLE 19 Probability of cytology results, given a patient’s true underlying health state (HPV triage and HPV
primary protocols)
Cytology result
Probability of cytology result by health state
SourceClear HPV CIN 1 CIN 2/3 Cancer
Inadequate 0.027 0.027 0.027 0.027 0.027 Cervical Screening Programme,
England – 2015–201618
Borderline 0.002 0.266 0.262 0.086 0.082a Hadwin et al.125
Mild 0.003 0.077 0.213 0.126 0.134a Hadwin et al.125
Moderate 0.001 0.065 0.148 0.187 0.153a Hadwin et al.125
Severe 0.000 0.025 0.056 0.228 0.604a Hadwin et al.125
a Adjusted for higher inadequate results.
TABLE 21 The HPV primary protocol: probabilities of a positive HPV test, by health state
Health state Probability of a positive HPV test Source
Clear 0.014 Kitchener et al.149
HPV 0.821 Kitchener et al.149
CIN 1 0.842 Kitchener et al.149
CIN 2/3 0.955 Kitchener et al.149
Cancer 0.957 Kitchener et al.149
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Underlying health state and reason for referral
Women referred for colposcopy from the NHSCSP enter the model with two initial characteristics: a true
underlying health state (clear, HPV, CIN 1, CIN 2/3 or cancer) and a reason for referral (low-grade or
high-grade dyskaryosis). The joint distribution of health state and the reason for referral is linked to disease
prevalence as well as routine screening diagnostic accuracy. For instance, the distribution under HPV triage
is likely to be different from the distribution under HPV primary screening. For example, HPV primary
screening is expected to be more sensitive (i.e. more CIN 2+ cases are likely to be referred for colposcopy)
but less specific, leading to more low-grade referrals. Consequently, different estimates are used for the
HPV triage and HPV primary screening protocols.
Human papillomavirus triage
Table 55 in Appendix 11 reports the joint distribution of the health state and the reason for referral in a
HPV triage protocol. Because the HPV triage protocol is currently implemented in the NHSCSP in England,
the joint distribution of the health state and the reason for referral was based on the outcomes of
colposcopy referrals published in Cervical Screening Programme, England – 2015–2016.18 From April 2015
to June 2015, all 55 operating laboratories in England collected outcomes of colposcopy referrals and
linked these results to the reason for referral. Consistently with the model structure, women who were
referred after non-negative samples showing either BMD with a positive HPV test or persistent inadequate
results were considered as having a low-grade referral. Women who were referred after a potentially
significant abnormality, including high-grade dyskaryosis (moderate or severe); high-grade, invasive
squamous carcinoma; or glandular neoplasia of the endocervical type, were considered as having a
high-grade referral. In total, 31,114 samples were collected. We excluded 570 cases whose results were
unknown or showed non-cervical cancer. Of the remaining 30,544 women, 68.6% had a low-grade
referral and 31.4% had a high-grade referral. The outcomes of colposcopy referral (cervical cancer,
CIN 3, CIN 2, CIN 1, HPV only, no CIN/no HPV) were confirmed by biopsy when the colposcopy revealed
an abnormality. When no abnormalities were detected at the colposcopy examination, patients were
considered to be ‘clear’. However, because colposcopy is not 100% sensitive, an unknown proportion of
patients with no abnormality detected might have been misdiagnosed. Consequently, the distribution may
underestimate the proportion of CIN 2 and worse in the population.
Human papillomavirus primary screening
Table 56 in Appendix 11 reports the joint distribution of the health state and the reason for referral in a
HPV primary screening protocol. The data came from unpublished preliminary results collected in the HPV
primary pilot sites and included a total of 15,781 women referred for colposcopy. A total of 12,626 women
were referred after the first round of routine screening (HPV-positive result and cytology result of borderline
dyskaryosis or worse), 2628 women were referred after the second round of screening (12-month repeat)
and 527 women were referred after the third round of screening (24-month repeat). As expected, the
proportion of low-grade referrals under the HPV primary screening protocol was slightly higher than that
under the HPV triage protocol (70.56% vs. 68.6%).
However, these preliminary results must be interpreted with caution. First, data collection is still incomplete,
especially for women referred after the third round of screening. Second, around 70% of the data on HPV
primary screening (n = 11,139) came from laboratories that were implementing the HPV genotyping triage.
During the second round of screening, women detected as being infected with HPV 16/18 were immediately
referred for colposcopy, even if their cytology test result was negative. The impact of genotyping on the
characteristics of the population referred for colposcopy is hard to predict, with potentially more low-grade
referrals (women with HPV-positive and cytology-negative results are referred sooner), but also more severe
cases resulting from the presence of HPV 16/18. Finally, because pilot sites were not randomly selected, we
can expect selection issues, and especially variability, in the prevalence of HPV and CIN lesions compared
with that in the general population, regardless of the impact of a change in the routine screening protocol.
For the analysis on the HPV primary screening protocol, we used data reported by all pilot sites (with and
without genotyping) as a base case (see Table 56) and provided sensitivity analyses around the characteristics
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of the initial population using data from pilot sites that are and are not implementing genotyping
(see Underlying health state and reason for referral).
Treatment probabilities
See-and-treat and watchful-waiting clinics
Treatment decisions after a positive colposcopy result (i.e. diagnostic biopsy or immediate treatment)
vary considerably across England. Currently, for women referred with high-grade abnormalities, the most
common treatment at first attendance is excision (53.2%), followed by diagnostic biopsy (35%). The use
of excision at first attendance for women with high-grade referrals ranges from 11.6% in London to
65.4% in the North West of England (Cervical Screening Programme, England – 2015–2016).18
Heterogeneity in treatment decisions after a positive colposcopy result is modelled as two different types
of clinic a patient may visit, and is independent of health state or diagnostic accuracy. A patient may visit
either a ‘see-and-treat’ clinic or a ‘watchful-waiting’ clinic. Because the NHSCSP guidance states that
the PPV for CIN 2 or worse should be at least 90% to undergo ‘see and treat’, the model assumes that
the use of excision at first attendance is possible for women with high-grade referrals with a positive
colposcopy result only. When patients have a low-grade referral, CIN 2 or worse must be confirmed by
the diagnostic biopsy result before being treated. This assumption has been validated by clinical experts.
As the cost-effectiveness of adjunctive colposcopy devices is likely to be driven by treatment practice, the
results are presented separately for the two types of clinics. Indeed, a low specificity of colposcopy leads
to overtreatment in a ‘see-and-treat’ clinic. In contrast, because biopsy is assumed to be 100% sensitive
and specific, watchful-waiting clinics are assumed to never overtreat patients. Furthermore, watchful
waiting requires two colposcopy examinations: a first one in which a diagnostic biopsy is performed and
a second one in which CIN 2 lesions or worse are treated. However, ‘see-and-treat’ clinics require only
one colposcopy.
Probability of cure from treatment biopsy
The probability of cure after treatment biopsy was derived from a study by Ghaem-Maghami et al.150 that
reported the failure rates for 2455 women treated for CIN for the first time between 1989 and 2004.
Failure was measured by the detection of high-grade cervical disease after treatment, defined as the
cytological findings of moderate dyskaryosis or more severe or histological findings of CIN 2 or worse.
The median length of follow-up was 238 weeks. The authors reported that the cumulative failure rate at
10 years was 4.9% for CIN 1 (n = 570), 9.8% for CIN 2 (n = 886) and 10.3% for CIN 3 (n = 999). We
calculated that the weighted excision failure rate of CIN 2/3 was 10.1% (see Appendix 11, Table 57).
Probabilities of adverse obstetric outcomes
For each 12-month period following treatment, the model captures the excess risk of preterm birth
(< 37 weeks’ gestation) based on age-specific conception rates (adjusted for legal abortion), the risk of
preterm birth for untreated women and the higher RR reported with treatment.
Age-specific conception rates were derived from national conception statistics reported by the Office for
National Statistics (ONS).151 The ONS statistics bring together records of birth registrations (including live
births or stillbirths) and abortion notifications. Hence, the conception input data applied in the model do
not include conceptions resulting in miscarriages or illegal abortions. The annual probability of conception
(adjusted for legal abortion) applied in the model was derived from age-specific conception and legal
abortion rates reported per 1000 women [England and Wales (see Appendix 11, Table 58)].
The excess risk of preterm birth was then estimated, based on applying a RR representing the additional
risk following treatment for CIN to the probability of preterm birth without treatment. The increase in
RR following treatment (LLETZ) was assumed to be 1.56. This was based on the results reported by
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Kyrgiou et al.119 for all treatments in all preterm births (< 37 weeks’ gestation), when the external
comparison includes the overall population.
The RR of preterm birth was then applied to the probability of preterm birth for untreated women. The
probability of preterm birth for untreated women was assumed to be 7.3% based on data reported in
the NICE guideline on preterm labour and birth.152 Consequently, the excess risk of preterm delivery for
women treated with LLETZ was estimated to be 4.09% [0.073 × (1.56 – 1); see Appendix 11, Table 59].
Natural history model
Precancerous lesions
The transition probabilities from the ‘clear’ state to CIN 2/3 were based on the transition probabilities
reported by Kulasingam et al.,147 an update of Myers et al.128 used in Wade et al.30 Kulasingam et al.147
took into account recent evidence that, in young women (aged < 30 years), high-grade CIN may occur
early in the course of a hrHPV infection. Recent studies also suggested that CIN may be more frequent in
young women, but that progression to cancer from high-grade CIN is low. Compared with Myers et al.,128
HPV and CIN incidence and regression estimates were higher, but progression rates between CIN states
and from CIN 2/3 to cancer were lower. Transition probabilities were reported by the authors as annual
probabilities and converted to 6-month probabilities in our model (see Appendix 11, Table 60).
Invasive cancer
Table 61 in Appendix 11 reports the parameters used to estimate the likelihood of symptoms of cervical
cancer, progression across stages and cancer-related mortality. Women with undetected cancer may
progress to a more severe stage (from local to regional to distant), with an increasing probability of
developing symptoms. Once cancer is detected, the model assumes that patients will receive stage-specific
treatment and face an excess risk of mortality as a result of having cervical cancer. Cancer-specific
mortality depends on stage and decreases by time since diagnosis. After 5 years, excess mortality as a
result of having cancer is assumed to be zero and patients are assumed to be cured. We assume that
women with undetected cancer continually face the year 1 probability of cancer mortality until diagnosis.
Our estimates were based on Campos et al.,148 which reported the monthly probability of symptoms,
progression and mortality by stage (local, regional, distant). Cancer-specific mortality in Campos et al.148
was derived from the Surveillance, Epidemiology, and End Results (SEER) Programme registry data from
2000 to 2009.149 Data reported by Campos et al.,148 which were based on US registry data, appeared to be
the most recent, complete and consistent data on cancer progression and mortality. Transition probabilities
(stage progression and mortality) when cancer is not detected should not be affected by differences in care
between the USA and the UK.148
All-cause mortality
Mortality rates from causes other than cervical cancer were calculated using data from the ONS in England
and Wales in 2015.153 Deaths resulting from cervical cancer were subtracted from the total number of
deaths for each age group. The 2015 ONS data on the population for each age group were then used to
calculate an annual mortality rate, converted to a 6-month probability in the model (see Appendix 11,
Table 62).
Resource utilisation and cost data
Devices costs
The cost-effectiveness analysis requires an estimate of the average cost per procedure of each of the
technologies being assessed. A colposcopy examination with DySIS or ZedScan is assumed to be equivalent
to colposcopy alone in terms of staff resources and the length of consultation. The average cost of a
procedure includes a set-up cost, annual recurring costs and per-patient costs. Information provided by
the manufacturers has been used to estimate the costs of DySIS and ZedScan. For the purchase price and
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maintenance costs of colposcopy, we used estimates provided by clinical advisors for the previous
diagnostics assessment report (Wade et al.30) and inflated these to 2016 prices.
The set-up cost consists of the capital cost of the machine. The purchase price of each technology was
annuitised over the expected lifetime of the technology. Consistent with Wade et al.,30 the lifetime of a
colposcopy was estimated to be 15 years. The lifetimes of DySIS and ZedScan were estimated to be 5 years
each. The equivalent annual cost was calculated from the purchase price of the technology and the useful
life of the equipment using the discount rate of costs of 3.5%.
The annual maintenance cost of the colposcope was estimated to be 10% of the purchase price and
the cost of disposables was estimated to be equivalent to the cost of a speculum (£2.15). The annual
maintenance costs and disposable costs of the adjunct technologies were provided by the manufacturers.
For DySIS, the annual maintenance costs included the DySIS viewer licence registration and renewal as
well as a 5-year service and maintenance plan. The price of a DySIS disposable speculum (£3.50) was
added to the per-patient cost. The ZedScan manufacturer claimed no routine maintenance costs. However,
a single-use EIS sensor (£30.00) is required for each patient examined. To estimate the total cost per
patient, it is necessary to estimate the number of patients expected to be treated each year. We assumed
that this number was independent of the type of devices and used the previous estimate of 1229 patients
per device per year (see Appendix 11, Table 63). Sensitivity analyses were undertaken to test this particular
assumption (see Underlying health state and reason for referral). As ZedScan uses a binocular colposcope
to guide the probe or to confirm diagnosis, the cost of a colposcope was also added to its total cost. DySIS
devices already include a colposcope and therefore do not require this additional cost.
In addition to the cost related to the device itself, the costs of a colposcopy visit, diagnostic biopsy and
treatment (LLETZ) were estimated from NHS Reference Costs 2015 to 2016.154 The NHS Reference Costs
reported the costs (2016 prices) of a ‘diagnostic colposcopy’, a ‘diagnostic colposcopy with biopsy’ and a
‘therapeutic colposcopy’ (see Appendix 11, Table 64). The uncertainty surrounding whether or not the NHS
reference costs accurately reflect resource use, and in particular if these include histology/pathology costs,
is explored in a sensitivity analysis (see Underlying health state and reason for referral).
In the base case, we estimated the cost of a colposcopy visit to be £175 with a binocular colposcope,
£180.49 with DySIS and £205.52 with ZedScan. The additional costs of a diagnostic biopsy and treatment
were estimated to be £47 and £63, respectively. The costs of a cytology test and a HPV test were derived
from the TOMBOLA study,130 inflated to 2016 prices, and were estimated to be £37.19 and £29.66,
respectively (see Appendix 11, Table 65).132
Cancer costs
Cancer costs by stage were taken from a UK-based study by Martin-Hirsch et al.,155 which estimated the
costs associated with the management of women with abnormal cervical cytology. The unit costs for
cancer treatment (including chemotherapy, radiotherapy and inpatient care) were obtained by the authors
from the national reference costs, the British National Formulary156 and from personal communications
with the purchasing departments of clinics included in the study (six centres in England and Wales). The
average costs per cancer treatment were reported in pounds sterling at 2006 prices by cancer stage, using
the FIGO grading (stages I–IV). We assumed that the average cost of stage I and stage II refers to ‘local’
stage, the average cost of stage III refers to ‘regional’ stage and the average cost of ‘stage IV’ refers to
‘distant’ stage. In the model, all costs were inflated to 2016 prices (see Appendix 11, Table 66).
Costs associated with adverse obstetric outcomes
The additional costs associated with preterm birth were derived from the same source157 as the QALY
decrements. The study by Lomas et al.157 reported an expected incremental (discounted) lifetime cost of
£24,071 per birth (inflated to £24,610 in 2016 prices). This estimate incorporates an estimate of the initial
inpatient neonatal care and ongoing costs over the following 18 years of life in survivors, associated with
higher rates of disability.
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Health outcomes
Health utility values refer to the patient’s health measured on an interval scale, where 0 represents death
and 1 represents perfect health. QALY estimates combine both the utility value of health states and the
time spent in those health states, with 1 QALY representing a year in perfect health. A QALY decrement is
the decrease in health utility over a set time period converted into lost QALYs.
Screening disutility
The disutility associated with screening and treatment was based on a recent study, especially designed
to estimate utility values for HPV testing and cytology-based screening states among women targeted
for cervical screening (Simonella et al.).158 A total of 43 women (mean age 49 years), living in Sydney,
Australia, participated in the study. The participants were asked to state their preferences (rank and utility
scores) for hypothetical states relating to cytology and HPV screening and precancerous lesions. The
utility values were estimated via a two-stage standard gamble. The model uses utility values reported by
Simonella et al.158 for four types of screening episodes: (1) a routine screening episode with a normal
cytology result, (2) a false-positive referral to colposcopy, (3) a colposcopy referral that leads to confirmed
but not treated CIN 1 and (4) a colposcopy referral that leads to the treatment of CIN lesions. Each
scenario was described in a narrative format in Simonella et al.158 to characterise the screening process and
possible adverse outcomes associated with examination and treatment. Consequently, this set of values
captures the disutility associated with the screening process, from the experience of being screened (even
if the test result is negative) to the possible short-term adverse outcomes of colposcopy and treatment.
Simonella et al.158 reported the mean standard gamble utility values over a 12-month period. In the model,
we converted these scores into QALY decrements (1 – mean utility value) of undergoing a screening
episode (initial referral for colposcopy, follow-ups or routine screening). A screening episode with cytology
and/or HPV test that did not result in a referral for colposcopy induced a QALY decrement of 0.0062. The
QALY decrement associated with a false-positive referral for colposcopy (the cytology test and/or HPV test
are positive, but the colposcopy or histopathology are negative) or a confirmed but not treated CIN 1
lesion was estimated to be 0.0276. Finally, a positive diagnosis followed by excision treatment of the CIN
lesion induced a QALY decrement of 0.0296 (see Appendix 11, Table 67).
Health-related quality of life of underlying true health states
As HPV, CIN 1, CIN 2/3 and undetected cancer are considered to be asymptomatic, we applied age- and
gender-specific utilities from the Measurement and Valuation of Health survey, a nationally representative
interview survey of 3395 men and women living in the UK conducted in 1993. The objective of the survey
was to collect data on the health state valuations using a time-trade-off procedure and on individuals’
self-reported health status using the EuroQol-5 Dimensions descriptive classification system (Kind et al.)159
(see Appendix 11, Table 68). The possible disutility that patients can experience once CIN lesions are
identified is subsequently captured by screening disutility as outlined previously.
Quality-adjusted life-year decrements associated with invasive cancer were obtained from a published
study (Goldie et al.5). The authors reported the HRQoL for ‘detected invasive cancer’ and ‘after treatment
for invasive cancer’ by stage (local, regional and distant). These weights were constructed based on expert
elicitation. We considered the first set of HRQoL to be a utility score associated with the first year post
diagnosis, during which period patients undergo treatment. We used the second set for the remaining
4 years, during which time patients are not yet considered to be cured from cancer but do not receive
further treatments (see Appendix 11, Table 69).
Quality-adjusted life-year decrement associated with adverse obstetric outcomes
A QALY decrement was applied to capture the HRQoL and mortality consequences of the increased risk
of preterm birth following treatment for CIN. We did not attempt to identify evidence for this parameter
systemically. Instead, we restricted our search to the evidence reported in the NICE guideline on preterm
labour and birth (NG25);152 although this guideline reports utility and QALY estimates, none of these
directly provided the required estimates for our model (i.e. the QALY decrement associated with preterm
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birth at < 37 weeks’ gestation). Instead, we sourced estimates based on discussions with colleagues and
identified a recent study by Lomas et al.157 that reported cost and QALY decrements that matched the
requirements of the model. The QALY decrement reported in Lomas et al.157 was 1.3 QALYs and was
derived from calculations based on the QALY loss associated with neonatal mortality and the discounted
QALY loss associated with increased disability rates reported among survivors.
Analytic methods
A decision model was developed to estimate the cost-effectiveness of adjunctive colposcopy technologies
(DySIS and ZedScan) for women referred for colposcopy through the NHSCSP under either HPV triage
(including test of cure) or the HPV primary screening protocol (including test of cure).
The decision model is implemented using a patient-level state-transition modelling approach. The time
horizon of the evaluation is 60 years, the costs and outcomes are discounted at a rate of 3.5% and a
2015–16 price year is used.
The model captures the long-term impact of standard colposcopy and adjunctive colposcopy technologies
in terms of average cost and average QALYs per patient. The analysis compares colposcopy alone with
DySIS, colposcopy alone with ZedScan and DySIS with ZedScan, based on incremental costs and QALYs
and the incremental cost-effectiveness ratio (ICER). In addition, the model predicts several outcomes that
include, for 1000 women referred for colposcopy, the number of CIN 2+ cases missed, the number of
women who developed cancer, the number of women who died from cancer, the number of women
who received treatment (LLETZ), the number of unnecessary treatments and diagnostic biopsies, and the
number of women who experienced adverse obstetric outcomes (preterm delivery).
The model was run to simulate 500,000 women referred for colposcopy. This large number of iterations
was necessary to ensure that the proportion of patients in each state equalled the individual probability.
Unseeded simulations were undertaken for different sample sizes (from 1000 to 800,000). Based on the
visual examination of the graphical representation of mean estimates of incremental QALYs, incremental
costs and associated SEs, a sample of 500,000 women was considered to be sufficient to ensure the
stability of the simulation results and therefore an appropriate characterisation of first-order uncertainty
with a reasonable computation time.
In the base-case and scenario analyses, simulations were run separately for each routine screening model
(HPV triage protocol and HPV primary protocol), each type of clinic (see and treat, watchful waiting) and
for each reason for referral (all referrals, low grade and high grade). In order to obtain reproducible results
and to limit statistical variation from one simulation to the next, the same number (or ‘seed’) was used to
initialise the sequence of pseudo-random number.
Structural assumptions are identical for the three strategies (colposcopy alone, DySIS, ZedScan); only the
diagnostic accuracy and the cost of the devices vary. The differences between HPV triage and HPV primary
models are the characteristics of the population referred for colposcopy, the routine screening pathways
and the diagnostic accuracy of the HPV test. We assumed that women who visit a see-and-treat clinic are
treated at initial appointments only if the colposcopy result is positive (CIN 2+) and the cytology result is
moderate or severe (high-grade referral smear). Women who visit watchful-waiting clinics are never treated
at their initial appointment. A diagnostic biopsy is assumed to be systematically performed to confirm the
diagnostic results. As we assumed 100% specificity and sensitivity for diagnostic biopsy, patients never
received unnecessary treatment in a simulation with watchful-waiting clinics.
Structural assumptions that determine screening and treatment pathways are also identical for the three
strategies. Indeed, the present assessment does not aim to evaluate a change in clinical practice as a result
of the use of the adjuncts to colposcopy. Therefore, we use national guidelines to model treatment practice
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and rely on two structural assumptions to model diagnostic and treatment pathways. First, the decision
to treat patients at first examination does not depend on the device used for colposcopy. The decision
depends on the reason for referral (cytology result) and the dichotomous colposcopy result (CIN 2+) only;
patients are treated at first examination if and only if the colposcopy result is positive and the cytology
indicates high-grade lesions. Therefore, the fact that the ZedScan device can use different thresholds
to influence the see-and-treat decision is not taken into account in the model. The second structural
assumption is that patients with a high-grade referral smear are assumed to undergo diagnostic biopsy
regardless of the colposcopy diagnostic result. Hence, the possible impact of ZedScan on the decision
to discharge patients with a high-grade referral smear without a diagnostic biopsy is not modelled.
Consequently, the main impact of ZedScan in the economic evaluation lies in the higher proportion of
patients with CIN 2+ detected with ZedScan than with colposcopy alone, as reported in Tidy et al.94
Finally, in the economic model, the performances of colposcopy alone, DySIS and ZedScan are assessed in
the same way: the probability of a patient being diagnosed as having CIN 2+, given the patient’s true health
state. This probability is estimated based on the proportion of patients with confirmed CIN 2+ detected by the
device (sensitivity) and the proportion of patients with confirmed CIN 1 or less ‘truly’ diagnosed as having a
negative result by the device (specificity). We believe that the sensitivity and specificity values reported in Tidy
et al.94 are the best-available evidence of the probability of a patient being diagnosed by ZedScan as having
CIN 2+ and can be compared, within the limits identified in Chapter 3, Risk of bias of the included studies,
with the diagnostic accuracy of colposcopy alone and that of DySIS reported in the meta-analysis studies.
Base-case analysis
The characteristics of the base-case analysis are summarised in Tables 70 and 71 in Appendix 11. Details
on the structural assumptions and input parameters are provided in Contribution of the York model and
Model structure.
Sensitivity and scenario analyses
To investigate the impact of parameter uncertainty on the results, several sensitivity analyses were undertaken,
which focused on diagnostic accuracy; the costs of technologies, treatment and biopsies; and the initial
characteristics of the population referred for colposcopy under the HPV primary protocol. In addition, three
scenario analyses were undertaken to explore alternative structural assumptions: (1) restricting the analysis to
a 3-year period to evaluate the costs and outcomes within a single screening interval, (2) excluding adverse
obstetric outcomes and (3) assuming that ZedScan is used alongside colposcopy at all appointments. The
sensitivity analyses and scenarios used the same assumptions and parameter values as the base-case analysis,
unless stated otherwise.
Uncertainty around diagnostic accuracy
Sensitivity analysis 1: colposcopy alone and Dynamic Spectral Imaging System
(Louwers et al.)64
In the first sensitivity analysis, the diagnostic accuracy for colposcopy alone and DySIS were based on a
single study by Louwers et al.64 This study was selected as it is the only study that was rated as being
at a low risk of bias (see Chapter 3, Risk of bias of the included studies). It also provides a PPV of
colposcopy alone above the NHS standard of 65% (PPV = 70.37; see Chapter 3, Dynamic Spectral Imaging
System). Compared with the base-case analysis, the Louwers et al.64 study reported slightly lower sensitivity
and specificity values for both colposcopy alone and DySIS (Table 22). As similar data were not available
for ZedScan, sensitivity analysis 1 compares DySIS with colposcopy alone only.
Sensitivity analysis 2: impact of a CIN 2+ cut-off point (colposcopy alone and DySIS)
Sensitivity analysis 2 explores the implications of using a CIN 2+ cut-off point (i.e. the assumption that
specificity is independent of a patient being clear, being infected with HPV or having CIN 1 and sensitivity is
independent of a patient having CIN 2/3 or cancer). Unpublished data provided by the DySIS manufacturer
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from the Louwers et al.64 study were used to estimate the probability of a positive colposcopy result
(i.e. detecting CIN 2 or worse) by the health state for colposcopy alone and DySIS (Table 23). As similar data
were not available for ZedScan, sensitivity analysis 2 compares DySIS with colposcopy alone only.
Sensitivity analysis 3: diagnostic accuracy of colposcopy alone from Tidy et al.110
Sensitivity analysis 3 compared ZedScan with colposcopy alone using the diagnostic accuracy reported by
Tidy et al.110 for colposcopy alone and by Tidy et al.94 for ZedScan. The former was a study of a ZedScan
prototype, conducted in a similar context to the latter, and therefore provides an alternative estimate for
colposcopy alone to inform the direct comparison between ZedScan and colposcopy (see Chapter 3,
Comparison of Dynamic Spectral Imaging System and ZedScan). Tidy et al.110 reported significantly higher
sensitivity and specificity values for colposcopy alone than the meta-analysis results (Table 24).
Sensitivity analyses 4.1 and 4.2: lower and upper bounds of specificity and
correlated sensitivity of Dynamic Spectral Imaging System
Sensitivity analyses 4.1 and 4.2 characterise the uncertainty around the estimates of specificity and
sensitivity of DySIS compared with colposcopy alone (Table 25). Sensitivity analysis 4.1 used the lower
bound of specificity from the 95% CI of the regression model estimates and the correlated sensitivity from
the ROC curve (see Chapter 3, Dynamic Spectral Imaging System). Sensitivity analysis 4.2 used the upper
bound of specificity from the 95% CI of the regression model estimates and the correlated sensitivity
from the ROC curve. In both analyses, we used the base-case values for colposcopy alone (average point
estimates of the regression model).
TABLE 23 Sensitivity analysis: probabilities of a positive colposcopy result (CIN 2+), by health state for colposcopy
alone and DySIS
Health state
Probability of a positive colposcopy result by technology
SourceColposcopy alone DySIS
Clear or HPV 0.1905 0.2857 Louwers et al.64
CIN 1 0.1960 0.4366 Louwers et al.64
CIN 2/3 0.50 0.7778 Louwers et al.64
Cancer 1 1 Louwers et al.64
TABLE 24 Sensitivity analysis: diagnostic accuracy of colposcopy alone based on Tidy et al.110
Technology Sensitivity, % (95% CI) Specificity, % (95% CI) Source
Colposcopy alone 73.56 (64.3 to 82.8) 83.49 (76.5 to 90.5) Tidy et al.110
ZedScan 97.85 (96.5 to 99.2) 58.63 (55.1 to 62.1) Tidy et al.94
TABLE 22 Sensitivity analysis: diagnostic accuracy of colposcopy alone and DySIS based on Louwers et al.64
Technology Sensitivity, % (95% CI) Specificity, % (95% CI) Source
Colposcopy alone 51.35 (42.05 to 60.65) 82.09 (75.60 to 88.58) Louwers et al.64
DySIS 78.38 (70.72 to 86.04) 63.43 (55.285 to 71.59) Louwers et al.64
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Sensitivity analyses 4.3 and 4.4: lower and upper bounds of specificity and sensitivity
of ZedScan
Sensitivity analyses 4.3 and 4.4 characterise the uncertainty around the estimates of specificity and
sensitivity of ZedScan compared with colposcopy alone (Table 26). As there was only one study available
(Tidy et al.94), we were not able to estimate the correlated sensitivity for extreme values of specificity.
Instead, in order to reflect the negative correlation between specificity and sensitivity, sensitivity analysis
4.3 used the upper bound of specificity from the 95% CI reported in Tidy et al.94 and the lower bound of
sensitivity (from the 95% CI); sensitivity analysis 4.4 used the lower bound of specificity and the upper
bound of sensitivity. In both analyses, we used the base-case values for colposcopy alone.
Uncertainty around costs
Sensitivity analysis 5.1 and 5.2: impact of throughput on the cost of devices
Sensitivity analyses 5.1 and 5.2 explore the impact of throughput on the cost of devices by assuming
alternative estimates of the number of patients examined per colposcope per year. This parameter is
used to estimate the cost per patient of DySIS and ZedScan. Sensitivity analysis 5.1 simulated a 50%
decrease in the number of patients per colposcope per year (614 patients instead of 1229 patients),
which drives up the costs of DySIS and ZedScan. Sensitivity analysis 5.2 simulated a 50% increase in the
number of patients per colposcope per year (1844 patients instead of 1229 patients). Because the cost
of a colposcopy examination with a binocular colposcope is based on the NHS Reference Costs,154 the
cost of colposcopy alone remains unchanged. Given its higher purchase price, the cost of DySIS is more
sensitive to a variation in the number of patients than the cost of ZedScan (Table 27).
Sensitivity analysis 6: costs of diagnostic biopsy and large-loop excision of the
transformation zone
We noted an important discrepancy in the estimates of the cost of a colposcopy with treatment (LLETZ)
between the NHS reference cost (£238) and the cost reported by Whyte et al.124 (£590). The costs for a
LLETZ reported by Whyte et al.124 included an estimated pathology cost of £407. The NHS Reference Costs
should theoretically include all associated costs of a LLETZ (including associated histology/pathology costs).
However, there is some uncertainty surrounding whether or not the reference costs accurately reflect
actual resource use, and particularly histology/pathology costs.
TABLE 25 Sensitivity analysis for DySIS: lower- and upper-bound specificity and correlated sensitivity
Technology Sensitivity (%) Specificity (%) Source
Colposcopy alone 57.91 87.41 Regression model (average point estimates)
Sensitivity analysis 4.1: lower-bound (2.5%) specificity
DySIS 83.60 59.40 Regression model
Sensitivity analysis 4.2: upper-bound (97.5%) specificity
DySIS 78.50 79.50 Regression model
TABLE 26 Sensitivity analysis ZedScan: lower and upper bounds (95% CI) of sensitivity and specificity
Technology Sensitivity (%) Specificity (%) Source
Colposcopy alone 57.91 87.41 Regression model (average point estimates)
Sensitivity analysis 4.3: 97.5% sensitivity – 2.5% specificity
ZedScan 99.20 55.10 Tidy et al.94
Sensitivity analysis 4.4: 2.5% sensitivity – 97.5% specificity
ZedScan 96.50 62.10 Tidy et al.94
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Consequently, in sensitivity analysis 6, the cost estimates of histology/pathology for a diagnostic biopsy and
a LLETZ reported in Whyte et al.124 (£53 and £407, respectively, in 2011–12 prices) were added to the NHS
Reference Costs154 (Table 28).
Population referred for colposcopy under the human papillomavirus primary
screening protocol
Sensitivity analyses 7.1 and 7.2: alternative distributions of the health state and the
reason for referral from human papillomavirus screening pilot sites
To address the uncertainty around the characteristics of the population referred for colposcopy under
the HPV primary screening protocol (see Main features of the model), sensitivity analyses 7.1 and 7.2
used data from pilot sites without HPV 16/18 genotyping and pilot sites with HPV 16/18 genotyping,
respectively. Although the proportion of low-grade and high-grade referrals appears to be very similar
between the two types of pilot sites, the prevalence of HPV is higher in pilot sites that do not implement
genotyping (see Appendix 11, Table 72). It is important to note that this sensitivity analysis is not intended
to explore the impact of alternative HPV primary screening protocols, but rather to use the variation
observed between different sites as a means of exploring the potential impact of uncertainty around the
characteristics of the population referred.
Scenario analyses
Scenario analyses were undertaken to consider the impact of three key structural assumptions.
TABLE 27 Sensitivity analysis: number of patients examined per colposcope per year (± 50%)
Cost (£) of colposcopy examination
by technology
Lower bound of 614 patients
per colposcope per year
Upper bound of 1844 patients
per colposcope per year
Colposcopy alone 175.00 175.00
DySIS 184.63 179.11
ZedScan 206.05 205.35
TABLE 28 Sensitivity analysis: costs of biopsies and LLETZ
Type of cost Cost per treatment (£) Source
NHS reference cost
Diagnostic biopsy 47.00 NHS Reference Costs 2015 to
2016154
LLETZ 63.00
Histology/pathology costs
Diagnostic biopsy 55.72a Whyte et al.124
LLETZ 427.89a
Total cost (NHS reference cost and histology/pathology cost)
Diagnostic biopsy 102.72
LLETZ 490.89
a Inflated to 2015–16 prices, assuming that Whyte et al.124 reported 2011–12 prices.
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Scenario 1: time horizon of 3 years
In scenario 1, the model was run for only 3 years to evaluate the cost-effectiveness of adjunctive
technologies with a short-term perspective. Indeed, a 3-year window captures the costs and health
outcomes of the initial colposcopy appointment and immediate follow-ups (including test-of-cure or CIN 1
follow-up), but it does not capture the potential long-term consequences, such as future screenings,
disease progression and adverse obstetric outcomes.
Scenario 2: adverse obstetric outcomes were excluded
Scenario 2 simulated the cost-effectiveness results of adjunctive technology without taking into account
the potential adverse obstetric outcomes of treatment excision.
Scenario 3: ZedScan was used alongside colposcopy at all appointments
Although the base-case analysis assumed that ZedScan was alongside colposcopy only during the initial
appointment (before histology results), scenario 3 was run with the assumption that ZedScan would be
used at all appointments, including therapeutic colposcopies after confirmation by histology results. Note
that, as is the case for DySIS, no additional benefit is associated with the use of adjunctive technologies
during therapeutic colposcopies.
Model validation
The face validity of the model structure and the key assumptions were evaluated by our clinical advisors.
A series of steps were undertaken to ensure the internal validity of the model, including (1) double-checking
model input estimates with the original sources, (2) repeated testing of individual elements of the model and
(3) extensive logical tests and sensitivity analyses to ensure that the model behaved as would be expected.
The results of the model were cross-validated by comparing the results to the previous published studies to
ensure that any possible differences were identified and could be explained.
Results of the independent economic assessment
The economic evaluation compares DySIS with colposcopy alone, ZedScan with colposcopy alone and
ZedScan with DySIS. Tables 29–34 and Tables 73 and 74 in Appendix 12 display the average cost and
QALYs per patient and the incremental cost and QALYs per patient, as well as the ICER and secondary
outcomes for the base case. Figures 14, 15, 29 and 30 and Figures 31–38 in Appendix 13 graphically
summarise the base-case results and the results of the sensitivity and scenario analyses, using a
cost-effectiveness plane to plot the incremental costs and the incremental QALYs. Detailed results for
the sensitivity and scenario analyses are given in Appendix 13.
Base-case results
The base-case results are presented separately for the HPV triage and HPV primary screening protocols.
The results are presented based on clinical practice (see and treat, watchful waiting) and in accordance
with the reason for referral (all referrals, high grade and low grade).
Human papillomavirus triage protocol: base-case results
The results for the base-case analysis under the HPV triage protocol are summarised in Figure 14 and
presented in more detail in Tables 29–31 (costs and QALYs) and in Table 73 in Appendix 12
(secondary outcomes).
In Figure 14, the incremental costs and QALYs of DySIS versus colposcopy alone, ZedScan versus colposcopy
alone and ZedScan versus DySIS are represented visually using separate cost-effectiveness planes. The
horizontal axis divides the plane according to the incremental cost (positive above and negative below) and
the vertical axis divides the plane according to the incremental QALYs (positive to the right and negative to
the left). The cost-effectiveness plane is thus divided into four quadrants, with different implications for
decision-making. If an intervention falls in the south-east quadrant, then it dominates the comparator
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technology (i.e. is less costly and more effective). Similarly, the intervention would be dominated by the
comparator in the north-west quadrant. When non-dominance exists (north-east and south-west
quadrants), the resulting ICER can be compared against the conventional cost-effectiveness threshold
(£20,000–30,000 per QALY) to determine whether or not the intervention is cost-effective. In Figure 14,
a £20,000 threshold is represented by the straight line that further divides the north-east and south-west
quadrants. Points above and below the line indicate that the ICER of the intervention is higher or lower than
the threshold, respectively. The results by type of clinic and the reason for referral are represented in each
plane by distinct markers.
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FIGURE 14 Base-case analysis cost-effectiveness results: HPV triage protocol. (a) DySIS vs. colposcopy alone;
(b) ZedScan vs. colposcopy alone; and (c) ZedScan vs. DySIS. HG, high grade; LG, low grade. (continued )
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The main results of the base-case analysis under the HPV triage protocol can be summarised as follows:
l Dynamic Spectral Imaging System routinely dominated colposcopy alone, regardless of the type of clinic
or the reason for referral (Table 29). The only exception was for referrals for high-grade abnormalities
in watchful-waiting clinic settings, in which DySIS was more costly and more effective, with an
associated ICER of £675 per QALY.
l ZedScan also dominated colposcopy alone in see-and-treat clinics (Table 30). However, in watchful-waiting
clinics, ZedScan was always more effective than colposcopy alone, but was also more costly. The ICER for
ZedScan in watchful-waiting clinics ranged from £272 (referrals for low-grade abnormalities) to £4070 per
QALY (referrals for high-grade abnormalities).
l The higher sensitivity of DySIS and ZedScan resulted in increased QALYs compared with conventional
colposcopy alone in all sets of results. In addition, the incremental gain in QALYs always appeared to be
higher for referrals for low-grade abnormalities. The higher incremental gain for referrals for low-grade
abnormalities is attributable to the assumption that a diagnostic biopsy will not be performed if the
colposcopy result is negative. Hence, false-negative results for referrals for low-grade abnormalities will
therefore potentially be missed, making higher sensitivity a more critical consideration for referrals for
low-grade abnormalities.
l The impact on total cost appears to depend on the technology and clinic practice. Both adjunctive
technologies generally decrease the average cost per patient in see-and-treat clinics. In watchful-
waiting clinics, however, the average cost generally decreases to a smaller extent with DySIS and
appears to increase with ZedScan compared with colposcopy alone.
l The indirect comparison between ZedScan and DySIS showed that ZedScan routinely appears to be
more effective but also more costly than DySIS (Table 31). The ICER for ZedScan ranged from £109 per
QALY for referrals for high-grade abnormalities in see-and-treat clinics to £9918 per QALY for referrals
for high-grade abnormalities in watchful-waiting clinics.
l The secondary outcomes from the simulations show that a higher specificity (colposcopy alone) limits
the number of unnecessary treatments and biopsies and consequently reduces the number of
adverse obstetric outcomes (see Appendix 12, Table 73). In contrast, a higher sensitivity (adjunctive
technologies) reduces the number of undetected CIN 2+, new cancer cases and deaths as a result of
developing cancer.
– 0.01 0.01 0.02 0.03 0.04 0.05
In
cr
e
m
e
n
ta
l 
co
st
 (
£
)
(c)
0.00
– 60
– 50
– 40
– 30
– 20
– 10
0
10
20
30
40
Base case: see and treat
Base case: watchful waiting
ICER £20,000
All
HG
LG
LG
All
HG
Incremental QALYs
FIGURE 14 Base-case analysis cost-effectiveness results: HPV triage protocol. (a) DySIS vs. colposcopy alone;
(b) ZedScan vs. colposcopy alone; and (c) ZedScan vs. DySIS. HG, high grade; LG, low grade.
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TABLE 29 Base-case results for the HPV triage protocol: DySIS vs. colposcopy alone
Grade of referral smear
by clinic and technology Cost (£) QALYs Incremental cost (£) Incremental QALYs ICER
See-and-treat clinics
All referrals
Colposcopy alone 903.28 19.16500
DySIS 872.34 19.18516 –30.94 0.02016 Dominant
LG referrals
Colposcopy alone 793.97 19.16330
DySIS 770.65 19.18794 –23.33 0.02464 Dominant
HG referrals
Colposcopy alone 1139.13 19.16122
DySIS 1091.43 19.17156 –47.70 0.01034 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 953.02 19.16286
DySIS 941.33 19.18194 –11.69 0.01908 Dominant
LG referrals
Colposcopy alone 812.85 19.16283
DySIS 799.47 19.18601 –13.38 0.02318 Dominant
HG referrals
Colposcopy alone 1252.07 19.16008
DySIS 1255.93 19.16580 3.85 0.00571 675
HG, high grade; LG, low grade.
TABLE 30 Base-case results for HPV triage protocol: ZedScan vs. colposcopy alone
Grade of referral smear
by clinic and technology Cost (£) QALYs Incremental cost (£) Incremental QALYs ICER
See-and-treat clinics
All referrals
Colposcopy alone 903.28 19.16500
ZedScan 885.91 19.19901 –17.37 0.03401 Dominant
LG referrals
Colposcopy alone 793.97 19.16330
ZedScan 789.30 19.20307 –4.68 0.03978 Dominant
HG referrals
Colposcopy alone 1139.13 19.16122
ZedScan 1091.97 19.17651 –47.16 0.01529 Dominant
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TABLE 30 Base-case results for HPV triage protocol: ZedScan vs. colposcopy alone (continued )
Grade of referral smear
by clinic and technology Cost (£) QALYs Incremental cost (£) Incremental QALYs ICER
Watchful-waiting clinics
All referrals
Colposcopy alone 953.02 19.16286
ZedScan 965.87 19.19363 12.85 0.03078 418
LG referrals
Colposcopy alone 812.85 19.16283
ZedScan 823.19 19.20082 10.34 0.03799 272
HG referrals
Colposcopy alone 1252.07 19.16008
ZedScan 1288.82 19.16911 36.75 0.00903 4070
HG, high grade; LG, low grade.
TABLE 31 Base-case results for HPV triage protocol: ZedScan vs. DySIS
Grade of referral smear
by clinic and technology Cost (£) QALYs Incremental cost (£) Incremental QALYs ICER
See-and-treat clinics
All referrals
DySIS 872.34 19.18516
ZedScan 885.91 19.19901 13.57 0.01385 980
LG referrals
DySIS 770.65 19.18794
ZedScan 789.30 19.20307 18.65 0.01514 1232
HG referrals
DySIS 1091.43 19.17156
ZedScan 1091.97 19.17651 0.54 0.00495 109
Watchful-waiting clinics
All referrals
DySIS 941.33 19.18194
ZedScan 965.87 19.19363 24.54 0.01170 2098
LG referrals
DySIS 799.47 19.18601
ZedScan 823.19 19.20082 23.72 0.01481 1601
HG referrals
DySIS 1255.93 19.16580
ZedScan 1288.82 19.16911 32.89 0.00332 9918
HG, high grade; LG, low grade.
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Human papillomavirus primary protocol: base-case results
The results for the base-case analysis under the HPV primary screening protocol are summarised in Figure 15
and presented in more detail in Tables 32–34 (costs and QALYs) and Appendix 12, Table 74 (secondary
outcomes). The interpretation of the cost-effectiveness planes in Figure 15 is the same as for Figure 14.
With regard to the cost-effectiveness of adjunctive technologies, the conclusions were quite similar under
the HPV primary screening and HPV triage protocols:
l In most instances, DySIS dominated colposcopy alone except for referrals for high-grade abnormalities
in watchful-waiting clinics, for which the ICER was estimated to be £1095 per QALY (Table 32).
l The results for ZedScan were more varied. ZedScan dominated colposcopy alone only for referrals
for high-grade abnormalities in a see-and-treat clinic. In all other cases, ZedScan was more effective
but also more costly than colposcopy alone. The ICER ranged from £417 per QALY for referrals
for low-grade abnormalities in see-and-treat clinics to £4922 per QALY for referrals for high-grade
abnormalities in watchful-waiting clinics (Table 33).
l ZedScan was always more effective but also more costly than DySIS. The ICER ranged from £426 per
QALY for referrals for high-grade abnormalities in see-and-treat clinics to £8190 per QALY for referrals
for high-grade abnormalities in watchful-waiting clinics (Table 34).
l Consistent with the findings reported in the ARTISTIC study149 simulations under the HPV primary
screening protocol predicted higher health outcomes and a lower average cost per patient than under
the HPV triage protocol. With regard to the cost-effectiveness of adjunctive technologies, the most
significant impact of the HPV primary protocol was to reduce the incremental effect of the adjunctive
technologies on health outcomes. Because HPV primary routine screening presents a higher sensitivity
overall, cases of patients with CIN 2+ that were missed at the initial colposcopy appointment have a
higher probability of being diagnosed 3 years later during routine screening, which would avoid the
subsequent development of cancer. The lower sensitivity of colposcopy alone than that of adjunctive
technologies therefore appears to be less critical in this context.
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FIGURE 15 Base-case analysis cost-effectiveness results: HPV primary screening protocol. (a) DySIS vs. colposcopy
alone; (b) ZedScan vs. colposcopy alone; and (c) ZedScan vs. DySIS. HG, high grade; LG, low grade. (continued )
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FIGURE 15 Base-case analysis cost-effectiveness results: HPV primary screening protocol. (a) DySIS vs. colposcopy
alone; (b) ZedScan vs. colposcopy alone; and (c) ZedScan vs. DySIS. HG, high grade; LG, low grade.
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TABLE 32 Base-case results for HPV primary screening: DySIS vs. colposcopy alone
Grade of referral smear
by clinic and technology Cost (£) QALYs Incremental cost (£) Incremental QALYs ICER
See-and-treat clinics
All referrals
Colposcopy alone 850.08 19.17506
DySIS 825.46 19.19120 –24.62 0.01614 Dominant
LG referrals
Colposcopy alone 732.33 19.19008
DySIS 715.46 19.20787 –16.87 0.01779 Dominant
HG referrals
Colposcopy alone 1126.93 19.16192
DySIS 1079.83 19.16774 –47.11 0.00581 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 894.41 19.17511
DySIS 889.04 19.18937 –5.37 0.01426 Dominant
LG referrals
Colposcopy alone 748.86 19.18496
DySIS 738.10 19.20646 –10.77 0.02150 Dominant
HG referrals
Colposcopy alone 1236.94 19.15863
DySIS 1240.99 19.16234 4.06 0.00371 1095
HG, high grade; LG, low grade.
TABLE 33 Base-case results for HPV primary screening: ZedScan vs. colposcopy alone
Grade of referral smear
by clinic and technology Cost (£) QALYs Incremental cost (£) Incremental QALYs ICER
See-and-treat clinics
All referrals
Colposcopy alone 850.08 19.17506
ZedScan 844.41 19.20206 –5.67 0.02700 Dominant
LG referrals
Colposcopy alone 732.33 19.19008
ZedScan 744.85 19.22007 12.52 0.03000 417
HG referrals
Colposcopy alone 1126.93 19.16192
ZedScan 1082.27 19.17347 –44.66 0.01155 Dominant
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TABLE 33 Base-case results for HPV primary screening: ZedScan vs. colposcopy alone (continued )
Grade of referral smear
by clinic and technology Cost (£) QALYs Incremental cost (£) Incremental QALYs ICER
Watchful-waiting clinics
All referrals
Colposcopy alone 894.41 19.17511
ZedScan 918.78 19.19977 24.37 0.02466 988
LG referrals
Colposcopy alone 748.86 19.18496
ZedScan 770.26 19.21984 21.40 0.03487 614
HG referrals
Colposcopy alone 1236.94 19.15863
ZedScan 1276.58 19.16668 39.64 0.00805 4922
HG, high grade; LG, low grade.
TABLE 34 Base-case results for HPV primary screening protocol: ZedScan vs. DySIS
Grade of referral smear
by clinic and technology Cost (£) QALYs Incremental cost (£) Incremental QALYs ICER
See-and-treat clinics
All referrals
DySIS 825.46 19.19120
ZedScan 844.41 19.20206 18.95 0.01085 1746
LG referrals
DySIS 715.46 19.20787
ZedScan 744.85 19.22007 29.39 0.01220 2408
HG referrals
DySIS 1079.83 19.16774
ZedScan 1082.27 19.17347 2.45 0.00574 426
Watchful-waiting clinics
All referrals
DySIS 889.04 19.18937
ZedScan 918.78 19.19977 29.74 0.01040 2860
LG referrals
DySIS 738.10 19.20646
ZedScan 770.26 19.21984 32.16 0.01338 2404
HG referrals
DySIS 1240.99 19.16234
ZedScan 1276.58 19.16668 35.58 0.00434 8190
HG, high grade; LG, low grade.
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Sensitivity analyses results
To investigate the impact of parameter uncertainty on the results, several sensitivity analyses were
undertaken, which focused on diagnostic accuracy, costs and the initial characteristics of the population
referred for colposcopy under the HPV primary screening protocol.
Uncertainty around diagnostic accuracy
Uncertainty around the diagnostic accuracy of colposcopy alone, DySIS and ZedScan was assessed with
sensitivity analyses 1–4.4 (see 5.4.2.1 for a detailed description). Because the sensitivity analyses are
different for DySIS and ZedScan, the results are presented separately in Figures 29 and 30 in Appendix 13.
Detailed results for average and incremental costs and QALYs are presented in Appendix 13, Tables 75–88)
for each sensitivity analysis, under the HPV triage and HPV primary screening protocols.
For DySIS compared with colposcopy alone, the results were globally unchanged compared with the
base-case analysis:
l Dynamic Spectral Imaging System dominated colposcopy alone in most instances except for referrals
for high-grade abnormalities in watchful-waiting settings, in which the ICER ranged from £188
[sensitivity analysis 2 under the HPV triage protocol (see Appendix 13, Table 77)] to £1633 [sensitivity
analysis 2 under the HPV primary screening protocol (see Appendix 13, Table 78)].
The results of sensitivity analyses comparing ZedScan with colposcopy alone were more varied:
l The lower and upper bounds of ZedScan specificity and sensitivity (sensitivity analysis 4.3 and sensitivity
analysis 4.4) had little impact on the results. ZedScan still dominated colposcopy alone in see-and-treat
clinics and was more effective but also more costly than colposcopy alone in watchful-waiting clinics,
under both the HPV triage and HPV primary screening protocols.
l When ZedScan was compared with colposcopy alone based on diagnostic accuracy data that stemmed
from a similar setting (sensitivity analysis 3), the incremental cost increased and the incremental QALYs
decreased. Overall, ZedScan no longer dominated colposcopy alone in see-and-treat clinics, with an
ICER ranging from £590 under the HPV triage protocol to £1457 under the HPV primary screening
protocol. In watchful-waiting clinics, the ICER increased from £418 in the base case to £1910 in
sensitivity analysis 3 under the HPV triage protocol and from £988 to £4023 under the HPV primary
screening protocol. Under HPV primary screening, the ICER exceeded £20,000 per QALY for referrals
for high-grade abnormalities in watchful-waiting clinics (see Appendix 13, Tables 79 and 80).
Uncertainty around costs
Sensitivity analyses results exploring the uncertainty around the costs of devices (sensitivity analyses 5.1
and 5.2) and the costs of diagnostic biopsy and LLETZ (sensitivity analysis 6) are summarised in Appendix 13,
Figure 31, for the HPV triage protocol and Appendix 13, Figure 32, for the HPV primary screening protocol.
As only the cost parameters were varied, the incremental QALYs are identical between the sensitivity analyses
and the base case for each type of simulation. Note that, in Chapter 3, Figures 5 and 6, the scale of the
vertical axis of the cost-effectiveness planes has been altered in order to represent higher incremental costs.
Detailed results are presented in Appendix 13, Tables 89–106.
Logically, sensitivity analyses 5.1 and 6 increased the incremental cost for both technologies, but they did
not appear to alter the base-case conclusions:
l Owing to the higher purchase price, the results for DySIS appeared to be more sensitive to a decrease
in the number of patients per colposcope per year (sensitivity analysis 5.1). DySIS no longer dominated
colposcopy alone in watchful-waiting clinics under the HPV primary screening protocol, with an ICER of
£270 for all referrals (see Appendix 13, Table 92).
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l Owing to the lower purchase price of ZedScan, the results did not appear to be sensitive to the
assumed variation in throughput (sensitivity analyses 5.1 and 5.2). However, because of its high
sensitivity and low specificity, the higher cost estimates for diagnostic biopsies and LLETZ (sensitivity
analysis 6) had an impact on the results for ZedScan more significantly than the results for DySIS,
especially for referrals for low-grade abnormalities in watchful-waiting clinics. ZedScan no longer
dominated colposcopy alone, regardless of the type of clinics or the routine screening protocol. The
ICER increased to £6709 for referrals for high-grade abnormalities in watchful-waiting clinics under the
HPV primary screening protocol (see Appendix 13, Table 105).
l The results on the indirect comparison between ZedScan and DySIS were unchanged.
Population referred for colposcopy under the human papillomavirus primary protocol
Sensitivity analyses 7.1 and 7.2 used the variation observed between pilot sites without and with HPV 16/18
genotyping, respectively, to explore the potential impact of uncertainty around the characteristics of the
population referred for colposcopy under the HPV primary screening protocol. The results are summarised in
Appendix 13, Figure 33, and presented in more detail in Appendix 13, Tables 107–112. Overall, the results are
unchanged compared with those of the base case and the impact of a variation in population characteristics
appears to be relatively small.
Scenarios
Three scenario analyses were undertaken to explore alternative structural assumptions: restricting the
analysis to a 3-year period, excluding adverse obstetric outcomes and assuming that ZedScan was used
alongside colposcopy at all appointments.
Scenario 1: time horizon of 3 years
The model was run for only 3 years to capture the cost and health outcomes of colposcopy and adjunctive
technologies in the short term. Figures 31 and 32 in Appendix 13 summarise the results under the HPV
triage and HPV primary screening protocols. The average and incremental costs and QALYs, as well as the
secondary outcomes, are provided in Appendix 13 (see Tables 113–115).
The results were dramatically different when long-term costs and health outcomes were not taken into
account in the evaluation:
l In the short term, colposcopy alone routinely dominated DySIS and ZedScan (i.e. it was less costly and
more effective). The higher specificity of colposcopy alone limited the number of treatments and
therefore reduced the average cost compared with DySIS or ZedScan. Meanwhile, the lower specificity
of colposcopy alone was less penalised, as most individuals with untreated CIN 2+ would not have
developed cancer or died from cancer 3 years after their initial examination (see Appendix 13,
Tables 113 and 114).
l Colposcopy was not found to be dominant only for referrals for high-grade abnormalities in see-and-treat
clinics. DySIS and ZedScan were less costly, but also less effective, than colposcopy alone, with ICERs,
respectively, of £236,692 and £85,045 per QALY under the HPV triage protocol (see Appendix 13,
Tables 113 and 114).
Scenario 2: adverse obstetric outcomes were excluded
Scenario 2 excluded from the analysis the adverse consequences of CIN treatment on obstetric outcomes.
The results are summarised in Appendix 13, Figures 36 and 37 and presented in more detail in Tables 116–118.
When adverse obstetric outcomes were excluded, all technologies were found to be less costly than in the
base-case scenario.
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The cost-effectiveness results for DySIS and ZedScan compared with colposcopy alone were unchanged
under both the HPV triage protocol and the HPV primary screening protocol:
l Dynamic Spectral Imaging System routinely dominated colposcopy alone, regardless of the type of
clinic, the reason for referral or the routine screening protocol.
l ZedScan also dominated colposcopy alone in see-and-treat clinics. However, ZedScan was more
effective but also routinely more costly than colposcopy alone in watchful-waiting clinics.
As in the base case, ZedScan was routinely more effective and more costly than DySIS:
l Because ZedScan presents a lower specificity than DySIS, the ICER was lower when adverse obstetric
outcomes were excluded than in the base-case scenario: £427 per QALY compared with £980 per
QALY for see-and-treat clinics under the HPV triage protocol (all referrals) and £1476 per QALY
compared with £1746 per QALY under the HPV primary screening protocol (all referrals).
Scenario 3: ZedScan was used alongside colposcopy at all appointments
Scenario 3 assumed that ZedScan was used alongside colposcopy at all appointments, including
therapeutic colposcopies, after confirmation by histology results. As the costs and QALYs were not altered
for colposcopy alone and DySIS compared with the base case, Appendix 13, Figure 38, presents the results
for ZedScan compared with colposcopy alone, and for ZedScan compared with DySIS only, under the HPV
triage and HPV primary screening protocols. Detailed results are given in Tables 119–122 in Appendix 13.
As no additional benefit is associated with the use of ZedScan during therapeutic colposcopies, the impact of
scenario 3 is only an increase in the incremental cost of ZedScan compared with colposcopy alone and DySIS:
l Overall, the conclusions remain unchanged compared with those of the base case.
However, the impact of using ZedScan alongside colposcopy at all appointments varies depending on the
reason for referral and the type of clinic:
l The increase in cost was higher for referrals for high-grade abnormalities in watchful-waiting clinics –
when ZedScan was compared with colposcopy alone, the ICER was £7270 in the HPV triage protocol
(see Appendix 13, Table 119) and £8557 under the HPV primary screening protocol (see Appendix 13,
Table 121); when ZedScan was compared with DySIS, the ICER reached £18,628 under the HPV
triage protocol (see Appendix 13, Table 120) and £14,928 under the HPV primary screening protocol
(see Appendix 13, Table 122).
Discussion of the independent economic assessment
Only two studies that reported on the cost-effectiveness of DySIS and ZedScan were included. Neither
study was considered to fully inform the stated decision problem, which includes the current HPV triage
protocol (including test of cure) and also the proposed HPV primary screening protocol.
A de novo decision-analytic model (the ‘York model’) was developed using a patient-level state-transition
modelling approach to estimate the cost-effectiveness of adjunctive colposcopy technologies (DySIS
with DySISmap and ZedScan) for people who are referred for colposcopy through the NHSCSP under
either HPV triage (including test of cure) or the HPV primary screening algorithm (including test of cure).
The York model was specifically developed to address the limitations of existing studies and concerns
regarding the generalisability to both the HPV triage protocol and the HPV primary screening protocols.
The main strength of the decision model is the linkage between the diagnostic accuracy of a given
identification strategy, the impact on subsequent treatment decisions and the ultimate effect on health
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outcomes and costs. A potential limitation of the model is that the patient-level modelling approach
precluded a probabilistic assessment of cost-effectiveness and hence decision uncertainty could also not
be fully represented in our analyses. Although the inclusion of a probabilistic assessment was technically
feasible, repeating simulations to appropriately represent second-order uncertainty was not considered to
be feasible within the time frame. However, a broad range of scenario and sensitivity analyses were
undertaken to address key assumptions and uncertainties.
The base-case cost-effectiveness results showed that DySIS routinely dominated colposcopy (i.e. it was less
costly and more effective than standard colposcopy). The only exception was for referrals for high-grade
abnormalities in a watchful-waiting clinic setting, in which the ICER of DySIS varied between £675 and
£1095 per QALY under the HPV triage and primary screening protocols. ZedScan also dominated colposcopy
alone for referrals for high-grade abnormalities in see-and-treat clinics. The ICER for ZedScan varied between
£272 (referral for low-grade abnormality in a watchful-waiting clinic, HPV triage protocol) and £4922 per
QALY (referral for high-grade abnormality in a watchful-waiting clinic, HPV primary screening). These findings
appeared to be robust to a wide range of sensitivity and scenario analyses. Only in one of the analyses did
the ICER exceed a £20,000-per-QALY threshold. This arose in a sensitivity analysis for ZedScan in which the
diagnostic performance of colposcopy was derived from a separate study to the base-case analysis and
only for referrals for high-grade abnormalities in a watchful-waiting clinic under the HPV primary
screening protocol.
In the absence of a direct comparison between the alternative technologies, an indirect comparison was
performed. However, these results should be considered to be exploratory in nature given the lack of a
robust direct comparison and the challenges identified more generally, which arose from the limitations in
the evidence base for ZedScan. The base-case cost-effectiveness results showed that ZedScan was always
more effective but also more costly than DySIS. The ICER ranged from £109 per QALY for referrals for
high-grade abnormalities in see-and-treat clinics under the HPV primary screening protocol to £9918 per
QALY for referrals for high-grade abnormalities in watchful-waiting clinics under the HPV triage protocol.
These findings appeared to be robust to a wide range of sensitivity and scenario analyses.
There remains uncertainty regarding the cost-effectiveness of ZedScan, given the challenges of comparing
it with colposcopy and DySIS. Moreover, the cost-effectiveness results presented for the HPV primary
screening protocols also require careful consideration. Our analysis is based on the current protocol and
the assumption that the final HPV primary screening protocol may alter prior to HPV primary screening
being rolled out nationally. Furthermore, key input data were derived from unpublished and preliminary
results collected in the HPV pilot sites. Data collection is still ongoing and selection issues may limit the
generalisability of the data used. Hence, the results under the HPV primary screening protocol should be
considered to be exploratory and further analyses should ideally be undertaken when data collection has
been completed and the implications of any selection effect is clearer.
Conclusions of the cost-effectiveness section
The cost-effectiveness of both adjunctive technologies compared with standard colposcopy, under both
the HPV triage and HPV primary screening algorithms, appears to be favourable when compared with the
conventional threshold used to determine value in the NHS. However, the limitations and uncertainties in
the evidence base identified for ZedScan need to be carefully considered. The cost-effectiveness of both
adjunctive technologies under the HPV primary screening protocol should also be reassessed when
additional data become available from the pilot sites.
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Chapter 6 Discussion
Statement of the principal findings
Diagnostic accuracy
Nine studies compared adjunctive DySIS (DySISmap and DySIS colposcope) with DySIS video colposcopy
alone. Adjunctive DySIS use was found to have a higher sensitivity to detect CIN 2+ (81.25%, 95% CI
72.2% to 87.9%) than standard colposcopy alone (57.91%, 95% CI 47.2% to 67.9%), but a lower
specificity (70.40%, 95% CI 59.4% to 79.5%) than colposcopy (87.41%, 95% CI 81.7% to 91.5%).
This difference appears to be because adjunctive DySIS leads to more positive test results (i.e. more women
are judged to have possible high-grade CIN).
Only two included studies investigated ZedScan, one of which was a study of a precommercial prototype.
The results from the prototype study suggested that adjunctive ZedScan could improve diagnostic accuracy
when compared with colposcopy alone (i.e. it could increase sensitivity at the same specificity as colposcopy
or vice versa). (Confidential information has been removed.)
Data on participant subgroups, including women infected with hrHPV or referred with high-grade
abnormalities, were limited. The results suggested that colposcopy alone has a poor sensitivity to detect
high-grade CIN in women referred with low-grade abnormalities (e.g. mild dyskaryosis). Adjunctive DySIS
and ZedScan appeared to improve diagnosis in women referred with low-grade abnormalities. There was
some limited evidence that the diagnostic accuracy of adjunctive DySIS may be greater in women with
hrHPV infection.
The sensitivity analyses suggested that the sensitivity and specificity of adjunctive and standard colposcopy
were dependent on what reference standard was used in women with no colposcope-detected high-grade
CIN. Both sensitivity and specificity tended to be higher when no biopsies were performed in those
women, which suggests a possible verification bias. This suggests that the actual accuracy of colposcopy
and adjunctive colposcopy is uncertain. However, the comparative results are valid, because any possible
verification bias is likely to affect the results of adjunctive and standard colposcopy equally.
Clinical effectiveness
Only three studies that reported data on our prespecified clinical effectiveness outcomes were included.
One study of ZedScan reported three adverse events, of which one was serious, and two studies of DySIS
with DySISmap reported that no adverse events occurred following colposcopy examination. No data were
reported on mortality, morbidity and HRQoL in studies of DySIS and ZedScan.
Implementation
Five studies reported data on our prespecified implementation outcomes, including four studies of DySIS
and one of ZedScan.
There is reasonable evidence that DySISmap as an adjunct to colposcopy is generally well received by patients
referred for colposcopy and that patients are generally satisfied with the duration of the examination. There
is evidence that adjunctive DySIS was generally perceived by clinicians to improve the accuracy of colposcopy
and confidence in their diagnostic decisions and biopsy site selection. There is also evidence that adjunctive
DySIS was intuitive for clinicians with limited colposcopy experience and improved their evaluations. In
addition, there is evidence that the additional time required to use ZedScan is minimal in experienced
colposcopists. However, all included studies had significant limitations, and therefore these findings need to
be interpreted with caution.
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No evidence was found for several of the prespecified outcomes: successful database and record
management, capacity to perform colposcopies, and uptake and compliance. No evidence was found
regarding the training requirements for DySIS. The limited evidence for ZedScan precludes conclusions
for any of the implementation review prespecified outcomes.
Cost-effectiveness
Only two studies that reported on the cost-effectiveness of DySIS and ZedScan were included. Neither
study was considered to fully inform the stated decision problem, which includes the current HPV triage
protocol (including test of cure) and also the proposed HPV primary screening protocol.
A de novo decision-analytic model (the ‘York model’) was developed using a patient-level state-transition
modelling approach to estimate the cost-effectiveness of adjunctive colposcopy technologies (DySIS with
DySISmap and ZedScan) for people who are referred for colposcopy through the NHSCSP under either HPV
triage (including test of cure) or the HPV primary screening algorithm (including test of cure).
The York model provides a link between diagnostic test accuracy and final health outcomes expressed in
terms of QALYs. It provides a quantitative framework, using the best available evidence, to determine how
the diagnostic performance of both adjunctive colposcopy technologies is likely to affect subsequent
treatment and/or monitoring options and their effect on disease progression. The model also captures the
potential impact of the technologies on unnecessary biopsies and excisions, which may increase the risk of
adverse obstetric outcomes.
The base-case cost-effectiveness results showed that adjunctive DySISmap routinely dominated (i.e. was less
costly and more effective than) standard colposcopy. The only exception was for referrals for high-grade
abnormalities in a watchful-waiting clinic setting, in which the ICER of DySISmap varied between £675 and
£1095 per QALY under the HPV triage and HPV primary screening protocols. ZedScan also dominated
colposcopy alone for referrals for high-grade abnormalities in see-and-treat clinics. The ICER for ZedScan
varied between £272 (referral for low-grade abnormality in a watchful-waiting clinic, HPV triage protocol)
and £4922 per QALY (referral for high-grade abnormality in a watchful-waiting clinic, HPV primary screening
protocol). These findings appeared to be robust to a wide range of sensitivity and scenario analyses.
Strengths and limitations of the assessment
Clinical effectiveness
Extensive literature searches were conducted with an attempt to maximise the retrieval of potentially
relevant studies. These included electronic searches of a variety of bibliographic databases, as well as the
screening of clinical trial registers and conference proceedings to identify unpublished studies. The search
strategy did not restrict by study design. The device manufacturers and study authors were contacted to
provide additional data, and the review includes additional data from published studies and data from
as-yet-unpublished studies. The review process followed recommended methods to minimise the potential
for error and/or bias. The quality of the included studies was assessed and accounted for when interpreting
the review results. Appropriate synthesis methods were employed by taking into account the heterogeneity
of the study characteristics.
One study of DySIS was rated as being at a low risk of bias, and all other included studies were rated as
being at a high risk of bias. The evidence for ZedScan was particularly limited. Only one study of ZedScan
was available, and there was no evidence directly comparing ZedScan with standard colposcopy. The
evidence for ZedScan came mostly from a single centre and excluded relevant patient populations (including
patients with transformation zone type 3), which limits the extent to which the evidence for ZedScan is
applicable to the broader population of women referred through the NHSCSP.
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No studies directly compared DySIS with ZedScan. Very few data on participant subgroups were available.
In particular, there were few data on diagnostic accuracy in women referred through HPV primary screening.
There was very limited evidence relating to the clinical effectiveness of adjunctive DySIS or ZedScan, with
little reporting of any potential adverse effects.
Cost-effectiveness
The York model was specifically developed to address the limitations of existing studies and concerns
regarding the generalisability of the current decision problem under both the HPV triage and HPV primary
screening protocols. The main strength of the decision model is that it directly addresses several of the key
assumptions and areas of uncertainties identified in our review of previously published studies, including
the consideration of the potential impact of unnecessary treatment on adverse obstetric outcomes.
A potential limitation of the model is that the patient-level modelling approach precluded a probabilistic
assessment of cost-effectiveness, and hence decision uncertainty could also not be fully represented in
our analyses. The decision to use a patient-level approach was taken with careful consideration and we
consider that alternative modelling approaches were not appropriate, given the high level of complexity
that arises from interactions between the natural history model and the screening and treatment pathways
and the need to characterise two separate screening paradigms. Although the inclusion of a probabilistic
assessment was technically feasible, each analysis (i.e. for each type of clinic and for each of the different
reasons for referral) required 500,000 simulations, and took approximately 15 minutes to run. Repeating
this simulation to appropriately represent second-order uncertainty was not considered to be feasible
within the time frame. However, a broad range of scenario and sensitivity analyses were undertaken to
address key assumptions and uncertainties.
Finally, given the complexity of the modelling and resource constraints, it was not possible to undertake
systematic reviews for several of the model parameters (e.g. utilities, costs). Instead, estimates were
sourced pragmatically based on sources used in other modelling studies.
Uncertainties
Clinical effectiveness
There were no data comparing ZedScan with colposcopy, so any improvement in diagnostic accuracy with
ZedScan over colposcopy alone is uncertain. Owing to design limitations, the extent to which the evidence
for ZedScan is applicable to the broader population of women referred through the NHSCSP is uncertain.
No studies compared DySIS with ZedScan directly, limiting the possibility of comparing the diagnostic
accuracy of the technologies. Most studies were performed in women referred for colposcopy on the basis
of cytology screening, so the diagnostic accuracy of all methods in women referred from HPV primary
screening is uncertain, particularly as the data on the diagnostic accuracy in women infected with hrHPV
were also limited.
The reference standard (histopathology of samples from punch biopsy or excision) was applied variably
across studies. In particular, biopsies were not performed in women with normal colposcopy examination
results in several DySIS studies and in all ZedScan studies. This may have led to positive bias in estimates
of the diagnostic accuracy for both adjunctive colposcopy and colposcopy alone. Hence, the estimates of
sensitivity and specificity reported may not be the same as the diagnostic accuracy that will be observed in
the UK.
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Cost-effectiveness
The uncertainties noted regarding the design limitations for the evidence of ZedScan also raise important
uncertainties regarding the generalisability of the cost-effectiveness results for ZedScan to routine
NHS usage.
The introduction of HPV primary screening will alter the population of women referred for colposcopy
through the NHSCSP. However, the data are still incomplete, especially for women referred at the third
round, and, because the pilot sites were not randomly selected, the data are subject to selection issues,
especially variability in the prevalence of HPV and CIN lesions compared with the general population. The
impact of these issues on the cost-effectiveness of the adjunctive technologies is not possible to determine.
As a result, we would recommend that the cost-effectiveness analysis of the adjunctive technologies is
updated when data collection from the HPV primary screening protocol has been completed and the
implications of any selection effects are clearer.
Other relevant factors
The population of women referred for colposcopy is likely to change significantly in the future, as females
who have received the HPV vaccine reach screening age. The implication of this for the cost-effectiveness
of the adjunctive technologies has not been included in the current assessment.
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Chapter 7 Conclusions
Implications for service provision
The use of adjunctive DySIS (DySISmap with DySIS video colposcope) increases sensitivity when compared
with colposcopy alone, so it increases the number of women detected with high-grade CIN. However, it
also reduces specificity when compared with colposcopy, so that more women with no or low-grade CIN
will be incorrectly judged as possibly having high-grade CIN. This could lead to an increase in the number
of unnecessary diagnostic biopsies, excisions and ‘see-and-treat’ cases, although the evidence on whether
or not this is actually the case is limited. The use of adjunctive DySIS might therefore increase unnecessary
anxiety and complications in subsequent pregnancies in women who did not require treatment. The use of
DySIS is likely to be cost-saving when compared with standard colposcopy.
The limited evidence precludes any definitive conclusions regarding the diagnostic accuracy of ZedScan
(confidential information has been removed). It is, therefore, also likely to be cost-saving compared with
standard colposcopy. There is currently too little evidence to compare the relative diagnostic accuracy of
ZedScan with that of DySIS.
The introduction of any of these adjunctive technologies may require additional staff training, which may
impose additional costs that were not considered in the analysis.
Suggested research priorities
Given the limited evidence for ZedScan, further diagnostic accuracy studies of ZedScan are needed,
particularly to compare its diagnostic accuracy with that of standard colposcopy, and in groups that are
independent of the manufacturers. Diagnostic accuracy studies comparing both DySIS and ZedScan as
adjunct to colposcopy directly and against colposcopy alone may also be useful.
As most current studies have been in women referred to colposcopy on the basis of cytology screening,
diagnostic accuracy studies in women referred through HPV primary screening are needed to assess
whether or not the new screening programme will alter diagnostic accuracy. Similarly, studies in women
who have been vaccinated against HPV may be required in the future.
All future diagnostic accuracy studies should have robust designs with sufficient power, including
consecutive patients from a representative population of NHS referrals, ensuring adequate blinding of
all assessors and taking biopsies in all women, including those with no colposcopic evidence of CIN.
There is limited evidence on the clinical impact of using adjunctive colposcopy, such as its impact on biopsy
rates or longer-term health. Appropriate audits of centres using adjunctive colposcopy should be used to
gather evidence.
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Appendix 1 ZedScan algorithm
FIGURE 16 ZedScan diagnostic flow chart. (Confidential information has been removed.)
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Appendix 2 Literature search strategies
MEDLINE (via OvidSP: http://ovidsp.ovid.com/)
Epub Ahead of Print, MEDLINE In-Process & Other Non-Indexed Citations, Ovid MEDLINE (R) Daily and Ovid
MEDLINE (R).
Date range searched: 1946 to present.
Date searched: 3 January 2017.
Records retrieved: 2505.
An updated search was carried out on 10 April 2017, retrieving 2436 records.
Search strategy
1. Cervix Uteri/ (27,749)
2. cervix.ti,ab. (44,380)
3. cervic$.ti,ab. (217,889)
4. (endocervix or endo-cervix).ti,ab. (1165)
5. (endocervic$ or endo-cervic$).ti,ab. (5220)
6. (ectocervix or ecto-cervix).ti,ab. (402)
7. (ectocervic$ or ecto-cervic$).ti,ab. (654)
8. ((squamocolumnar or squamo-columnar) adj2 junction).ti,ab. (568)
9. transformation zone$.ti,ab. (1061)
10. or/1-9 (252,639)
11. Colposcopy/ (6321)
12. Colposcopes/ (193)
13. Spectrum Analysis/ (47,414)
14. Dielectric Spectroscopy/ (1674)
15. (colposcop$ adj4 (adjunct$ or digital$ or DSI or computer$ or video$ or alternative$ or conventional$)).ti,ab.
(217)
16. (impedance adj2 spectroscop$).ti,ab. (5309)
17. (Dielectric adj2 Spectroscop$).ti,ab. (1232)
18. (impedance adj2 spectrometr$).ti,ab. (35)
19. (Dielectric adj2 Spectrometr$).ti,ab. (6)
20. (impedance adj2 spectrum analys$).ti,ab. (4)
21. (Dielectric adj2 Spectrum analys$).ti,ab. (0)
22. (telecolposcop$ or tele-colposcop$).ti,ab. (20)
23. (optical adj2 spectroscop$).ti,ab. (5149)
24. ((point or pencil or impedance) adj2 probe$).ti,ab. (546)
25. (microcolposcop$ or micro-colposcop$).ti,ab. (20)
26. (dysis or dysismap).ti,ab. (31)
27. dynamic spectral imaging.ti,ab. (16)
28. Zilico.ti,ab. (0)
29. (ZedScan or Zed Scan).ti,ab. (0)
30. (APX 100 or APX100).ti,ab. (2)
31. EIS.ti,ab. (3007)
32. epitheliometer$.ti,ab. (1)
33. MKIII.ti,ab. (33)
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34. or/11-33 (66,616)
35. 10 and 34 (4876)
36. exp animals/ not humans/ (4,837,860)
37. 35 not 36 (4845)
38. limit 37 to yr=“2000 -Current” (2505)
Key
l / = indexing term [medical subject heading (MeSH)]
l exp = exploded indexing term (MeSH)
l $ = truncation
l ti,ab = terms in either title or abstract fields
l adj2 = terms within two words of each other (any order).
Cochrane Central Register of Controlled Trials (via Wiley Online Library:
http://onlinelibrary.wiley.com/)
Issue 1 of 12, November 2016.
Date searched: 3 January 2017.
Records retrieved: 175.
An updated search was carried out on 10 April 2017, retrieving 183 records from CENTRAL.
Search strategy
#1. MeSH descriptor: [Cervix Uteri] this term only (1031)
#2. cervix:ti,ab,kw (4427)
#3. cervic*:ti,ab,kw (11,455)
#4. (endocervix or endo-cervix):ti,ab,kw (49)
#5. (endocervic* or endo-cervic*):ti,ab,kw (287)
#6. (ectocervix or ecto-cervix):ti,ab,kw (19)
#7. (ectocervic* or ecto-cervic*):ti,ab,kw (25)
#8. ((squamocolumnar or squamo-columnar) near/2 junction):ti,ab,kw (23)
#9. (transformation next zone*):ti,ab,kw (91)
#10. 156-#9 (12900)
#11. MeSH descriptor: [Colposcopy] this term only (353)
#12. MeSH descriptor: [Colposcopes] this term only (10)
#13. MeSH descriptor: [Spectrum Analysis] this term only (90)
#14. MeSH descriptor: [Dielectric Spectroscopy] this term only (11)
#15. (colposcop* near/4 (adjunct* or digital* or DSI or computer* or video* or alternative* or
conventional*)):ti,ab,kw (35)
#16. (impedance near/2 spectroscop*):ti,ab,kw (35)
#17. (Dielectric near/2 Spectroscop*):ti,ab,kw (12)
#18. (impedance near/2 spectrometr*):ti,ab,kw (1)
#19. (Dielectric near/2 Spectrometr*):ti,ab,kw (0)
#20. (impedance near/2 (spectrum next analys*)):ti,ab,kw (0)
#21. (Dielectric near/2 (Spectrum next analys*)):ti,ab,kw (0)
#22. (telecolposcop* or tele-colposcop*):ti,ab,kw (2)
#23. (optical near/2 spectroscop*):ti,ab,kw (19)
#24. ((point or pencil or impedance) near/2 probe*):ti,ab,kw (44)
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#25. (microcolposcop* or micro-colposcop*):ti,ab,kw (1)
#26. (dysis or dysismap):ti,ab,kw (5)
#27. (dynamic next spectral next imaging):ti,ab,kw (2)
#28. Zilico:ti,ab,kw (1)
#29. (ZedScan or Zed Scan):ti,ab,kw (0)
#30. (APX 100 or APX100):ti,ab,kw (0)
#31. EIS:ti,ab,kw (78)
#32. epitheliometer*:ti,ab,kw (0)
#33. MKIII:ti,ab,kw (3)
#34. 157-#33 (637)
#35. #10 and #34 (304)
#36. #10 and #34 Publication Year from 2000 to 2017 (229)
#37. #10 and #34 Publication Year from 2000 to 2017, in Cochrane Reviews (Reviews and Protocols) (2)
#38. #10 and #34 Publication Year from 2000 to 2017, in Trials (175)
Key
l MeSH descriptor = indexing term (MeSH)
l * = truncation
l ti,ab,kw = terms in either title or abstract or keyword fields
l near/2 = terms within two words of each other (any order)
l next = terms are next to each other.
Cochrane Database of Systematic Reviews (via Wiley Online Library:
http://onlinelibrary.wiley.com/)
Issue 1 of 12, January 2017.
Date searched: 3 January 2017.
Records retrieved: 2.
An updated search was carried out on 10 April 2017, retrieving two records from CDSR.
See Cochrane Central Register of Controlled Trials (via Wiley Online Library: http://onlinelibrary.wiley.com/)
for the search strategy used.
Cumulative Index to Nursing and Allied Health Literature (CINAHL Plus
via EBSCOhost: www.ebscohost.com)
Date range searched: inception to 2 January 2017.
Date searched: 3 January 2017.
Records retrieved: 762.
An updated search was carried out on 10 April 2017, retrieving 786 records.
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Search strategy
S1 (MH “Cervix”) (2037)
S2 TI cervix OR AB cervix (2536)
S3 TI cervic* OR AB cervic* (30,166)
S4 TI ( endocervix or endo-cervix ) OR AB ( endocervix or endo-cervix) (32)
S5 TI ( endocervic* or endo-cervic* ) OR AB ( endocervic* or endo-cervic* ) (339)
S6 TI ( ectocervix or ecto-cervix ) OR AB ( ectocervix or ecto-cervix ) (16)
S7 TI ( ectocervic* or ecto-cervic* ) OR AB ( ectocervic* or ecto-cervic* ) (28)
S8 TI ( (squamocolumnar or squamo-columnar) N2 junction ) OR AB ( (squamocolumnar or squamo-columnar)
N2 junction ) (29)
S9 TI transformation N1 zone* OR AB transformation N1 zone* (101)
S10 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 (32,130)
S11 (MH “Colposcopy”) (1218)
S12 (MH “Spectrum Analysis”) (1861)
S13 TI ( colposcop* N4 (adjunct* or digital* or DSI or computer* or video* or alternative* or
conventional*) ) OR AB ( colposcop* N4 (adjunct* or digital* or DSI or computer* or video* or alternative*
or conventional*) ) (53)
S14 TI impedance N2 spectroscop* OR AB impedance N2 spectroscop* (80)
S15 TI dielectric N2 spectroscop* OR AB dielectric N2 spectroscop* (9)
S16 TI impedance N2 spectrometr* OR AB impedance N2 spectrometr* (3)
S17 TI dielectric N2 spectrometr* OR AB dielectric N2 spectrometr* (4)
S18 TI impedance N2 “spectrum analys*” OR AB impedance N2 “spectrum analys*” (2)
S19 TI dielectric N2 “spectrum analys*” OR AB dielectric N2 “spectrum analys*” (2)
S20 TI ( telecolposcop* or tele-colposcop* ) OR AB ( telecolposcop* or tele-colposcop* ) (7)
S21 TI optical N2 spectroscop* OR AB optical N2 spectroscop* (105)
S22 TI ( (point or pencil or impedance) N2 probe* ) OR AB ( (point or pencil or impedance) N2 probe* ) (37)
S23 TI ( microcolposcop* or micro-colposcop* ) OR AB ( microcolposcop* or micro-colposcop* ) (1)
S24 TI ( dysis or dysismap ) OR AB ( dysis or dysismap ) (9)
S25 TI “dynamic spectral imaging” OR AB “dynamic spectral imaging” (5)
S26 TI Zilico OR AB Zilico (0)
S27 TI ( ZedScan or Zed Scan ) OR AB ( ZedScan or Zed Scan ) (0)
S28 TI ( APX 100 or APX100 ) OR AB ( APX 100 or APX100 ) (1)
S29 TI EIS OR AB EIS (287)
S30 TI epitheliometer* OR AB epitheliometer* (0)
S31 TI MKIII OR AB MKIII (3)
S32 S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR
S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 (3551)
S33 S10 AND S32 (838)
S34 S10 AND S32 Limiters - Published Date: 20000101-20170131 (762)
Key
l MH = indexing term (CINAHL heading)
l * = truncation
l TI = terms in the title
l AB = terms in the abstract
l N2 = terms within two words of each other (any order).
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Database of Abstracts of Reviews of Effects (via www.crd.york.ac.uk/
CRDWeb)
Date range searched: inception to 31 March 2015.
Date searched: 4 January 2017.
Records retrieved: 16.
As DARE closed on 31 March 2015, an updated search was not carried out for this database.
Search strategy
1. (MeSH DESCRIPTOR Cervix Uteri) FROM 2000 TO 2017 (67)
2. (cervix) OR (cervic*) FROM 2000 TO 2017 (1302)
3. (endocervix) OR (endo-cervix) FROM 2000 TO 2017 (0)
4. (endocervic*) OR (endo-cervic*) FROM 2000 TO 2017 (28)
5. (ectocervix) OR (ecto-cervix) FROM 2000 TO 2017 (0)
6. (ectocervic*) OR (ecto-cervic*) FROM 2000 TO 2017 (0)
7. (((squamocolumnar or squamo-columnar) NEAR2 junction)) FROM 2000 TO 2017 (1)
8. ((junction NEAR2 (squamocolumnar or squamo-columnar))) FROM 2000 TO 2017 (0)
9. (transformation zone*) FROM 2000 TO 2017 (14)
10. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 (1308)
11. (MeSH DESCRIPTOR Colposcopy) FROM 2000 TO 2017 (55)
12. (MeSH DESCRIPTOR Colposcopes) FROM 2000 TO 2017 (3)
13. (MeSH DESCRIPTOR Spectrum Analysis) FROM 2000 TO 2017 (6)
14. (MeSH DESCRIPTOR Dielectric Spectroscopy) FROM 2000 TO 2017 (2)
15. ((colposcop* NEAR4 (adjunct* or digital* or DSI or computer* or video* or alternative* or
conventional*))) FROM 2000 TO 2017 (3)
16. (((adjunct* or digital* or DSI or computer* or video* or alternative* or conventional*) NEAR4
colposcop*)) FROM 2000 TO 2017 (12)
17. (impedance NEAR2 spectroscop*) FROM 2000 TO 2017 (0)
18. (spectroscop* NEAR2 impedance) FROM 2000 TO 2017 (0)
19. (Dielectric NEAR2 Spectroscop*) FROM 2000 TO 2017 (2)
20. (Spectroscop* NEAR2 Dielectric) FROM 2000 TO 2017 (0)
21. (impedance NEAR2 spectrometr*) FROM 2000 TO 2017 (0)
22. (spectrometr* NEAR2 impedance) FROM 2000 TO 2017 (0)
23. (Dielectric NEAR2 Spectrometr*) FROM 2000 TO 2017 (0)
24. (Spectrometr* NEAR2 Dielectric) FROM 2000 TO 2017 (0)
25. (impedance NEAR2 spectrum analys*) FROM 2000 TO 2017 (0)
26. (spectrum analys* NEAR2 impedance) FROM 2000 TO 2017 (0)
27. (Dielectric NEAR2 Spectrum analys*) FROM 2000 TO 2017 (0)
28. (Spectrum analys* NEAR2 Dielectric) FROM 2000 TO 2017 (0)
29. (telecolposcop* or tele-colposcop*) FROM 2000 TO 2017 (1)
30. (optical NEAR2 spectroscop*) FROM 2000 TO 2017 (2)
31. (spectroscop* NEAR2 optical) FROM 2000 TO 2017 (0)
32. (((point or pencil or impedance) NEAR2 probe*)) FROM 2000 TO 2017 (0)
33. ((probe* NEAR2 (point or pencil or impedance))) FROM 2000 TO 2017 (0)
34. (microcolposcop* or micro-colposcop*) FROM 2000 TO 2017 (0)
35. (dysis or dysismap) FROM 2000 TO 2017 (3)
36. (dynamic spectral imaging) FROM 2000 TO 2017 (0)
37. (Zilico) FROM 2000 TO 2017 (1)
38. (ZedScan or Zed Scan) FROM 2000 TO 2017 (0)
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39. (APX 100 or APX100) FROM 2000 TO 2017 (0)
40. (EIS) FROM 2000 TO 2017 (3)
41. (epitheliometer*) FROM 2000 TO 2017 (0)
42. (MKIII) FROM 2000 TO 2017 (0)
43. #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR
#23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR
#35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 (72)
44. #10 AND #43 (59)
45. (*) IN DARE FROM 2000 TO 2017 (43,354)
46. #44 AND #45 (16)
47. (*) IN NHSEED FROM 2000 TO 2017 (14,762)
48. #44 AND #47 (38)
49. (*) IN HTA FROM 2000 TO 2017 (14,138)
50. #44 AND #49 (5)
Key
l MeSH DESCRIPTOR = indexing term (MeSH)
l * = truncation
l NEAR2 = terms within two words of each other (order specified).
EMBASE (via Ovid: http://ovidsp.ovid.com/)
Date range searched: 1974 to 30 December 2016.
Date searched: 3 January 2017.
Records retrieved: 6177.
An updated search was carried out on 10 April 2017, retrieving 6300 records.
Search strategy
1. exp uterine cervix/ (27,722)
2. cervix.ti,ab. (48,465)
3. cervic$.ti,ab. (247,849)
4. (endocervix or endo-cervix).ti,ab. (1296)
5. (endocervic$ or endo-cervic$).ti,ab. (6123)
6. (ectocervix or ecto-cervix).ti,ab. (458)
7. (ectocervic$ or ecto-cervic$).ti,ab. (663)
8. ((squamocolumnar or squamo-columnar) adj2 junction).ti,ab. (747)
9. transformation zone$.ti,ab. (1202)
10. or/1-9 (283,656)
11. colposcopy/ (11,114)
12. colposcope/ (251)
13. spectroscopy/ (95,966)
14. electrochemical impedance spectroscopy/ (5008)
15. (colposcop$ adj4 (adjunct$ or digital$ or DSI or computer$ or video$ or alternative$ or conventional
$)).ti,ab. (281)
16. (impedance adj2 spectroscop$).ti,ab. (4587)
17. (Dielectric adj2 Spectroscop$).ti,ab. (843)
18. (impedance adj2 spectrometr$).ti,ab. (40)
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19. (Dielectric adj2 Spectrometr$).ti,ab. (10)
20. (impedance adj2 spectrum analys$).ti,ab. (7)
21. (Dielectric adj2 Spectrum analys$).ti,ab. (0)
22. (telecolposcop$ or tele-colposcop$).ti,ab. (20)
23. (optical adj2 spectroscop$).ti,ab. (3982)
24. ((point or pencil or impedance) adj2 probe$).ti,ab. (473)
25. (microcolposcop$ or micro-colposcop$).ti,ab. (31)
26. (dysis or dysismap).ti,ab,dv,dm. (111)
27. dynamic spectral imaging.ti,ab. (27)
28. Zilico.ti,ab,dm. (0)
29. (ZedScan or Zed Scan).ti,ab,dv. (3)
30. (APX 100 or APX100).ti,ab,dv. (4)
31. EIS.ti,ab. (3150)
32. epitheliometer$.ti,ab,dv. (1)
33. MKIII.ti,ab,dv. (48)
34. or/11-33 (117,271)
35. 10 and 34 (8853)
36. (animal/ or nonhuman/) not exp human/ (5,039,945)
37. 35 not 36 (8818)
38. limit 37 to yr=“2000 -Current” (6177)
Key
l / = indexing term (Emtree heading)
l exp = exploded indexing term (Emtree heading)
l $ = truncation
l ti,ab = terms in either title or abstract fields
l dm = terms in device manufacturer field
l dv = terms in the device trade name field
l adj2 = terms within two words of each other (any order).
Health Management Information Consortium (via Ovid: http://ovidsp.
ovid.com/)
Date range searched: 1979 to November 2016.
Date searched: 3 January 2017.
Records retrieved: 19.
An updated search was carried out on 10 April 2017, retrieving 19 records.
Search strategy
1. cervix uteri/ (18)
2. cervix.ti,ab. (136)
3. cervic$.ti,ab. (1398)
4. (endocervix or endo-cervix).ti,ab. (1)
5. (endocervic$ or endo-cervic$).ti,ab. (17)
6. (ectocervix or ecto-cervix).ti,ab. (0)
7. (ectocervic$ or ecto-cervic$).ti,ab. (1)
8. ((squamocolumnar or squamo-columnar) adj2 junction).ti,ab. (1)
DOI: 10.3310/hta22540 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 54
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Peron et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
121
9. transformation zone$.ti,ab. (6)
10. or/1-9 (1472)
11. colposcopy/ (49)
12. spectroscopy/ (20)
13. (colposcop$ adj4 (adjunct$ or digital$ or DSI or computer$ or video$ or alternative$ or conventional$)).ti,
ab. (4)
14. (impedance adj2 spectroscop$).ti,ab. (0)
15. (Dielectric adj2 Spectroscop$).ti,ab. (0)
16. (impedance adj2 spectrometr$).ti,ab. (0)
17. (Dielectric adj2 Spectrometr$).ti,ab. (0)
18. (impedance adj2 spectrum analys$).ti,ab. (0)
19. (Dielectric adj2 Spectrum analys$).ti,ab. (0)
20. (telecolposcop$ or tele-colposcop$).ti,ab. (0)
21. (optical adj2 spectroscop$).ti,ab. (0)
22. ((point or pencil or impedance) adj2 probe$).ti,ab. (0)
23. (microcolposcop$ or micro-colposcop$).ti,ab. (0)
24. (dysis or dysismap).ti,ab. (0)
25. dynamic spectral imaging.ti,ab. (0)
26. Zilico.ti,ab. (0)
27. (ZedScan or Zed Scan).ti,ab. (0)
28. (APX 100 or APX100).ti,ab. (0)
29. EIS.ti,ab. (26)
30. epitheliometer$.ti,ab. (0)
31. MKIII.ti,ab. (0)
32. or/11-31 (97)
33. 10 and 32 (36)
34. limit 33 to yr=“2000 -Current” (19)
Key
l / = indexing term
l $ = truncation
l ti,ab = terms in either title or abstract fields
l adj2 = terms within two words of each other (any order).
Health Technology Assessment database (via www.crd.york.ac.uk/
CRDWeb)
Date range searched: inception to 3 January 2017.
Date searched: 4 January 2017.
Records retrieved: 5.
See Database of Abstracts of Reviews of Effects (via www.crd.york.ac.uk/CRDWeb) for the search
strategy used.
An updated search was carried out on 10 April 2017, retrieving five records.
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NHS Economic Evaluation Database (via www.crd.york.ac.uk/CRDWeb)
Date range searched: inception to 31 March 2015.
Date searched: 4 January 2017.
Records retrieved: 38.
As NHS EED closed on 31 March 2015, an updated search was not carried out for this database.
See Database of Abstracts of Reviews of Effects (via www.crd.york.ac.uk/CRDWeb) for search strategy used.
PubMed (via www.ncbi.nlm.nih.gov/pubmed)
Date searched: 4 January 2017.
Records retrieved: 63.
An updated search was carried out on 10 April 2017, retrieving 59 records.
Search strategy
((((((((((((((((((((((((((((((“Colposcopy”[Mesh:NoExp]) OR “Colposcopes”[Mesh:NoExp]) OR “Spectrum
Analysis”[Mesh:NoExp]) OR “Dielectric Spectroscopy”[Mesh:NoExp]) OR ((colposcop*[Title/Abstract]) AND
(adjunct*[Title/Abstract] OR digital*[Title/Abstract] OR DSI[Title/Abstract] OR computer*[Title/Abstract] OR
video*[Title/Abstract] OR alternative*[Title/Abstract] OR conventional*[Title/Abstract]))) OR ((impedance
[Title/Abstract]) AND spectroscop*[Title/Abstract])) OR ((Dielectric[Title/Abstract]) AND Spectroscop*[Title/
Abstract])) OR ((impedance[Title/Abstract]) AND spectrometr*[Title/Abstract])) OR ((impedance[Title/
Abstract]) AND spectrum analys*[Title/Abstract])) OR ((Dielectric[Title/Abstract]) AND Spectrum analys*
[Title/Abstract])) OR ((Dielectric[Title/Abstract]) AND Spectrometr*[Title/Abstract])) OR ((telecolposcop*
[Title/Abstract] OR tele-colposcop*[Title/Abstract]))) OR ((optical[Title/Abstract]) AND spectroscop*[Title/
Abstract])) OR (((point[Title/Abstract] OR pencil[Title/Abstract] OR impedance[Title/Abstract])) AND
probe*[Title/Abstract])) OR ((microcolposcop*[Title/Abstract] OR micro-colposcop*[Title/Abstract]))) OR
((dysis[Title/Abstract] OR dysismap[Title/Abstract]))) OR dynamic spectral imaging[Title/Abstract]) OR Zilico
[Title/Abstract]) OR ((ZedScan[Title/Abstract] OR Zed Scan[Title/Abstract]))) OR ((“APX 100”[Title/Abstract]
OR APX100[Title/Abstract]))) OR EIS[Title/Abstract]) OR epitheliometer*[Title/Abstract]) OR MKIII[Title/
Abstract])) AND ((((“Cervix Uteri”[Mesh:NoExp]) OR ((((((cervix[Title/Abstract]) OR cervic*[Title/Abstract]) OR
(endocervix[Title/Abstract] OR endo-cervix[Title/Abstract])) OR (endocervic*[Title/Abstract] OR endo-cervic*
[Title/Abstract])) OR (ectocervix[Title/Abstract] OR ecto-cervix[Title/Abstract])) OR (ectocervic*[Title/Abstract]
OR ecto-cervic*[Title/Abstract]))) OR (((squamocolumnar[Title/Abstract] OR squamo-columnar[Title/
Abstract])) AND junction[Title/Abstract])) OR ((“transformation zone”[Title/Abstract]) OR “transformation
zones”[Title/Abstract])))) AND ((pubstatusaheadofprint OR publisher[sb] OR pubmednotmedline[sb])))) AND
(“2000/01/01”[Date - Publication] : “3000”[Date - Publication]))) NOT ((animals [mh] NOT humans [mh]))
The above search strategy incorporates the following search line to limit it to studies found in PubMed but
not available in Ovid MEDLINE: (pubstatusaheadofprint OR publisher[sb] OR pubmednotmedline[sb]).160
Key
l [Mesh] = exploded indexing term (MeSH)
l [Mesh:noexp] = indexing term (MeSH) not exploded
l * = truncation
l ‘‘ ’’ = phrase search
l [Title/Abstract]) = terms in either title or abstract fields.
DOI: 10.3310/hta22540 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 54
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Peron et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
123
Science Citation Index (via Web of Science, Clarivate Analytics;
http://thomsonreuters.com/thomson-reuters-web-of-science/)
Date range searched: 1900 to 2 January 2017.
Date searched: 3 January 2017.
Records retrieved: 279.
An updated search was carried out on 10 April 2017, retrieving 286 records.
Search strategy
#30. #28 AND #8 (279)
Indexes=SCI-EXPANDED Timespan=2000-2017
#29. #28 AND #8 (318)
#28. #27 OR #26 OR #25 OR #24 OR #23 OR #22 OR #21 OR #20 OR #19 OR #18 OR #17 OR #16
OR #15 OR #14 OR #13 OR #12 OR #11 OR #10 OR #9 (91,903)
#27. TS=MKIII (64)
#26. TS=epitheliometer* (2)
#25. TS=EIS (20,286)
#24. TS=(“APX 100” or APX100) (2)
#23. TS=(ZedScan or “Zed Scan”) (1)
#22. TS=Zilico (0)
#21. TS=“dynamic spectral imaging” (20)
#20. TS=(dysis or dysismap) (75)
#19. TS=(microcolposcop* or micro-colposcop*) (15)
#18. TS=((point or pencil or impedance) NEAR/2 probe*) (4324)
#17. TS=(optical NEAR/2 spectroscop*) (31,129)
#16. TS=(telecolposcop* or tele-colposcop*) (20)
#15. TS=(Dielectric NEAR/2 “Spectrum analys*”) (8)
#14. TS=(impedance NEAR/2 “spectrum analys*”) (35)
#13. TS=(Dielectric NEAR/2 Spectrometr*) (89)
#12. TS=(impedance NEAR/2 spectrometr*) (225)
#11. TS=(Dielectric NEAR/2 Spectroscop*) (7615)
#10. TS=(impedance NEAR/2 spectroscop*) (44,134)
#9. TS=(colposcop* NEAR/4 (adjunct* or digital* or DSI or computer* or video* or alternative* or
conventional*)) (198)
#8. #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1 (197,500)
#7. TS=“transformation zone*” (1431)
#6. TS=((squamocolumnar or squamo-columnar) NEAR/2 junction) (448)
#5. TS=(ectocervic* or ecto-cervic*) (457)
#4. TS=(ectocervix or ecto-cervix) (248)
#3. TS=(endocervic* or endo-cervic*) (3940)
#2. TS=(endocervix or endo-cervix) (754)
#1. TS=(cervix or cervic*) (194,743)
Key
l TS = topic tag; searches terms in title, abstract, author keywords and keywords plus fields
l * = truncation
l ‘‘ ’’ = phrase search
l NEAR/2 = terms within 2 words of each other (any order).
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Ongoing, unpublished or grey literature search strategies
ClinicalTrials.gov (https://clinicaltrials.gov)
Date searched: 4 January 2017.
Records retrieved: 173.
An updated search was carried out on 10 April 2017, retrieving eight new records.
Search strategy
A total of 169 studies found for (Cervix OR cervical) AND (Colposcopy OR spectroscopy OR spectrometry
OR ‘spectrum analysis’).
Four studies found for dysis OR dysismap OR ‘dynamic spectral imaging’ OR Zilico OR ZedScan OR Zed
Scan OR ‘APX 100’ OR APX100 OR epitheliometer OR MKIII.
Conference Proceedings Citation Index – Science (via Web of Science, Clarivate Analytics;
http://thomsonreuters.com/thomson-reuters-web-of-science)
Date range searched: 1990 to 2 January 2017.
Date searched: 3 January 2017.
Records retrieved: 62.
An updated search was carried out on 10 April 2017, retrieving 63 records.
Search strategy
#30. #28 AND #8 (62)
Indexes=CPCI-S Timespan=2000-2017
#29. #28 AND #8 (67)
#28. #27 OR #26 OR #25 OR #24 OR #23 OR #22 OR #21 OR #20 OR #19 OR #18 OR #17 OR #16
OR #15 OR #14 OR #13 OR #12 OR #11 OR #10 OR #9 (20,223)
#27. TS=MKIII (27)
#26. TS=epitheliometer* (0)
#25. TS=EIS (3376)
#24. TS=(“APX 100” or APX100) (0)
#23. TS=(ZedScan or “Zed Scan”) (0)
#22. TS=Zilico (0)
#21. TS=“dynamic spectral imaging” (4)
#20. TS=(dysis or dysismap) (32)
#19. TS=(microcolposcop* or micro-colposcop*) (0)
#18. TS=((point or pencil or impedance) NEAR/2 probe*) (1606)
#17. TS=(optical NEAR/2 spectroscop*) (8132)
#16. TS=(telecolposcop* or tele-colposcop*) (3)
#15. TS=(Dielectric NEAR/2 “Spectrum analys*”) (3)
#14. TS=(impedance NEAR/2 “spectrum analys*”) (15)
#13. TS=(Dielectric NEAR/2 Spectrometr*) (19)
#12. TS=(impedance NEAR/2 spectrometr*) (51)
#11. TS=(Dielectric NEAR/2 Spectroscop*) (2063)
#10. TS=(impedance NEAR/2 spectroscop*) (7234)
#9. TS=(colposcop* NEAR/4 (adjunct* or digital* or DSI or computer* or video* or alternative* or
conventional*)) (38)
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#8. #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1 (16,544)
#7. TS=“transformation zone*” (135)
#6. TS=((squamocolumnar or squamo-columnar) NEAR/2 junction) (60)
#5. TS=(ectocervic* or ecto-cervic*) (36)
#4. TS=(ectocervix or ecto-cervix) (20)
#3. TS=(endocervic* or endo-cervic*) (400)
#2. TS=(endocervix or endo-cervix) (54)
#1. TS=(cervix or cervic*) (16,171)
Key
l TS = topic tag; searches terms in title, abstract, author keywords and keywords plus fields
l * = truncation
l ‘‘ ’’ = phrase search
l NEAR/2 = terms within two words of each other (any order).
European Union Clinical Trials Register (www.clinicaltrialsregister.eu/ctr-search/search)
Date searched: 4 January 2017.
Records retrieved: 15.
An updated search was carried out on 10 April 2017, retrieving 16 records.
Search strategy
1. 15 result(s) found for (Cervix OR cervical) AND (Colposcopy OR spectroscopy OR spectrometry OR
“spectrum analysis”).
2. Dysis OR dysismap OR “dynamic spectral imaging” – 0 results.
3. Zilico OR ZedScan OR “Zed Scan” OR “APX 100” OR APX100 OR epitheliometer OR MKIII – 0 results.
PROSPERO (www.crd.york.ac.uk/PROSPERO)
Date searched: 4 January 2017.
Records retrieved: 4.
An updated search was carried out on 10 April 2017, retrieving three new records.
Search strategy
#1. MeSH DESCRIPTOR Cervix Uteri (10)
#2. cervix OR cervic* (399)
#3. endocervix OR endo-cervix (1)
#4. endocervic* OR endo-cervic* (4)
#5. ectocervix OR ecto-cervix (0)
#6. ectocervic$or ecto-cervic$ (0)
#7. ectocervic* OR ecto-cervic* (0)
#8. squamocolumnar OR squamo-columnar (1)
#9. transformation zone* (3)
#10. #1 OR #2 OR #3 OR #4 OR #5 OR #7 OR #8 OR #9 (400)
#11. MeSH DESCRIPTOR colposcopy (2)
#12. MeSH DESCRIPTOR Colposcopes (0)
#13. MeSH DESCRIPTOR Spectrum Analysis (1)
#14. MeSH DESCRIPTOR Dielectric Spectroscopy (0)
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#15. (colposcop* AND (adjunct* OR digital* OR DSI OR computer* OR video* OR alternative* OR
conventional*)) (3)
#16. ((impedance OR Dielectric) AND (spectroscop* OR spectrometr* OR spectrum analys*)) (1)
#17. telecolposcop* OR tele-colposcop* (0)
#18. telecolposcop* OR tele-colposcop* (0)
#19. optical AND spectroscop* (5)
#20. ((point OR pencil OR impedance) AND probe*) (16)
#21. microcolposcop* OR micro-colposcop* (1)
#22. dysis OR dysismap (2)
#23. dynamic spectral imaging (1)
#24. Zilico (1)
#25. ZedScan OR Zed Scan (0)
#26. APX 100 OR APX100 (1)
#27. EIS (1)
#28. epitheliometer* (0)
#29. MKIII (0)
#30. #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #19 OR #20 OR #21 OR #18 OR #22
OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 (26)
#31. #30 AND #10 (4)
Key
l MeSH DESCRIPTOR = indexing term (MeSH)
l * = truncation.
World Health Organization, International Clinical Trials Registry Platform
(www.who.int/ictrp/search/en)
Date searched: 4 January 2017.
Records retrieved: 17.
An updated search was carried out on 10 April 2017, retrieving 15 records.
Search strategy
1. cervix OR cervical (Condition field) AND Colposcopy OR spectroscopy OR spectrometry OR spectrum
analysis (Intervention field) – 16 records retrieved.
2. dysis OR dysismap OR dynamic spectral imaging OR Zilico OR ZedScan OR Zed Scan OR APX 100 OR
APX100 OR epitheliometer OR MKIII (Intervention field) – 1 record retrieved.
Guideline searches
The following websites were all searched on 10 January 2017. An updated search was carried out on
10 April 2017; however, no new guidelines were identified.
Scottish Intercollegiate Guidelines Network (www.sign.ac.uk)
Searched the website using the terms ‘colposcopy’, ‘DySIS’, ‘ZedScan’, ‘Zed Scan’. Also browsed all
guidelines. No new guidance found.
National Institute for Health and Clinical Excellence (www.nice.org.uk)
Searched the website using the terms ‘colposcopy’, ‘DySIS’, ‘ZedScan’, ‘Zed Scan’. Also browsed
documents within the cervical cancer guidance section. Four relevant guidance documents were found.
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National Guideline Clearinghouse (www.guideline.gov)
Searched using the terms ‘colposcopy OR DySIS OR ZedScan OR Zed Scan’, limited to publications from
2011 to 2017. A total of 19 results were browsed for relevance. Eight relevant guidelines were found.
NHS Evidence (www.evidence.nhs.uk)
Searched using the terms ‘colposcopy OR dysis OR ZedScan OR Zed Scan’. Filtered results by guidance and
by date (1 January 2011 to 10 January 2017). A total of 40 records were retrieved and downloaded.
Turning Research into Practice database (www.tripdatabase.com)
Searched using the terms ‘colposcopy OR dysis OR ZedScan OR Zed Scan’. Filtered results by guidelines;
48 records were retrieved and browsed for relevance. One relevant record was found after duplicates
were removed.
Public Health England (www.gov.uk/search)
Searched the website using the terms ‘colposcopy’, ‘DySIS’, ‘ZedScan’ and ‘Zed Scan’. Filtered by Public
Health England. Nine results were retrieved and browsed for relevance. Seven relevant documents
were found.
Royal College of Obstetricians and Gynaecologists (www.rcog.org.uk/en/
guidelines-research-services/guidelines)
Searched all guidelines using the terms ‘colposcopy’, ‘DySIS’, ‘ZedScan’ and ‘Zed Scan’. Eight records were
retrieved and browsed for relevance. One relevant report was found.
The British Society for Colposcopy and Cervical Pathology (www.bsccp.org.uk)
Searched the website using the terms ‘colposcopy’, ‘DySIS’, ‘ZedScan’ and ‘Zed Scan’, using the website
general search box. A total of 110 results were returned and browsed for relevance. No guidelines were found.
Additional searches
The following search strategies were used to identify systematic reviews or meta-analyses examining the
diagnostic test accuracy of cervical screening or HPV testing.
MEDLINE [Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid
MEDLINE(R) Daily and Ovid MEDLINE(R), via OvidSP: http://ovidsp.ovid.com]
Date range searched: 1946 to present.
Date searched: 29 March 2017.
Records retrieved: 267.
Search strategy
1. Uterine Cervical Neoplasms/ (67,631)
2. Cervical Intraepithelial Neoplasia/ (8926)
3. exp Uterine Cervical Dysplasia/ (4058)
4. Cervix Uteri/ (25,999)
5. ((cervix or cervic*) adj3 (cancer* or neoplas* or carcinoma* or adenocarcinoma* or tumour* or
tumor* dysplas* or dyskaryo* or precancer* or pre-cancer*)).ti,ab. (65,985)
6. ((cervix or cervic*) adj3 (abnormal* or lesion* or atypical or squamous)).ti,ab. (13,430)
7. (cervix or cervic*).ti,ab. (227,836)
8. (LSIL or HSIL or ASCUS or ASC-US or ASC-H or ASC).ti,ab. (8776)
9. ((intraepithelial or intra-epithelial) adj2 lesion$).ti,ab. (4844)
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10. (atypical adj2 squamous).ti,ab. (1989)
11. 8 or 9 or 10 (12,051)
12. 7 and 11 (5015)
13. (CIN or CIN1* or CIN2* or CIN3* or CIN 1* or CIN 2* or CIN 3* or CIN I* or CIN II* or CIN III* or
CINI* or CINII* or CINIII* or CGIN*).ti,ab. (10,256)
14. 1 or 2 or 3 or 4 or 5 or 6 or 12 or 13 (114,337)
15. exp Papillomavirus Infections/ (28,658)
16. Papillomaviridae/ (21,795)
17. exp Alphapapillomavirus/ (6098)
18. (human* adj2 (papillomavirus* or papillomaviridae or papilloma virus*)).ti,ab. (33,953)
19. (HPV* or hrHPV* or hr-HPV*).ti,ab. (35,059)
20. or/15-19 (53,740)
21. Vaginal Smears/ (21,441)
22. Papanicolaou Test/ (5902)
23. Cytological Techniques/ (10,199)
24. Cytodiagnosis/ (15,335)
25. Mass Screening/ (92,108)
26. “Early Detection of Cancer”/ (15,713)
27. DNA Probes, HPV/ (1080)
28. Human Papillomavirus DNA Tests/ (340)
29. ((vagina* or pap or papanicolaou) adj2 smear*).ti,ab. (9876)
30. ((pap or papanicolaou) adj2 (test* or analys* or screen*)).ti,ab. (4980)
31. cytolog*.ti,ab. (85,141)
32. or/21-31 (214,406)
33. 14 and 32 (26,028)
34. 20 and 32 (10,837)
35. (screen* adj3 (cervic* or cervix)).ti,ab. (9587)
36. ((cervic* or cervix) adj2 smear$).ti,ab. (4102)
37. ((HPV* or hrHPV* or hr-HPV*) adj4 (screen* or test* or detect* or triage*)).ti,ab. (11,312)
38. (human* adj2 (papillomavirus* or papillomaviridae or papilloma virus*) adj2 (screen* or test* or
detect* or triage*)).ti,ab. (3300)
39. 35 or 36 or 37 or 38 (22,413)
40. 33 or 34 or 39 (36,627)
41. systematic$ review$.ti,ab. (103,638)
42. meta-analysis as topic/ (15,759)
43. meta-analytic$.ti,ab. (5302)
44. meta-analysis.ti,ab,pt. (116,352)
45. metanalysis.ti,ab. (157)
46. metaanalysis.ti,ab. (1389)
47. meta analysis.ti,ab. (94,402)
48. meta-synthesis.ti,ab. (524)
49. metasynthesis.ti,ab. (231)
50. meta synthesis.ti,ab. (524)
51. meta-regression.ti,ab. (4549)
52. metaregression.ti,ab. (442)
53. meta regression.ti,ab. (4549)
54. (synthes$ adj3 literature).ti,ab. (2221)
55. (synthes$ adj3 evidence).ti,ab. (6509)
56. integrative review.ti,ab. (1692)
57. data synthesis.ti,ab. (9772)
58. (research synthesis or narrative synthesis).ti,ab. (1591)
59. (systematic study or systematic studies).ti,ab. (9808)
60. (systematic comparison$ or systematic overview$).ti,ab. (2592)
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61. evidence based review.ti,ab. (1694)
62. comprehensive review.ti,ab. (10,438)
63. critical review.ti,ab. (13,445)
64. quantitative review.ti,ab. (583)
65. structured review.ti,ab. (641)
66. realist review.ti,ab. (158)
67. realist synthesis.ti,ab. (118)
68. or/41-67 (239,126)
69. review.pt. (2,263,518)
70. medline.ab. (84,579)
71. pubmed.ab. (65,446)
72. cochrane.ab. (51,941)
73. embase.ab. (54,367)
74. cinahl.ab. (17,283)
75. psyc?lit.ab. (937)
76. psyc?info.ab. (17,111)
77. (literature adj3 search$).ab. (41,423)
78. (database$ adj3 search$).ab. (39,606)
79. (bibliographic adj3 search$).ab. (1816)
80. (electronic adj3 search$).ab. (14,770)
81. (electronic adj3 database$).ab. (18,516)
82. (computeri?ed adj3 search$).ab. (3229)
83. (internet adj3 search$).ab. (2468)
84. included studies.ab. (13,602)
85. (inclusion adj3 studies).ab. (10,824)
86. inclusion criteria.ab. (57,533)
87. selection criteria.ab. (25,429)
88. predefined criteria.ab. (1537)
89. predetermined criteria.ab. (904)
90. (assess$ adj3 (quality or validity)).ab. (58,471)
91. (select$ adj3 (study or studies)).ab. (51,767)
92. (data adj3 extract$).ab. (43,710)
93. extracted data.ab. (10,058)
94. (data adj2 abstracted).ab. (4252)
95. (data adj3 abstraction).ab. (1226)
96. published intervention$.ab. (143)
97. ((study or studies) adj2 evaluat$).ab. (145,298)
98. (intervention$ adj2 evaluat$).ab. (8561)
99. confidence interval$.ab. (314,381)
100. heterogeneity.ab. (125,402)
101. pooled.ab. (65,443)
102. pooling.ab. (9876)
103. odds ratio$.ab. (205,883)
104. (Jadad or coding).ab. (150,343)
105. or/70-104 (1,105,052)
106. 69 and 105 (179,404)
107. review.ti. (35,4575)
108. 107 and 105 (85,749)
109. (review$ adj4 (papers or trials or studies or evidence or intervention$ or evaluation$)).ti,ab. (142,763)
110. 68 or 106 or 108 or 109 (418,128)
111. letter.pt. (964,951)
112. editorial.pt. (434,093)
113. comment.pt. (685,970)
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114. 111 or 112 or 113 (1,570,204)
115. 110 not 114 (408,039)
116. exp animals/ not humans/ (4,364,879)
117. 115 not 116 (396,895)
118. 40 and 117 (921)
119. limit 118 to yr=“2014 -Current” (267)
Key
l / = indexing term (MeSH)
l exp = exploded indexing term (MeSH)
l * = truncation
l $ = truncation
l ? = optional wildcard – stands for zero or one character
l .ti,ab. = terms in either title or abstract fields
l .pt. = publication type
l adj = terms next to each other (order specified)
l adj2 = terms within two words of each other (any order).
Cochrane Database of Systematic Reviews (via Wiley Online Library: http://onlinelibrary.
wiley.com)
Issue 3 of 12, March 2017.
Date searched: 29 March 2017.
Records retrieved: 20.
Search strategy
#1. MeSH descriptor: [Uterine Cervical Neoplasms] this term only (1975)
#2. MeSH descriptor: [Cervical Intraepithelial Neoplasia] this term only (518)
#3. MeSH descriptor: [Uterine Cervical Dysplasia] explode all trees (129)
#4. MeSH descriptor: [Cervix Uteri] this term only (1045)
#5. ((cervix or cervic*) near/3 (cancer* or neoplas* or carcinoma* or adenocarcinoma* or tumour* or
tumor* dysplas* or dyskaryo* or precancer* or pre-cancer*)):ti,ab,kw (3701)
#6. ((cervix or cervic*) near/3 (abnormal* or lesion* or atypical or squamous)):ti,ab,kw (725)
#7. (cervix or cervic*):ti,ab,kw (13509)
#8. (LSIL or HSIL or ASCUS or ASC-US or ASC-H or ASC):ti,ab,kw (383)
#9. ((intraepithelial or intra-epithelial) near/2 lesion*):ti,ab,kw (217)
#10. (atypical near/2 squamous):ti,ab,kw (118)
#11. #8 or #9 or #10 (521)
#12. #7 and #11 (270)
#13. (CIN or CIN1* or CIN2* or CIN3* or CIN 1* or CIN 2* or CIN 3* or CIN I* or CIN II* or CIN III* or
CINI* or CINII* or CINIII* or CGIN*):ti,ab,kw (1165)
#14. #1 or #2 or #3 or #4 or #5 or #6 or #12 or #13 (5623)
#15. MeSH descriptor: [Papillomavirus Infections] explode all trees (1107)
#16. MeSH descriptor: [Papillomaviridae] this term only (419)
#17. MeSH descriptor: [Alphapapillomavirus] explode all trees (220)
#18. (human* near/2 (papillomavirus* or papillomaviridae or papilloma next virus*)):ti,ab,kw (1353)
#19. (HPV* or hrHPV* or hr-HPV*):ti,ab,kw (1438)
#20. #15 or #16 or #17 or #18 or #19 (2137)
#21. MeSH descriptor: [Vaginal Smears] explode all trees (802)
#22. MeSH descriptor: [Papanicolaou Test] this term only (228)
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#23. MeSH descriptor: [Cytological Techniques] this term only (82)
#24. MeSH descriptor: [Cytodiagnosis] this term only (120)
#25. MeSH descriptor: [Mass Screening] this term only (4758)
#26. MeSH descriptor: [Early Detection of Cancer] this term only (955)
#27. MeSH descriptor: [DNA Probes, HPV] this term only (16)
#28. MeSH descriptor: [Human Papillomavirus DNA Tests] this term only (8)
#29. ((vagina* or pap or papanicolaou) near/2 (smear*)):ti,ab,kw (1139)
#30. ((pap or papanicolaou) near/2 (test* or analys* or screen*)):ti,ab,kw (581)
#31. cytolog*:ti,ab,kw (2751)
#32. #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 (8679)
#33. #14 and #32 (1330)
#34. #20 and #32 (666)
#35. (screen* near/2 (cervic* or cervix)):ti,ab,kw (730)
#36. ((cervic* or cervix) near/2 smear*):ti,ab,kw (189)
#37. ((HPV* or hrHPV* or hr-HPV*) near/4 (screen* or test* or detect* or triage*)):ti,ab,kw (519)
#38. (human* near/2 (papillomavirus* or papillomaviridae or papilloma next virus*) near/2 (screen* or
test* or detect* or triage*)):ti,ab,kw (240)
#39. #35 or #36 or #37 or #38 (1211)
#40. #33 or #34 or #39 (1740)
Key
l MeSH descriptor = indexing term (MeSH)
l * = truncation
l ti,ab,kw = terms in either title or abstract or keyword fields
l near/2 = terms within two words of each other (any order)
l next = terms are next to each other.
Database of Abstracts of Reviews of Effects (www.crd.york.ac.uk/CRDWeb)
Date ranged searched: inception to 31 March 2015.
Date searched: 29 March 2017.
Records retrieved: 128.
Search strategy
1. MeSH DESCRIPTOR Uterine Cervical Neoplasms (540)
2. MeSH DESCRIPTOR Cervical Intraepithelial Neoplasia (136)
3. MeSH DESCRIPTOR Uterine Cervical Dysplasia EXPLODE ALL TREES (22)
4. MeSH DESCRIPTOR Cervix Uteri (89)
5. (((cervix or cervic*) ADJ3 (cancer* or neoplas* or carcinoma* or adenocarcinoma* or tumour* or
tumor* dysplas* or dyskaryo* or precancer* or pre-cancer*))) (693)
6. (((cancer* or neoplas* or carcinoma* or adenocarcinoma* or tumour* or tumor* dysplas* or
dyskaryo* or precancer* or pre-cancer*) ADJ3 (cervix or cervic*))) (168)
7. (((cervix or cervic*) ADJ3 (abnormal* or lesion* or atypical or squamous))) (60)
8. (((abnormal* or lesion* or atypical or squamous) ADJ3 (cervix or cervic*))) (43)
9. ((cervix or cervic*)) AND (LSIL or HSIL or ASCUS or ASC-US or ASC-H or ASC) (41)
10. ((cervix or cervic*)) (1481)
11. (((intraepithelial or intra-epithelial) ADJ2 lesion*)) (66)
12. ((lesion* ADJ2 (intraepithelial or intra-epithelial))) (0)
13. ((atypical ADJ2 squamous)) (36)
14. ((squamous ADJ2 atypical)) (1)
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
132
15. #11 OR #12 OR #13 OR #14 (76)
16. #10 AND #15 (73)
17. ((CIN or CIN1* or CIN2* or CIN3* or CIN 1* or CIN 2* or CIN 3* or CIN I* or CIN II* or CIN III* or
CINI* or CINII* or CINIII* or CGIN*)) (111)
18. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #16 OR #17 (801)
19. MeSH DESCRIPTOR Papillomavirus Infections EXPLODE ALL TREES (283)
20. MeSH DESCRIPTOR Papillomaviridae (114)
21. MeSH DESCRIPTOR Alphapapillomavirus EXPLODE ALL TREES (54)
22. ((human* ADJ2 (papillomavirus* or papillomaviridae or papilloma virus*))) (304)
23. (((papillomavirus* or papillomaviridae or papilloma virus*) ADJ2 human*)) (35)
24. (HPV* or hrHPV* or hr-HPV*) (259)
25. #19 OR #20 OR #21 OR #22 OR #23 OR #24 (409)
26. MeSH DESCRIPTOR Vaginal Smears EXPLODE ALL TREES (213)
27. MeSH DESCRIPTOR Papanicolaou Test (56)
28. MeSH DESCRIPTOR Cytological Techniques (34)
29. MeSH DESCRIPTOR Cytodiagnosis (40)
30. MeSH DESCRIPTOR Mass Screening (2100)
31. MeSH DESCRIPTOR Early Detection of Cancer (273)
32. MeSH DESCRIPTOR DNA Probes, HPV (6)
33. MeSH DESCRIPTOR Human Papillomavirus DNA Tests (6)
34. (((vagina* or pap or papanicolaou) ADJ2 smear*)) (258)
35. ((smear* ADJ2 (vagina* or pap or papanicolaou))) (10)
36. (((pap or papanicolaou) ADJ2 (test* or analys* or screen*))) (128)
37. (((test* or analys* or screen*) ADJ2 (pap or papanicolaou))) (63)
38. (cytolog*) (483)
39. #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 (2727)
40. #18 AND #39 (393)
41. #25 AND #39 (233)
42. ((screen* ADJ3 (cervic* or cervix))) (142)
43. (((cervic* or cervix) ADJ3 screen*)) (264)
44. (((cervic* or cervix) ADJ3 smear*)) (81)
45. ((smear* ADJ2 (cervic* or cervix))) (18)
46. (((HPV* or hrHPV* or hr-HPV*) ADJ4 (screen* or test* or detect* or triage*))) (135)
47. (((screen* or test* or detect* or triage*) ADJ4 (HPV* or hrHPV* or hr-HPV*))) (92)
48. ((papillomavirus* or papillomaviridae or papilloma virus*) ADJ2 (screen* or test* or detect* or
triage*)) (115)
49. (((screen* or test* or detect* or triage*) ADJ2 (papillomavirus* or papillomaviridae or papilloma
virus*))) (75)
50. (human) (3164)
51. #48 OR #49 (144)
52. #50 AND #51 (123)
53. #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #52 (392)
54. #40 OR #41 OR #53 (472)
55. (*) IN DARE (45,418)
56. #54 AND #55 (128)
57. (*) IN HTA (16,846)
58. #54 AND #57 (108)
Key
l MeSH DESCRIPTOR = indexing term (MeSH)
l * = truncation
l ADJ2 = terms within two words of each other (order specified).
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EMBASE (via Ovid: http://ovidsp.ovid.com)
Date range searched: 1974 to 28 March 2017.
Date searched: 29 March 2017.
Records retrieved: 676.
Search strategy
1. exp uterine cervix tumor/ (101,917)
2. exp uterine cervix dysplasia/ (5017)
3. exp uterine cervix/ (28,075)
4. ((cervix or cervic*) adj3 (cancer* or neoplas* or carcinoma* or adenocarcinoma* or tumour* or
tumor* dysplas* or dyskaryo* or precancer* or pre-cancer*)).ti,ab. (81,511)
5. ((cervix or cervic*) adj3 (abnormal* or lesion* or atypical or squamous)).ti,ab. (17,047)
6. (cervix or cervic*).ti,ab. (279,094)
7. (LSIL or HSIL or ASCUS or ASC-US or ASC-H or ASC).ti,ab. (12,691)
8. ((intraepithelial or intra-epithelial) adj2 lesion$).ti,ab. (6060)
9. (atypical adj2 squamous).ti,ab. (2491)
10. 7 or 8 or 9 (16,616)
11. 6 and 10 (6886)
12. (CIN or CIN1* or CIN2* or CIN3* or CIN 1* or CIN 2* or CIN 3* or CIN I* or CIN II* or CIN III* or
CINI* or CINII* or CINIII* or CGIN*).ti,ab. (14,461)
13. 1 or 2 or 3 or 4 or 5 or 11 or 12 (147,667)
14. exp papillomavirus infection/ (25,629)
15. papillomaviridae/ (816)
16. exp alphapapillomavirus/ (12,821)
17. wart virus/ (37,172)
18. (human* adj2 (papillomavirus* or papillomaviridae or papilloma virus*)).ti,ab. (39,987)
19. (HPV* or hrHPV* or hr-HPV*).ti,ab. (45,330)
20. 14 or 15 or 16 or 17 or 18 or 19 (71,133)
21. vagina smear/ (10,593)
22. papanicolaou test/ (15,851)
23. uterine cervix cytology/ (12,091)
24. cytology/ (382,601)
25. cancer screening/ (66,243)
26. early cancer diagnosis/ (1191)
27. Human papillomavirus DNA test/ (1518)
28. DNA probe/ (27,048)
29. screening test/ (65,290)
30. diagnostic accuracy/ (217,693)
31. diagnostic test accuracy study/ (75,141)
32. ((vagina* or pap or papanicolaou) adj2 smear*).ti,ab. (11,672)
33. ((pap or papanicolaou) adj2 (test* or analys* or screen*)).ti,ab. (6474)
34. cytolog*.ti,ab. (105,880)
35. 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 (854,789)
36. 13 and 35 (36,343)
37. 20 and 35 (17,008)
38. (screen* adj3 (cervic* or cervix)).ti,ab. (11,964)
39. ((cervic* or cervix) adj2 smear$).ti,ab. (4794)
40. ((HPV* or hrHPV* or hr-HPV*) adj4 (screen* or test* or detect* or triage*)).ti,ab. (14,930)
41. (human* adj2 (papillomavirus* or papillomaviridae or papilloma virus*) adj2 (screen* or test* or
detect* or triage*)).ti,ab. (3861)
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42. 38 or 39 or 40 or 41 (28,042)
43. 36 or 37 or 42 (49,894)
44. systematic$ review$.ti,ab. (127,491)
45. systematic$ literature review$.ti,ab. (9255)
46. “systematic review”/ (159,479)
47. “systematic review (topic)”/ (28,244)
48. meta analysis/ (161,820)
49. “meta analysis (topic)”/ (39,256)
50. meta-analytic$.ti,ab. (5990)
51. meta-analysis.ti,ab. (121,194)
52. metanalysis.ti,ab. (390)
53. metaanalysis.ti,ab. (5712)
54. meta analysis.ti,ab. (121,194)
55. meta-synthesis.ti,ab. (482)
56. metasynthesis.ti,ab. (226)
57. meta synthesis.ti,ab. (482)
58. meta-regression.ti,ab. (5717)
59. metaregression.ti,ab. (735)
60. meta regression.ti,ab. (5717)
61. (synthes$ adj3 literature).ti,ab. (2538)
62. (synthes$ adj3 evidence).ti,ab. (7290)
63. (synthes$ adj2 qualitative).ti,ab. (1370)
64. integrative review.ti,ab. (1388)
65. data synthesis.ti,ab. (11,134)
66. (research synthesis or narrative synthesis).ti,ab. (1581)
67. (systematic study or systematic studies).ti,ab. (10,580)
68. (systematic comparison$ or systematic overview$).ti,ab. (2810)
69. (systematic adj2 search$).ti,ab. (19,687)
70. systematic$ literature research$.ti,ab. (218)
71. (review adj3 scientific literature).ti,ab. (1419)
72. (literature review adj2 side effect$).ti,ab. (12)
73. (literature review adj2 adverse effect$).ti,ab. (2)
74. (literature review adj2 adverse event$).ti,ab. (12)
75. (evidence-based adj2 review).ti,ab. (3042)
76. comprehensive review.ti,ab. (12,025)
77. critical review.ti,ab. (14,564)
78. critical analysis.ti,ab. (7278)
79. quantitative review.ti,ab. (653)
80. structured review.ti,ab. (841)
81. realist review.ti,ab. (141)
82. realist synthesis.ti,ab. (95)
83. (pooled adj2 analysis).ti,ab. (13,908)
84. (pooled data adj6 (studies or trials)).ti,ab. (2176)
85. (medline and (inclusion adj3 criteria)).ti,ab. (17,624)
86. (search adj (strateg$ or term$)).ti,ab. (27,662)
87. or/44-86 (397,542)
88. medline.ab. (101,252)
89. pubmed.ab. (83,024)
90. cochrane.ab. (65,587)
91. embase.ab. (67,292)
92. cinahl.ab. (19,062)
93. psyc?lit.ab. (977)
94. psyc?info.ab. (15,707)
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95. lilacs.ab. (5248)
96. (literature adj3 search$).ab. (51,495)
97. (database$ adj3 search$).ab. (48,637)
98. (bibliographic adj3 search$).ab. (2080)
99. (electronic adj3 search$).ab. (17,339)
100. (electronic adj3 database$).ab. (24,395)
101. (computeri?ed adj3 search$).ab. (3688)
102. (internet adj3 search$).ab. (3184)
103. included studies.ab. (16,745)
104. (inclusion adj3 studies).ab. (13,046)
105. inclusion criteria.ab. (94,570)
106. selection criteria.ab. (27,646)
107. predefined criteria.ab. (2021)
108. predetermined criteria.ab. (1098)
109. (assess$ adj3 (quality or validity)).ab. (74,945)
110. (select$ adj3 (study or studies)).ab. (65,709)
111. (data adj3 extract$).ab. (57,099)
112. extracted data.ab. (12,500)
113. (data adj2 abstracted).ab. (6653)
114. (data adj3 abstraction).ab. (1741)
115. published intervention$.ab. (167)
116. ((study or studies) adj2 evaluat$).ab. (198,404)
117. (intervention$ adj2 evaluat$).ab. (11,277)
118. confidence interval$.ab. (367,946)
119. heterogeneity.ab. (154,328)
120. pooled.ab. (88,249)
121. pooling.ab. (12,583)
122. odds ratio$.ab. (252,412)
123. (Jadad or coding).ab. (172,491)
124. evidence-based.ti,ab. (104,203)
125. or/88-124 (1,482,382)
126. review.pt. (2,263,944)
127. 125 and 126 (181,834)
128. review.ti. (404,112)
129. 125 and 128 (105,785)
130. (review$ adj10 (papers or trials or trial data or studies or evidence or intervention$ or evaluation$ or
outcome$ or findings)).ti,ab. (413,152)
131. (retriev$ adj10 (papers or trials or studies or evidence or intervention$ or evaluation$ or outcome$ or
findings)).ti,ab. (21,339)
132. 87 or 127 or 129 or 130 or 131 (776,417)
133. letter.pt. (983,216)
134. editorial.pt. (537,824)
135. 133 or 134 (1,521,040)
136. 132 not 135 (761,183)
137. (animal/ or nonhuman/) not exp human/ (5,103,479)
138. 136 not 137 (735,678)
139. 43 and 138 (2214)
140. limit 139 to yr=“2014 -Current” (676)
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Key
l / = indexing term (Emtree heading)
l exp = exploded indexing term (Emtree heading)
l * = truncation
l $ = truncation
l ti,ab = terms in either title or abstract fields
l adj = terms next to each other (order specified)
l adj2 = terms within two words of each other (any order)
l .pt. = publication type
l ? = optional wildcard – stands for zero or one character.
Health Technology Assessment database (www.crd.york.ac.uk/CRDWeb)
Date ranged searched: inception to 28 March 2017.
Date searched: 29 March 2017.
Records retrieved: 108.
See Database of Abstracts of Reviews of Effects (via www.crd.york.ac.uk/CRDWeb) for the search strategy used.
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Appendix 3 Quality assessment of the diagnostic
accuracy studies
An assessment relating to the risk of bias and concerns about the applicability of all studies included inthe diagnostic accuracy review was performed using a modified version of the QUADAS-2 checklist.
The modified version of the QUADAS-2 checklist used in Wade et al.30 and further described elsewhere38
to assess the risk of bias in comparative diagnostic accuracy studies (i.e. a comparison of the index test
with both standard care and the gold standard) was used. Further questions, presented in Table 35, were
added to the following domains: index/comparator test (one question), flow and timing (two questions)
and other concerns (three questions). A question about the predicted direction of bias, similar to that used
in the Cochrane Risk Of Bias In Non-randomised Studies – of Interventions (ROBINS-I) tool161 for domains
rated as being at a high risk of bias, was also added. The full results of the QUADAS-2 quality assessment
are reported in Tables 36–41.
TABLE 35 Additional QUADAS-2 questions
Question Domain Difference with Wade et al.30
Were the comparator test results interpreted and recorded
without knowledge of the adjunctive technology results?
Index/comparator test New
Were additional biopsies taken on random sites or sites with
no apparent abnormality with colposcopy?
Flow and timing New
Did all patients receive a reference standard? Flow and timing New
Any concerns about the size/power of the study? Other concerns New, replaced ‘Was a sample
size calculation used?’
Did the index test manufacturer have any involvement in the
design, conduct of the study and/or in the interpretation of
the results?
Other concerns New
Was it a multicentre study and were several colposcopists
involved?
Other concerns New
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TABLE 36 Patient selection
First author of
the study (year
of publication)
Was a consecutive or
random sample of
patients enrolled?
Was a case–control
design avoided?
Did the study avoid
inappropriate exclusions?
Risk: could the selection of
patients have introduced
bias?
Is there concern that the
included patients do not
match the review question?
Budithi (2018)45 Confidential information
has been removed
Confidential information
has been removed
Confidential information has
been removed
Confidential information has
been removed
Confidential information has
been removed
Coronado
(2016)50
Yes Yes Yes
36 patients (8.1%) with DSI map
not calculated because of
excessive movement. No other
exclusions
Low High
Low prevalence of hrHPV,
referred following Spanish
guidelines
Founta (2018)54 Confidential information
has been removed
Confidential information
has been removed
Confidential information has
been removed
Confidential information has
been removed
Confidential information has
been removed
Louwers (2011)60 Yes Yes Yes
Excluded current pregnancy and
pregnancy in the last 3 months,
previous cervix surgery or pelvic
radiotherapy
Low
(ITT population)
High
Not HPV primary screening,
66.1% hrHPV positive
Natsis (2016)74 Unclear Yes Unclear Unclear conference abstract of
ongoing study
Low
Relevant subgroup was women
with LG cytology and infected
with hrHPV in England
Roensbo (2015)79 Unclear (NR) Yes Unclear if ‘sufficient view of the
cervix’ was required, with no
further details reported
Unclear
Unclear if consecutive patients
were recruited and unclear
definition of inclusion criterion
Unclear
No data on hrHPV prevalence or
whether participants underwent
hrHPV screening/triage
Salter (2016)80 Unclear Yes Unclear Unclear Unclear
No data on hrHPV prevalence
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of publication)
Was a consecutive or
random sample of
patients enrolled?
Was a case–control
design avoided?
Did the study avoid
inappropriate exclusions?
Risk: could the selection of
patients have introduced
bias?
Is there concern that the
included patients do not
match the review question?
Soutter (2009)88 Yes Yes Unclear
Issues relating to the software,
speculum and a batch of faulty
disposable nozzles, leading to
the exclusion of a large
proportion of eligible
participants (31%)
Unclear
Unclear if there were systematic
differences in relevant baseline
characteristics between included
and excluded participants
Unclear
No data on hrHPV prevalence
and cytology results
Tidy (2013)103 No ‘non-consecutive’ Yes Unclear High: non-consecutive selection
of patients, exclusion of women
with active menstruation
High: non-consecutive selection
of patients
Predicted direction of bias:
favours index test (menstruation
affects spectroscopy)
Tidy (2018)94 Confidential information
has been removed
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has been removed
Confidential information has
been removed
Confidential information has
been removed
Confidential information has
been removed
Tsetsa (2012)111 Unclear Yes Unclear Unclear Unclear
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TABLE 37 Index and comparator tests: risk of bias
First author of
study (year of
publication)
Were the index test
results interpreted
without knowledge
of the results of the
reference standard?
Were the comparator
test results interpreted
and recorded without
knowledge of the
adjunctive technology
results?
If a threshold was used,
was it prespecified?
Were the colposcopists
undertaking the tests
experienced in colposcopy?
Were the colposcopists
undertaking the new
technologies given
training/experience in the
new technology?
Risk: could the conduct
or interpretation of the
index test have
introduced bias?
Risk: could the conduct or
interpretation of the
comparator test have
introduced bias?
Budithi (2018)
45
Confidential
information has been
removed
Confidential information
has been removed
Confidential information
has been removed
Confidential information has
been removed
Confidential information has
been removed
Confidential information
has been removed
Confidential information
has been removed
Coronado
(2016)
50
Yes Unclear
Performed before DySIS
map, but no reporting of
measures to ensure that
the two were recorded
independently
Yes Yes Unclear Low Unclear
Unclear if colposcopy results
were interpreted and
recorded independently of
knowledge of index test
results
Founta (2018)
54
Confidential
information has been
removed
Confidential information
has been removed
Confidential information
has been removed
Confidential information has
been removed
Confidential information has
been removed
Confidential information
has been removed
Confidential information
has been removed
Louwers
(2011)
60
Yes Yes Yes Yes Yes Low Low
Natsis (2016)
74
Yes No Unclear Unclear Unclear Unclear
Insufficient information
(conference abstract)
Unclear
Insufficient information
(conference abstract)
Roensbo
(2015)
79
Yes No
Clinicians were not
blinded to DySISmap
results when performing
colposcopy
Unclear Partly
Almost 50% of colposcopies
were performed by
colposcopists with a low level
of experience (general
practitioner residents),
although one of two licensed
and experienced nurses
supervised all examinations.
Licensed and experienced
nurses performed all other
colposcopies
Unclear
The DySIS colposcope had
been in use in the outpatient
clinic for 2 months before
study initiation, but it is
unclear whether or not all
colposcopists had received
sufficient training
High
50% of colposcopies
were performed by
colposcopists with a
low level of experience
(although all were
supervised by experienced
and licenced nurses).
Unclear whether or not
colposcopists were
sufficiently trained with
adjunctive technology
High
Colposcopists were not
blinded to DySISmap results,
low level of experience of
colposcopists who
performed almost 50% of
colposcopies
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First author of
study (year of
publication)
Were the index test
results interpreted
without knowledge
of the results of the
reference standard?
Were the comparator
test results interpreted
and recorded without
knowledge of the
adjunctive technology
results?
If a threshold was used,
was it prespecified?
Were the colposcopists
undertaking the tests
experienced in colposcopy?
Were the colposcopists
undertaking the new
technologies given
training/experience in the
new technology?
Risk: could the conduct
or interpretation of the
index test have
introduced bias?
Risk: could the conduct or
interpretation of the
comparator test have
introduced bias?
Salter (2016)
80
Unclear Unclear Unclear Unclear Unclear Unclear Unclear
Soutter (2009)
88
Yes Yes
Done independently by a
separate blinded
colposcopist
Yes
Specified following
training on 82 patients,
prior to starting test on
actual study population.
Yes
UK colposcopists all
experienced and accredited
by BSCCP. Colposcopists in
Greek clinic were similarly
experienced
Unclear
Unclear if all colposcopists
were involved in the training
group
Low Low
Tidy (2013)
103
Unclear (Phase II); no
(Phase I): colposcopic
impression and
histological data used
concurrently
Yes
The colposcopist was
blinded at all times to the
EIS result to prevent bias
No
The cut-off points were
further tested and refined
in post-hoc analyses
during Phase II ’on
pragmatic grounds’
Yes Yes High
The cut-off points were
further tested and refined
in post-hoc analyses
during Phase II ’on
pragmatic grounds’
Low
The colposcopist was
blinded at all times to the
EIS result to prevent bias
Tidy (2018)
94
Confidential
information has been
removed
Confidential information
has been removed
Confidential information
has been removed
Confidential information has
been removed
Confidential information has
been removed
Confidential information
has been removed
Confidential information
has been removed
Tsetsa (2012)
111
Unclear Unclear Unclear Unclear Unclear Unclear
Each patient was
examined three times
with three different
concentrations of acetic
acid (minimum of 45
minutes between
examinations). It is not
clear whether or not
colposcopists were blinded
to the results of
examinations using
different concentrations
Unclear
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TABLE 38 Index and comparator tests: level of concern about applicability
First author of
study (year of
publication)
Were relevant clinical
data available to the
colposcopist during the
examination (cytology/
Pap smear and HPV test
results)?
Was the execution of the
intervention technology as it
would be in practice?
Was the execution
of the comparator
technology as it would
be in practice?
Applicability concern: is there
concern that the index test or
its conduct or interpretation
differs from the review
question?
Applicability concern: is
there concern that the
comparator test or its
conduct or interpretation
differs from the review
question?
Budithi (2018)45 Confidential information has
been removed
Confidential information has
been removed
Confidential information
has been removed
Confidential information has
been removed
Confidential information has
been removed
Coronado (2016)50 Yes Yes Yes Low Low
Founta (2018)54 Confidential information has
been removed
Confidential information has
been removed
Confidential information
has been removed
Confidential information has
been removed
Confidential information has
been removed
Louwers (2011)60 Unclear
Presumably yes
Yes No
Use of multiple/random
biopsies in all patients
Low High
Natsis (2016)74 Likely yes Unclear Unclear Unclear
Insufficient information
(conference abstract of ongoing
study)
Unclear
Insufficient information
(conference abstract of
ongoing study)
Roensbo (2015)79 Unclear No
DySISmap not used as an
adjunct to colposcopy. Areas
with weaker acetowhitening
(dark blue and green on the
DySISmap results) were treated
as ‘suspicious for HG disease’
No
High number of biopsies
performed (three to five in
all participants) and use of
random biopsies
High
DySISmap not used as an
adjunct to colposcopy. Areas
with less acetowhitening on the
DySISmap treated as potential
cases of CIN 2+
High
Differs significantly from
standard UK practice because
of the number of biopsies
performed (three–five in all
participants) and the use of
random biopsies
Salter (2016)80 Unclear Unclear Unclear Unclear
DySIS Medical played a role in
study conduct, so the use of an
index test likely to have been
consistent with other trials, but
information was too sparse
Unclear
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First author of
study (year of
publication)
Were relevant clinical
data available to the
colposcopist during the
examination (cytology/
Pap smear and HPV test
results)?
Was the execution of the
intervention technology as it
would be in practice?
Was the execution
of the comparator
technology as it would
be in practice?
Applicability concern: is there
concern that the index test or
its conduct or interpretation
differs from the review
question?
Applicability concern: is
there concern that the
comparator test or its
conduct or interpretation
differs from the review
question?
Soutter (2009)88 Yes No
Precommercial prototype, with
different DySISmap algorithm
No
Biopsies performed in all
patients, including those
with normal transformation
zone colposcopy result
High
Pre-commercial prototype, with
different DySISmap algorithm
High
Tidy (2013)103 Yes No
Prototype version with
(confidential information has
been removed) and with video
display
Yes High
Prototype used with video
display and different cut-off
point from ZedScan
Low
Tidy (2018)94 Confidential information has
been removed
Confidential information has
been removed
Confidential information
has been removed
Confidential information has
been removed
Confidential information has
been removed
Tsetsa (2012)111 Unclear No
Patients were examined three
times using different
concentrations of acetic acid
Unclear High
Patients were examined
three times using different
concentrations of acetic acid
High
Patients were examined
three times using different
concentrations of acetic acid
HG, high grade.
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TABLE 39 Reference standard
First author
of the study
(year of
publication)
Is the reference standard
likely to correctly classify
the target condition?
Were the reference standard results
interpreted without knowledge of the
results of the index test?
Risk: could the reference
standard, its conduct or
its interpretation have
introduced bias?
Was the execution of the
reference standard as it
would be in practice (e.g.
performed by experienced
pathologists)?
Concern: is there concern
that the target condition as
defined by the reference
standard does not match
the review question?
Budithi (2018)45 Confidential information
has been removed
Confidential information has been removed Confidential information
has been removed
Confidential information has
been removed
Confidential information has
been removed
Coronado
(2016)50
Noa Unclear Higha Yes Low
Founta (2018)54 Confidential information
has been removed
Confidential information has been removed Confidential information
has been removed
Confidential information has
been removed
Confidential information has
been removed
Louwers
(2011)60
Noa Yes
All histology was independently reviewed
by a specialist pathologist. In case of
disagreement between the original
assessment and the review, a third expert
reviewer graded the lesion (19.0% of all
tissue samples), blinded to all previous
results, and the majority decision determined
the diagnosis
Higha Yes Low
Natsis (2016)74 Noa Unclear Higha Unclear Unclear
Insufficient information
(conference abstract of
ongoing study)
Roensbo
(2015)79
Noa Unclear Higha Yes Low
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First author
of the study
(year of
publication)
Is the reference standard
likely to correctly classify
the target condition?
Were the reference standard results
interpreted without knowledge of the
results of the index test?
Risk: could the reference
standard, its conduct or
its interpretation have
introduced bias?
Was the execution of the
reference standard as it
would be in practice (e.g.
performed by experienced
pathologists)?
Concern: is there concern
that the target condition as
defined by the reference
standard does not match
the review question?
Salter (2016)80 Noa Unclear Higha Unclear Unclear
Soutter (2009)88 Noa Yes
Histopathologists were unaware of the
DySIS result and the histopathology
reports of the other pathologists
Reproduced from Soutter et al.88
Higha Yes Low
Tidy (2013)103 Noa Unclear Higha Yes Low
Tidy (2018)94 Confidential information
has been removed
Confidential information has been removed Confidential information
has been removed
Confidential information has
been removed
Confidential information has
been removed
Tsetsa (2012)111 Noa Unclear Higha Unclear Unclear
a Histology mostly based on biopsies, which have limited accuracy. The direction of bias is unclear.
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TABLE 40 Flow and timing
First author of
the study (year
of publication)
Was there an
appropriate interval
between index test(s)
and reference
standard?
Did all patients receive
a reference standard?
Did the patients who
received a reference
standard all receive the
same reference standard?
(e.g. histology based on
punch biopsy vs. LLETZ)
Were additional biopsies
taken on random sites or
seemingly normal sites?
Were all patients
included in the
analysis?
Risk: could the patient
flow have introduced
bias?
Budithi (2018)45 Confidential information
has been removed
Confidential information
has been removed
Confidential information has
been removed
Confidential information has
been removed
Confidential information
has been removed
Confidential information
has been removed
Coronado (2016)50 Yes No No
An endocervical curettage
was performed when the
transformation zone was
type 3. A LEEP was
performed on all CIN 2+
cases diagnosed by a punch
biopsy, in all women referred
with a HSIL Pap smear that
had transformation zone
type 3 and on all cases of
biopsy-confirmed CIN 1 that
was persistent for > 2 years
No No
8.1% excluded. Reasons
for exclusion appeared to
be appropriate
High
High risk of verification
bias as a result of absence
of biopsy for lower-risk
patients. May positively
bias sensitivity estimates
Founta (2018)54 Confidential information
has been removed
Confidential information
has been removed
Confidential information has
been removed
Confidential information has
been removed
Confidential information
has been removed
Confidential information
has been removed
Louwers (2011)60 Yes Yes No
All histology, mostly through
biopsy (89%), others via
LLETZ
Yes
One additional control biopsy of
apparently normal cervical
tissue on the opposite side of
abnormal looking lesion(s), or
one biopsy at 12 o’clock if both
colposcopy and DySIS found no
abnormal sites
No
9.5% excluded. Reasons
for exclusion appeared to
be appropriate
Low
Natsis (2016)74 Unclear No
80.8% in DySIS group,
85.9% in control group
Unclear
Unclear how many, if any,
underwent LLETZ
Unclear
Unlikely (not UK practice)
Unclear
Insufficient information
High
Risk of verification bias
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First author of
the study (year
of publication)
Was there an
appropriate interval
between index test(s)
and reference
standard?
Did all patients receive
a reference standard?
Did the patients who
received a reference
standard all receive the
same reference standard?
(e.g. histology based on
punch biopsy vs. LLETZ)
Were additional biopsies
taken on random sites or
seemingly normal sites?
Were all patients
included in the
analysis?
Risk: could the patient
flow have introduced
bias?
Roensbo (2015)79 Yes Yes Yes Yes
Biopsies taken in accordance
with the clinician’s judgement/
randomly. All participants
received between three and five
biopsies
No
9.8% excluded. Reasons
for exclusion appeared to
be appropriate
High
Exclusion of significant
proportion of enrolled
participants
Salter (2016)80 Unclear No Unclear No Unclear Unclear
Soutter (2009)88 Yes Yes No
Most from punch biopsies,
others from treatment and
follow-up biopsies
Yes
All received biopsies. Random
biopsies taken from 115 sites
thought by the colposcopist to
be normal, metaplasia or HPV
infection and 101 treatment
or follow-up biopsies. The
sensitivities of colposcopy and
DySIS were 48.6% and 79.2%,
respectively. If the cases of HG
disease detected by biopsies
taken to limit verification bias
were excluded, the sensitivities
would have seemed to be
55.6% and 83.8%, respectively
No
31% excluded. Main
reasons: unsatisfactory
view (10%) and problem
with acid-faulty acetic
nozzles (8.3%)
High
High proportion of
patients were included,
although it is unclear
whether or not there
were any systematic
differences in the baseline
characteristics between
patients included and
patients excluded from
the analyses
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TABLE 40 Flow and timing (continued )
First author of
the study (year
of publication)
Was there an
appropriate interval
between index test(s)
and reference
standard?
Did all patients receive
a reference standard?
Did the patients who
received a reference
standard all receive the
same reference standard?
(e.g. histology based on
punch biopsy vs. LLETZ)
Were additional biopsies
taken on random sites or
seemingly normal sites?
Were all patients
included in the
analysis?
Risk: could the patient
flow have introduced
bias?
Tidy (2013)103 Yes No
Biopsies taken as
clinically indicated
Reproduced from
Tidy et al.103
No No No
12 women were excluded
in Phase II: nine had
incomplete clinical data,
one did not meet the
inclusion criteria, one was
unable to complete the
colposcopic examination
and one was excluded
because of a protocol
violation. For five women,
the device exhibited
technical problems that
prevented the collection
of EIS data. In addition,
110/7706 recorded
measurements (1.4%)
were unacceptable when
the spectra were visually
reviewed
High
Risk of verification bias:
biopsies performed only in
patients with suspected
abnormalities based on
examination
Tidy (2018)94 Confidential information
has been removed
Confidential information
has been removed
Confidential information has
been removed
Confidential information has
been removed
Confidential information
has been removed
Confidential information
has been removed
Tsetsa (2012)111 Unclear Unclear Unclear
Potentially no: loop excisions
and punch biopsies were
taken
No No Unclear
HG, high grade; HSIL, high-grade squamous intraepithelial lesion; LEEP, loop electrosurgical excision procedure.
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TABLE 41 Additional issues and overall quality
First author
of the study
(year of
publication)
Were the data
analysed by lesion,
patient or both?
Were the results for
all prespecified
outcomes reported?
Did the index test
manufacturer have any
involvement in the
design, conduct of
the study and/or in the
interpretation of the
results?
Any concerns about
the size/power of the
study?
Was it a multicentre
study, and were
several colposcopists
involved? Overall quality
Budithi (2018)45 Confidential information
has been removed
Confidential information
has been removed
Confidential information
has been removed
Confidential information
has been removed
Confidential information
has been removed
Confidential information has
been removed
Coronado
(2016)50
Patient Unclear
No protocol found
No No No
One centre, one
colposcopist
Unsound
High risk of verification bias
(no biopsy for all participants),
limited applicability (population
and single centre/colposcopist)
Founta (2018)54 Confidential information
has been removed
Confidential information
has been removed
Confidential information
has been removed
Confidential information
has been removed
Confidential information
has been removed
Confidential information has
been removed
Louwers (2011)60 Patient Unclear
No protocol found
Sensitivity and
specificity, number and
reasons for exclusions
were all reported
Yes
Role in the study design
and critically appraised the
manuscript
No Yes Sound
Natsis (2016)74 Patient Unclear
No protocol found
Yes No Yes Unsound
Ongoing study, conference
abstract, with significant
proportion of patients (18.6%)
who did not receive a biopsy
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TABLE 41 Additional issues and overall quality (continued )
First author
of the study
(year of
publication)
Were the data
analysed by lesion,
patient or both?
Were the results for
all prespecified
outcomes reported?
Did the index test
manufacturer have any
involvement in the
design, conduct of
the study and/or in the
interpretation of the
results?
Any concerns about
the size/power of the
study?
Was it a multicentre
study, and were
several colposcopists
involved? Overall quality
Roensbo (2015)79 Patient Unclear
No protocol found
No No No
Single centre, multiple
colposcopists with
varying levels of
experience
Unsound
(1) Almost 50% of
colposcopies performed by
colposcopists with a low level
of experience (although
supervised by experienced
nurses), (2) lack of blinding of
colposcopists to initial DySIS
map results and (3) exclusion
of 17% of participants
following enrolment, including
as a result of protocol failures
Salter (2016)80 Patient Yes Yes
Specific role unclear
No Yes Unsound
Conference abstract of
ongoing study, limited data
on diagnostic accuracy (full
diagnostic accuracy data
reported for only a small
subgroup of two colposcopy
clinics)
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First author
of the study
(year of
publication)
Were the data
analysed by lesion,
patient or both?
Were the results for
all prespecified
outcomes reported?
Did the index test
manufacturer have any
involvement in the
design, conduct of
the study and/or in the
interpretation of the
results?
Any concerns about
the size/power of the
study?
Was it a multicentre
study, and were
several colposcopists
involved? Overall quality
Soutter (2009)88 Patient Unclear
Protocol not found
Yes
Contributed to the study
design and the writing of
the report. The collection
and collation of the data
were supervised by the
principal investigator and
corresponding author.
The analysis of data was
undertaken by the principal
investigator. Corresponding
author is a member of the
speakers bureau of Forth
Photonics [(Edinburgh, UK)
manufacturer]. Principal
investigator has an
ownership interest in Forth
Photonics
No Yes Unsound, owing to the
exclusion of a large proportion
of participants (31%).
Significant levels of concern
about the applicability of the
study (FPC-03 pre-commercial
prototype used)
Tidy (2013)103 Patient Unclear
No protocol found
Yes
First and second authors
hold patents related to the
technology. They are
shareholders in Zilico Ltd
and receive consultancy
fees
Another author is also a
shareholder. A fourth
author is a medical advisor
to Zilico Ltd and receives
consultancy fees
No Yes Unsound
High risk of verification bias,
selection bias, significant
concerns about applicability
(patient selection and use of
precommercial prototype)
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TABLE 41 Additional issues and overall quality (continued )
First author
of the study
(year of
publication)
Were the data
analysed by lesion,
patient or both?
Were the results for
all prespecified
outcomes reported?
Did the index test
manufacturer have any
involvement in the
design, conduct of
the study and/or in the
interpretation of the
results?
Any concerns about
the size/power of the
study?
Was it a multicentre
study, and were
several colposcopists
involved? Overall quality
Tidy (2018)94 Confidential information
has been removed
Confidential information
has been removed
Confidential information
has been removed
Confidential information
has been removed
Confidential information
has been removed
Confidential information has
been removed
Tsetsa (2012)111 Patient Unclear
No protocol found
Yes
No formal declaration,
though E. Papagiannakis is
an employee of DySIS
Medical
Yes
Small study (n= 54)
No Unsound
Conference abstract, small
study with little information
available
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Appendix 4 Cervical intraepithelial neoplasia and
cancer prevalence
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TABLE 42 Histology-confirmed CIN and cancer prevalence in diagnostic accuracy studies
First author of the
study (year of
publication)
Number of
participants Normal, %
CIN grade
CIN 1
prevalence, %
CIN 1 or lower
prevalence, %
CIN 2
prevalence, %
CIN 2 or higher
prevalence, %
CIN 3
prevalence, %
Worse than
CIN 3, %
Budithi (2018)45 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Coronado (2016)50 443 66.1 24.6 90.7 3.2 9.3 6.1 1.1
Founta (2018)54 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Louwers (2011)60 239 NR NR NR NR 45.2 NR Confidential
information has
been removed
Natsis (2016)74 287 (+ 948 in
the control
group)
NR NR NR NR 17.1 NR NR
Roensbo (2015)79 239 71.5 NR 71.5 NR 28.5 0.0 NR
Salter [2016
(IMPROVE-COLPO)]80
210 56.7 28.6 85.2 9.0 14.8 5.7 0.5a
Soutter (2009)88 308 NR NR 76.6 8.4 23.4 14.9 1.0
Tidy (2013)103 196 NR NR 55.6 NR 44.4 NR NR
Tidy (2018)94 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Tsetsa (2012)111 54 NR NR NR NR NR NR NR
IMPROVE-COLPO, IMproved PRactice Outcomes and Value Excellence in Colposcopy; NR, not reported.
a Prevalence was 0.4% in a linked ongoing study, including a total of 1839 patients across two trial arms, by Livingston and Papagiannakis.84
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Appendix 5 Patient selection criteria and test
failures in diagnostic accuracy studies
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TABLE 43 Patient selection criteria in the diagnostic accuracy studies and test failure rates, with reasons
First author of
the study (year
of publication) Inclusion criteria Exclusion criteria
Test failure rate,
n (%) Reasons for test failures
Budithi (2018)45 Women referred to the colposcopy clinic
because of abnormal cervical cytology,
abnormal-appearing cervix or postcoital
bleeding
Non-cervical disease (e.g. vulval and vaginal
referrals) and pregnant women excluded
from the analyses
26 (6.2) Missing colposcopic impression and DSI
map (n= 25), missing histology data (n= 1)
Coronado
(2016)50
Women aged ≥ 18 years referred for
colposcopy following Spanish national
guidance
NR 36 (8.1) Excessive movements during the
measurement
Founta (2018)54 Women referred to the colposcopy clinic
with negative cytology and testing positive
for hrHPV either 6 months after treatment
or in the context of the catch-up
programme and who underwent DySIS
colposcopy
NR 3 (2.9) Poor-quality imaging because of user errors
Louwers (2011)60 Women aged ≥ 18 years with abnormal
cervical cytology or follow-up of a CIN
grade 1 or 2 lesion
Previous surgery on the cervix, pelvic
radiotherapy. Current pregnancy and
pregnancy in the last 3 months
25 (9.5) DySIS did not start (n= 7), no map (n= 9)
and exam data not saved (n= 9)
Natsis (2016)74 NR NR NR NR
Roensbo (2015)79 Women aged ≥ 18 years with adequate
DySIS colposcopy (such as sufficient view of
the cervix and no patient movement
resulting in adequate DySIS analysis)
NR 28 (9.8) 48 women were excluded because biopsies
were not sent separately (n= 28), it was not
possible to classify the biopsy (n= 6), there
were technical difficulties (n = 9) and other
reasons (n= 5)
Salter (2016)80 NR NR NR NR
Soutter (2009)88 Cervical smear showing squamous or
glandular cell dyskaryosis or borderline
nuclear change (ASCUS or AGUS), or
symptoms of postcoital bleeding,
postmenopausal bleeding or intermenstrual
bleeding
Self-referring women without an abnormal
smear, an inadequate or an inflammatory
smear, any other clinical indication for
referral to colposcopy, pregnancy, previous
pelvic radiotherapy or any woman for
whom any prolongation of the examination
was thought to be inadvisable
139 (31) Software problems (n= 15), no biopsy
(n= 23), unsatisfactory view (n= 45), not
eligible (n = 6), 5% acetic acid (n = 1), lost
data form (n= 1), lost biopsy slides (n= 5),
blood or mucus (n= 1), biopsies from
wrong point (n = 3), excessive movement
(n= 2) and problem with acid-faulty acetic
nozzles (n= 37)
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First author of
the study (year
of publication) Inclusion criteria Exclusion criteria
Test failure rate,
n (%) Reasons for test failures
Tidy (2013)103 Women referred with abnormal cervical
cytology
Type 3 transformation zone, pregnancy and
active menstruation
Phase I: 33 (15.4);
Phase II: 19 (8.8)
Phase I: 31 women treated ‘as part of
training’, two women with incomplete
clinical data
Phase II: biopsy not coincident with EIS
reading or inadequate for histological
examination (n= 14). Failure of EIS device
(n= 12, including nine women who had
incomplete clinical data), did not meet the
inclusion criteria (n= 1), unable to complete
the colposcopic examination (n= 1) and
excluded because of a protocol violation
(n= 1). In five cases, the device exhibited
technical problems that prevented the
collection of EIS data. In addition, 110/7706
recorded measurements (1.4%) were
unacceptable when the spectra were
visually reviewed
Tidy (2018)94 Women referred to the colposcopy clinic
with abnormal cervical cytology from
the NHSCSP. Adequate colposcopic
examination (i.e. type 1 or 2 transformation
zone with the upper extent of the lesion
seen)
Type 3 transformation zone, pregnancy 73 (5.6) 73 results were not considered to be
analysable: 61 related to the use of
ZedScan, mainly occurred in the early
stages of adopting the device and were a
combination of device failures and user
errors, seven had problems unrelated to
ZedScan (e.g. discomfort because of a
speculum) and five had incomplete data or
self-reported as being pregnant
Tsetsa (2012)111 NR NR NR NR
AGUS, atypical glandular cells of undetermined significance; ASCUS, atypical squamous cells of undetermined significance; NR, not reported.
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Appendix 6 Meta-analysis of the diagnostic
accuracy studies: additional figures and table
FIGURE 17 Diagnostic odds ratios from the DySIS studies. (Confidential information has been removed.)
FIGURE 18 Positive predictive values in the DySIS studies. (Confidential information has been removed.)
FIGURE 19 Negative predictive values in the DySIS studies. (Confidential information has been removed.)
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FIGURE 20 Summary ROC plot from bivariate models.
FIGURE 21 Percentage of positive test results in DySIS studies. (Confidential information has been removed.)
FIGURE 22 Percentage of positive test results in ZedScan studies. (Confidential information has been removed.)
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TABLE 44 Overview of patient populations and results reported in the diagnostic accuracy studies
First author of
the study (year
of publication) Comparisons Subgroups reported Primary source of data
DySIS studies
Budithi (2018)45 Confidential information
has been removed
Confidential information has
been removed
Confidential information
has been removed
Coronado
(2016)50
DySISmap and colposcopy hrHPV Coronado and Fasero50
DySISmap alone hrHPV Coronado and Fasero50
Colposcopy alone hrHPV Coronado and Fasero50
Founta (2018)
DyS-CO154
Confidential information
has been removed
Confidential information has
been removed
Confidential information
has been removed
IMPROVE-COLPO DySISmap alone
Colposcopy alone
(matched control)
LG Pap smear result Conference abstract:
Papagiannakis et al.83 and
Weinberg et al.85
Louwers (2011)60 DySISmap and colposcopy Confidential information has
been removed
Confidential information
has been removed
DySISmap alone Referral for LG cervical
abnormalities
Linked publication
(i.e. Louwers et al.)61
Colposcopy alone Referral for HG cervical
abnormalities
Linked publication
(i.e. Louwers et al.)61
Positive hrHPV test and BMD,
or HG cytology resulta
Linked publication
(i.e. Zaal et al.)62
BMD cytology and a hrHPV
positive test or HG cytology
result, irrespective of the
hrHPV test resultb
Linked publication
(i.e. Zaal et al.)62
Natsis (2016)74 DySISmap and colposcopy hrHPV with a referral for LG
cervical abnormalities
Conference abstract74
Colposcopy alone hrHPV with a referral for LG
cervical abnormalities
Conference abstract74
Colposcopy alone
(contemporaneous control
group)
hrHPV with a referral for LG
cervical abnormalities
Conference abstract74
Roensbo (2015)79 DySISmap alone
Colposcopy and random
biopsies
None Publication79
Salter (2016)80 DySISmap and colposcopy Initial results from two clinics Conference abstract80
Soutter (2009)88 DySIS and colposcopy LG Pap smear result Publication: Soutter et al.88
and Soutter et al.89
Colposcopy alone HG Pap smear result
DySISmap alone
Tsetsa (2012)111 DySIS and colposcopy 3% acetic acid treatment,
4% acetic acid treatment and
5% acetic acid treatment
Conference abstract111,162
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TABLE 44 Overview of patient populations and results reported in the diagnostic accuracy studies (continued )
First author of
the study (year
of publication) Comparisons Subgroups reported Primary source of data
ZedScan studies
Tidy (2013)103 ZedScan and colposcopy
Colposcopy alone
Confidential information has
been removed
Confidential information
has been removed
Tidy (2018)94 ZedScan and colposcopy Confidential information has
been removed
Confidential information
has been removed
Colposcopy alone Low-risk HPV Linked manuscript95
hrHPV Linked manuscript95
HG, high grade; IMPROVE-COLPO, IMproved PRactice Outcomes and Value Excellence in Colposcopy; LG, low grade.
a Referred through cytology-based screening, but retrospectively treated as HPV primary screening with cytology.
b Cytology based, with the exclusion of hrHPV-negative BMD.
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Appendix 7 Narrative synthesis of the diagnostic
accuracy studies: additional tables
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TABLE 45 Results of the diagnostic accuracy studies of DySIS included in the narrative synthesis (cut-off point: CIN 2+)
First author of
the study (year
of publication) Population
Number of
participants Comparisons
Sensitivity, %
(95% CI)
Specificity, %
(95% CI) PPV, % (95% CI)a NPV, % (95% CI)a
Founta (2018)54
DySIS colposcopy
1 study
Confidential information has been
removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Louwers,61
subgroup of
Louwers60
Referral strategy 1: HPV primary
screening with cytology triage
(subgroup with a positive hrHPV
test and BMD or HG cytology)
165 DySISmap and
colposcopy
81 (72 to 89) 64 (53 to 74) 71.7 (62.8 to 80.6) 74.2 (63.7 to 84.8)
DySISmap alone 68 (58 to 78) 69 (58 to 79) 71.4 (61.8 to 81.1) 65.4 (55.1 to 75.8)
Colposcopy alone 53 (43 to 64) 82 (73 to 90) 77.0 (66.5 to 87.6) 60.6 (51.2 to 70.0)
Referral strategy 2: cytology
primary with hrHPV triage
(subgroup with BMD cytology and
a hrHPV-positive test or HG
cytology, irrespective of the hrHPV
test result)
186 DySISmap and
colposcopy
80 (73 to 88) 61 (51 to 71) 69.0 (60.5 to 77.6) 74.0 (63.9 to 84.0)
DySISmap alone 65 (55 to 74) 69 (59 to 78) 69.2 (59.7 to 78.7) 64.2 (54.6 to 73.9)
Colposcopy alone 54 (44 to 64) 78 (69 to 86) 72.2 (61.9 to 82.6) 60.5 (51.6 to 69.5)
Natsis (2016)74 LG cytology, hrHPV-positive result 287 DySISmap and
colposcopy
82 (71.2 to 92.8)a 36 (29.9 to 42.1)a 20.9 (15.1 to 26.6) 90.7 (84.8 to 96.5)
Colposcopy alone 27 (14.6 to 39.4)a 91 (87.4 to 94.6)a 38.2 (22.0 to 54.4) 85.8 (81.5 to 90.1)
814 Colposcopy alone
(contemporaneous
control group)
36 (28.5 to 43.5)a 88 (85.7 to 90.3)a 37.1 (29.4 to 44.8) 87.5 (85.2 to 89.8)
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First author of
the study (year
of publication) Population
Number of
participants Comparisons
Sensitivity, %
(95% CI)
Specificity, %
(95% CI) PPV, % (95% CI)a NPV, % (95% CI)a
Salter (2016)80
Papagiannakis
(2016)83
IMPROVE-COLPO
Abnormal cytology/pap (99%), test
of cure (1%) from two colposcopy
clinics (subgroup)
210 DySISmap and
colposcopy
83.9 (70.9 to 96.8)a 75.4 (69.1 to 81.7)a 37.1 (25.8 to 48.5) 96.4 (93.4 to 99.5)
DySISmap alone 74.2 (58.8 to 89.6)a 60.3 (53.1 to 67.5)a 24.7 (16.0 to 33.5)b 93.1 (88.5 to 97.7)
Colposcopy 61.3 (44.1 to 78.4)a 91.1 (86.9 to 95.2)a 54.3 (37.8 to 70.8)b 93.1 (89.4 to 96.9)
LG Pap smearc (subgroup), 44
colposcopy clinics
1857 DySISmap and
colposcopy
NR NR 13.3 (11.4 to 15.1) NR
1788 Colposcopy
(retrospective
matched control)
NR NR 10.1 (8.4 to 11.7) NR
Tsetsa (2012)111 Abnormal cytology 54 DySIS and
colposcopy
(3% acetic acid)
86 81 NR NR
DySIS and
colposcopy
(4% acetic acid)
79 77 NR NR
DySIS and
colposcopy
(5% acetic acid)
82 77 NR NR
HG, high grade; IMPROVE-COLPO, IMproved PRactice Outcomes and Value Excellence in Colposcopy; LG, low grade; NR, not reported.
a Calculated.
b Study reported 17.1% for DySISmap and 16.9% for colposcopy alone.
c Low-grade squamous intraepithelial lesion and atypical squamous cells of undetermined significance/hrHPV.
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TABLE 46 Results of the diagnostic accuracy study of ZedScan included in the narrative synthesis (cut-off point: CIN 2+)
First author of the study
(year of publication) Population
Number of
participants Comparisons
Sensitivity, %
(95% CI)
Specificity, %
(95% CI) PPV, % NPV, %
Macdonald (2017),95
substudy of Tidy (2018)94
All known hrHPV
genotypes
839 ZedScan and
colposcopy
100 NR NR NR
ZedScan alone 96.2 (93.1 to 98.0) NR NR NR
Colposcopy alone 83.4 (78.4 to 87.4) NR NR NR
All known HPV
16
303 ZedScan and
colposcopy
100 NR NR NR
ZedScan alone 95.6 (90.6 to 98.2) NR NR NR
Colposcopy alone 86.9 (80.1 to 91.6) NR NR NR
All known hrHPV
other than HPV
16
536 ZedScan and
colposcopy
100 NR NR NR
ZedScan alone 96.9 (91.9 to 99.0) NR NR NR
Colposcopy alone 79.7 (71.9 to 85.8) NR NR NR
Tidy (2016),102 substudy of
Tidy (2018)94
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
NR, not reported.
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TABLE 47 Cervical cancer reporting in DySIS studies
Study (first author)
Number of
confirmed cases
of cervical cancer
Number
identified by
DySISmap and
colposcopy
Number
identified by
colposcopy alone
Number of
additional cases
identified by
DySISmap
Coronado50 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Livingston84
(IMPROVE-COLPO)a
7/1839 (0.4%) 3 (of 5 recorded) 1 (of 5 recorded) 2
Louwers60 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
IMPROVE-COLPO, IMproved PRactice Outcomes and Value Excellence in Colposcopy.
a Conference abstract of ongoing cohort study linked to Salter and Livingston80 that included a total of 1839 patients
across two trial arms: one prospective arm undergoing colposcopy with adjunctive DySIS and one retrospective arm
undergoing standard colposcopy. The number of participants in each trial arm was not reported.
TABLE 48 Test failure rates and reasons
First author of the study
(year of publication)
Number of test
failures, n (%) Reasons for test failure
Budithi (2018)45 Confidential information
has been removed
Confidential information has been removed
Coronado (2016)50 36 (8.1) A total of 36 excessive movements during the measurement
Founta (2018)54 Confidential information
has been removed
Confidential information has been removed
Louwers (2011)60 33 (12.1) DySIS did not start (n= 7), no map (n= 9), examination data
not saved (n= 9), no available histology (n= 5) and no DySIS
colposcopy after signing informed consent (n = 3)
Roensbo (2015)79 48 (16.7) A total of 48 women were excluded because biopsies were not
sent separately (n= 28), it was not possible to classify the biopsy
(n= 6), technical difficulties (n = 9) and other reasons (n= 5)
Soutter (2009)88 139 (31.4) Software problems (n = 15), no biopsy (n= 23), unsatisfactory
view (n= 45) in 45 women, not eligible (n= 6), 5% acetic acid
(n= 1), lost data form (n= 1), lost biopsy slides (n= 5), blood
or mucus (n= 1), biopsies from wrong point (n= 3), excessive
movement (n = 2) and problem with acid-faulty acetic nozzles
(n= 37)
Tidy (2013)103 Phase I: 33 (13.4);
Phase II: 19 (13.6)
Phase I: ‘as part of training’ (n = 31), with incomplete clinical
data (n = 2)
Phase II: biopsy not coincident with EIS reading or inadequate
for histology (n= 14), failure of EIS device (n = 5)
Tidy (2018)94 Confidential information
has been removed
Confidential information has been removed
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TABLE 49 Treatments performed
First author of
the study (year of
publication)
Total number of
patient analysed
Patients receiving
diagnostic/treatment
biopsies, n (%)
Number of diagnostic
biopsies (punch
biopsies) performed
Patients receiving
treatment biopsies,
n (%)
Number of treatment
biopsies performed
Mean number of
biopsies per patient
Budithi (2018)45 Confidential information
has been removed
Confidential information
has been removed
Confidential information
has been removed
Confidential information
has been removed
Confidential information
has been removed
Confidential information
has been removed
Coronado (2016)50 443 372 (84.0) 332 59 (13.3) NR NR
Founta (2018)54 Confidential information
has been removed
Confidential information
has been removed
Confidential information
has been removed
Confidential information
has been removed
Confidential information
has been removed
Confidential information
has been removed
Louwers (2011)60 239 239 (100) NR (≥ 332)a 84 NR (≥ 84) 2.27
Natsis (2016)74 DySIS and colposcopy:
287
DySIS and colposcopy:
232 (80.8)
NR NR NR NR
Colposcopy alone: 948 Colposcopy alone:
814 (85.9)
NR NR NR NR
Roensbo (2015)79 239 239 (100) NR NR NR 3–5
Salter (2016)80 210 173 (82.3) NR NR 39 NR
Papagiannakis
(2016)83
DySIS and colposcopy:
1857
NR DySIS and colposcopy:
2332
NR NR DySIS and colposcopy:
1.26
Colposcopy alone: 1788 Colposcopy alone: 1846 Colposcopy alone: 1.03
Soutter (2009)88 308 308 (100) 603 86 (27.9) 86 1.96
Tidy (2013)103 196 (Phase II) NR Confidential information
has been removed
Confidential information
has been removed
Confidential information
has been removed
Confidential information
has been removed
Tidy (2018)94 Confidential information
has been removed
Confidential information
has been removed
Confidential information
has been removed
Confidential information
has been removed
Confidential information
has been removed
Confidential information
has been removed
Tsetsa (2012)111 54 NR NR NR NR NR
NR, not reported.
Confidential information has been removed only reported for the according-to-protocol cohort.
a In the according-to-protocol cohort (n= 183),153 control biopsies were taken from apparently normal tissue, of which 39 results (25.5%) were classed as CIN 2+.
b In linked Palmer96 study, which included all 1237 participants plus an additional 333 patients, 746 biopsies were taken with an average of 1.08 biopsies per biopsied patient. More than
one biopsy was taken in 53 patients.
(Confidential information has been removed.)
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Appendix 8 Quality assessment of the
implementation studies
TABLE 50 Budithi et al. (2018)45 quality assessment
Question Yes No
Cannot
tell
Was the objective clearly stated? ✓
Was the setting clearly described? ✓
Were the methods described clearly enough to permit other researchers to duplicate the study? ✓
Was the survey sample likely to be representative of the population to which the findings refer? ✓
Was the questionnaire described adequately? ✓
Have the validity and reliability of the questionnaire been established? ✓
Was the sample size based on prestudy considerations of statistical power? ✓
Was statistical significance assessed appropriately? ✓
Were all relevant confounding factors adjusted/accounted for? ✓
Did the results address the objective? ✓
Was a satisfactory response rate achieved? ✓
Were the results clearly and logically presented? ✓
Were the tables and figures appropriate? ✓
Were the numbers consistent in the text and the tables? ✓a
Were CIs given for the main results? ✓
a Multiple small discrepancies.
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TABLE 51 Coronado and Fasero51 quality assessment
Question Yes No
Cannot
tell
Was the objective clearly stated? ✓
Was the setting clearly described? ✓
Were the methods described clearly enough to permit other researchers to duplicate the study? ✓
Was the survey sample likely to be representative of the population to which the findings are refer? ✓a
Was the questionnaire described adequately? ✓
Have the validity and reliability of the questionnaire been established? ✓b
Was the sample size based on prestudy considerations of statistical power? ✓
Was statistical significance assessed appropriately? ✓
Were all relevant confounding factors adjusted/accounted for? ✓c
Did the results address the objective? ✓
Was a satisfactory response rate achieved? ✓
Were the results clearly and logically presented? ✓
Were the tables and figures appropriate? ✓
Were the numbers consistent in the text and the tables? ✓
Were CIs given for the main results? ✓
a Colposcopists from a single centre.
b Only internal consistency was assessed, which was rated as being at a high level (α = 0.9691).
c Colposcopist experience accounted for.
TABLE 52 Louwers et al.63 quality assessment
Question Yes No
Cannot
tell
Was the objective clearly stated? ✓
Was the setting clearly described? ✓
Were the methods described clearly enough to permit other researchers to duplicate the study? ✓
Was the survey sample likely to be representative of the population to which the findings refer? ✓
Was the questionnaire described adequately? ✓
Have the validity and reliability of the questionnaire been established? ✓
Was the sample size based on prestudy considerations of statistical power? ✓
Was statistical significance assessed? ✓
Were all relevant confounding factors adjusted/accounted for? ✓a
Were the statistical methods used appropriately? ✓
Did the results address the objective? ✓
Was a satisfactory response rate achieved? ✓
Were the results clearly and logically presented? ✓
Were the tables and figures appropriate? ✓
Were the numbers consistent in the text and the tables? ✓
Were CIs given for the main results? ✓
a Age, education, number of pregnancies and sexual behaviour.
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TABLE 53 Lowe et al.72 quality assessment
Question Yes No
Cannot
tell
Was the objective clearly stated? ✓
Was the setting clearly described? ✓
Were the methods described clearly enough to permit other researchers to duplicate the study? ✓
Was the survey sample likely to be representative of the population to which the findings refer? ✓
Was the questionnaire described adequately? ✓
Have the validity and reliability of the questionnaire been established? ✓
Was the sample size based on prestudy considerations of statistical power? ✓
Was statistical significance assessed? ✓
Were all relevant confounding factors adjusted/accounted for? ✓
Were the statistical methods used appropriately? ✓
Did the results address the objective? ✓
Was a satisfactory response rate achieved? ✓
Were the results clearly and logically presented? ✓
Were the tables and figures appropriate? ✓
Were the numbers consistent in the text and the tables? ✓
Were CIs given for the main results? ✓
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Appendix 9 Quality assessment of the
cost-effectiveness studies
TABLE 54 Quality assessment of the studies included in the economic review
Criteria
Study
Wade
et al.30
Whyte
et al.124
The research question is stated Y Y
The economic importance of the research question is stated Y Y
The viewpoint(s) of the analysis are clearly stated and justified Y Y
The rationale for choosing alternative programmes or interventions compared is stated Y Partially
The alternatives being compared are clearly described Y Y
The form of economic evaluation used is stated Y Y
The choice of form of economic evaluation is justified in relation to the question addressed Y N
The source(s) of effectiveness estimates used are stated Y Y
Details of the design and results of the effectiveness study are given (if based on a single study) Partially Partially
Details of the methods of synthesis or meta-analysis of estimates are given (if based on a
synthesis of a number of effectiveness studies)
NA NA
The primary outcome measure(s) for the economic evaluation are clearly stated Y Y
Methods to value benefits are stated Y Y
Details of the subjects from whom valuations were obtained are given N N
Productivity changes (if included) are reported separately NA NA
The relevance of productivity changes to the study question is discussed NA NA
Quantities of resource use are reported separately from their unit costs Y Y
Methods for the estimation of quantities and unit costs are described Y Y
Currency and price date are recorded Y N
Details of currency of price adjustments for inflation or currency conversion are given Y N
Details of any model used are given Y Y
The choice of model used and the key parameters on which it is based are justified Y Y
Time horizon of costs and benefits is stated Y Y
The discount rate(s) are stated Y Y
The choice of discount rate(s) is justified Y Y
N, no; NA, not applicable; Y, yes.
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Appendix 10 Main features of the economic
model
DOI: 10.3310/hta22540 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 54
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Peron et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
177
LL
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
Update tracker/
full natural history
Normal
Stay New HS: normal
Clone 6: adverse obstetric outcomes model
Clone 6: adverse obstetric outcomes model
Clone 6: adverse obstetric outcomes model
Clone 6: adverse obstetric outcomes model
New HS: CIN 1
New HS: CIN 2/3
Clone 6: adverse obstetric outcomes model
Clone 6: adverse obstetric outcomes model
Clone 6: adverse obstetric outcomes model
Clone 6: adverse obstetric outcomes model
Clone 6: adverse obstetric outcomes model
Clone 6: adverse obstetric outcomes model
Clone 6: adverse obstetric outcomes model
Clone 6: adverse obstetric outcomes model
Clone 6: adverse obstetric outcomes model
Clone 6: adverse obstetric outcomes model
Clone 6: adverse obstetric outcomes model
Clone 6: adverse obstetric outcomes model
Clone 6: adverse obstetric outcomes model
Clone 6: adverse obstetric outcomes model
Clone 6: adverse obstetric outcomes model
Clone 6: adverse obstetric outcomes model
New HS: normal
Die from other causes
Die from other causes
New HS: HPV
New HS: HPV
to CIN 1
to CIN 2/3
to normal
Die from other causes
Die from other causes
Die from other
causes
Die from other
causes
Die from other causes
Die from other causes
Update tracker
Update tracker
Progress
Not cured
Cured
New HS: CIN 1
New HS: HPV
New HS: normal
New HS: normal
New HS: cancer
Die from cancer
Symptoms
Update stage
Die from cancer
No symptoms
Symptoms
New HS: cancer
New HS: cancer and
update SC
New HS: cancer
New HS: cancer and
update SC
No symptoms
New HS: normal
Stay
Die from cancer
Die from cancer
Survive
Survive
to normal
to HPV
to CIN 1
Stay
Stay
Stay
Progress
Progress
Progress
New HS: CIN 1
New HS: CIN 2/3
New HS: CIN 2/3
New HS: cancer
(undetected)Progress
Regress
Regress
Regress
Die
Die
Die
Die
Treated
Undetected
7
10
11
1
12
13
HPV
CIN 1
CIN 2/3
Cancer
FIGURE 23 Natural history model. HS, health state; SC, sypmtomatic cancer.
A
P
P
E
N
D
IX
1
0
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
1
7
8
LL
L
L
L
L
L
L
L
L
L
L
Colposcopic exam
Colposcopy positive
See-and-treat clinic
Watchful-waiting 
clinic
HG referral smear
LG referral smear Sent to routine screening Full natural history
Clone 9: diagnostic biopsy LG result
Clone 1: full natural history
Diagnostic biopsy 
HG result
Diagnostic biopsy 
LG result
Treatment biopsy and
histology
If normal or HPV
If normal or HPV
If normal or HPV
If CIN 1 or CIN 2/3
If cancer
If cancer
If cancer
If CIN 2/3
If CIN 2/3
If CIN 1
If CIN 1
Sent to test of cure
Natural history – normal
Natural history normal
Clone 7: natural history – normal
Clone 10: natural history – HPV
Clone 7: natural history – normal
Clone 7: natural history – normal
Clone 10: natural history – HPV
Clone 10: natural history – HPV
Clone 11: natural history – CIN 1
Cured
Clone 11: natural history – CIN 1
Cured
Not cured
Not cured
Natural history – CIN 1
Natural history – CIN 2/3
Clone 7: natural history – normal
Clone 11: natural history – CIN 1
Clone 12: natural history – CIN 2/3
Clone 13: natural history-treated cancer
Natural history-treated cancer
Natural history-treated cancer
Natural history – normal
Natural history – normal
Natural history – CIN 2/3
Natural history – CIN 2/3
Clone 13: natural history-treated cancer
Clone 13: natural history-treated cancer
Clone 12: natural 
history – CIN 2/3
Clone 7: natural 
history – normal
Clone 12: natural 
history – CIN 2/3
Clone 7: natural 
history – normal
Natural history-treated cancer
Natural history – normal
Natural history – normal
Natural history – HPV
Natural history – HPV
Natural history – HPV
Natural history – CIN 1
Natural history – CIN 1
Sent to test of cure
Sent to test of cure
Cured
Not cured
Cancer update
Cancer update
Cancer update
Sent to routine 
screening
Sent to 6 months
colposcopy follow-up
Sent to test of cure
Cancer treatment
Cancer treatment
Cancer treatment
Treatment
Treatment
Sent to CIN 1 follow-up
Sent to CIN 1 follow-up
Clone 3: diagnostic biopsy HG result
LG referral smear
HG referral smear
LG referral smear
9
3
HG referral smear
Colposcopy negative
FIGURE 24 Treatment pathway after colposcopy. HG, high grade; LG, low grade.
D
O
I:
1
0
.3
3
1
0
/h
ta
2
2
5
4
0
H
E
A
L
T
H
T
E
C
H
N
O
L
O
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
8
V
O
L
.
2
2
N
O
.
5
4
©
Q
u
e
e
n
’s
P
rin
te
r
a
n
d
C
o
n
tro
lle
r
o
f
H
M
S
O
2
0
1
8
.
T
h
is
w
o
rk
w
a
s
p
ro
d
u
ce
d
b
y
P
e
ro
n
e
t
a
l.
u
n
d
e
r
th
e
te
rm
s
o
f
a
co
m
m
issio
n
in
g
co
n
tra
ct
issu
e
d
b
y
th
e
S
e
cre
ta
ry
o
f
S
ta
te
fo
r
H
e
a
lth
a
n
d
S
o
cia
l
C
a
re
.
T
h
is
issu
e
m
a
y
b
e
fre
e
ly
re
p
ro
d
u
ce
d
fo
r
th
e
p
u
rp
o
se
s
o
f
p
riva
te
re
se
a
rch
a
n
d
stu
d
y
a
n
d
e
xtra
cts
(o
r
in
d
e
e
d
,
th
e
fu
ll
re
p
o
rt)
m
a
y
b
e
in
clu
d
e
d
in
p
ro
fe
ssio
n
a
l
jo
u
rn
a
ls
p
ro
vid
e
d
th
a
t
su
ita
b
le
a
ck
n
o
w
le
d
g
e
m
e
n
t
is
m
a
d
e
a
n
d
th
e
re
p
ro
d
u
ctio
n
is
n
o
t
a
sso
cia
te
d
w
ith
a
n
y
fo
rm
o
f
a
d
ve
rtisin
g
.
A
p
p
lica
tio
n
s
fo
r
co
m
m
e
rcia
l
re
p
ro
d
u
ctio
n
sh
o
u
ld
b
e
a
d
d
re
sse
d
to
:
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry,
N
a
tio
n
a
l
In
stitu
te
fo
r
H
e
a
lth
R
e
se
a
rch
,
E
va
lu
a
tio
n
,
T
ria
ls
a
n
d
S
tu
d
ie
s
C
o
o
rd
in
a
tin
g
C
e
n
tre
,
A
lp
h
a
H
o
u
se
,
U
n
ive
rsity
o
f
S
o
u
th
a
m
p
to
n
S
cie
n
ce
P
a
rk
,
S
o
u
th
a
m
p
to
n
S
O
1
6
7
N
S
,
U
K
.
1
7
9
LL
L
Cytology test
Negative
Borderline
Moderate or severe
Inadequate
Mild
HPV triage
Positive
Positive
Positive
Negative
Negative
Negative
LG referral smear
LG referral smear
LG referral smear
Sent to routine screening
Sent to routine screening
Sent to routine screening
Full natural history
Full natural history
Clone 8: colposcopy
Clone 8: colposcopy
Clone 1: full natural history
Clone 1: full natural history
Clone 1: full natural history
Clone 8: colposcopy
Full natural history
Clone 8: colposcopy
Clone 8: colposcopy
HPV triage
HG referral smear
LG referral smear
HPV triage
FIGURE 25 Test of cure. HG, high grade; LG, low grade.
Low grade
High grade
Cytology test
LG referral
Clone 8: colposcopy
Clone 8: colposcopy
HG referral
FIGURE 26 Colposcopy at 6 months. HG, high grade; LG, low grade.
A
P
P
E
N
D
IX
1
0
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
1
8
0
LL
L
L
L
L
L
L
Cytology test
Negative Full natural history
Clone 1: full natural history
Clone 1: full natural history
Clone 1: full natural history
Clone 1: full natural history
Clone 5: colposcopy CIN 1 follow-up
Clone 5: colposcopy CIN 1 follow-up
Clone 5: colposcopy CIN 1 follow-up
Colposcopy exam CIN 1
Colposcopy positive
Colposcopy negative
LG referral smear Full natural history
If cancer
If CIN 2/3
If CIN 1
If normal or HPV
Cancer treatment
Treatment
Sent to routine screening
Not treated
Treated
Cancer update
Sent to test of cure
Sent to CIN 1 follow-up
Natural history – normal
Clone 7: natural history – normal
Clone 11: natural history – CIN 1
Clone 7: natural history – normal
Clone 12: natural history – CIN 2/3
Clone 7: natural 
history – normal
Clone 11: natural 
history – CIN 1
Clone 13: natural history – treated cancer
Natural history – CIN 2/3
Natural history – normal
Natural history – CIN 1
Natural history – normalCured
Not cured
Clone 10: natural history – HPV
Natural history – CIN 1
Natural history – treated
cancer
Sent to test of cure
Cured
Not cured
Natural history – HPV
Treatment
HG referral smear
Clone 4: diagnostic biopsy CIN 1
Sent to routine screening
Diagnostic biopsy CIN 1
Full natural history
Positive
5
4
Positive
LG referral smear
Sent to routine screening
LG referral smear
Sent to routine screening Full natural history
Negative
Negative
Borderline
Moderate or severe
Inadequate
Mild
HG referral smear
LG referral smear
HPV triage
HPV triage
Sent to routine
screening
FIGURE 27 Cervical intraepithelial neoplasia grade 1 follow-up.
L
Adverse obstetric outcomes
Enter model
Pregnant
Not pregnant
Alive
Alive
#
Excess risk of
preterm birth
Preterm birth
due to treatment
Alive
Alive
Do not6
FIGURE 28 Adverse obstetric outcomes. #, no preterm birth because of treatment.
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Appendix 11 Model input parameters
Underlying health state and reason for referral
TABLE 55 Initial characteristics of women referred for colposcopy under the HPV triage protocol
Health state; reason for referral % Source
Clear; LG result 27.59 NHSCSP18
Clear; HG result 1.20 NHSCSP18
HPV; LG result 10.32 NHSCSP18
HPV; HG result 0.89 NHSCSP18
CIN 1; LG result 19.44 NHSCSP18
CIN 1; HG result 2.53 NHSCSP18
CIN 2/3; LG result 11.16 NHSCSP18
CIN 2/3; HG result 25.97 NHSCSP18
Cancer; LG result 0.07 NHSCSP18
Cancer; HG result 0.82 NHSCSP18
HG, high grade; LG, low grade.
TABLE 56 Initial characteristics of women referred for colposcopy under the HPV primary screening protocol
Health state; reason for referral % Source
Clear; LG result 32.07 HPV primary screening pilot sites
Clear; HG result 1.28 HPV primary screening pilot sites
HPV; LG result 12.6 HPV primary screening pilot sites
HPV; HG result 0.72 HPV primary screening pilot sites
CIN 1; LG result 15.14 HPV primary screening pilot sites
CIN 1; HG result 1.99 HPV primary screening pilot sites
CIN 2/3; LG result 10.68 HPV primary screening pilot sites
CIN 2/3; HG result 24.57 HPV primary screening pilot sites
Cancer; LG result 0.07 HPV primary screening pilot sites
Cancer; HG result 0.87 HPV primary screening pilot sites
HG, high grade; LG, low grade.
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Treatment probabilities
TABLE 57 Probability of treatment failure with excision
Diagnosis Failures n Probability of failure, % Source
CIN 1 28 570 4.9 Ghaem-Maghami et al.151
CIN 2 87 886 9.8 Ghaem-Maghami et al.151
CIN 3 103 999 10.3 Ghaem-Maghami et al.151
CIN 2/3 190 1885 10.1 Calculated from Ghaem-Maghami et al.151
TABLE 58 Annual probability of conception, by age group
Age group (years)
Conception rate
per 1000 women
in age group
Percentage of conceptions
leading to abortion
Annual probability
of conception Source
25–29 127.2 18.2 0.1040a ONS151
30–34 125.5 13.6 0.1084 ONS151
35–39 68.9 16.7 0.0574 ONS151
≥ 40 15.4 15.4 0.0111 ONS151
a Calculation: 127.2/1000 × (1 – 18.2/100) = 0.1040.
TABLE 59 Excess risk of preterm delivery
Parameter Value Source
Risk of preterm delivery for untreated women 0.073 NICE152
Increase in RR following treatment 1.56 Kyrgiou et al.119
Excess risk of preterm delivery 0.0409 Calculated
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Natural history model
TABLE 60 Transition probabilities in the natural history model (clear to cancer)
Parameters Age (years)
Probability
Reported
(annual unless statedˆ) 6-month Source
Clear to HPV 24–29 0.05 0.0253 Kulasingam et al.147
30–49 0.01 0.0050 Kulasingam et al.147
≥ 50 0.005 0.0025 Kulasingam et al.147
HPV to clear 15–24 0.7ˆ 0.2081 Kulasingam et al.147
25–29 0.5ˆ 0.1535 Kulasingam et al.147
30–39 0.25ˆ 0.0800 Kulasingam et al.147
40–49 0.15ˆ 0.0488 Kulasingam et al.147
≥ 50 0.05ˆ 0.0165 Kulasingam et al.147
HPV to CIN 1 – 0.9 × 0.06 0.9 × 0.0305 Kulasingam et al.147
HPV to CIN 2/3 – 0.1 × 0.06 0.1 × 0.0305 Kulasingam et al.147
CIN 1 to clear 15–34 0.9 × 0.1 0.9 × 0.0513 Kulasingam et al.147
≥ 35 0.9 × 0.06 0.9 × 0.0305 Kulasingam et al.147
CIN 1 to HPV 15–34 0.1 × 0.1 0.1 × 0.0513 Kulasingam et al.147
≥ 35 0.1 × 0.06 0.1 × 0.0305 Kulasingam et al.147
CIN 1 to CIN 2/3 15–34 0.02 0.0101 Kulasingam et al.147
≥ 35 0.06 0.0305 Kulasingam et al.147
CIN 2/3 to clear – 0.5 × 0.06 0.5 × 0.0305 Kulasingam et al.147
CIN 2/3 to CIN 1 – 0.5 × 0.06 0.5 × 0.0305 Kulasingam et al.147
CIN 2/3 to cancer 15–29 0.01 0.0050 Kulasingam et al.147
≥ 30 0.04 0.0202 Kulasingam et al.147
ˆ, 18-month probability.
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TABLE 61 Symptoms, progression and mortality of invasive cancer
Parameters Cancer stage Reported value
6-month
probability Source
Probability of symptoms: undetected cancer Local 0.0174/1 month 0.1000 Campos et al.148
Regional 0.0735/1 month 0.3675 Campos et al.148
Distant 0.1746/1 month 0.6838 Campos et al.148
Progression: undetected cancer Local to regional 0.02/1 month 0.1142 Campos et al.148
Regional to distant 0.025/1 month 0.1409 Campos et al.148
Mortality: undetected cancer Local 0.0016/1 month 0.0096 Campos et al.148
Regional 0.0095/1 month 0.0557 Campos et al.148
Distant 0.0293/1 month 0.1634 Campos et al.148
Mortality: detected cancer
1 year post diagnosis Local 0.0016/1 month 0.0096 Campos et al.148
Regional 0.0095/1 month 0.0557 Campos et al.148
Distant 0.0293/1 month 0.1634 Campos et al.148
2–3 years post diagnosis Local 0.0014/1 month 0.0084 Campos et al.148
Regional 0.0078/1 month 0.0459 Campos et al.148
Distant 0.0195/1 month 0.1114 Campos et al.148
4–5 years post diagnosis Local 0.0009/1 month 0.0054 Campos et al.148
Regional 0.0036/1 month 0.0214 Campos et al.148
Distant 0.0076/1 month 0.0447 Campos et al.148
TABLE 62 All-cause mortality excluding cervical cancer (6-month probability)
Age
group
(years)
Total
number
of deaths
Deaths
attributable
to cervical
cancer
Deaths
excluding
cervical cancer
Population
size
Annual
mortality
rate
6-month
probability
of death Source
15–24 678 2 676 3,516,313 0.00019 0.00010 ONS153
25–34 1368 54 1314 3,927,723 0.00033 0.00017 ONS153
35–44 3265 92 3173 3,754,387 0.00085 0.00042 ONS153
45–54 8438 119 8319 4,116,650 0.00202 0.00101 ONS153
55–64 16,389 108 16,281 3,334,140 0.00488 0.00244 ONS153
65–74 35,752 137 35,615 2,917,683 0.01221 0.00612 ONS153
75–84 72,044 135 71,909 1,837,553 0.03913 0.01976 ONS153
≥ 85 132,917 73 132,844 894,520 0.14851 0.07724 ONS153
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Resource utilisation and cost data
TABLE 63 Base-case costs of colposcopy alone, DySIS and ZedScan
Cost component
Technology
SourceColposcopy alone DySIS ZedScan
Assumed useful life of equipment
(years)
15 5 5 Clinical advisors
Purchase price (£) 10,734 30,500 3000 Manufacturers
Equivalent annual cost (£)a 900 6527 642 Calculations based on cost
components
Annual maintenance cost (£) 1073 530 0 Manufacturers
Disposables (per patient, £) 2.15 3.5 30 Manufacturers
Total cost per patient (£)b 3.75 9.24 30.52 Calculations based on cost
components
a Assumes a 3.5% interest rate.
b Assumes that 1229 patients are examined each year per device.
TABLE 64 Treatment costs
Treatment Unit cost (£), 2016 prices Source
Colposcopy examination only 175 NHS Reference Costs 2015 to 2016154
Colposcopy with biopsy 222 NHS Reference Costs 2015 to 2016154
Colposcopy with LLETZ 238 NHS Reference Costs 2015 to 2016154
TABLE 65 Costs per treatment, by device, used in the model
Treatment Technology Cost (£) per treatment
Colposcopy examination only Colposcopy alone 175
DySIS 180.49 (175 – 3.75± 9.24)
ZedScan 205.52 (175± 30.52)
Diagnostic biopsy 47 (222 – 175)
LLETZ 63 (238 – 175)
Cytology test 37.19
HPV test 29.66
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Health outcomes
TABLE 67 Disutility associated with screening, diagnosis and treatment of CIN
Screening episode QALY decrement Source
Negative cytology and/or HPV 0.0062 Simonella et al.158
False-positive referral for colposcopy 0.0276 Simonella et al.158
Diagnosed CIN 1 0.0276 Simonella et al.158
Treatment of CIN 0.0296 Simonella et al.158
TABLE 68 Health-related quality of life (utilities) for women, by age group
Age group (years) Utility Source
25–34 0.93 Kind et al.159
35–44 0.91 Kind et al.159
45–54 0.85 Kind et al.159
55–64 0.81 Kind et al.159
65–74 0.78 Kind et al.159
≥ 75 0.71 Kind et al.159
TABLE 69 Quality-adjusted life-year decrements associated with detected invasive cancer
Invasive cancer Stage QALY decrement Source
Year 1 post diagnosis Local 0.35 Goldie et al.5
Regional 0.44 Goldie et al.5
Distant 0.52 Goldie et al.5
Years 2, 3, 4 and 5 post diagnosis Local 0.03 Goldie et al.5
Regional 0.10 Goldie et al.5
Distant 0.38 Goldie et al.5
TABLE 66 Total treatment cost per cancer stage
Cancer treatment
by stage
Cost (£) per event
Source2006 2016
Stage I 2785 3434 Martin-Hirsch et al.157
Stage II 4448 5484 Martin-Hirsch et al.157
Stage III 12,562 15,487 Martin-Hirsch et al.157
Stage IV 12,777 15,752 Martin-Hirsch et al.157
Local – 4459 Calculated from Martin-Hirsch et al.157
Regional – 15,487 Calculated from Martin-Hirsch et al.157
Distant – 15,752 Calculated from Martin-Hirsch et al.157
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Characteristics of the base-case analyses
TABLE 70 Characteristics of the base-case analyses (1/2)
Parameters Value/source Comment
Number of cycles 120 (60 years)
Discount rate 3.5%
Structure
Adverse obstetric outcomes Yes Excess risk of preterm delivery
See and treat for HG results only Yes
Use of ZedScan Diagnostic colposcopy only
Treatment pathways NHSCSP guidelines15 and clinical experts
Attendance rate 100% No patients were lost to follow-up
Input parameters
Diagnostic accuracy
Colposcopy Regression Cut-off CIN 2+
DySIS Regression Cut-off CIN 2+
ZedScan Tidy et al.94 Cut-off CIN 2+
Cytology S Eggington, personal communication
HPV test (HPV triage) Cotton et al.127
HPV test (HPV primary) Kitchener et al.149
Initial population
Age at start 36 Average age under the NHSCSP
guideline15
HPV triage protocol NHSCSP18
HPV primary screening protocol Pilot sites No genotyping of HPV, 16/18
Treatment probabilities
Cured after LLETZ Ghaem-Maghami et al.150
Adverse obstetric outcomes Kyrgiou et al.119
Natural history
CIN Kulasingam et al.147
Cancer Campos et al.148
All-cause mortality ONS data153
HG, high grade.
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TABLE 71 Characteristics of the base-case analyses (2/2)
Costs Value/source Comment
Colposcopy alone NHS Reference Costs 2015 to 2016154
DySIS Manufacturer
ZedScan Manufacturer
Number of patients treated per colposcope per year 1229, clinical advisors
LLETZ and biopsy NHS Reference Costs 2015 to 2016154
Cytology and HPV tests TOMBOLA study130
Cancer costs Martin-Hirsch et al.155
Adverse obstetric outcomes Lomas et al.157
Health outcomes
Screening disutility Simonella et al.158 Screening episodes
Baseline Kind et al.159 Age and gender specific
Cancer Goldie et al.5 5-year decrement
Preterm births Lomas et al.157
TABLE 72 Characteristics of women referred for colposcopy under HPV primary screening, by types of pilot sites
Health state; reason for referral
Pilot site
No genotyping (%) Genotyping (%)
Clear; LG result 25.42 34.84
Clear; HG result 1.27 1.28
HPV; LG result 18.07 10.32
HPV; HG result 0.99 0.61
CIN 1; LG result 16.85 14.43
CIN 1; HG result 2.18 1.91
CIN 2/3; LG result 9.63 11.12
CIN 2/3; HG result 24.71 24.52
Cancer; LG result 0.11 0.05
Cancer; HG result 0.78 0.92
HG, high grade; LG, low grade.
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Appendix 12 Base-case analysis: secondary
outcomes
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TABLE 73 Base-case analysis: HPV triage, secondary outcomes (per 1000 women referred)
Grade of referral smear, by clinic and
technology
Secondary outcome
Missed
CIN 2+
Developed
cancer
Died from
cancer LLETZ
Unnecessary treatment
(clear, HPV)
Unnecessary
treatment (CIN 1)
Unnecessary
diagnostic biopsy
Preterm
delivery
See-and-treat clinics
All referrals
Colposcopy alone 69 43 9 466 9 18 139 4.0
DySIS 30 34 7 501 22 39 229 4.4
ZedScan 3 29 6 524 30 52 291 4.8
LG referrals
Colposcopy alone 91 51 10 276 6 18 131 1.4
DySIS 39 40 8 318 15 39 245 1.8
ZedScan 4 33 6 343 22 51 323 2.1
HG referrals
Colposcopy alone 22 26 7 879 14 16 149 10.0
DySIS 9 22 6 902 34 36 192 10.3
ZedScan 1 20 6 916 49 50 220 10.5
Watchful-waiting clinics
All referrals
Colposcopy alone 69 44 9 449 0 0 147 3.9
DySIS 30 37 8 465 0 0 252 4.1
ZedScan 3 32 7 477 0 0 325 4.2
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TABLE 74 HPV primary screening protocol: secondary outcomes, base case (per 1000 women referred)
Grade of referral smear, by clinic and
technology
Secondary outcome
Missed
CIN 2+
Developed
cancer
Died from
cancer LLETZ
Unnecessary treatment
(clear, HPV)
Unnecessary
treatment (CIN 1)
Unnecessary
diagnostic biopsy
Preterm
delivery
See-and-treat clinics
All referrals
Colposcopy alone 82 33 7 446 8 14 164 3.9
DySIS 34 25 5 478 20 30 296 4.2
ZedScan 4 20 4 498 28 40 386 4.5
LG referrals
Colposcopy alone 103 38 7 263 6 14 164 1.3
DySIS 42 28 5 300 15 30 323 1.6
ZedScan 5 22 4 322 21 40 433 2.0
HG referrals
Colposcopy alone 30 21 6 883 14 14 162 10.0
DySIS 12 18 5 904 33 31 231 10.2
ZedScan 1 16 5 917 46 42 276 10.4
Watchful-waiting clinics
All referrals
Colposcopy alone 82 34 7 432 0 0 172 3.8
DySIS 34 27 6 450 0 0 316 4.0
ZedScan 4 22 5 460 0 0 417 4.1
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Appendix 13 Sensitivity and scenario analyses
results
Scenario analysis 1: diagnostic accuracy from Louwers et al.60
for colposcopy and Dynamic Spectral Imaging System
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FIGURE 29 Uncertainty around diagnostic accuracy: DySIS vs. colposcopy alone. (a) HPV triage; and (b) HPV primary
screening. HG, high grade; LG, low grade.
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TABLE 75 Scenario analysis 1: HPV triage – DySIS vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 916.73 19.16145
DySIS 880.39 19.18359 –36.35 0.02214 Dominant
LG referrals
Colposcopy alone 806.20 19.15627
DySIS 778.57 19.18554 –27.63 0.02928 Dominant
HG referrals
Colposcopy alone 1155.24 19.15946
DySIS 1099.83 19.17080 –55.41 0.01134 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 964.91 19.15709
DySIS 949.98 19.17972 –14.93 0.02263 Dominant
LG referrals
Colposcopy alone 826.11 19.15563
DySIS 809.60 19.18314 –16.51 0.02751 Dominant
HG referrals
Colposcopy alone 1257.65 19.15866
DySIS 1259.59 19.16660 1.94 0.00794 245
HG, high grade; LG, low grade.
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TABLE 76 Scenario analysis 1: HPV primary screening – DySIS vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 864.77 19.17079
DySIS 832.84 19.18872 –31.93 0.01794 Dominant
LG referrals
Colposcopy alone 746.32 19.18168
DySIS 722.98 19.20610 –23.34 0.02442 Dominant
HG referrals
Colposcopy alone 1144.79 19.16330
DySIS 1087.97 19.16779 –56.81 0.00448 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 906.82 19.17033
DySIS 897.72 19.18658 –9.10 0.01625 Dominant
LG referrals
Colposcopy alone 764.55 19.17674
DySIS 748.24 19.20428 –16.31 0.02754 Dominant
HG referrals
Colposcopy alone 1243.12 19.15871
DySIS 1246.03 19.16275 2.92 0.00404 722
HG, high grade; LG, low grade.
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Scenario analysis 2: additional data from Louwers et al.60 for colposcopy
and Dynamic Spectral Imaging System
TABLE 77 Scenario analysis 2: HPV triage – DySIS vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 915.59 19.16400
DySIS 877.11 19.18527 –38.47 0.02126 Dominant
LG referrals
Colposcopy alone 803.82 19.15971
DySIS 775.53 19.18647 –28.30 0.02676 Dominant
HG referrals
Colposcopy alone 1158.06 19.16338
DySIS 1095.93 19.17186 –62.14 0.00848 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 961.66 19.16057
DySIS 948.72 19.18188 –12.94 0.02131 Dominant
LG referrals
Colposcopy alone 823.01 19.16003
DySIS 808.43 19.18335 –14.59 0.02332 Dominant
HG referrals
Colposcopy alone 1255.99 19.16118
DySIS 1256.93 19.16619 0.94 0.00501 188
HG, high grade; LG, low grade.
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TABLE 78 Scenario analysis 2: HPV primary screening – DySIS vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 862.25 19.17320
DySIS 829.31 19.19171 –32.94 0.01850 Dominant
LG referrals
Colposcopy alone 741.00 19.18583
DySIS 720.31 19.20695 –20.69 0.02112 Dominant
HG referrals
Colposcopy alone 1146.90 19.16260
DySIS 1083.95 19.16881 –62.95 0.00621 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 901.92 19.17230
DySIS 895.97 19.18840 –5.95 0.01609 Dominant
LG referrals
Colposcopy alone 759.00 19.18034
DySIS 746.69 19.20509 –12.31 0.02475 Dominant
HG referrals
Colposcopy alone 1240.88 19.16197
DySIS 1244.50 19.16419 3.62 0.00222 1633
HG, high grade; LG, low grade.
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Scenario analysis 3: diagnostic accuracy from Tidy et al.110 for colposcopy
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FIGURE 30 Uncertainty around diagnostic accuracy: ZedScan vs. colposcopy alone. (a) HPV triage; and (b) HPV
primary screening. HG, high grade; LG, low grade.
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TABLE 79 Scenario analysis 3: HPV triage – ZedScan vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 873.87 19.17860
ZedScan 885.91 19.19901 12.04 0.02041 590
LG referrals
Colposcopy alone 768.32 19.17826
ZedScan 789.30 19.20307 20.98 0.02482 845
HG referrals
Colposcopy alone 1101.18 19.16626
ZedScan 1091.97 19.17651 –9.22 0.01024 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 933.64 19.17676
ZedScan 965.87 19.19363 32.23 0.01687 1910
LG referrals
Colposcopy alone 790.35 19.17872
ZedScan 823.19 19.20082 32.85 0.02210 1486
HG referrals
Colposcopy alone 1243.40 19.16514
ZedScan 1288.82 19.16911 45.42 0.00397 11,448
HG, high grade; LG, low grade.
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TABLE 80 Scenario analysis 3: HPV primary – ZedScan vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 822.80 19.18722
ZedScan 844.41 19.20206 21.61 0.01483 1457
LG referrals
Colposcopy alone 708.37 19.20451
ZedScan 744.85 19.22007 36.49 0.01557 2344
HG referrals
Colposcopy alone 1088.46 19.16641
ZedScan 1082.27 19.17347 –6.19 0.00707 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 876.13 19.18917
ZedScan 918.78 19.19977 42.65 0.01060 4023
LG referrals
Colposcopy alone 726.69 19.19959
ZedScan 770.26 19.21984 43.57 0.02025 2152
HG referrals
Colposcopy alone 1228.18 19.16472
ZedScan 1276.58 19.16668 48.39 0.00196 24,686
HG, high grade; LG, low grade.
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Scenario analysis 4.1: Dynamic Spectral Imaging System – lower-bound
specificity (2.5%) and correlated sensitivity
TABLE 81 Scenario analysis 4.1: HPV triage – DySIS vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 903.55 19.16672
DySIS 873.06 19.18922 –30.48 0.02250 Dominant
LG referrals
Colposcopy alone 793.82 19.16515
DySIS 771.78 19.19215 –22.03 0.02700 Dominant
HG referrals
Colposcopy alone 1139.70 19.16221
DySIS 1087.56 19.17411 –52.13 0.01190 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 953.16 19.16161
DySIS 946.17 19.18190 –6.98 0.02029 Dominant
LG referrals
Colposcopy alone 812.81 19.16406
DySIS 804.49 19.18743 –8.33 0.02337 Dominant
HG referrals
Colposcopy alone 1252.23 19.16011
DySIS 1258.67 19.16576 6.44 0.00565 1140
HG, high grade; LG, low grade.
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TABLE 82 Scenario analysis 4.1: HPV primary – DySIS vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 850.17 19.17452
DySIS 825.20 19.19201 –24.97 0.01749 Dominant
LG referrals
Colposcopy alone 731.84 19.18497
DySIS 718.51 19.20383 –13.33 0.01885 Dominant
HG referrals
Colposcopy alone 1126.46 19.16164
DySIS 1075.05 19.16989 –51.41 0.00825 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 894.53 19.17496
DySIS 894.58 19.19188 0.05 0.01692 3
LG referrals
Colposcopy alone 748.21 19.18388
DySIS 744.58 19.20499 –3.63 0.02112 Dominant
HG referrals
Colposcopy alone 1237.65 19.15840
DySIS 1245.44 19.16424 7.79 0.00584 1334
HG, high grade; LG, low grade.
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Scenario analysis 4.2: Dynamic Spectral Imaging System – upper-bound
specificity (97.5%) and correlated sensitivity
TABLE 83 Scenario analysis 4.2: HPV triage – DySIS vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 902.94 19.16637
DySIS 874.62 19.18261 –28.33 0.01624 Dominant
LG referrals
Colposcopy alone 794.28 19.16183
DySIS 771.24 19.18206 –23.04 0.02023 Dominant
HG referrals
Colposcopy alone 1139.09 19.16116
DySIS 1099.15 19.16860 –39.94 0.00744 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 952.89 19.16303
DySIS 940.43 19.18000 –12.46 0.01696 Dominant
LG referrals
Colposcopy alone 812.37 19.16024
DySIS 794.50 19.18385 –17.87 0.02360 Dominant
HG referrals
Colposcopy alone 1251.78 19.15972
DySIS 1256.10 19.16660 4.32 0.00688 628
HG, high grade; LG, low grade.
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TABLE 84 Scenario analysis 4.2: HPV primary – DySIS vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 849.66 19.17576
DySIS 826.70 19.18872 –22.96 0.01296 Dominant
LG referrals
Colposcopy alone 733.04 19.19014
DySIS 715.06 19.20599 –17.98 0.01585 Dominant
HG referrals
Colposcopy alone 1126.83 19.16170
DySIS 1087.79 19.16707 –39.04 0.00537 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 894.39 19.17731
DySIS 887.97 19.19055 –6.42 0.01323 Dominant
LG referrals
Colposcopy alone 748.25 19.18760
DySIS 733.48 19.20442 –14.77 0.01681 Dominant
HG referrals
Colposcopy alone 1237.22 19.16004
DySIS 1241.84 19.16457 4.62 0.00453 1021
HG, high grade; LG, low grade.
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Scenario analysis 4.3: ZedScan – lower-bound specificity (2.5%) and
upper-bound sensitivity (97.5%)
TABLE 85 Scenario analysis 4.3: HPV triage – ZedScan vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 903.55 19.16672
ZedScan 885.01 19.20070 –18.54 0.03398 Dominant
LG referrals
Colposcopy alone 793.82 19.16515
ZedScan 788.41 19.20559 –5.40 0.04044 Dominant
HG referrals
Colposcopy alone 1139.70 19.16221
ZedScan 1089.75 19.17831 –49.95 0.01611 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 953.16 19.16161
ZedScan 967.10 19.19443 13.94 0.03282 425
LG referrals
Colposcopy alone 812.81 19.16406
ZedScan 822.94 19.20219 10.12 0.03814 265
HG referrals
Colposcopy alone 1252.23 19.16011
ZedScan 1289.12 19.16965 36.88 0.00954 3865
HG, high grade; LG, low grade.
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TABLE 86 Scenario analysis 4.3: HPV primary – ZedScan vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 850.17 19.17452
ZedScan 843.97 19.20515 –6.20 0.03063 Dominant
LG referrals
Colposcopy alone 731.84 19.18497
ZedScan 745.03 19.21610 13.19 0.03112 424
HG referrals
Colposcopy alone 1126.46 19.16164
ZedScan 1079.65 19.17438 –46.81 0.01274 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 894.53 19.17496
ZedScan 920.70 19.20378 26.17 0.02881 908
LG referrals
Colposcopy alone 748.21 19.18388
ZedScan 770.96 19.21819 22.74 0.03431 663
HG referrals
Colposcopy alone 1237.65 19.15840
ZedScan 1278.66 19.16758 41.00 0.00918 4466
HG, high grade; LG, low grade.
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Scenario analysis 4.4: ZedScan: upper-bound specificity (97.5%) and
lower-bound sensitivity (2.5%)
TABLE 87 Scenario analysis 4.4: HPV triage – ZedScan vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 902.94 19.16637
ZedScan 886.84 19.19761 –16.10 0.03124 Dominant
LG referrals
Colposcopy alone 794.28 19.16183
ZedScan 788.79 19.20177 –5.49 0.03994 Dominant
HG referrals
Colposcopy alone 1139.09 19.16116
ZedScan 1095.33 19.17545 –43.76 0.01429 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 952.89 19.16303
ZedScan 966.94 19.19209 14.05 0.02906 484
LG referrals
Colposcopy alone 812.37 19.16024
ZedScan 822.06 19.19885 9.70 0.03861 251
HG referrals
Colposcopy alone 1251.78 19.15972
ZedScan 1289.24 19.16956 37.46 0.00984 3805
HG, high grade; LG, low grade.
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TABLE 88 Scenario analysis 4.4: HPV primary screening – ZedScan vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 849.66 19.17576
ZedScan 844.47 19.20290 –5.20 0.02714 Dominant
LG referrals
Colposcopy alone 733.04 19.19014
ZedScan 745.03 19.21860 11.99 0.02846 421
HG referrals
Colposcopy alone 1126.83 19.16170
ZedScan 1085.86 19.17054 –40.97 0.00884 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 894.39 19.17731
ZedScan 918.89 19.20128 24.50 0.02396 1022
LG referrals
Colposcopy alone 748.25 19.18760
ZedScan 768.47 19.22001 20.22 0.03241 624
HG referrals
Colposcopy alone 1237.22 19.16004
ZedScan 1277.83 19.16834 40.61 0.00830 4891
HG, high grade; LG, low grade.
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Scenario analysis 5.1: number of patients per colposcope per year – 50%
compared with the base case
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FIGURE 31 Uncertainty around costs: HPV triage. (a) DySIS vs. colposcopy alone; (b) ZedScan vs. colposcopy alone;
and (c) ZedScan vs. DySIS. HG, high grade; LG, low grade. (continued )
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FIGURE 31 Uncertainty around costs: HPV triage. (a) DySIS vs. colposcopy alone; (b) ZedScan vs. colposcopy alone;
and (c) ZedScan vs. DySIS. HG, high grade; LG, low grade.
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FIGURE 32 Uncertainty around costs: HPV primary screening. (a) DySIS vs. colposcopy alone; (b) ZedScan vs.
colposcopy alone; and (c) ZedScan vs. DySIS. HG, high grade; LG, low grade. (continued )
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FIGURE 32 Uncertainty around costs: HPV primary screening. (a) DySIS vs. colposcopy alone; (b) ZedScan vs.
colposcopy alone; and (c) ZedScan vs. DySIS. HG, high grade; LG, low grade.
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TABLE 89 Scenario analysis 5.1: HPV triage – DySIS vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 903.28 19.16500
DySIS 879.49 19.18516 –23.79 0.02016 Dominant
LG referrals
Colposcopy alone 793.97 19.16330
DySIS 777.71 19.18794 –16.26 0.02464 Dominant
HG referrals
Colposcopy alone 1139.13 19.16122
DySIS 1098.77 19.17156 –40.36 0.01034 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 953.02 19.16286
DySIS 949.78 19.18194 –3.24 0.01908 Dominant
LG referrals
Colposcopy alone 812.85 19.16283
DySIS 806.96 19.18601 –5.89 0.02318 Dominant
HG referrals
Colposcopy alone 1252.07 19.16008
DySIS 1266.47 19.16580 14.40 0.00571 2521
HG, high grade; LG, low grade.
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TABLE 90 Scenario analysis 5.1: HPV triage – ZedScan vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 903.28 19.16500
ZedScan 886.72 19.19901 –16.56 0.03401 Dominant
LG referrals
Colposcopy alone 793.97 19.16330
ZedScan 790.09 19.20307 –3.88 0.03978 Dominant
HG referrals
Colposcopy alone 1139.13 19.16122
ZedScan 1092.79 19.17651 –46.34 0.01529 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 953.02 19.16286
ZedScan 966.69 19.19363 13.68 0.03078 444
LG referrals
Colposcopy alone 812.85 19.16283
ZedScan 824.01 19.20082 11.16 0.03799 294
HG referrals
Colposcopy alone 1252.07 19.16008
ZedScan 1289.67 19.16911 37.60 0.00903 4164
HG, high grade; LG, low grade.
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TABLE 91 Scenario analysis 5.1: HPV triage – ZedScan vs. DySIS
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
DySIS 879.49 19.18516
ZedScan 886.72 19.19901 7.22 0.01385 522
LG referrals
DySIS 777.71 19.18794
ZedScan 790.09 19.20307 12.38 0.01514 818
HG referrals
DySIS 1098.77 19.17156
ZedScan 1092.79 19.17651 –5.99 0.00495 Dominant
Watchful-waiting clinics
All referrals
DySIS 949.78 19.18194
ZedScan 966.69 19.19363 16.91 0.01170 1446
LG referrals
DySIS 806.96 19.18601
ZedScan 824.01 19.20082 17.05 0.01481 1151
HG referrals
DySIS 1266.47 19.16580
ZedScan 1289.67 19.16911 23.19 0.00332 6994
HG, high grade; LG, low grade.
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TABLE 92 Scenario analysis 5.1: HPV primary – DySIS vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 850.08 19.17506
DySIS 833.46 19.19120 –16.62 0.01614 Dominant
LG referrals
Colposcopy alone 732.33 19.19008
DySIS 723.49 19.20787 –8.85 0.01779 Dominant
HG referrals
Colposcopy alone 1126.93 19.16192
DySIS 1087.72 19.16774 –39.22 0.00581 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 894.41 19.17511
DySIS 898.26 19.18937 3.85 0.01426 270
LG referrals
Colposcopy alone 748.86 19.18496
DySIS 746.49 19.20646 –2.37 0.02150 Dominant
HG referrals
Colposcopy alone 1236.94 19.15863
DySIS 1252.13 19.16234 15.19 0.00371 4097
HG, high grade; LG, low grade.
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TABLE 93 Scenario analysis 5.1: HPV primary – ZedScan vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 850.08 19.17506
ZedScan 845.31 19.20206 –4.77 0.02700 Dominant
LG referrals
Colposcopy alone 732.33 19.19008
ZedScan 745.76 19.22007 13.43 0.03000 448
HG referrals
Colposcopy alone 1126.93 19.16192
ZedScan 1083.15 19.17347 –43.78 0.01155 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 894.41 19.17511
ZedScan 919.71 19.19977 25.30 0.02466 1026
LG referrals
Colposcopy alone 748.86 19.18496
ZedScan 771.19 19.21984 22.33 0.03487 640
HG referrals
Colposcopy alone 1236.94 19.15863
ZedScan 1277.49 19.16668 40.56 0.00805 5036
HG, high grade; LG, low grade.
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TABLE 94 Scenario analysis 5.1: HPV primary screening – ZedScan vs. DySIS
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
DySIS 833.46 19.19120
ZedScan 845.31 19.20206 11.85 0.01085 1092
LG referrals
DySIS 723.49 19.20787
ZedScan 745.76 19.22007 22.28 0.01220 1825
HG referrals
DySIS 1087.72 19.16774
ZedScan 1083.15 19.17347 –4.56 0.00574 Dominant
Watchful-waiting clinics
All referrals
DySIS 898.26 19.18937
ZedScan 919.71 19.19977 21.45 0.01040 2063
LG referrals
DySIS 746.49 19.20646
ZedScan 771.19 19.21984 24.70 0.01338 1846
HG referrals
DySIS 1252.13 19.16234
ZedScan 1277.49 19.16668 25.36 0.00434 5838
HG, high grade; LG, low grade.
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Scenario analysis 5.2: number of patients per colposcope per year –
+ 50% compared with base case
TABLE 95 Scenario analysis 5.2: HPV triage – DySIS vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 903.28 19.16500
DySIS 869.96 19.18516 –33.32 0.02016 Dominant
LG referrals
Colposcopy alone 793.97 19.16330
DySIS 768.29 19.18794 –25.68 0.02464 Dominant
HG referrals
Colposcopy alone 1139.13 19.16122
DySIS 1088.98 19.17156 –50.15 0.01034 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 953.02 19.16286
DySIS 938.51 19.18194 –14.50 0.01908 Dominant
LG referrals
Colposcopy alone 812.85 19.16283
DySIS 796.97 19.18601 –15.87 0.02318 Dominant
HG referrals
Colposcopy alone 1252.07 19.16008
DySIS 1252.41 19.16580 0.34 0.00571 59
HG, high grade; LG, low grade.
APPENDIX 13
NIHR Journals Library www.journalslibrary.nihr.ac.uk
222
TABLE 96 Scenario analysis 5.2: HPV triage – ZedScan vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 903.28 19.16500
ZedScan 885.66 19.19901 –17.63 0.03401 Dominant
LG referrals
Colposcopy alone 793.97 19.16330
ZedScan 789.04 19.20307 –4.93 0.03978 Dominant
HG referrals
Colposcopy alone 1139.13 19.16122
ZedScan 1091.71 19.17651 –47.42 0.01529 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 953.02 19.16286
ZedScan 965.60 19.19363 12.59 0.03078 409
LG referrals
Colposcopy alone 812.85 19.16283
ZedScan 822.93 19.20082 10.08 0.03799 265
HG referrals
Colposcopy alone 1252.07 19.16008
ZedScan 1288.55 19.16911 36.47 0.00903 4040
HG, high grade; LG, low grade.
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TABLE 97 Scenario analysis 5.2: HPV triage – ZedScan vs. DySIS
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
DySIS 869.96 19.18516
ZedScan 885.66 19.19901 15.70 0.01385 1134
LG referrals
DySIS 768.29 19.18794
ZedScan 789.04 19.20307 20.75 0.01514 1371
HG referrals
DySIS 1088.98 19.17156
ZedScan 1091.71 19.17651 2.72 0.00495 550
Watchful-waiting clinics
All referrals
DySIS 938.51 19.18194
ZedScan 965.60 19.19363 27.09 0.01170 2316
LG referrals
DySIS 796.97 19.18601
ZedScan 822.93 19.20082 25.96 0.01481 1752
HG referrals
DySIS 1252.41 19.16580
ZedScan 1288.55 19.16911 36.13 0.00332 10,896
HG, high grade; LG, low grade.
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TABLE 98 Scenario analysis 5.2: HPV primary – DySIS vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 850.08 19.17506
DySIS 822.80 19.19120 –27.28 0.01614 Dominant
LG referrals
Colposcopy alone 732.33 19.19008
DySIS 712.78 19.20787 –19.55 0.01779 Dominant
HG referrals
Colposcopy alone 1126.93 19.16192
DySIS 1077.20 19.16774 –49.74 0.00581 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 894.41 19.17511
DySIS 885.97 19.18937 –8.44 0.01426 Dominant
LG referrals
Colposcopy alone 748.86 19.18496
DySIS 735.30 19.20646 –13.56 0.02150 Dominant
HG referrals
Colposcopy alone 1236.94 19.15863
DySIS 1237.28 19.16234 0.35 0.00371 94
HG, high grade; LG, low grade.
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TABLE 99 Scenario analysis 5.2: HPV primary – ZedScan vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 850.08 19.17506
ZedScan 844.12 19.20206 –5.96 0.02700 Dominant
LG referrals
Colposcopy alone 732.33 19.19008
ZedScan 744.56 19.22007 12.23 0.03000 408
HG referrals
Colposcopy alone 1126.93 19.16192
ZedScan 1081.99 19.17347 –44.94 0.01155 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 894.41 19.17511
ZedScan 918.48 19.19977 24.07 0.02466 976
LG referrals
Colposcopy alone 748.86 19.18496
ZedScan 769.96 19.21984 21.10 0.03487 605
HG referrals
Colposcopy alone 1236.94 19.15863
ZedScan 1276.28 19.16668 39.35 0.00805 4886
HG, high grade; LG, low grade.
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TABLE 100 Scenario analysis 5.2: HPV primary – ZedScan vs. DySIS
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
DySIS 822.80 19.19120
ZedScan 844.12 19.20206 21.33 0.01085 1965
LG referrals
DySIS 712.78 19.20787
ZedScan 744.56 19.22007 31.78 0.01220 2604
HG referrals
DySIS 1077.20 19.16774
ZedScan 1081.99 19.17347 4.79 0.00574 835
Watchful-waiting clinics
All referrals
DySIS 885.97 19.18937
ZedScan 918.48 19.19977 32.52 0.01040 3127
LG referrals
DySIS 735.30 19.20646
ZedScan 769.96 19.21984 34.66 0.01338 2591
HG referrals
DySIS 1237.28 19.16234
ZedScan 1276.28 19.16668 39.00 0.00434 8977
HG, high grade; LG, low grade.
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Scenario analysis 6: costs of diagnostic biopsy and large-loop excision of
the transformation zone
TABLE 101 Scenario analysis 6: HPV triage – DySIS vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 1142.55 19.16500
DySIS 1133.92 19.18516 –8.64 0.02016 Dominant
LG referrals
Colposcopy alone 933.40 19.16330
DySIS 939.31 19.18794 5.91 0.02464 240
HG referrals
Colposcopy alone 1595.81 19.16122
DySIS 1555.78 19.17156 –40.03 0.01034 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 1191.48 19.16286
DySIS 1198.24 19.18194 6.76 0.01908 355
LG referrals
Colposcopy alone 945.18 19.16283
DySIS 955.93 19.18601 10.75 0.02318 464
HG referrals
Colposcopy alone 1721.66 19.16008
DySIS 1732.53 19.16580 10.87 0.00571 1903
HG, high grade; LG, low grade.
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TABLE 102 Scenario 6: HPV triage – ZedScan vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 1142.55 19.16500
ZedScan 1162.49 19.19901 19.94 0.03401 586
LG referrals
Colposcopy alone 933.40 19.16330
ZedScan 977.37 19.20307 43.97 0.03978 1105
HG referrals
Colposcopy alone 1595.81 19.16122
ZedScan 1561.11 19.17651 –34.70 0.01529 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 1191.48 19.16286
ZedScan 1235.83 19.19363 44.35 0.03078 1441
LG referrals
Colposcopy alone 945.18 19.16283
ZedScan 996.19 19.20082 51.02 0.03799 1343
HG referrals
Colposcopy alone 1721.66 19.16008
ZedScan 1770.28 19.16911 48.62 0.00903 5385
HG, high grade; LG, low grade.
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TABLE 103 Scenario analysis 6: HPV triage – ZedScan vs. DySIS
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
DySIS 1133.92 19.18516
ZedScan 1162.49 19.19901 28.57 0.01385 2064
LG referrals
DySIS 939.31 19.18794
ZedScan 977.37 19.20307 38.06 0.01514 2515
HG referrals
DySIS 1555.78 19.17156
ZedScan 1561.11 19.17651 5.33 0.00495 1077
Watchful-waiting clinics
All referrals
DySIS 1198.24 19.18194
ZedScan 1235.83 19.19363 37.58 0.01170 3213
LG referrals
DySIS 955.93 19.18601
ZedScan 996.19 19.20082 40.26 0.01481 2718
HG referrals
DySIS 1732.53 19.16580
ZedScan 1770.28 19.16911 37.75 0.00332 11,383
HG, high grade; LG, low grade.
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TABLE 104 Scenario analysis 6: HPV primary – DySIS vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 1080.43 19.17506
DySIS 1079.04 19.19120 –1.39 0.01614 Dominant
LG referrals
Colposcopy alone 865.95 19.19008
DySIS 878.28 19.20787 12.33 0.01779 693
HG referrals
Colposcopy alone 1587.75 19.16192
DySIS 1549.14 19.16774 –38.61 0.00581 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 1125.28 19.17511
DySIS 1140.86 19.18937 15.59 0.01426 1093
LG referrals
Colposcopy alone 877.84 19.18496
DySIS 892.41 19.20646 14.57 0.02150 678
HG referrals
Colposcopy alone 1712.09 19.15863
DySIS 1724.71 19.16234 12.62 0.00371 3402
HG, high grade; LG, low grade.
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TABLE 105 Scenario analysis 6: HPV primary – ZedScan vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 1080.43 19.17506
ZedScan 1113.02 19.20206 32.59 0.02700 1207
LG referrals
Colposcopy alone 865.95 19.19008
ZedScan 927.00 19.22007 61.05 0.03000 2035
HG referrals
Colposcopy alone 1587.75 19.16192
ZedScan 1556.56 19.17347 –31.18 0.01155 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 1125.28 19.17511
ZedScan 1184.20 19.19977 58.92 0.02466 2390
LG referrals
Colposcopy alone 877.84 19.18496
ZedScan 941.93 19.21984 64.09 0.03487 1838
HG referrals
Colposcopy alone 1712.09 19.15863
ZedScan 1766.12 19.16668 54.03 0.00805 6709
HG, high grade; LG, low grade.
APPENDIX 13
NIHR Journals Library www.journalslibrary.nihr.ac.uk
232
TABLE 106 Scenario analysis 6: HPV primary – ZedScan vs. DySIS
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
DySIS 1079.04 19.19120
ZedScan 1113.02 19.20206 33.98 0.01085 3131
LG referrals
DySIS 878.28 19.20787
ZedScan 927.00 19.22007 48.72 0.01220 3992
HG referrals
DySIS 1549.14 19.16774
ZedScan 1556.56 19.17347 7.43 0.00574 1295
Watchful-waiting clinics
All referrals
DySIS 1140.86 19.18937
ZedScan 1184.20 19.19977 43.34 0.01040 4168
LG referrals
DySIS 892.41 19.20646
ZedScan 941.93 19.21984 49.52 0.01338 3701
HG referrals
DySIS 1724.71 19.16234
ZedScan 1766.12 19.16668 41.41 0.00434 9531
HG, high grade; LG, low grade.
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Scenario analysis 7: alternative distributions of health state and reason
for referral from human papillomavirus screening pilot sites
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FIGURE 33 Population referred for colposcopy under the HPV primary screening protocol. (a) DySIS vs. colposcopy
alone; (b) ZedScan vs. colposcopy alone; and (c) ZedScan vs. DySIS. HG, high grade; LG, low grade. (continued )
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FIGURE 33 Population referred for colposcopy under the HPV primary screening protocol. (a) DySIS vs. colposcopy
alone; (b) ZedScan vs. colposcopy alone; and (c) ZedScan vs. DySIS. HG, high grade; LG, low grade.
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TABLE 107 Scenario analysis 7.1: HPV primary – DySIS vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 869.15 19.17797
DySIS 843.81 19.19374 –25.34 0.01577 Dominant
LG referrals
Colposcopy alone 761.78 19.18360
DySIS 748.31 19.19999 –13.47 0.01639 Dominant
HG referrals
Colposcopy alone 1109.78 19.16614
DySIS 1063.28 19.17235 –46.50 0.00622 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 916.54 19.17587
DySIS 911.90 19.19021 –4.64 0.01433 Dominant
LG referrals
Colposcopy alone 780.26 19.18110
DySIS 772.76 19.19683 –7.50 0.01573 Dominant
HG referrals
Colposcopy alone 1224.74 19.15938
DySIS 1229.50 19.16602 4.75 0.00663 716
HG, high grade; LG, low grade.
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TABLE 108 Scenario analysis 7.1: HPV primary – ZedScan vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 869.15 19.17797
ZedScan 864.85 19.20464 –4.30 0.02668 Dominant
LG referrals
Colposcopy alone 761.78 19.18360
ZedScan 779.52 19.21213 17.74 0.02853 622
HG referrals
Colposcopy alone 1109.78 19.16614
ZedScan 1065.96 19.17820 –43.81 0.01206 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 916.54 19.17587
ZedScan 948.19 19.19542 31.64 0.01954 1619
LG referrals
Colposcopy alone 780.26 19.18110
ZedScan 808.42 19.20864 28.16 0.02754 1023
HG referrals
Colposcopy alone 1224.74 19.15938
ZedScan 1265.75 19.17010 41.00 0.01072 3826
HG, high grade; LG, low grade.
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TABLE 109 Scenario analysis 7.1: HPV primary – ZedScan vs. DySIS
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
DySIS 843.81 19.19374
ZedScan 864.85 19.20464 21.03 0.01091 1929
LG referrals
DySIS 748.31 19.19999
ZedScan 779.52 19.21213 31.21 0.01214 2571
HG referrals
DySIS 1063.28 19.17235
ZedScan 1065.96 19.17820 2.69 0.00585 459
Watchful-waiting clinics
All referrals
DySIS 911.90 19.19021
ZedScan 948.19 19.19542 36.28 0.00521 6965
LG referrals
DySIS 772.76 19.19683
ZedScan 808.42 19.20864 35.66 0.01181 3021
HG referrals
DySIS 1229.50 19.16602
ZedScan 1265.75 19.17010 36.25 0.00408 8878
HG, high grade; LG, low grade.
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TABLE 110 Scenario analysis 7.2: HPV primary – DySIS vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 840.64 19.18448
DySIS 813.05 19.20309 –27.59 0.01861 Dominant
LG referrals
Colposcopy alone 718.86 19.19501
DySIS 705.08 19.20804 –13.78 0.01303 Dominant
HG referrals
Colposcopy alone 1130.13 19.15967
DySIS 1082.72 19.16813 –47.42 0.00846 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 882.93 19.17807
DySIS 876.39 19.19619 –6.54 0.01812 Dominant
LG referrals
Colposcopy alone 735.43 19.19023
DySIS 725.96 19.20749 –9.47 0.01726 Dominant
HG referrals
Colposcopy alone 1243.76 19.16096
DySIS 1250.08 19.16665 6.31 0.00570 1109
HG, high grade; LG, low grade.
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TABLE 111 Scenario analysis 7.2: HPV primary – ZedScan vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 840.64 19.18448
ZedScan 832.59 19.21357 –8.05 0.02909 Dominant
LG referrals
Colposcopy alone 718.86 19.19501
ZedScan 731.56 19.21836 12.69 0.02336 543
HG referrals
Colposcopy alone 1130.13 19.15967
ZedScan 1084.55 19.17361 –45.59 0.01394 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 882.93 19.17807
ZedScan 908.53 19.20169 25.60 0.02362 1084
LG referrals
Colposcopy alone 735.43 19.19023
ZedScan 756.10 19.21774 20.67 0.02751 751
HG referrals
Colposcopy alone 1243.76 19.16096
ZedScan 1285.29 19.16882 41.53 0.00786 5285
HG, high grade; LG, low grade.
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TABLE 112 Scenario analysis 7.2: HPV primary – ZedScan vs. DySIS
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
DySIS 813.05 19.20309
ZedScan 832.59 19.21357 19.54 0.01047 1866
LG referrals
DySIS 705.08 19.20804
ZedScan 731.56 19.21836 26.47 0.01033 2564
HG referrals
DySIS 1082.72 19.16813
ZedScan 1084.55 19.17361 1.83 0.00548 334
Watchful-waiting clinics
All referrals
DySIS 876.39 19.19619
ZedScan 908.53 19.20169 32.14 0.00550 5848
LG referrals
DySIS 725.96 19.20749
ZedScan 756.10 19.21774 30.13 0.01025 2940
HG referrals
DySIS 1250.08 19.16665
ZedScan 1285.29 19.16882 35.22 0.00216 16,277
HG, high grade; LG, low grade.
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Scenario 1: time horizon of 3 years
– 0.004 – 0.001– 0.002 0.000 0.001 0.002 0.003
Incremental QALYs
In
cr
e
m
e
n
ta
l 
co
st
 (
£
)
(a)
– 0.003
– 40
– 20
0
20
40
100
80
60
Scenario 1: see and treat
Scenario 1: watchful waiting
ICER £20,000
All
HG
LG
All
LG
HG
– 0.004 – 0.001– 0.002 0.000 0.001 0.002 0.003
In
cr
e
m
e
n
ta
l 
co
st
 (
£
)
(b)
– 0.003
– 40
– 20
0
20
40
100
80
60
Scenario 1: see and treat
Scenario 1: watchful waiting
ICER £20,000
All
HG
LG
All
LG
HG
Incremental QALYs
FIGURE 34 Scenario analysis: 3-year time horizon – HPV triage. (a) DySIS vs. colposcopy alone; (b) ZedScan vs.
colposcopy alone; and (c) ZedScan vs. DySIS. HG, high grade; LG, low grade. (continued )
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FIGURE 34 Scenario analysis: 3-year time horizon – HPV triage. (a) DySIS vs. colposcopy alone; (b) ZedScan vs.
colposcopy alone; and (c) ZedScan vs. DySIS. HG, high grade; LG, low grade.
– 0.004 – 0.001– 0.002 0.000 0.001 0.002 0.003
In
cr
e
m
e
n
ta
l 
co
st
 (
£
)
(a)
– 0.003
– 40
– 20
0
20
40
100
80
60
Scenario 1: see and treat
Scenario 1: watchful waiting
ICER £20,000
All
HG
All
HG
LG
LG
Incremental QALYs
FIGURE 35 Scenario analysis: 3-year time horizon – HPV primary screening. (a) DySIS vs. colposcopy alone;
(b) ZedScan vs. colposcopy alone; and (c) ZedScan vs. DySIS. HG, high grade; LG, low grade. (continued )
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FIGURE 35 Scenario analysis: 3-year time horizon – HPV primary screening. (a) DySIS vs. colposcopy alone;
(b) ZedScan vs. colposcopy alone; and (c) ZedScan vs. DySIS. HG, high grade; LG, low grade.
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TABLE 113 Scenario 1: HPV triage – DySIS vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 411.06 2.57359
DySIS 427.74 2.57234 16.69 –0.00126 Dominated
LG referrals
Colposcopy alone 265.59 2.58218
DySIS 303.39 2.58039 37.80 –0.00180 Dominated
HG referrals
Colposcopy alone 732.77 2.55474
DySIS 703.19 2.55461 –29.58 –0.00012 236,692
Watchful-waiting clinics
All referrals
Colposcopy alone 446.62 2.57361
DySIS 478.14 2.57239 31.53 –0.00122 Dominated
LG referrals
Colposcopy alone 265.84 2.58217
DySIS 303.98 2.58039 38.14 –0.00178 Dominated
HG referrals
Colposcopy alone 839.24 2.55471
DySIS 857.51 2.55450 18.27 –0.00021 Dominated
HG, high grade; LG, low grade.
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TABLE 114 Scenario 1: HPV triage – ZedScan vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 411.06 2.57359
ZedScan 463.86 2.57147 52.80 –0.00213 Dominated
LG referrals
Colposcopy alone 265.59 2.58218
ZedScan 353.48 2.57909 87.89 –0.00310 Dominated
HG referrals
Colposcopy alone 732.77 2.55474
ZedScan 710.95 2.55448 –21.82 –0.00026 85,045
Watchful-waiting clinics
All referrals
Colposcopy alone 446.62 2.57361
ZedScan 524.47 2.57138 77.85 –0.00223 Dominated
LG referrals
Colposcopy alone 265.84 2.58217
ZedScan 354.30 2.57911 88.47 –0.00306 Dominated
HG referrals
Colposcopy alone 839.24 2.55471
ZedScan 893.65 2.55427 54.41 –0.00043 Dominated
HG, high grade; LG, low grade.
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TABLE 115 Scenario 1: HPV triage – ZedScan vs. DySIS
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
DySIS 427.74 2.57234
ZedScan 463.86 2.57147 36.12 –0.00087 Dominated
LG referrals
DySIS 303.39 2.58039
ZedScan 353.48 2.57909 50.09 –0.00130 Dominated
HG referrals
DySIS 703.19 2.55461
ZedScan 710.95 2.55448 7.76 –0.00013 Dominated
Watchful-waiting clinics
All referrals
DySIS 478.14 2.57239
ZedScan 524.47 2.57138 46.33 –0.00101 Dominated
LG referrals
DySIS 303.98 2.58039
ZedScan 354.30 2.57911 50.32 –0.00128 Dominated
HG referrals
DySIS 857.51 2.55450
ZedScan 893.65 2.55427 36.14 –0.00022 Dominated
HG, high grade; LG, low grade.
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Scenario 2: adverse obstetric outcomes excluded
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FIGURE 36 Scenario analysis: no adverse obstetric outcomes – HPV triage. (a) DySIS vs. colposcopy alone;
(b) ZedScan vs. colposcopy alone; and (c) ZedScan vs. DySIS. HG, high grade; LG, low grade. (continued )
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FIGURE 36 Scenario analysis: no adverse obstetric outcomes – HPV triage. (a) DySIS vs. colposcopy alone;
(b) ZedScan vs. colposcopy alone; and (c) ZedScan vs. DySIS. HG, high grade; LG, low grade.
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FIGURE 37 Scenario analysis: no adverse obstetric outcomes – HPV primary screening. (a) DySIS vs. colposcopy
alone; (b) ZedScan vs. colposcopy alone; and (c) ZedScan vs. DySIS. HG, high grade; LG, low grade. (continued )
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FIGURE 37 Scenario analysis: no adverse obstetric outcomes – HPV primary screening. (a) DySIS vs. colposcopy
alone; (b) ZedScan vs. colposcopy alone; and (c) ZedScan vs. DySIS. HG, high grade; LG, low grade.
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TABLE 116 Scenario 2: HPV triage – DySIS vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 812.38 19.16794
DySIS 772.72 19.18643 –39.66 0.01849 Dominant
LG referrals
Colposcopy alone 764.95 19.16568
DySIS 731.55 19.19163 –33.40 0.02595 Dominant
HG referrals
Colposcopy alone 916.64 19.16996
DySIS 864.11 19.17924 –52.53 0.00928 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 866.34 19.17183
DySIS 851.85 19.18963 –14.49 0.01781 Dominant
LG referrals
Colposcopy alone 785.18 19.16212
DySIS 762.82 19.18799 –22.36 0.02587 Dominant
HG referrals
Colposcopy alone 1040.04 19.17105
DySIS 1045.25 19.17569 5.21 0.00464 1122
HG, high grade; LG, low grade.
DOI: 10.3310/hta22540 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 54
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Peron et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
251
TABLE 117 Scenario 2: HPV triage – ZedScan vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 812.38 19.16794
ZedScan 777.24 19.19700 –35.14 0.02906 Dominant
LG referrals
Colposcopy alone 764.95 19.16568
ZedScan 742.35 19.20822 –22.60 0.04254 Dominant
HG referrals
Colposcopy alone 916.64 19.16996
ZedScan 858.46 19.18343 –58.18 0.01348 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 866.34 19.17183
ZedScan 871.25 19.19886 4.91 0.02703 182
LG referrals
Colposcopy alone 785.18 19.16212
ZedScan 778.96 19.20125 –6.22 0.03912 Dominant
HG referrals
Colposcopy alone 1040.04 19.17105
ZedScan 1074.92 19.17690 34.87 0.00585 5959
HG, high grade; LG, low grade.
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TABLE 118 Scenario 2: HPV triage – ZedScan vs. DySIS
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
DySIS 772.72 19.18643
ZedScan 777.24 19.19700 4.51 0.01057 427
LG referrals
DySIS 731.55 19.19163
ZedScan 742.35 19.20822 10.80 0.01659 651
HG referrals
DySIS 864.11 19.17924
ZedScan 858.46 19.18343 –5.65 0.00419 Dominant
Watchful-waiting clinics
All referrals
DySIS 851.85 19.18963
ZedScan 871.25 19.19886 19.40 0.00922 2104
LG referrals
DySIS 762.82 19.18799
ZedScan 778.96 19.20125 16.14 0.01325 1218
HG referrals
DySIS 1045.25 19.17569
ZedScan 1074.92 19.17690 29.66 0.00121 24,493
HG, high grade; LG, low grade.
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Scenario 3: ZedScan was used alongside colposcopy at all appointments
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FIGURE 38 Scenario analysis: ZedScan was used alongside colposcopy at all appointments. (a) ZedScan vs.
colposcopy alone – HPV triage protocol; (b) ZedScan vs. DySIS – HPV triage protocol; (c) ZedScan vs. colposcopy
alone – HPV primary screening protocol; and (d) ZedScan vs. DySIS – HPV primary screening protocol. HG, high
grade; LG, low grade. (continued )
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FIGURE 38 Scenario analysis: ZedScan was used alongside colposcopy at all appointments. (a) ZedScan vs.
colposcopy alone – HPV triage protocol; (b) ZedScan vs. DySIS – HPV triage protocol; (c) ZedScan vs. colposcopy
alone – HPV primary screening protocol; and (d) ZedScan vs. DySIS – HPV primary screening protocol. HG, high
grade; LG, low grade.
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TABLE 119 Scenario 3: HPV triage – ZedScan vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 903.28 19.16500
ZedScan 890.89 19.19901 –12.40 0.03401 Dominant
LG referrals
Colposcopy alone 793.97 19.16330
ZedScan 795.63 19.20307 1.65 0.03978 42
HG referrals
Colposcopy alone 1139.13 19.16122
ZedScan 1094.01 19.17651 –45.12 0.01529 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 953.02 19.16286
ZedScan 980.93 19.19363 27.92 0.03078 907
LG referrals
Colposcopy alone 812.85 19.16283
ZedScan 831.92 19.20082 19.07 0.03799 502
HG referrals
Colposcopy alone 1252.07 19.16008
ZedScan 1317.70 19.16911 65.63 0.00903 7270
HG, high grade; LG, low grade.
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TABLE 120 Scenario 3: HPV triage – ZedScan vs. DySIS
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
DySIS 872.34 19.18516
ZedScan 890.89 19.19901 18.54 0.01385 1339
LG referrals
DySIS 770.65 19.18794
ZedScan 795.63 19.20307 24.98 0.01514 1651
HG referrals
DySIS 1091.43 19.17156
ZedScan 1094.01 19.17651 2.58 0.00495 521
Watchful-waiting clinics
All referrals
DySIS 941.33 19.18194
ZedScan 980.93 19.19363 39.60 0.01170 3385
LG referrals
Colposcopy alone 799.47 19.18601
ZedScan 831.92 19.20082 32.45 0.01481 2191
HG referrals
DySIS 1255.93 19.16580
ZedScan 1317.70 19.16911 61.78 0.00332 18,628
HG, high grade; LG, low grade.
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TABLE 121 Scenario 3: HPV primary – ZedScan vs. colposcopy alone
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
Colposcopy alone 850.08 19.17506
ZedScan 849.70 19.20206 –0.38 0.02700 Dominant
LG referrals
Colposcopy alone 732.33 19.19008
ZedScan 751.31 19.22007 18.98 0.03000 633
HG referrals
Colposcopy alone 1126.93 19.16192
ZedScan 1084.58 19.17347 –42.35 0.01155 Dominant
Watchful-waiting clinics
All referrals
Colposcopy alone 894.41 19.17511
ZedScan 933.32 19.19977 38.91 0.02466 1578
LG referrals
Colposcopy alone 748.86 19.18496
ZedScan 778.64 19.21984 29.78 0.03487 854
HG referrals
Colposcopy alone 1236.94 19.15863
ZedScan 1305.85 19.16668 68.91 0.00805 8557
HG, high grade; LG, low grade.
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TABLE 122 Scenario 3: HPV primary – ZedScan vs. DySIS
Grade of referral smear,
by clinic and technology Cost (£) QALYs
Incremental
ICERCost (£) QALYs
See-and-treat clinics
All referrals
DySIS 825.46 19.19120
ZedScan 849.70 19.20206 24.24 0.01085 2233
LG referrals
DySIS 715.46 19.20787
ZedScan 751.31 19.22007 35.85 0.01220 2938
HG referrals
DySIS 1079.83 19.16774
ZedScan 1084.58 19.17347 4.75 0.00574 829
Watchful-waiting clinics
All referrals
DySIS 889.04 19.18937
ZedScan 933.32 19.19977 44.28 0.01040 4259
LG referrals
DySIS 738.10 19.20646
ZedScan 778.64 19.21984 40.54 0.01338 3030
HG referrals
DySIS 1240.99 19.16234
ZedScan 1305.85 19.16668 64.85 0.00434 14,928
HG, high grade; LG, low grade.
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